BindingDB Reactant_set_id,Ligand SMILES,Ligand InChI,Ligand InChI Key,BindingDB MonomerID,BindingDB Ligand Name,Target Name,Target Source Organism According to Curator or DataSource,IC50 (nM)
51075338,O=C(CCc1cccnc1)N(Cc1cccs1)Cc1nc2CCOCc2c(=O)[nH]1,"InChI=1S/C21H22N4O3S/c26-20(6-5-15-3-1-8-22-11-15)25(12-16-4-2-10-29-16)13-19-23-18-7-9-28-14-17(18)21(27)24-19/h1-4,8,10-11H,5-7,9,12-14H2,(H,23,24,27)",WEHBTALITPPXOG-UHFFFAOYSA-N,50439808,"CHEMBL2419717::US9227982, 12",Protein Wnt-3a,Homo sapiens, 41000
1138818,COc1cccc(OC)c1-c1noc(C2CC2)c1COc1ccc(c(Cl)c1)C1(O)CN(C1)c1ncc(cc1F)C(O)=O,"InChI=1S/C30H27ClFN3O7/c1-39-23-4-3-5-24(40-2)25(23)26-19(27(42-34-26)16-6-7-16)13-41-18-8-9-20(21(31)11-18)30(38)14-35(15-30)28-22(32)10-17(12-33-28)29(36)37/h3-5,8-12,16,38H,6-7,13-15H2,1-2H3,(H,36,37)",JJVVPLHMDOFRRR-UHFFFAOYSA-N,402336,"6-(3-(2-chloro-4-((5- cyclopropyl-3-(2,6- dimethoxyphenyl)isoxazol-4- yl)methoxy)phenyl)-3- hydroxyazetidin-1-yl)-5- fluoronicotinic acid::US10329286, Example 8::US11247986, Example 8",Bile acid receptor,Homo sapiens,
50666048,CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,25117,"AG-013736::AXITINIB::N-methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide::US10464902, Axitinib::US9205078, Axitinib ::US9617222, Compound A",Dual specificity protein kinase TTK,Homo sapiens,
50390373,CC(C)NCCN([C@@H]1CC[C@@]2(CC2C1)c1cccc(c1)C#N)C(=O)Nc1cc(Cl)nc(Cl)c1,"InChI=1S/C25H29Cl2N5O/c1-16(2)29-8-9-32(24(33)30-20-12-22(26)31-23(27)13-20)21-6-7-25(14-19(25)11-21)18-5-3-4-17(10-18)15-28/h3-5,10,12-13,16,19,21,29H,6-9,11,14H2,1-2H3,(H,30,31,33)/t19?,21-,25-/m1/s1",LCRYFIQZHFQDJZ-ZMFCXZKHSA-N,50215645,"1-((3R,6S)-6-(3-cyanophenyl)bicyclo[4.1.0]heptan-3-yl)-3-(2,6-dichloropyridin-4-yl)-1-(2-(isopropylamino)ethyl)urea::CHEMBL374844",Melanin-concentrating hormone receptor 1,Homo sapiens,
51338864,Clc1cccc2c(ccnc12)-n1cnc2c(cc(cc12)N1CCOCC1)-c1nnc[nH]1,"InChI=1S/C22H18ClN7O/c23-17-3-1-2-15-18(4-5-24-20(15)17)30-13-26-21-16(22-25-12-27-28-22)10-14(11-19(21)30)29-6-8-31-9-7-29/h1-5,10-13H,6-9H2,(H,25,27,28)",GDZNVPWDBYHIJL-UHFFFAOYSA-N,357385,"US10214519, Example 111","Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens, 12
51394416,Cc1cc(C)cc(c1)-c1ccc2c(NC(=O)c3ccccc3NC(=O)C=C)n[nH]c2c1,"InChI=1S/C25H22N4O2/c1-4-23(30)26-21-8-6-5-7-20(21)25(31)27-24-19-10-9-17(14-22(19)28-29-24)18-12-15(2)11-16(3)13-18/h4-14H,1H2,2-3H3,(H,26,30)(H2,27,28,29,31)",SBXDCZQCEQZTSA-UHFFFAOYSA-N,50563500,CHEMBL4765104,Fibroblast growth factor receptor 4,, 423
715859,CCCNC(=O)Nc1cccc(c1)-n1c(nc2cccc(Cl)c2c1=O)[C@H](C)Nc1ncnc(N)c1C#N,"InChI=1S/C25H24ClN9O2/c1-3-10-29-25(37)33-15-6-4-7-16(11-15)35-23(34-19-9-5-8-18(26)20(19)24(35)36)14(2)32-22-17(12-27)21(28)30-13-31-22/h4-9,11,13-14H,3,10H2,1-2H3,(H2,29,33,37)(H3,28,30,31,32)/t14-/m0/s1",YJGKKPWELJLAPJ-AWEZNQCLSA-N,362132,"(S)-1-(3-(2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-5-chloro-4-oxoquinazolin-3(4H)-yl)phenyl)-3-cyclopropylurea::US10221197, Compound 125","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens, 7000
51176088,CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O)N=C(N)N,"InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1",ARAIBEBZBOPLMB-UFGQHTETSA-N,50330326,"(4S,5R,6R)-5-Acetylamino-4-guanidino-6-((1R,3R)-1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid::(4S,5R,6R)-5-Acetylamino-4-guanidino-6-((R)-1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid::(4S,5R,6R)-5-Acetylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid::(4S,5R,6R)-5-acetamido-4-(diaminomethyleneamino)-6-((1R,2R)-1,2,3-trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid::(4S,5R,6R)-5-acetylamino-4-guanidino-6-((1R,2R)-1,2,3-trihydroxy-propy)-5,6-dihydro-4H-pyran-2-carboxylic acid::(4S,5R,6R)-5-acetylamino-4-guanidino-6-((1R,2R)-1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid::4-diaminomethylamino-3-methylcarboxamido-2-(1,2,3-trihydroxypropyl)-(3R)-3,4-dihydro-2H-6-pyrancarboxylic acid(Zanamivir)::5-Acetylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid::5-Acetylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid(zanamivir)::5-Formylamino-4-guanidino-6-(1,2,3-trihydroxy-propyl)-5,6-dihydro-4H-pyran-2-carboxylic acid::CHEMBL222813::GR-121167X::Relenza::Zanamivi",Neuraminidase,Influenza A virus, 8.6
497642,Nc1ccc(CN[C@H]2CCC(CC2)c2ccc(c(c2-c2nnn[nH]2)S(N)(=O)=O)C(F)(F)F)cn1,,,262829,"3-(4-{[(6-aminopyridin-3- yl)methyl]amino}cyclohex- yl)-2-(1H-tetrazol-5-yl)- 6- (trifluoromethyl)benzene sulfonamide::US9708336, 682",Metallo-beta-lactamase type 2,, 4.12
51247047,OC(CNCCCc1ccccc1)c1ccc(O)c2[nH]c(=O)ccc12,"InChI=1S/C20H22N2O3/c23-17-10-8-15(16-9-11-19(25)22-20(16)17)18(24)13-21-12-4-7-14-5-2-1-3-6-14/h1-3,5-6,8-11,18,21,23-24H,4,7,12-13H2,(H,22,25)",UTODCRACBJDRGN-UHFFFAOYSA-N,50510101,CHEMBL4536813,Beta-2 adrenergic receptor,Homo sapiens,
51020112,CC(C)(C)OC(=O)N1CCC2(CCN(C2)C(=O)c2cc(Cc3n[nH]c(=O)c4ccccc34)ccc2F)C1,"InChI=1S/C28H31FN4O4/c1-27(2,3)37-26(36)33-13-11-28(17-33)10-12-32(16-28)25(35)21-14-18(8-9-22(21)29)15-23-19-6-4-5-7-20(19)24(34)31-30-23/h4-9,14H,10-13,15-17H2,1-3H3,(H,31,34)",MOYOUBMGSIHZJF-UHFFFAOYSA-N,50288516,CHEMBL4159240,Poly [ADP-ribose] polymerase tankyrase-1,, 1000
860670,CC(C)n1nc(-c2cc3c(C)cccc3[nH]2)c2c(N)ncnc12,"InChI=1S/C17H18N6/c1-9(2)23-17-14(16(18)19-8-20-17)15(22-23)13-7-11-10(3)5-4-6-12(11)21-13/h4-9,21H,1-3H3,(H2,18,19,20)",HEDDQUIXAAICJH-UHFFFAOYSA-N,340899,"1-isopropyl-3-(4-methyl-1H-indol-2-yl)-1H- pyrazolo[3,4-d]pyrimidin-4-amine::US10544104, Compound 25::US11247972, Compound 25::US9765037, Compound 25",Proto-oncogene tyrosine-protein kinase Src,, 5020
51332154,Clc1nc(Nc2ccc(cc2)N2CCOCC2=O)nc(n1)N1CCCC1,"InChI=1S/C17H19ClN6O2/c18-15-20-16(22-17(21-15)23-7-1-2-8-23)19-12-3-5-13(6-4-12)24-9-10-26-11-14(24)25/h3-6H,1-2,7-11H2,(H,19,20,21,22)",XUCNQRWIELTSLI-UHFFFAOYSA-N,50369080,CHEMBL4167700,Prostaglandin G/H synthase 1,,>10000
493439,OC(c1ccc(CBr)cc1)(C(F)(F)F)C(F)(F)F,"InChI=1S/C10H7BrF6O/c11-5-6-1-3-7(4-2-6)8(18,9(12,13)14)10(15,16)17/h1-4,18H,5H2",LVLBRKWIJOFEHS-UHFFFAOYSA-N,261498,"2-(4-(bromomethyl)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol::US9708268, 1",Interleukin-17F,,<10000
864522,COc1cc(cn2ncnc12)-c1[nH]c2ccc(nc2c1C(C)C)N1CC(C1)NCC(=O)N(C)C,"InChI=1S/C24H30N8O2/c1-14(2)21-22(15-8-18(34-5)24-26-13-27-32(24)10-15)28-17-6-7-19(29-23(17)21)31-11-16(12-31)25-9-20(33)30(3)4/h6-8,10,13-14,16,25,28H,9,11-12H2,1-5H3",ICZMCTWORPHBMY-UHFFFAOYSA-N,427582,"US10544143, Example 18::US10544143, Example 27::US10730877, Example 27::US11053244, Example 27",Toll-like receptor 9,,>50000
51053015,O=C(NC1CCCCC1)Nc1ccc(Oc2ncnc3n[nH]cc23)cc1,"InChI=1S/C18H20N6O2/c25-18(22-12-4-2-1-3-5-12)23-13-6-8-14(9-7-13)26-17-15-10-21-24-16(15)19-11-20-17/h6-12H,1-5H2,(H2,22,23,25)(H,19,20,21,24)",CQEDTVBKKZWBLM-UHFFFAOYSA-N,50429488,CHEMBL2332863,Vascular endothelial growth factor receptor 2,Danio rerio,>100000
239964,COc1cc(ccn1)-c1cccnc1Oc1ccc(Nc2ccccn2)cc1,"InChI=1S/C22H18N4O2/c1-27-21-15-16(11-14-24-21)19-5-4-13-25-22(19)28-18-9-7-17(8-10-18)26-20-6-2-3-12-23-20/h2-15H,1H3,(H,23,26)",NNGQJZZBQQNMCU-UHFFFAOYSA-N,115311,"US8637500, 129","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Rattus norvegicus, 7.393
50907562,COc1ccc2NC(=O)C(=Cc3cnc[nH]3)c2c1,"InChI=1S/C13H11N3O2/c1-18-9-2-3-12-10(5-9)11(13(17)16-12)4-8-6-14-7-15-8/h2-7H,1H3,(H,14,15)(H,16,17)",QNUKRWAIZMBVCU-UHFFFAOYSA-N,7238,"(3Z)-3-(1H-imidazol-5-ylmethylidene)-5-methoxy-2,3-dihydro-1H-indol-2-one::3-(3H-Imidazol-4-ylmethylene)-5-methoxy-1,3-dihydro-indol-2-one::SU9516::cid_5289419::imidazole indolinone driv.",Proto-oncogene tyrosine-protein kinase receptor Ret,Homo sapiens, 1600
50951706,CC(C)C(NC(=O)NC(C)(C)C)C(=O)c1ccc(Cl)cc1,"InChI=1S/C16H23ClN2O2/c1-10(2)13(18-15(21)19-16(3,4)5)14(20)11-6-8-12(17)9-7-11/h6-10,13H,1-5H3,(H2,18,19,21)",OPWGBOAEYGMIKX-UHFFFAOYSA-N,50390462,CHEMBL2071587,Transient receptor potential cation channel subfamily A member 1,, 2511.89
50253372,CC[C@@H]1N=C(N)O[C@H]1C,"InChI=1S/C6H12N2O/c1-3-5-4(2)9-6(7)8-5/h4-5H,3H2,1-2H3,(H2,7,8)/t4-,5-/m0/s1",KHXXSTHNMREFPM-WHFBIAKZSA-N,50138187,"(4S,5S)-4-Ethyl-5-methyl-oxazolidin-(2Z)-ylideneamine::CHEMBL105830","Nitric oxide synthase, inducible",Mus musculus, 170
634199,CC(C)(C)c1nc(-c2ccc(F)nc2)c2nnn(Cc3ccccc3Cl)c2n1,"InChI=1S/C20H18ClFN6/c1-20(2,3)19-24-16(12-8-9-15(22)23-10-12)17-18(25-19)28(27-26-17)11-13-6-4-5-7-14(13)21/h4-10H,11H2,1-3H3",JKBPPZMJKCLZOC-UHFFFAOYSA-N,322975,"5-tert-butyl-3-[(2-chlorophenyl)methyl]-7-(6-fluoropyridin-3-yl)triazolo[4,5-d]pyrimidine::US10183946, Example 6",Cannabinoid receptor 1,Homo sapiens,
50360735,Nc1c(Cl)cc(cc1Cl)C(=O)N(C1CC1)[C@H]1CC[C@H](CC1)C(=O)NCC(O)=O,"InChI=1S/C19H23Cl2N3O4/c20-14-7-11(8-15(21)17(14)22)19(28)24(13-5-6-13)12-3-1-10(2-4-12)18(27)23-9-16(25)26/h7-8,10,12-13H,1-6,9,22H2,(H,23,27)(H,25,26)/t10-,12+",PIVHVYCTSLIOPL-KLPPZKSPSA-N,50195490,"2-((1s,4s)-4-(4-amino-3,5-dichloro-N-cyclopropylbenzamido)cyclohexanecarboxamido)acetic acid::CHEMBL374318",11-beta-hydroxysteroid dehydrogenase 1,Homo sapiens,
231268,CCN(CCF)S(=O)(=O)NC(=O)[C@]1(C[C@H]1C=C)NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)[C@]21CCC1,"InChI=1S/C45H74FN7O7S/c1-10-31-26-45(31,40(58)50-61(59,60)51(11-2)25-23-46)49-37(55)33-27-44(42(8,9)43(44)21-17-22-43)28-53(33)39(57)35(41(5,6)7)48-38(56)34(30-18-13-12-14-19-30)47-36(54)32-20-15-16-24-52(32)29(3)4/h10,29-35H,1,11-28H2,2-9H3,(H,47,54)(H,48,56)(H,49,55)(H,50,58)/t31-,32+,33+,34+,35-,44-,45-/m1/s1",XFYOTNPRWVBFPP-LDFRYFKTSA-N,110382,"US8613914, 156::US9206232, 156",Genome polyprotein,Hepatitis C virus, 1.3
153714,CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc(nn1)C1(N)CCNCC1,"InChI=1S/C20H25F4N5O2/c1-2-3-4-14(29-10-16(27-28-29)20(25)5-7-26-8-6-20)15(30)11-31-19-17(23)12(21)9-13(22)18(19)24/h9-10,14,26H,2-8,11,25H2,1H3",QQEWYMAAWBFRBU-UHFFFAOYSA-N,81410,ML4162,Dipeptidyl peptidase 1,Mus musculus,>20000
620710,O=c1[nH]nc2CCCCc3[nH]c4cccc1c4c23,"InChI=1S/C14H13N3O/c18-14-8-4-3-7-9-12(8)13-10(15-9)5-1-2-6-11(13)16-17-14/h3-4,7,15H,1-2,5-6H2,(H,17,18)",FLCHMGRFSJQORK-UHFFFAOYSA-N,207557,"US9260440, 2::US9617273, Example 2",Poly [ADP-ribose] polymerase 2,, 1100
50276845,CC(C)(C)OC(=O)NCCCC(=O)NCCc1ccc(cc1)S(N)(=O)=O,"InChI=1S/C17H27N3O5S/c1-17(2,3)25-16(22)20-11-4-5-15(21)19-12-10-13-6-8-14(9-7-13)26(18,23)24/h6-9H,4-5,10-12H2,1-3H3,(H,19,21)(H,20,22)(H2,18,23,24)",CNVDNCXHNMHAIL-UHFFFAOYSA-N,50049519,CHEMBL3314168,Carbonic anhydrase 1,Homo sapiens,
50841735,COc1ccc(F)cc1C(C)(C)CC(O)(Cn1ccc(=O)c2ccccc12)C(F)(F)F,"InChI=1S/C23H23F4NO3/c1-21(2,17-12-15(24)8-9-20(17)31-3)13-22(30,23(25,26)27)14-28-11-10-19(29)16-6-4-5-7-18(16)28/h4-12,30H,13-14H2,1-3H3",PVYTWCNJUWKUOG-UHFFFAOYSA-N,50201109,1-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]-1H-quinolin-4-one::CHEMBL386465,Mineralocorticoid receptor,Homo sapiens, 120
499449,O=C(N[C@H]1CC[C@H](CCN2CCN(CC2)c2nsc3ccccc23)CC1)c1cc2ccccc2s1,"InChI=1S/C28H32N4OS2/c33-28(26-19-21-5-1-3-7-24(21)34-26)29-22-11-9-20(10-12-22)13-14-31-15-17-32(18-16-31)27-23-6-2-4-8-25(23)35-30-27/h1-8,19-20,22H,9-18H2,(H,29,33)/t20-,22-",PDADFIJOFSWDJB-AQYVVDRMSA-N,263372,"US9550741, I-6",D(2) dopamine receptor,Homo sapiens,
50905446,CCCc1ncc2Cc3c(ncn3-c3ccccc3-c2n1)C(=O)OCC,"InChI=1S/C20H20N4O2/c1-3-7-17-21-11-13-10-16-19(20(25)26-4-2)22-12-24(16)15-9-6-5-8-14(15)18(13)23-17/h5-6,8-9,11-12H,3-4,7,10H2,1-2H3",ISAMWRRMVCVCCO-UHFFFAOYSA-N,50378524,CHEMBL584546,Gamma-aminobutyric acid receptor subunit alpha-5/beta-3/gamma-2,Homo sapiens,
659605,OC(c1nccs1)c1ccc(F)c(c1)-c1ncnc2cc(sc12)N1CCOCC1,"InChI=1S/C20H17FN4O2S2/c21-14-2-1-12(18(26)20-22-3-8-28-20)9-13(14)17-19-15(23-11-24-17)10-16(29-19)25-4-6-27-7-5-25/h1-3,8-11,18,26H,4-7H2",AIDFNPQAXSJWSH-UHFFFAOYSA-N,315723,"US10172859, Example 144::US10172859, Example 145::US10172859, Example 146::US11065253, Example 146::US9732094, Example 146::[4-Fluoro-3-(6- morpholin-4-yl- thieno[3,2-d}- pyrimidin-4-yl)- phenyl]thiazol-2- yl-methanol1H NMR (500 MHz, DMSO-d6) ppm = 8.89 (s,1H), 7.76 (dd, J = 7.0, 2.3, 1H), 7.73 (d, J = 3.2,1H), 7.69-7.64 (m, 2H), 7.43-7.38 (m, 1H),6.96 (d, J = 4.6, 1H), 6.53 (s, 1H), 6.07 (d,J = 4.6, 1H), 3.77-3.71 (m, 4H), 3.44-3.38 (m,4H)",DNA-dependent protein kinase catalytic subunit,Homo sapiens,<3
696411,COc1ccc(F)cc1-c1c(cnc2[nH]c(cc12)C1CCN(CC(=O)N(C)C)CC1)C#N,"InChI=1S/C24H26FN5O2/c1-29(2)22(31)14-30-8-6-15(7-9-30)20-11-19-23(16(12-26)13-27-24(19)28-20)18-10-17(25)4-5-21(18)32-3/h4-5,10-11,13,15H,6-9,14H2,1-3H3,(H,27,28)",NDTXKBSFGOQMPJ-UHFFFAOYSA-N,167784,"US9073922, 275::US9796708, Example 275",Cyclin-T1/Cyclin-dependent kinase 9,Homo sapiens, 90.0
50255129,ClCCC(=O)N1CCN(CC1)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1,"InChI=1S/C22H22ClN3O2/c23-10-9-21(27)26-13-11-25(12-14-26)17-7-5-16(6-8-17)15-19-18-3-1-2-4-20(18)24-22(19)28/h1-8,15H,9-14H2,(H,24,28)/b19-15-",LSMZOIVOZFFQQJ-CYVLTUHYSA-N,50037258,CHEMBL3356290,Aurora kinase B,Homo sapiens, 587
505573,Cc1ccc(Cn2\c(=N\c3cccc(c3F)C(F)(F)F)[nH]c(=O)n(CCC(O)=O)c2=O)cc1,"InChI=1S/C21H18F4N4O4/c1-12-5-7-13(8-6-12)11-29-18(27-19(32)28(20(29)33)10-9-16(30)31)26-15-4-2-3-14(17(15)22)21(23,24)25/h2-8H,9-11H2,1H3,(H,30,31)(H,26,27,32)",UQDNDHAICJQXSJ-UHFFFAOYSA-N,266011,"US9718790, I-2086",P2X purinoceptor 3,Homo sapiens, 234
592198,Cn1cnc(c1)S(=O)(=O)N1C[C@@H](Nc2ccc(F)c(Cl)c2)[C@@H](C1)c1ccccc1,"InChI=1S/C20H20ClFN4O2S/c1-25-12-20(23-13-25)29(27,28)26-10-16(14-5-3-2-4-6-14)19(11-26)24-15-7-8-18(22)17(21)9-15/h2-9,12-13,16,19,24H,10-11H2,1H3/t16-,19+/m0/s1",OAGSQIPRTHVASO-QFBILLFUSA-N,308701,"US9656955, Example 215::trans-N-(3-chloro-4-fluorophenyl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-phenylpyrrolidin-3-amine","Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase",Homo sapiens,
613912,CCOc1cc(-c2ccc(nc2)N2CCC(CN3CCN(CC)[C@H](C)C3)(CC2)C(=O)NCC(C)C)c2c(cnn2c1)C#N,"InChI=1S/C33H46N8O2/c1-6-39-15-14-38(21-25(39)5)23-33(32(42)36-18-24(3)4)10-12-40(13-11-33)30-9-8-26(19-35-30)29-16-28(43-7-2)22-41-31(29)27(17-34)20-37-41/h8-9,16,19-20,22,24-25H,6-7,10-15,18,21,23H2,1-5H3,(H,36,42)/t25-/m1/s1",QNAHRFJLRIRZMM-RUZDIDTESA-N,305636,"US10144734, Example 654::US10172845, Example 654::US10441581, Example 654::US10881652, Example 654",Proto-oncogene tyrosine-protein kinase receptor Ret [G810R],, 114
1176541,FC1CC(C1)n1cnc(c1-c1ccc2ncc(C#N)n2n1)-c1ccc(F)c(Cl)c1,"InChI=1S/C20H13ClF2N6/c21-15-5-11(1-2-16(15)23)19-20(28(10-26-19)13-6-12(22)7-13)17-3-4-18-25-9-14(8-24)29(18)27-17/h1-5,9-10,12-13H,6-7H2",QTSUEIBSKWPOLS-UHFFFAOYSA-N,282899,"6-(4-(3-chloro-4-fluorophenyl)-1-(3-fluorocyclobutyl)- 1H-imidazol-5-yl)imidazo[1,2-b]pyridazine-3- carbonitrile::US10287295, Example 104'::US11352360, Example 104'::US9884868, Example 104'",TGF-beta receptor type-1,, 0.500
50854004,CS(=O)(=O)NC(=O)CCCc1c([nH]c2ccc(cc12)C#N)-c1ccc(F)cc1,"InChI=1S/C20H18FN3O3S/c1-28(26,27)24-19(25)4-2-3-16-17-11-13(12-22)5-10-18(17)23-20(16)14-6-8-15(21)9-7-14/h5-11,23H,2-4H2,1H3,(H,24,25)",OVTPSSRHMPJRCX-UHFFFAOYSA-N,50236305,4-(5-cyano-2-(4-fluorophenyl)-1H-indol-3-yl)-N-(methylsulfonyl)butanamide::CHEMBL440405,C-X-C chemokine receptor type 2,Oryctolagus cuniculus, 2100
50153574,COc1cc(cc(OC)c1OC)-c1cc(=O)c2cc(O)ccc2o1,"InChI=1S/C18H16O6/c1-21-16-6-10(7-17(22-2)18(16)23-3)15-9-13(20)12-8-11(19)4-5-14(12)24-15/h4-9,19H,1-3H3",ZSGFQNBMEKWZEV-UHFFFAOYSA-N,50025558,CHEMBL519022,Tyrosine-protein kinase Lck,, 2
750716,CC(C)n1cc(C(=O)Nc2ccc(Oc3cc(cn4nccc34)N3CCS(=O)(=O)CC3)c(F)c2)c(=O)n(-c2ccc(F)cc2)c1=O,"InChI=1S/C31H28F2N6O6S/c1-19(2)37-18-24(30(41)39(31(37)42)22-6-3-20(32)4-7-22)29(40)35-21-5-8-27(25(33)15-21)45-28-16-23(17-38-26(28)9-10-34-38)36-11-13-46(43,44)14-12-36/h3-10,15-19H,11-14H2,1-2H3,(H,35,40)",JUEGXARGWCNIPG-UHFFFAOYSA-N,375853,"US9914731, Ex. No. 74",Tyrosine-protein kinase receptor UFO,, 55
50245168,O=C(NCCCCN1CCN(CC1)c1ccccc1)c1cc2ccccc2o1,"InChI=1S/C23H27N3O2/c27-23(22-18-19-8-4-5-11-21(19)28-22)24-12-6-7-13-25-14-16-26(17-15-25)20-9-2-1-3-10-20/h1-5,8-11,18H,6-7,12-17H2,(H,24,27)",CAWFRCMJYFIMLP-UHFFFAOYSA-N,50031448,CHEMBL3358494,D(2) dopamine receptor,Homo sapiens,
631094,Fc1ccccc1Cn1nc(cc1-c1ccon1)-c1nccc(NS(=O)(=O)CC(F)(F)F)n1,"InChI=1S/C19H14F4N6O3S/c20-13-4-2-1-3-12(13)10-29-16(14-6-8-32-27-14)9-15(26-29)18-24-7-5-17(25-18)28-33(30,31)11-19(21,22)23/h1-9H,10-11H2,(H,24,25,28)",AXCYEGAZZZCENL-UHFFFAOYSA-N,321763,"US10183021, Compound I-444",Guanylate cyclase soluble subunit alpha-1,,
50244503,Cc1noc(C)c1-c1ccc(cc1)-c1nc2cnccn2c1NC(C)(C)C,"InChI=1S/C21H23N5O/c1-13-18(14(2)27-25-13)15-6-8-16(9-7-15)19-20(24-21(3,4)5)26-11-10-22-12-17(26)23-19/h6-12,24H,1-5H3",YXPVTKHEWGXKEY-UHFFFAOYSA-N,50030894,CHEMBL3356559,Transcription initiation factor TFIID subunit 1,,
50426680,Nc1nc(N)c2c(CCCc3cc(cs3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)coc2n1,"InChI=1S/C19H21N5O6S/c20-15-14-9(7-30-17(14)24-19(21)23-15)2-1-3-11-6-10(8-31-11)16(27)22-12(18(28)29)4-5-13(25)26/h6-8,12H,1-5H2,(H,22,27)(H,25,26)(H,28,29)(H4,20,21,23,24)/t12-/m0/s1",YSCGOYFEYRSGDL-LBPRGKRZSA-N,50126175,CHEMBL3628347,Folate receptor alpha,Homo sapiens,>1000
727861,CN1CCc2cc(ccc2C(C1)NC(=O)c1cn(nn1)C(C)(C)C)-c1ccnc(Nc2cnn(C)c2)n1,"InChI=1S/C26H32N10O/c1-26(2,3)36-16-23(32-33-36)24(37)30-22-15-34(4)11-9-17-12-18(6-7-20(17)22)21-8-10-27-25(31-21)29-19-13-28-35(5)14-19/h6-8,10,12-14,16,22H,9,11,15H2,1-5H3,(H,30,37)(H,27,29,31)",UQBXNYTXHLBRME-UHFFFAOYSA-N,324360,"1-(tert-butyl)-N-(3- methyl-7-(2-((1- methyl-1H-pyrazol-4- yl)amino)pyrimidin-4- yl)-2,3,4,5-tetrahydro- 1H-benzo[d]azepin-1- yl)-1H-1,2,3-triazole-4- carboxamide::US10189829, Compound 52::US10227341, Compound 52::US10961237, Compound 52",Tyrosine-protein kinase BTK,Homo sapiens, 5.50
51043749,Cc1nn(C)c2n(Cc3ccccc3)cc(C(=O)NC3CCCCC3)c(=O)c12,"InChI=1S/C22H26N4O2/c1-15-19-20(27)18(21(28)23-17-11-7-4-8-12-17)14-26(22(19)25(2)24-15)13-16-9-5-3-6-10-16/h3,5-6,9-10,14,17H,4,7-8,11-13H2,1-2H3,(H,23,28)",JYEFPJKEFHNPMZ-UHFFFAOYSA-N,50426113,CHEMBL2316292,Cannabinoid receptor 1,Rattus norvegicus,
368555,Fc1ccc(nc1)-c1ccn(CC2OCCCN2C(=O)c2cc(F)ccc2-c2ncccn2)n1,"InChI=1S/C24H20F2N6O2/c25-16-3-5-18(23-27-8-1-9-28-23)19(13-16)24(33)32-10-2-12-34-22(32)15-31-11-7-21(30-31)20-6-4-17(26)14-29-20/h1,3-9,11,13-14,22H,2,10,12,15H2",YZRHBGIKWQSFJJ-UHFFFAOYSA-N,208518,"US9266870, 34",Orexin receptor type 2,Homo sapiens, 6.2
50924782,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3CNC(=O)c3c3-c4cn(C)nc4CCc3c12,"InChI=1S/C28H27N7O/c1-15(2)13-35-22-8-5-16(32-28-29-9-4-10-30-28)11-18(22)24-19-12-31-27(36)25(19)23-17(26(24)35)6-7-21-20(23)14-34(3)33-21/h4-5,8-11,14-15H,6-7,12-13H2,1-3H3,(H,31,36)(H,29,30,32)",AEULIVPVIDOLIN-UHFFFAOYSA-N,50379186,CEP-11981::CHEMBL2010872,Macrophage colony-stimulating factor 1 receptor,, 78
475460,CCS(=O)(=O)Nc1cccc(c1)-c1ccc(cn1)[C@H]1C[C@@H]1N,"InChI=1S/C16H19N3O2S/c1-2-22(20,21)19-13-5-3-4-11(8-13)16-7-6-12(10-18-16)14-9-15(14)17/h3-8,10,14-15,19H,2,9,17H2,1H3/t14-,15+/m1/s1",IXIZAMPTBONALH-CABCVRRESA-N,179864,"US9676701, 98 N-(3-(5-((trans)-2-aminocyclopropyl)pyridin-2-yl)phenyl)ethanesulfonamide hydrochloride",Lysine-specific histone demethylase 1A,Homo sapiens,
51171114,CCN(CC)C(=O)CC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C)C(=O)c1nccs1,"InChI=1S/C31H45N5O6S/c1-7-36(8-2)25(37)15-14-23(27(38)30-32-16-17-43-30)33-28(39)24(18-20(3)4)34-29(40)26(21(5)6)35-31(41)42-19-22-12-10-9-11-13-22/h9-13,16-17,20-21,23-24,26H,7-8,14-15,18-19H2,1-6H3,(H,33,39)(H,34,40)(H,35,41)/t23-,24-,26-/m0/s1",HOSKYYVLDSUHCJ-GNKBHMEESA-N,50480496,CHEMBL555221,Replicase polyprotein 1ab,Human SARS coronavirus,
51254691,CC(=O)N1CCC(CC1)C(=O)N1N=CC[C@H]1c1ccccc1,"InChI=1S/C17H21N3O2/c1-13(21)19-11-8-15(9-12-19)17(22)20-16(7-10-18-20)14-5-3-2-4-6-14/h2-6,10,15-16H,7-9,11-12H2,1H3/t16-/m0/s1",RAZBNWZNUFECAN-INIZCTEOSA-N,50512989,CHEMBL4474320,Receptor-interacting serine/threonine-protein kinase 1,, 10.0
50432480,Cc1cc(COc2ccc(cc2)C(=O)NCC2(N3CCN(CC3)S(C)(=O)=O)C(=O)NC(=O)NC2=O)c2ccccc2n1,"InChI=1S/C28H30N6O7S/c1-18-15-20(22-5-3-4-6-23(22)30-18)16-41-21-9-7-19(8-10-21)24(35)29-17-28(25(36)31-27(38)32-26(28)37)33-11-13-34(14-12-33)42(2,39)40/h3-10,15H,11-14,16-17H2,1-2H3,(H,29,35)(H2,31,32,36,37,38)",FMMBVZGWJZFRLY-UHFFFAOYSA-N,50195898,"4-((2-methylquinolin-4-yl)methoxy)-N-((5-(4-(methylsulfonyl)piperazin-1-yl)-2,4,6-trioxo-hexahydropyrimidin-5-yl)methyl)benzamide::4-((2-methylquinolin-4-yl)methoxy)-N-((5-(4-(methylsulfonyl)piperazin-1-yl)-2,4,6-trioxohexahydropyrimidin-5-yl)methyl)benzamide::CHEMBL395880",Matrilysin,Homo sapiens,
50338308,CC(=O)c1c(O)c(OCc2ccccc2)c2occc2c1OCc1ccccc1,"InChI=1S/C24H20O5/c1-16(25)20-21(26)24(29-15-18-10-6-3-7-11-18)23-19(12-13-27-23)22(20)28-14-17-8-4-2-5-9-17/h2-13,26H,14-15H2,1H3",LLIUIMCUXHPION-UHFFFAOYSA-N,50182597,"5-acetyl-4,7-benzyloxy-6-hydroxybenzofuran::CHEMBL203909",Potassium voltage-gated channel subfamily A member 2,Homo sapiens,
50056733,COc1ccc(cc1O)-c1c2c(n3ccc4cc(OC)c(OC)cc4c13)c(=O)oc1cc(OS([O-])(=O)=O)c(OC)cc21,"InChI=1S/C29H23NO11S/c1-36-19-6-5-15(9-18(19)31)25-26-17-12-23(39-4)24(41-42(33,34)35)13-20(17)40-29(32)28(26)30-8-7-14-10-21(37-2)22(38-3)11-16(14)27(25)30/h5-13,31H,1-4H3,(H,33,34,35)/p-1",JMOHRMCZYHDLSW-UHFFFAOYSA-M,50077357,"14-(3-hydroxy-4-methoxyphenyl)-2,11,12-trimethoxy-6H-chromeno[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one-2-sulphonyl sodium::CHEMBL430776",Integrase,Human immunodeficiency virus 1, 8000
73288,Cc1cccc2cc3CN(Cc4ccco4)\C(Sc3nc12)=N\CC1CCCO1,"InChI=1S/C22H23N3O2S/c1-15-5-2-6-16-11-17-13-25(14-19-8-4-10-27-19)22(28-21(17)24-20(15)16)23-12-18-7-3-9-26-18/h2,4-6,8,10-11,18H,3,7,9,12-14H2,1H3/b23-22-",NWBNUVKWUXHDII-FCQUAONHSA-N,39084,"3-(2-furanylmethyl)-9-methyl-N-(2-oxolanylmethyl)-4H-[1,3]thiazino[6,5-b]quinolin-2-imine::3-(furan-2-ylmethyl)-9-methyl-N-(oxolan-2-ylmethyl)-4H-[1,3]thiazino[6,5-b]quinolin-2-imine::MLS000032944::SMR000005542::[3-(2-furfuryl)-9-methyl-4H-[1,3]thiazino[6,5-b]quinolin-2-ylidene]-(tetrahydrofurfuryl)amine::[3-Furan-2-ylmethyl-8-methyl-3,4-dihydro-1-thia-3,9-diaza-anthracen-(2E)-ylidene]-(tetrahydro-furan-2-ylmethyl)-amine::cid_653192",Steroidogenic factor 1,Homo sapiens, 63660
50936164,C[C@H]1COCCN1c1cc(CS(C)(=O)=O)nc(n1)-c1ccc2[nH]ccc2c1,"InChI=1S/C19H22N4O3S/c1-13-11-26-8-7-23(13)18-10-16(12-27(2,24)25)21-19(22-18)15-3-4-17-14(9-15)5-6-20-17/h3-6,9-10,13,20H,7-8,11-12H2,1-2H3/t13-/m0/s1",XMHSFTLIAYTIQQ-ZDUSSCGKSA-N,50384251,CHEMBL2030446,Serine/threonine-protein kinase mTOR,Homo sapiens, 303
436402,COc1ccc(nc1)C(=O)Nc1ccc(cc1)C1CCNC1,"InChI=1S/C17H19N3O2/c1-22-15-6-7-16(19-11-15)17(21)20-14-4-2-12(3-5-14)13-8-9-18-10-13/h2-7,11,13,18H,8-10H2,1H3,(H,20,21)",NFRDYVXNBLCOIP-UHFFFAOYSA-N,250184,"US10501411, Example 94::US9452980, 94",Trace amine-associated receptor 1,Rattus norvegicus,
50508545,CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C,"InChI=1S/C16H18N3S/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13/h5-10H,1-4H3/q+1",RBTBFTRPCNLSDE-UHFFFAOYSA-N,50241461,"3,7-bis(dimethylamino)phenothiazin-5-ium chloride::Basic Blue 9::CHEMBL405110::Methylenblau::Methylene Blue anhydrous::Methylene blue::Methylene blue (10)::SAMPL5, CBC-G10::azul de metileno::bleu de methylene::cid_6099::methylthioninium chloride","Dihydrolipoyl dehydrogenase, mitochondrial",Sus scrofa,>1000000
50589101,CC(=O)NCCNc1cccc2ccccc12,"InChI=1S/C14H16N2O/c1-11(17)15-9-10-16-14-8-4-6-12-5-2-3-7-13(12)14/h2-8,16H,9-10H2,1H3,(H,15,17)",HZYHRPXUOHTHQR-UHFFFAOYSA-N,50323750,"2,2,2-Trifluoro-N-(2-(naphthalen-1-ylamino)-acetamide::CHEMBL1214323",Carbonic anhydrase 3,Homo sapiens,
684441,CCOC(=O)c1c(C)[nH]c2c1c(cn(C)c2=O)C#CC1(O)CCCCC1,"InChI=1S/C20H24N2O4/c1-4-26-19(24)15-13(2)21-17-16(15)14(12-22(3)18(17)23)8-11-20(25)9-6-5-7-10-20/h12,21,25H,4-7,9-10H2,1-3H3",WLTWGIAEBTYAAZ-UHFFFAOYSA-N,346468,"US10202378, Example 81::ethyl 4-[2-(1-hydroxycyclohexyl)ethynyl]-2,6-dimethyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-3-carboxylate",Transcription initiation factor TFIID subunit 1 [1504-1635],, 63.2
968709,CCn1cc(c(n1)C(F)(F)F)-c1cc(CNC(=N)C2CCOC2)cc(c1)C(=O)N[C@@H](C1CC1)c1ccc(F)c(C)c1,"InChI=1S/C30H33F4N5O2/c1-3-39-15-24(27(38-39)30(32,33)34)22-11-18(14-36-28(35)21-8-9-41-16-21)12-23(13-22)29(40)37-26(19-4-5-19)20-6-7-25(31)17(2)10-20/h6-7,10-13,15,19,21,26H,3-5,8-9,14,16H2,1-2H3,(H2,35,36)(H,37,40)/t21?,26-/m0/s1",XPEWSUMUZIKCHW-UQTORGHUSA-N,468838,"US10807959, Example 108",WD repeat-containing protein 5,,
95038,CC1CCCCC1NC(=O)CN1C(=O)c2cccc(N)c2C1=O,"InChI=1S/C17H21N3O3/c1-10-5-2-3-8-13(10)19-14(21)9-20-16(22)11-6-4-7-12(18)15(11)17(20)23/h4,6-7,10,13H,2-3,5,8-9,18H2,1H3,(H,19,21)",OOGAHNNWQMSGNQ-UHFFFAOYSA-N,51211,"2-(4-amino-1,3-diketo-isoindolin-2-yl)-N-(2-methylcyclohexyl)acetamide::2-(4-amino-1,3-dioxo-2-isoindolyl)-N-(2-methylcyclohexyl)acetamide::2-(4-amino-1,3-dioxoisoindol-2-yl)-N-(2-methylcyclohexyl)acetamide::2-[4-azanyl-1,3-bis(oxidanylidene)isoindol-2-yl]-N-(2-methylcyclohexyl)ethanamide::MLS001003307::SMR000344768::cid_3590153",Glycoprotein 42,Human herpesvirus 4 type 2,2020.0
51454501,CN(C)CCNC(=O)c1cncc(c1)-c1cccc(c1)C(=O)N[C@H]1CN[C@H](C1)C(=O)Nc1ccc(Cl)c(c1)C(F)(F)F,"InChI=1S/C29H30ClF3N6O3/c1-39(2)9-8-35-26(40)20-11-19(14-34-15-20)17-4-3-5-18(10-17)27(41)38-22-13-25(36-16-22)28(42)37-21-6-7-24(30)23(12-21)29(31,32)33/h3-7,10-12,14-15,22,25,36H,8-9,13,16H2,1-2H3,(H,35,40)(H,37,42)(H,38,41)/t22-,25-/m1/s1",OQXRMEANXAJBPJ-RCZVLFRGSA-N,50587248,CHEMBL5071546,Breakpoint cluster region protein/Tyrosine-protein kinase ABL1,Homo sapiens, 2410
231065,CCCNC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(O)=O,"InChI=1S/C18H29N3O6/c1-4-8-19-15(22)13-14(27-13)16(23)20-12(10(3)5-2)17(24)21-9-6-7-11(21)18(25)26/h10-14H,4-9H2,1-3H3,(H,19,22)(H,20,23)(H,25,26)/t10-,11-,12-,13-,14-/m0/s1",ZEZGJKSEBRELAS-PEDHHIEDSA-N,16509,"(2S)-1-[(2S,3S)-3-methyl-2-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]formamido}pentanoyl]pyrrolidine-2-carboxylic acid::CA074::CHEMBL490920::N-{[(2S,3S)-3-(propylcarbamoyl)oxiran-2-yl]carbonyl}-L-isoleucyl-L-proline::PrNH-tES-Ile-Pro-OH::epoxysuccinyl derivative CA074",Procathepsin L,Homo sapiens,>1.00e+5
1120085,NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cccc(c1)C#N)C(F)(F)F,"InChI=1S/C30H27F3N6O/c31-30(32,33)27-15-26(39(38-27)25-9-2-5-21(13-25)17-35)29(40)37-24-8-3-7-23(14-24)28(36-18-19-10-11-19)22-6-1-4-20(12-22)16-34/h1-9,12-15,19,28,36H,10-11,17-18,35H2,(H,37,40)",VQJJJCIJWBDLSJ-UHFFFAOYSA-N,416879,"1-(3-(aminomethyl)phenyl)-N-(3-((3-cyanophenyl)(cyclopropylmethyl amino)methyl)phenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide::US10329260, Compound 152d::US10633345, Compound 152d::US10689346, Compound 152d::US11203574, Compound 152d::US11230530, Compound 152d",Plasma kallikrein,,
72376,CCCCOc1ncnc2c3cc(F)ccc3[nH]c12,"InChI=1S/C14H14FN3O/c1-2-3-6-19-14-13-12(16-8-17-14)10-7-9(15)4-5-11(10)18-13/h4-5,7-8,18H,2-3,6H2,1H3",RNRSUFSQCJVVCE-UHFFFAOYSA-N,36929,"4-butoxy-8-fluoranyl-5H-pyrimido[5,4-b]indole::4-butoxy-8-fluoro-5H-pyrimid[5,4-b]indole::4-butoxy-8-fluoro-5H-pyrimido[5,4-b]indole::MLS000041486::SMR000044810::cid_663916",Isoform 2 of Nuclear receptor ROR-alpha (Alpha-2),Homo sapiens, 13040
541930,COc1ncc(F)cc1CN1CCN(CC1)c1ccc(cn1)-c1cc(cn2ncc(C#N)c12)-c1cnn(C)c1,"InChI=1S/C28H26FN9O/c1-35-16-23(14-33-35)20-10-25(27-22(11-30)13-34-38(27)18-20)19-3-4-26(31-12-19)37-7-5-36(6-8-37)17-21-9-24(29)15-32-28(21)39-2/h3-4,9-10,12-16,18H,5-8,17H2,1-2H3",XKGRZWPYAYDGKY-UHFFFAOYSA-N,284447,"4-(6-(4-((5-fluoro-2- methoxypyridin-3- yl)methyl)piperazin-1- yl)pyridin-3-yl)-6-(1- methyl-1H-pyrazol-4- yl)pyrazolo[1,5-a]pyridine- 3-carbonitrile::US10023570, Example 457::US10174027, Example 457",Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114],, 13.1
50090048,COc1cc2c(Oc3ccc(NS(=O)(=O)c4cccc(c4)-c4ccoc4)cc3F)ccnc2cc1OCCCN1CCOCC1,"InChI=1S/C33H32FN3O7S/c1-40-32-20-27-29(21-33(32)43-14-3-11-37-12-16-41-17-13-37)35-10-8-30(27)44-31-7-6-25(19-28(31)34)36-45(38,39)26-5-2-4-23(18-26)24-9-15-42-22-24/h2,4-10,15,18-22,36H,3,11-14,16-17H2,1H3",PDVPMUDAAPKQBR-UHFFFAOYSA-N,50010384,CHEMBL3263960,Insulin receptor,Homo sapiens,>12500
1149347,NC1CCCN(C1)C1CC(CC1n1cccn1)c1ccc(F)cc1,"InChI=1S/C19H25FN4/c20-16-6-4-14(5-7-16)15-11-18(23-9-1-3-17(21)13-23)19(12-15)24-10-2-8-22-24/h2,4-8,10,15,17-19H,1,3,9,11-13,21H2",MZAOLBDFKVMZHQ-UHFFFAOYSA-N,542437,"1-[4-(4-fluorophenyl)-2-pyrazol-1-yl-cyclopentyl] piperidin-3-amine::US11274091, Example 8",Short transient receptor potential channel 3,Homo sapiens, 7.97
1235910,CC(NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#CC3(O)CN4CCC3CC4)c2c(=O)n1-c1ccccc1,"InChI=1S/C33H31N7O3/c1-21(36-31(41)28-29(34)37-39-16-6-15-35-30(28)39)26-19-23-8-5-7-22(11-14-33(43)20-38-17-12-24(33)13-18-38)27(23)32(42)40(26)25-9-3-2-4-10-25/h2-10,15-16,19,21,24,43H,12-13,17-18,20H2,1H3,(H2,34,37)(H,36,41)",GBPGXWBBGSRQDS-UHFFFAOYSA-N,588125,"US11541059, Compound 62","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Homo sapiens, 2000
51421485,Clc1ccc(CNc2ncc(C(=O)NCCCN3CCCC3=O)c(NC3CCCC3)n2)c(Cl)c1,"InChI=1S/C24H30Cl2N6O2/c25-17-9-8-16(20(26)13-17)14-28-24-29-15-19(22(31-24)30-18-5-1-2-6-18)23(34)27-10-4-12-32-11-3-7-21(32)33/h8-9,13,15,18H,1-7,10-12,14H2,(H,27,34)(H2,28,29,30,31)",RUAVAAXWRAUNAC-UHFFFAOYSA-N,50574221,CHEMBL4847568,Peripheral plasma membrane protein CASK,Homo sapiens,
300700,FC(F)Oc1cccc(CNC(=O)Nc2ccc(cc2F)[C@H]2CNCCO2)c1,"InChI=1S/C19H20F3N3O3/c20-15-9-13(17-11-23-6-7-27-17)4-5-16(15)25-19(26)24-10-12-2-1-3-14(8-12)28-18(21)22/h1-5,8-9,17-18,23H,6-7,10-11H2,(H2,24,25,26)/t17-/m1/s1",QWRFRBFGFHDFNT-QGZVFWFLSA-N,158284,"US9029370, 78",Trace amine-associated receptor 1,Mus musculus,
582852,Cc1cccc(CNC(=O)c2nn(CCO)c3CCN(Cc4c[nH]c5ccccc45)Cc23)c1,"InChI=1S/C26H29N5O2/c1-18-5-4-6-19(13-18)14-28-26(33)25-22-17-30(10-9-24(22)31(29-25)11-12-32)16-20-15-27-23-8-3-2-7-21(20)23/h2-8,13,15,27,32H,9-12,14,16-17H2,1H3,(H,28,33)",URSCQDBITYKHCI-UHFFFAOYSA-N,303969,"US10138242, Compound 55",PEX5-related protein/Peroxisomal membrane protein PEX14,, 78570
1111002,C[C@H]1CN(Cc2ccc(F)c(c2)-c2ccc(N3CCN(C)CC3)c(NC(=O)c3c[nH]c(=O)cc3C(F)(F)F)c2)C[C@@H](C)O1,,,525583,"US11174250, Example 1",P61964[22-334]/Q03164[3745-3969]/Q15291/Q9C005/Q9UBL3[2-534],, 764
1135199,C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C(C)(C)O,"InChI=1S/C19H23N5O2/c1-12-11-26-9-8-24(12)16-10-15(19(2,3)25)22-18(23-16)14-5-7-21-17-13(14)4-6-20-17/h4-7,10,12,25H,8-9,11H2,1-3H3,(H,20,21)/t12-/m1/s1",LKROHSRCVLZJLI-GFCCVEGCSA-N,535718,"US11236089, Compound CY-212",Serine/threonine-protein kinase ATR,,<3.00
50932,CN1CCC(CC1)c1cc(C)c2nc([nH]c2c1)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O,"InChI=1S/C27H30ClN5O2/c1-16-12-19(17-7-10-33(2)11-8-17)14-22-25(16)32-26(31-22)24-21(6-9-29-27(24)35)30-15-23(34)18-4-3-5-20(28)13-18/h3-6,9,12-14,17,23,34H,7-8,10-11,15H2,1-2H3,(H,31,32)(H2,29,30,35)/t23-/m1/s1",RNSWXWFQTKBNOT-HSZRJFAPSA-N,27880,"4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[4-methyl-6-(1-methylpiperidin-4-yl)-1H-1,3-benzodiazol-2-yl]-1,2-dihydropyridin-2-one::benzimidazole scaffold, 2",Cytochrome P450 3A4,Homo sapiens, 14000
965561,C[C@@]1(O)CCC[C@H]1n1c2nc(NC3CCN(CC3)S(N)(=O)=O)ncc2cc(Cl)c1=O,"InChI=1S/C18H25ClN6O4S/c1-18(27)6-2-3-14(18)25-15-11(9-13(19)16(25)26)10-21-17(23-15)22-12-4-7-24(8-5-12)30(20,28)29/h9-10,12,14,27H,2-8H2,1H3,(H2,20,28,29)(H,21,22,23)/t14-,18-/m1/s1",AQSKGIKUFDLXKA-RDTXWAMCSA-N,370241,"US10233188, Example 128::US10800783, Example 128::US11396512, Example 128",Cyclin-dependent kinase 2/G1/S-specific cyclin-E1,Homo sapiens,
382358,CC(C)(O)C(=O)NCC1CCc2c(C1)sc1ncnc(Nc3ccc4[nH]c(=O)sc4c3)c21,,,218703,"US9296757, 25",Glutathione S-transferase A1/Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D],, 42
50613192,OCCN1CCN(CC1)c1nc2CCN(CCc2c(Nc2ccc(cc2)C(F)(F)F)n1)c1ncccc1C(F)(F)F,"InChI=1S/C27H29F6N7O/c28-26(29,30)18-3-5-19(6-4-18)35-23-20-7-10-39(24-21(27(31,32)33)2-1-9-34-24)11-8-22(20)36-25(37-23)40-14-12-38(13-15-40)16-17-41/h1-6,9,41H,7-8,10-17H2,(H,35,36,37)",DGBYTQSMHNWONG-UHFFFAOYSA-N,50332852,"2-(4-(4-(4-(trifluoromethyl)phenylamino)-7-(3-(trifluoromethyl)pyridin-2-yl)-6,7,8,9-tetrahydro-5H-pyrimido[5,4-d]azepin-2-yl)piperazin-1-yl)ethanol::CHEMBL1630618",Transient receptor potential cation channel subfamily V member 1,Rattus norvegicus, 1161
50016233,N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O,"InChI=1S/C12H22N6O6/c13-6(2-1-3-16-12(14)15)10(22)17-5-8(19)18-7(11(23)24)4-9(20)21/h6-7H,1-5,13H2,(H,17,22)(H,18,19)(H,20,21)(H,23,24)(H4,14,15,16)/t6-,7-/m0/s1",IYMAXBFPHPZYIK-BQBZGAKWSA-N,50107402,(S)-2-[2-((S)-2-Amino-5-carbamimidoyl-pentanoylamino)-acetylamino]-succinic acid::(S)-2-[2-((S)-2-Amino-5-guanidino-pentanoylamino)-acetylamino]-succinic acid::2-[2-(2-Amino-5-guanidino-pentanoylamino)-acetylamino]-succinic acid(RGD)::CHEMBL313763,Integrin alpha-V/beta-3,Homo sapiens,>10000
109536,CC(C)OC(=O)c1cccnc1N1CCN(CC1)c1cccc(Cl)c1,"InChI=1S/C19H22ClN3O2/c1-14(2)25-19(24)17-7-4-8-21-18(17)23-11-9-22(10-12-23)16-6-3-5-15(20)13-16/h3-8,13-14H,9-12H2,1-2H3",AEBHMQALVKZIOJ-UHFFFAOYSA-N,57911,2-[4-(3-chlorophenyl)-1-piperazinyl]-3-pyridinecarboxylic acid propan-2-yl ester::2-[4-(3-chlorophenyl)piperazino]nicotinic acid isopropyl ester::MLS000763673::SMR000337259::cid_3783311::isopropyl 2-[4-(3-chlorophenyl)piperazino]nicotinate::propan-2-yl 2-[4-(3-chlorophenyl)piperazin-1-yl]pyridine-3-carboxylate,Streptokinase A,Streptococcus pyogenes M1 GAS,
51190178,CS(=O)(=O)CC[C@@H]1OCC[C@@]2([C@H]1COc1c(F)ccc(F)c21)S(=O)(=O)c1ccc(cc1)C#N,"InChI=1S/C22H21F2NO6S2/c1-32(26,27)11-8-19-16-13-31-21-18(24)7-6-17(23)20(21)22(16,9-10-30-19)33(28,29)15-4-2-14(12-25)3-5-15/h2-7,16,19H,8-11,13H2,1H3/t16-,19-,22-/m0/s1",MLWGZDGBSJDMEV-BPXKWBHBSA-N,50489350,CHEMBL2314616,Presenilin-1,, 66
51090868,Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)C1(CC1)S(=O)(=O)c1cccc(F)c1)C(F)(F)F,"InChI=1S/C23H21F4N5O3S/c24-14-2-1-3-15(10-14)36(33,34)22(4-5-22)19-12-18(30-21(31-19)32-6-8-35-9-7-32)16-13-29-20(28)11-17(16)23(25,26)27/h1-3,10-13H,4-9H2,(H2,28,29)",LESWEGHJBSSCQS-UHFFFAOYSA-N,50458751,CHEMBL4204166,"Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 14
147114,Cn1c2ccccc2n(CCOc2ccc(Cl)cc2Cl)c1=O,"InChI=1S/C16H14Cl2N2O2/c1-19-13-4-2-3-5-14(13)20(16(19)21)8-9-22-15-7-6-11(17)10-12(15)18/h2-7,10H,8-9H2,1H3",VAATXGICUHXDAV-UHFFFAOYSA-N,67822,"1-[2-(2,4-dichlorophenoxy)ethyl]-3-methyl-1,3-dihydro-2H-benzimidazol-2-one::1-[2-(2,4-dichlorophenoxy)ethyl]-3-methyl-2-benzimidazolone::1-[2-(2,4-dichlorophenoxy)ethyl]-3-methyl-benzimidazol-2-one::1-[2-(2,4-dichlorophenoxy)ethyl]-3-methylbenzimidazol-2-one::1-[2-[2,4-bis(chloranyl)phenoxy]ethyl]-3-methyl-benzimidazol-2-one::MLS000535113::SMR000142546::cid_748782",DNA damage-inducible transcript 3 protein,Mus musculus, 610
50949532,OC[C@H]1O[C@H](C[C@@H]1O)n1ccc(NCc2ccco2)nc1=O,"InChI=1S/C14H17N3O5/c18-8-11-10(19)6-13(22-11)17-4-3-12(16-14(17)20)15-7-9-2-1-5-21-9/h1-5,10-11,13,18-19H,6-8H2,(H,15,16,20)/t10-,11+,13+/m0/s1",IPAHXSYYUYRPBD-DMDPSCGWSA-N,50389505,CHEMBL2063041,Orphan methyltransferase M.SssI,,
50345212,CN1CCN(Cc2cnc(Nc3ncc(s3)-c3cc(C)nc(OC4CCCCC4)n3)cn2)CC1,"InChI=1S/C24H32N8OS/c1-17-12-20(29-23(28-17)33-19-6-4-3-5-7-19)21-14-27-24(34-21)30-22-15-25-18(13-26-22)16-32-10-8-31(2)9-11-32/h12-15,19H,3-11,16H2,1-2H3,(H,26,27,30)",DLIDUXYWQPLFEM-UHFFFAOYSA-N,50186375,CHEMBL210540::N-(5-(2-(cyclohexyloxy)-6-methylpyrimidin-4-yl)thiazol-2-yl)-5-((4-methylpiperazin-1-yl)methyl)pyrazin-2-amine,Cyclin-dependent kinase 5,Homo sapiens, 3000
1062032,COc1nc(ccc1Nc1ncc2ccnc(NCC(C)(C)OC)c2n1)-c1cnn(C)n1,"InChI=1S/C21H25N9O2/c1-21(2,32-5)12-24-18-17-13(8-9-22-18)10-23-20(28-17)27-15-7-6-14(26-19(15)31-4)16-11-25-30(3)29-16/h6-11H,12H2,1-5H3,(H,22,24)(H,23,27,28)",IBAASUCTOIZUSV-UHFFFAOYSA-N,241323,"US10479788, Example 167::US11046688, Example 167::US9409907, 167",Dual specificity protein kinase TTK,Homo sapiens, 23.0
1170988,CCN(CCN1CCC(CC1)c1c[nH]c2ccccc12)C(=O)[C@@H](C)O,,,555073,"US11339151, Example 49",Potassium voltage-gated channel subfamily H member 2,Homo sapiens,>10000
776728,CNC[C@@H]([C@@H](O)c1cc(F)cc(F)c1)c1ccc2ccccc2c1,"InChI=1S/C20H19F2NO/c1-23-12-19(20(24)16-9-17(21)11-18(22)10-16)15-7-6-13-4-2-3-5-14(13)8-15/h2-11,19-20,23-24H,12H2,1H3/t19-,20+/m1/s1",OKQCBRXAICHRKL-UXHICEINSA-N,388605,"US9944618, Compound ID No. 141",Sodium-dependent serotonin transporter,Homo sapiens,
832138,CCOc1cc(-c2ccc(nc2)N2CCC(CN3CCN(C)[C@@H](C)C3)(CC2)NC(=O)CC(C)C)c2c(cnn2c1)C#N,"InChI=1S/C32H44N8O2/c1-6-42-27-16-28(31-26(17-33)19-35-40(31)21-27)25-7-8-29(34-18-25)39-11-9-32(10-12-39,36-30(41)15-23(2)3)22-38-14-13-37(5)24(4)20-38/h7-8,16,18-19,21,23-24H,6,9-15,20,22H2,1-5H3,(H,36,41)/t24-/m0/s1",VZFTUFGJELBCMP-DEOSSOPVSA-N,305585,"US10144734, Example 603::US10172845, Example 603::US10441581, Example 603::US10881652, Example 603",Proto-oncogene tyrosine-protein kinase receptor Ret [V804M],, 158
312211,Cc1cc(=O)oc2cc(Oc3ccc(Nc4c5CCCCCc5nc5ccc(Cl)cc45)cc3)ccc12,"InChI=1S/C30H25ClN2O3/c1-18-15-29(34)36-28-17-22(12-13-23(18)28)35-21-10-8-20(9-11-21)32-30-24-5-3-2-4-6-26(24)33-27-14-7-19(31)16-25(27)30/h7-17H,2-6H2,1H3,(H,32,33)",RGNPGZWSRDIWQM-UHFFFAOYSA-N,192700,"7-(4-(2-Chloro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolin-11-ylamino)phenoxy)-4-methyl-2H-chromen-2-one (8q)",Acetylcholinesterase,Electrophorus electricus, 54120
458759,Cc1ncc(NC(=O)c2ccnc(c2)C(C)(C)F)cc1-c1cc(N2CCOCC2)c(nn1)S(C)(=O)=O,"InChI=1S/C24H27FN6O4S/c1-15-18(19-13-20(31-7-9-35-10-8-31)23(30-29-19)36(4,33)34)12-17(14-27-15)28-22(32)16-5-6-26-21(11-16)24(2,3)25/h5-6,11-14H,7-10H2,1-4H3,(H,28,32)",JCCDDEBFSGDCSJ-UHFFFAOYSA-N,87897,"US10245267, Example 927::US10709712, Example 927::US9694016, 927",Serine/threonine-protein kinase B-raf [V600E],, 7.91
771923,CS(=O)(=O)N[C@H]1CCCN([C@H]1COC1CCN(CC1)c1ccccc1F)C(=O)[C@@H]1C[C@@H]1F,"InChI=1S/C22H31F2N3O4S/c1-32(29,30)25-19-6-4-10-27(22(28)16-13-18(16)24)21(19)14-31-15-8-11-26(12-9-15)20-7-3-2-5-17(20)23/h2-3,5,7,15-16,18-19,21,25H,4,6,8-14H2,1H3/t16-,18+,19+,21+/m1/s1",RZJOCKDDAFARFG-SAJDGTNDSA-N,386793,"N-(cis-1-(((1S,2S)-2- fluorocyclopropyl)carbonyl)-2-(((1- (2-fluorophenyl)piperidin-4- yl)oxy)methyl)piperidin-3- yl)methanesulfonamide::US10287305, Example 221::US10508083, Example 221::US11292766, Example 221",Orexin receptor type 2,Homo sapiens,
996146,COc1nc(ccc1CN1CC2(C1)CCNC2)-c1cccc(c1Cl)-c1cccc(c1Cl)-c1ccc(CN2CC3(C2)CCNC3)c(OC)n1,"InChI=1S/C38H42Cl2N6O2/c1-47-35-25(17-45-21-37(22-45)13-15-41-19-37)9-11-31(43-35)29-7-3-5-27(33(29)39)28-6-4-8-30(34(28)40)32-12-10-26(36(44-32)48-2)18-46-23-38(24-46)14-16-42-20-38/h3-12,41-42H,13-24H2,1-2H3",OMMPPLVCLXIUDL-UHFFFAOYSA-N,479799,"US10899735, No. 258",Programmed cell death 1 ligand 1/2,, 339
50278667,NCCOCCOc1ccc(Cl)c2NC(=O)NC3(CCCCC3)c12,"InChI=1S/C17H24ClN3O3/c18-12-4-5-13(24-11-10-23-9-8-19)14-15(12)20-16(22)21-17(14)6-2-1-3-7-17/h4-5H,1-3,6-11,19H2,(H2,20,21,22)",PHMHLMDLVDNVJG-UHFFFAOYSA-N,50151643,"5''-[2-(2-aminoethoxy)ethoxy]-8''-chlorospiro[cyclohexane-1,4''-(1'',2'',3'',4''-tetrahydroquinazoline)]-2''-one::CHEMBL184701","High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A",Homo sapiens, 1620
50465648,Nc1nc2cc(ccc2c(=O)n1CC1CC(CO1)c1ccccc1)-c1ccccc1,"InChI=1S/C25H23N3O2/c26-25-27-23-14-19(17-7-3-1-4-8-17)11-12-22(23)24(29)28(25)15-21-13-20(16-30-21)18-9-5-2-6-10-18/h1-12,14,20-21H,13,15-16H2,(H2,26,27)",RNOWCBRECJJYFL-UHFFFAOYSA-N,50145779,CHEMBL3765557,Cathepsin D,Homo sapiens,>200000
849913,COC(=O)N1CCC[C@H](NS(C)(=O)=O)[C@@H]1CO[C@H]1CC[C@H](CC1)c1ccccc1C(F)F,"InChI=1S/C22H32F2N2O5S/c1-30-22(27)26-13-5-8-19(25-32(2,28)29)20(26)14-31-16-11-9-15(10-12-16)17-6-3-4-7-18(17)21(23)24/h3-4,6-7,15-16,19-21,25H,5,8-14H2,1-2H3/t15-,16+,19-,20-/m0/s1",YHXIAOBZMFWYQX-JSJNYSNDSA-N,386874,"US10287305, Example 322::US10508083, Example 324::US11292766, Example 324::methyl cis-2-(((cis-4-(2- (difluoromethyl)phenyl)cyclohexyl)- oxy)methyl)-3- ((methylsulfonyl)amino)piperidine- 1-carboxylate",Orexin receptor type 2,Homo sapiens,
1119208,CN(C)CCn1nc2C[C@]3(CCc4cc(OCCCC(F)(F)F)ccc34)NC(=O)c2c1NC(=O)CS(C)(=O)=O,"InChI=1S/C25H32F3N5O5S/c1-32(2)10-11-33-22(29-20(34)15-39(3,36)37)21-19(31-33)14-24(30-23(21)35)9-7-16-13-17(5-6-18(16)24)38-12-4-8-25(26,27)28/h5-6,13H,4,7-12,14-15H2,1-3H3,(H,29,34)(H,30,35)/t24-/m0/s1",NAIHFZJRGJOTHE-DEOSSOPVSA-N,528834,"US11198695, Example I-46","Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase",, 440
51048551,CN1CCN(CC1)c1cc(CCc2cc(C)cc(N)n2)cc(CCc2cc(C)cc(N)n2)c1,"InChI=1S/C27H36N6/c1-19-12-23(30-26(28)14-19)6-4-21-16-22(5-7-24-13-20(2)15-27(29)31-24)18-25(17-21)33-10-8-32(3)9-11-33/h12-18H,4-11H2,1-3H3,(H2,28,30)(H2,29,31)",PRWXJDNYQGFJKM-UHFFFAOYSA-N,50427866,CHEMBL2326357,"Nitric oxide synthase, inducible",Mus musculus,
50405444,COC(CN1CCN(CCc2ccc(C#N)c(OC)c2)CC1)c1ccc2C(=O)OCc2c1C,"InChI=1S/C26H31N3O4/c1-18-21(6-7-22-23(18)17-33-26(22)30)25(32-3)16-29-12-10-28(11-13-29)9-8-19-4-5-20(15-27)24(14-19)31-2/h4-7,14,25H,8-13,16-17H2,1-3H3",YKMBLNOHJFYUHE-UHFFFAOYSA-N,50116825,CHEMBL3612800,Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 9000
50027930,COc1cccc2OC(c3ccccc3)c3cc(ccc3-c12)N(C)S(C)(=O)=O,"InChI=1S/C22H21NO4S/c1-23(28(3,24)25)16-12-13-17-18(14-16)22(15-8-5-4-6-9-15)27-20-11-7-10-19(26-2)21(17)20/h4-14,22H,1-3H3",WWJZOFGIUZFPHR-UHFFFAOYSA-N,50144172,CHEMBL65074::N-(1-Methoxy-6-phenyl-6H-benzo[c]chromen-8-yl)-N-methyl-methanesulfonamide,Glucocorticoid receptor,, 210
1063242,COCc1ccc(NC(=O)c2c(-c3ccc(CO)cc3)n(c3ncnc(N)c23)C2(C)CC2)cc1,"InChI=1S/C26H27N5O3/c1-26(11-12-26)31-22(18-7-3-16(13-32)4-8-18)20(21-23(27)28-15-29-24(21)31)25(33)30-19-9-5-17(6-10-19)14-34-2/h3-10,15,32H,11-14H2,1-2H3,(H,30,33)(H2,27,28,29)",ZWRRUQKFMJNHNW-UHFFFAOYSA-N,311693,"Ex. Cpd. 145::US10807986, Example 145::US11046696, Compound 145",Proto-oncogene tyrosine-protein kinase receptor Ret,Homo sapiens, 1.000
51450013,CCc1cc(O)c(F)cc1-c1cc(N[C@H]2C[C@@H]3CC[C@H](C2)N3)c2nc(N)ncc2c1,"InChI=1S/C23H26FN5O/c1-2-12-7-21(30)19(24)10-18(12)13-5-14-11-26-23(25)29-22(14)20(6-13)28-17-8-15-3-4-16(9-17)27-15/h5-7,10-11,15-17,27-28,30H,2-4,8-9H2,1H3,(H2,25,26,29)/t15-,16+,17-",OOSFLRHKSBTYIX-BJWYYQGGSA-N,50585516,CHEMBL5075673,Tyrosine-protein kinase JAK3,Homo sapiens, 3.2
50181677,C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl,"InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1",KTEIFNKAUNYNJU-GFCCVEGCSA-N,50306682,"(R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine::3-(2,6-dichloro-3-fluorobenzyloxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine::3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine::CHEMBL601719::CRIZOTINIB::PF-2341066::US10370379, Crizotinib::US10543199, Compound Crizotinib::US10780082, Compound Crizotinib::US11059827, Compound Crizotinib::US11517561, Compound Crizotinib::US9126941, PF-2341066::US9199944, Crizotinib::US9226923, Crizotinib",Ribosomal protein S6 kinase alpha-5,Homo sapiens,
51370839,CC\C(=C(/c1cc2ccccc2[nH]1)c1ccc(\C=C\C(O)=O)cc1)c1ccc(Cl)cc1C(F)(F)F,"InChI=1S/C28H21ClF3NO2/c1-2-21(22-13-12-20(29)16-23(22)28(30,31)32)27(25-15-19-5-3-4-6-24(19)33-25)18-10-7-17(8-11-18)9-14-26(34)35/h3-16,33H,2H2,1H3,(H,34,35)/b14-9+,27-21+",RFWMQDCIHCMWHS-USYAYNFISA-N,50554250,CHEMBL4779838,Estrogen receptor,, 2.0
50871848,Nc1c2CCCCc2nc2ccccc12,"InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)",YLJREFDVOIBQDA-UHFFFAOYSA-N,8961,"1,2,3,4-tetrahydro-9-acridinamine::1,2,3,4-tetrahydroacridin-9-amine::9-THA::9-amino-1,2,3,4-tetrahydroacridine (THA)::CHEMBL1337960::CHEMBL95::Cognex::Tacrine::Tracine::US8999994, Tacrine::cid_1935::tacrine.HCl",Acetylcholinesterase,Homo sapiens, 205
50173750,Cc1cccnc1CCC1CCN(CC1)S(=O)(=O)CC1(CCOCC1)N(O)C=O,"InChI=1S/C20H31N3O5S/c1-17-3-2-10-21-19(17)5-4-18-6-11-22(12-7-18)29(26,27)15-20(23(25)16-24)8-13-28-14-9-20/h2-3,10,16,18,25H,4-9,11-15H2,1H3",IBSGSCYXBWXQDW-UHFFFAOYSA-N,50345508,"CHEMBL1784364::N-hydroxy-N-(4-((4-(2-(3-methylpyridin-2-yl)ethyl)piperidin-1-ylsulfonyl)methyl)tetrahydro-2H-pyran-4-yl)formamide::US10322143, Compound 13g",A disintegrin and metalloproteinase with thrombospondin motifs 5,Homo sapiens, 580
933181,OC(=O)COCc1ccc(\C=C\C23CCC(CC2)(CC3)OCc2c(onc2-c2c(Cl)cncc2Cl)C2CC2)cc1,"InChI=1S/C31H32Cl2N2O5/c32-24-15-34-16-25(33)27(24)28-23(29(40-35-28)22-5-6-22)18-39-31-12-9-30(10-13-31,11-14-31)8-7-20-1-3-21(4-2-20)17-38-19-26(36)37/h1-4,7-8,15-16,22H,5-6,9-14,17-19H2,(H,36,37)/b8-7+",ALUZIFDFSMWCNQ-BQYQJAHWSA-N,454152,"US10730863, Example 622",Bile acid receptor,Homo sapiens,
50208396,Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C,"InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37)",MVCOAUNKQVWQHZ-UHFFFAOYSA-N,13533,"1-[2-(4-methylphenyl)-5-tert-butyl-pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea::1-[5-tert-butyl-2-(4-methylphenyl)-3-pyrazolyl]-3-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]urea::1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea::1-[5-tert-butyl-2-(p-tolyl)pyrazol-3-yl]-3-[4-(2-morpholinoethoxy)-1-naphthyl]urea::3-[2-(4-methylphenyl)-5-tert-butyl-pyrazol-3-yl]-1-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea::3-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-1-{4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-yl}urea::BIRB 796::BIRB-796::BIRB-796, 3::CHEMBL103667::D3RKN_73::Doramapimod::US11407771, Compound 43::US8933228, BIRB 796::US9187470, 43 (BIRB-796)::US9242960, BIRB 796::US9260410, BIRB796::cid_156422::diaryl urea compound 10",RAF proto-oncogene serine/threonine-protein kinase,Homo sapiens, 1400
51444534,CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12CCC(CC1)(CC2)C(=O)NCCNC(=O)CCNC(=O)CCNC(=O)CCCCC[N+]1=C(\C=C\C=C\C=C2\N(C)c3ccc(cc3C2(C)C)S(O)(=O)=O)C(C)(C)c2cc(ccc12)S([O-])(=O)=O,"InChI=1S/C60H80N10O12S2/c1-8-35-69-52-51(53(74)70(36-9-2)56(69)76)65-54(66-52)59-25-28-60(29-26-59,30-27-59)55(75)64-34-33-63-50(73)24-32-62-49(72)23-31-61-48(71)18-14-11-15-37-68-45-22-20-41(84(80,81)82)39-43(45)58(5,6)47(68)17-13-10-12-16-46-57(3,4)42-38-40(83(77,78)79)19-21-44(42)67(46)7/h10,12-13,16-17,19-22,38-39H,8-9,11,14-15,18,23-37H2,1-7H3,(H6-,61,62,63,64,65,66,71,72,73,74,75,77,78,79,80,81,82)",RSQNWFQGKRBBTQ-UHFFFAOYSA-N,50583641,CHEMBL5086197,Adenosine receptor A1,Homo sapiens,
51047361,CC1=CC(=O)C(=O)c2c3CCCCc3ccc12,"InChI=1S/C15H14O2/c1-9-8-13(16)15(17)14-11(9)7-6-10-4-2-3-5-12(10)14/h6-8H,2-5H2,1H3",HLVLHKHCAQKXEK-UHFFFAOYSA-N,50458274,CHEMBL4206049,Liver carboxylesterase 1,,
235711,Oc1ccc(C[C@H]2CNC(=S)N2C[C@H]2CCCN2C[C@H](Cc2ccccc2)N2C[C@H](Cc3ccc(O)cc3)N(CCc3ccccc3)C2=S)cc1,"InChI=1S/C42H49N5O2S2/c48-39-17-13-33(14-18-39)24-36-27-43-41(50)46(36)29-35-12-7-22-44(35)28-37(25-32-10-5-2-6-11-32)47-30-38(26-34-15-19-40(49)20-16-34)45(42(47)51)23-21-31-8-3-1-4-9-31/h1-6,8-11,13-20,35-38,48-49H,7,12,21-30H2,(H,43,50)/t35-,36+,37+,38+/m1/s1",HJLIQEBRJUVETG-SPWOZAQASA-N,113969,(4S)-1-[(1S)-1-benzyl-2-[(2R)-2-[[(5S)-5-(4-hydroxybenzyl)-2-thioxo-imidazolidin-1-yl]methyl]pyrrolidino]ethyl]-4-(4-hydroxybenzyl)-3-phenethyl-imidazolidine-2-thione::(4S)-4-[(4-hydroxyphenyl)methyl]-1-[(2S)-1-[(2R)-2-[[(5S)-5-[(4-hydroxyphenyl)methyl]-2-sulfanylidene-1-imidazolidinyl]methyl]-1-pyrrolidinyl]-3-phenylpropan-2-yl]-3-(2-phenylethyl)-2-imidazolidinethione::(4S)-4-[(4-hydroxyphenyl)methyl]-1-[(2S)-1-[(2R)-2-[[(5S)-5-[(4-hydroxyphenyl)methyl]-2-sulfanylidene-imidazolidin-1-yl]methyl]pyrrolidin-1-yl]-3-phenyl-propan-2-yl]-3-(2-phenylethyl)imidazolidine-2-thione::(4S)-4-[(4-hydroxyphenyl)methyl]-1-[(2S)-1-[(2R)-2-[[(5S)-5-[(4-hydroxyphenyl)methyl]-2-sulfanylideneimidazolidin-1-yl]methyl]pyrrolidin-1-yl]-3-phenylpropan-2-yl]-3-(2-phenylethyl)imidazolidine-2-thione::MLS003177417::SMR001881196::cid_51359484,Disintegrin and metalloproteinase domain-containing protein 17,, 69489
50302986,CN(C)c1ccc(cc1)S(=O)(=O)c1sc2ncccc2c1-c1ccc(Cl)cc1,"InChI=1S/C21H17ClN2O2S2/c1-24(2)16-9-11-17(12-10-16)28(25,26)21-19(14-5-7-15(22)8-6-14)18-4-3-13-23-20(18)27-21/h3-13H,1-2H3",JDNNSFNYYPIQJR-UHFFFAOYSA-N,50066439,CHEMBL3401585,Metabotropic glutamate receptor 5,Rattus norvegicus,
50373125,N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,"InChI=1S/C32H37N5O5/c33-25(18-23-13-15-24(38)16-14-23)32(42)37-17-7-12-28(37)31(41)36-27(20-22-10-5-2-6-11-22)30(40)35-26(29(34)39)19-21-8-3-1-4-9-21/h1-6,8-11,13-16,25-28,38H,7,12,17-20,33H2,(H2,34,39)(H,35,40)(H,36,41)/t25-,26-,27-,28-/m0/s1",XIJHWXXXIMEHKW-LJWNLINESA-N,50139013,(S)-1-[(S)-2-Amino-3-(4-hydroxy-phenyl)-propionyl]-pyrrolidine-2-carboxylic acid [(S)-1-((S)-1-carbamoyl-2-phenyl-ethylcarbamoyl)-2-phenyl-ethyl]-amide::(S)-N-((S)-1-((S)-1-amino-1-oxo-3-phenylpropan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-1-((S)-2-amino-3-(4-hydroxyphenyl)propanoyl)pyrrolidine-2-carboxamide::1-[(S)-2-Amino-3-(4-hydroxy-phenyl)-propionyl]-pyrrolidine-2-carboxylicacid[1-((S)-(S)-1-carbamoyl-2-phenyl-ethylcarbamoyl)-2-phenyl-ethyl]-amide::CHEMBL333357::H-Tyr-Pro-Phe-Phe-NH2::Tyr-Pro-Phe-Phe-NH2::endomorphin-2,Mu-type opioid receptor,Homo sapiens,
51235651,CC(C)n1cc(cn1)-c1nc(Nc2ccc(N3CCC(CC3)N(C)CCO)c(F)c2)ncc1C,"InChI=1S/C25H34FN7O/c1-17(2)33-16-19(15-28-33)24-18(3)14-27-25(30-24)29-20-5-6-23(22(26)13-20)32-9-7-21(8-10-32)31(4)11-12-34/h5-6,13-17,21,34H,7-12H2,1-4H3,(H,27,29,30)",CVLXNRIQVFIVGY-UHFFFAOYSA-N,50505817,CHEMBL4447631,Tyrosine-protein kinase Lyn,Homo sapiens, 17
50775325,CC(C)=CCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1,"InChI=1S/C20H20N2O2/c1-15(2)13-14-18-19(23)21(16-9-5-3-6-10-16)22(20(18)24)17-11-7-4-8-12-17/h3-13,18H,14H2,1-2H3",RBBWCVQDXDFISW-UHFFFAOYSA-N,50248306,DA-2370::Feprazone,ATP-binding cassette sub-family C member 3,Homo sapiens, 133000
50083405,COc1ccc(cc1)[C@@H]1[C@H]([C@@H](CN1CC(=O)N(C)C1CCCCC1)c1ccc2OCOc2c1)C(O)=O,"InChI=1S/C28H34N2O6/c1-29(20-6-4-3-5-7-20)25(31)16-30-15-22(19-10-13-23-24(14-19)36-17-35-23)26(28(32)33)27(30)18-8-11-21(34-2)12-9-18/h8-14,20,22,26-27H,3-7,15-17H2,1-2H3,(H,32,33)/t22-,26-,27+/m0/s1",PJPSUSRDIRKFPW-WDDWZANVSA-N,50050972,"(2S,3S,4R)-4-Benzo[1,3]dioxol-5-yl-1-[(cyclohexyl-methyl-carbamoyl)-methyl]-2-(4-methoxy-phenyl)-pyrrolidine-3-carboxylic acid::CHEMBL8736",Endothelin-1 receptor,Rattus, 23.8
870962,C[C@H](N1C(=O)c2cc(ccc2[C@]1(OC1COC[C@@H]1O)c1ccc(Cl)cc1)C(C)(C)O)c1ccc(Cl)cc1,"InChI=1S/C29H29Cl2NO5/c1-17(18-4-9-21(30)10-5-18)32-27(34)23-14-20(28(2,3)35)8-13-24(23)29(32,19-6-11-22(31)12-7-19)37-26-16-36-15-25(26)33/h4-14,17,25-26,33,35H,15-16H2,1-3H3/t17-,25-,26?,29+/m0/s1",JLJRDOGQKDSPHW-QYEDSFCJSA-N,427091,"(3R)-3-(4-Chlorophenyl)-2-[(1S)-1-(4-chlorophenyl)ethyl]-3-{[(3S,4R)-4-hydroxyoxolan-3-yl]oxy}-6-(2-hydroxypropan-2-yl)-2,3-dihydro-1H-isoindol-1-one and (3R)-3-(4-chlorophenyl)-2-[(1S)-1-(4-chlorophenyl)ethyl]-3-{[(3R,4S)-4-hydroxyoxolan-3-yl]oxy}-6-(2-hydroxypropan-2-yl)-2,3-dihydro-1H-isoindol-1-one::US10544132, Example 46::US10981898, Example 46",E3 ubiquitin-protein ligase Mdm2,Homo sapiens, 10780
266262,Cc1onc(c1COc1ccc(cn1)C(=O)NCc1nc(no1)C1CC1)-c1ccccc1,"InChI=1S/C23H21N5O4/c1-14-18(21(27-31-14)15-5-3-2-4-6-15)13-30-19-10-9-17(11-24-19)23(29)25-12-20-26-22(28-32-20)16-7-8-16/h2-6,9-11,16H,7-8,12-13H2,1H3,(H,25,29)",ZJSBUMFNEAUGSZ-UHFFFAOYSA-N,133336,"US8846719, 19",Gamma-aminobutyric acid receptor subunit alpha-5,Homo sapiens,
50100015,Cc1ccc2c3CCN(Cc4ccccc4)Cc3c(=O)oc2c1,"InChI=1S/C20H19NO2/c1-14-7-8-17-16-9-10-21(12-15-5-3-2-4-6-15)13-18(16)20(22)23-19(17)11-14/h2-8,11H,9-10,12-13H2,1H3",JYTBEUORVGHEBI-UHFFFAOYSA-N,50059496,"3-Benzyl-8-methyl-1,2,3,4-tetrahydro-chromeno[3,4-c]pyridin-5-one::CHEMBL92489",5-hydroxytryptamine receptor 2A,Rattus norvegicus,
930423,Cn1cnc2ncn(Cc3nc(no3)[C@@H]3[C@H]4CN(C[C@@H]34)c3ccc(C#N)c(F)c3)c(=O)c12,"InChI=1S/C21H17FN8O2/c1-28-9-24-20-18(28)21(31)30(10-25-20)8-16-26-19(27-32-16)17-13-6-29(7-14(13)17)12-3-2-11(5-23)15(22)4-12/h2-4,9-10,13-14,17H,6-8H2,1H3/t13-,14+,17+",ZAGXFWMLCVBKQA-HALDLXJZSA-N,452757,"2-fluoro-4- ((1R,5S,6r)-6-(5-((7- methyl-6-oxo-6,7- dihydro-1H-purin-1- yl)methyl)-1,2,4- oxadiazol-3-yl)-3- azabicyclo[3.1.0]::US10711004, Example 79",Transient receptor potential cation channel subfamily A member 1,, 15.0
50088855,[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F.CCN(CC)c1ccc(cc1)C(=C1C=CC(C=C1)=[N+](CC)CC)c1ccc(cc1S([O-])(=O)=O)S(=O)(=O)NCCCC[C@H](NC(=O)Cc1csc(=[NH2+])n1C)C(=O)N[C@@H](Cc1cn(Cc2ccccc2)c[n+]1C)C(=O)NC1CC[NH+](C)CC1,"InChI=1S/C59H77N11O8S3.3C2HF3O2/c1-8-69(9-2)46-24-20-43(21-25-46)56(44-22-26-47(27-23-44)70(10-3)11-4)51-29-28-50(37-54(51)81(76,77)78)80(74,75)61-32-16-15-19-52(63-55(71)36-49-40-79-59(60)67(49)7)57(72)64-53(58(73)62-45-30-33-65(5)34-31-45)35-48-39-68(41-66(48)6)38-42-17-13-12-14-18-42;3*3-2(4,5)1(6)7/h12-14,17-18,20-29,37,39-41,45,52-53,60-61H,8-11,15-16,19,30-36,38H2,1-7H3,(H2-2,62,63,64,71,72,73,76,77,78);3*(H,6,7)/t52-,53-;;;/m0.../s1",XXAJFHKETAFVCS-GPPUWUEZSA-N,50009560,CHEMBL3234454,Type-1 angiotensin II receptor,Homo sapiens,
892836,CC(C)(O)[C@H](F)CNC(=O)c1cnc(cc1NCC1(O)CCC1)-c1cnn2cc(Cl)cnc12,"InChI=1S/C22H26ClFN6O3/c1-21(2,32)18(24)10-27-20(31)15-8-25-16(6-17(15)28-12-22(33)4-3-5-22)14-9-29-30-11-13(23)7-26-19(14)30/h6-9,11,18,32-33H,3-5,10,12H2,1-2H3,(H,25,28)(H,27,31)/t18-/m1/s1",LRBMKDOTRIPJPY-GOSISDBHSA-N,438423,"US10618903, Example 51",Interleukin-1 receptor-associated kinase 4,Homo sapiens, 10.00
402508,COc1cccc2CN(Cc3ccc(cc3)[C@H](C)NC(=O)c3cncs3)CCc12,"InChI=1S/C23H25N3O2S/c1-16(25-23(27)22-12-24-15-29-22)18-8-6-17(7-9-18)13-26-11-10-20-19(14-26)4-3-5-21(20)28-2/h3-9,12,15-16H,10-11,13-14H2,1-2H3,(H,25,27)/t16-/m0/s1",XIOSQPZGKNLCFC-INIZCTEOSA-N,230499,"US9340510, 2.001",Acetyl-CoA carboxylase 2,Homo sapiens, 135
836506,Cn1cc(nc1-c1ccc(Cn2c3nc(ncc3[nH]c2=O)-c2cccnc2N2CCOCC2)cc1)C(F)(F)F,"InChI=1S/C26H23F3N8O2/c1-35-15-20(26(27,28)29)33-22(35)17-6-4-16(5-7-17)14-37-24-19(32-25(37)38)13-31-21(34-24)18-3-2-8-30-23(18)36-9-11-39-12-10-36/h2-8,13,15H,9-12,14H2,1H3,(H,32,38)",CTJYCFRUKQMLFA-UHFFFAOYSA-N,325127,"9-(4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-::US10189841, Compound I-333::US10399980, Compound I-333",Ubiquitin carboxyl-terminal hydrolase 1,, 125
50382539,CC(C)OC(=O)N1CCC(CC1)O[C@H]1CC[C@@H](CC1)Oc1cnc(cn1)S(C)(=O)=O,"InChI=1S/C20H31N3O6S/c1-14(2)27-20(24)23-10-8-17(9-11-23)28-15-4-6-16(7-5-15)29-18-12-22-19(13-21-18)30(3,25)26/h12-17H,4-11H2,1-3H3/t15-,16-",OOZUGTUUVHOIQS-WKILWMFISA-N,50106163,CHEMBL3598094,Glucose-dependent insulinotropic receptor,Rattus norvegicus,
40784,CCCCOc1ccc(cc1)C(CC(O)=O)c1cccs1,"InChI=1S/C17H20O3S/c1-2-3-10-20-14-8-6-13(7-9-14)15(12-17(18)19)16-5-4-11-21-16/h4-9,11,15H,2-3,10,12H2,1H3,(H,18,19)",PNGSWCVAXCXVHE-UHFFFAOYSA-N,22492,"3-(4-butoxyphenyl)-3-(thiophen-2-yl)propanoic acid::3-Aryl-3-(4-phenoxy)-propionic Acid derivative, 46",Free fatty acid receptor 1,,
678258,Cc1cc(C)nc(c1)-c1cn[nH]c1C(=O)Nc1cc2nc(nn2cc1F)-c1ccccc1,"InChI=1S/C23H18FN7O/c1-13-8-14(2)26-18(9-13)16-11-25-29-21(16)23(32)27-19-10-20-28-22(15-6-4-3-5-7-15)30-31(20)12-17(19)24/h3-12H,1-2H3,(H,25,29)(H,27,32)",PEHBQLPLZWJRIY-UHFFFAOYSA-N,343318,"4-(4,6-dimethylpyridin-2-yl)-N-(6-fluoro-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1-methyl-1H-pyrazole-5-carboxamide::US9777000, Example 3.53","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens,<5
971396,COCCCN1C(=O)N(CC(=O)NCCO)C[C@]11CC[C@@](CC1)(N(C)C)c1ccccc1,"InChI=1S/C24H38N4O4/c1-26(2)24(20-8-5-4-6-9-20)12-10-23(11-13-24)19-27(18-21(30)25-14-16-29)22(31)28(23)15-7-17-32-3/h4-6,8-9,29H,7,10-19H2,1-3H3,(H,25,30)/t23-,24+",ATGGPTGXYMYNHH-PSWAGMNNSA-N,469949,"CIS-2-[8-Dimethylamino-1-(3-methoxy-propyl)-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-N-(2-hydroxy-ethyl)-acetamide::US10807989, Example SC_1180",Mu-type opioid receptor,Homo sapiens,
50179241,Cc1ccc(NC(=O)N(CCCCC2CCCCC2)CCc2ccc(SC(C)(C)C(O)=O)cc2)cc1[N+]([O-])=O,"InChI=1S/C30H41N3O5S/c1-22-12-15-25(21-27(22)33(37)38)31-29(36)32(19-8-7-11-23-9-5-4-6-10-23)20-18-24-13-16-26(17-14-24)39-30(2,3)28(34)35/h12-17,21,23H,4-11,18-20H2,1-3H3,(H,31,36)(H,34,35)",LRLDBAWAMQJEFB-UHFFFAOYSA-N,50099492,2-(4-{2-[1-(4-Cyclohexyl-butyl)-3-(4-methyl-3-nitro-phenyl)-ureido]-ethyl}-phenylsulfanyl)-2-methyl-propionic acid::CHEMBL281791,Peroxisome proliferator-activated receptor delta,,
840374,FC(F)(c1ccccc1)c1nc(N2CCC3(C2)N=N3)c2nnn(Cc3ccccc3Cl)c2n1,"InChI=1S/C22H17ClF2N8/c23-16-9-5-4-6-14(16)12-33-19-17(28-31-33)18(32-11-10-21(13-32)29-30-21)26-20(27-19)22(24,25)15-7-2-1-3-8-15/h1-9H,10-13H2",HHRNGZYZJQZLJO-UHFFFAOYSA-N,419262,"3-[(2-Chlorophenyl)methyl]-5-[difluoro(phenyl)methyl]-7-(1,2,5-triazaspiro[2.4]hept-1-en-5-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine::US10457684, Example 6",Cannabinoid receptor 2,Homo sapiens,
1181822,CCn1nc(Cl)c2cnc(Nc3cn(nc3Cl)C3CCN(CC3)S(=O)(=O)C3CC3)nc12,"InChI=1S/C18H22Cl2N8O2S/c1-2-27-17-13(15(19)24-27)9-21-18(23-17)22-14-10-28(25-16(14)20)11-5-7-26(8-6-11)31(29,30)12-3-4-12/h9-12H,2-8H2,1H3,(H,21,22,23)",UFOROFMJWKVGFV-UHFFFAOYSA-N,559619,"US11370796, Compound 47",Leucine-rich repeat serine/threonine-protein kinase 2,Homo sapiens, 6.48
51309976,CN1CCC2(CC1)N[C@@H](CO)C(=O)N(C2=O)c1c(C)cccc1C,"InChI=1S/C18H25N3O3/c1-12-5-4-6-13(2)15(12)21-16(23)14(11-22)19-18(17(21)24)7-9-20(3)10-8-18/h4-6,14,19,22H,7-11H2,1-3H3/t14-/m0/s1",GEALIVCGHVSQSW-AWEZNQCLSA-N,50531605,CHEMBL4552298,Sigma non-opioid intracellular receptor 1,Cavia porcellus,
435251,CC(=O)N1CCc2c(C1)[nH]nc2C(=O)N1CCC(CC1)c1cccc(F)c1C(F)(F)F,"InChI=1S/C21H22F4N4O2/c1-12(30)29-10-7-15-17(11-29)26-27-19(15)20(31)28-8-5-13(6-9-28)14-3-2-4-16(22)18(14)21(23,24)25/h2-4,13H,5-11H2,1H3,(H,26,27)",VICXOPXLVAUSNR-UHFFFAOYSA-N,249464,"US10072016, Compound 63::US10407433, Compound 63::US10913746, Compound 63::US9434727, 63::US9777010, Compound 63",Retinol-binding protein 4,Homo sapiens, 4.456853
50421733,O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O,"InChI=1S/C8H15NO3/c10-5-2-1-3-9-4-6(11)8(12)7(5)9/h5-8,10-12H,1-4H2/t5-,6-,7-,8-/m1/s1",FXUAIOOAOAVCGD-WCTZXXKLSA-N,50168995,"(-)-swainsonine::(1S,2R,8R,8aR)-Octahydro-indolizine-1,2,8-triol::1S-8AB-OCTAHYDRO-INDOLIZIDINE-1A,2A,8B-TRIOL::CHEMBL371197::SWAINSONINE",Lysosomal alpha-mannosidase,Homo sapiens, 50
966539,O=C(N[C@@H]1CCCNC1)c1sc2nccc3n(-c4cccc(c4)-c4ccccc4)c(=O)[nH]c1c23,,,467768,"(R)-5-([1,1'-Biphenyl]-3-yl)-4-oxo-N-(piperidin-3-yl)-4,5-dihydro- 3H-1-thia-3,5,8-triazaacenaphthylene-2-carboxamide;::US10800792, Example 426::US10822348, Example 426",Tyrosine-protein kinase BTK,Homo sapiens, 126
51130191,O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(cs1)-c1c[nH]c2ncccc12,"InChI=1S/C26H29N5O2S/c32-24(31-26-30-23(17-34-26)22-16-29-25-21(22)7-2-10-28-25)15-19-4-1-6-20(14-19)33-13-3-5-18-8-11-27-12-9-18/h1-2,4,6-7,10,14,16-18,27H,3,5,8-9,11-13,15H2,(H,28,29)(H,30,31,32)",OKUPZBPYLVKVSU-UHFFFAOYSA-N,50463483,CHEMBL4245242,Serine/threonine-protein kinase PAK 3,,
50820144,CC(C)Cn1c2nc([nH]c2c(=O)n(CC(C)C)c1=O)-c1cc(OCC(=O)Nc2ccc(F)cc2)nn1C,"InChI=1S/C25H30FN7O4/c1-14(2)11-32-23-21(24(35)33(25(32)36)12-15(3)4)28-22(29-23)18-10-20(30-31(18)5)37-13-19(34)27-17-8-6-16(26)7-9-17/h6-10,14-15H,11-13H2,1-5H3,(H,27,34)(H,28,29)",ZASWTQRANFXXQJ-UHFFFAOYSA-N,50140979,"2-[5-(1,3-Diisobutyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-N-(4-fluoro-phenyl)-acetamide::CHEMBL32697",Adenosine receptor A2a,Homo sapiens,
327839,Cn1c(nc2c(N)nc(CCCCO)nc12)-n1nccn1,"InChI=1S/C12H16N8O/c1-19-11-9(18-12(19)20-14-5-6-15-20)10(13)16-8(17-11)4-2-3-7-21/h5-6,21H,2-4,7H2,1H3,(H2,13,16,17)",LXKQSSJIYWOEPP-UHFFFAOYSA-N,181010,"US9133197, 1",Adenosine receptor A2a,Homo sapiens,
50287315,CN1CCC(CC1)N1CNc2ccc(NC(=O)c3c(F)cc(F)cc3F)cc12,"InChI=1S/C20H21F3N4O/c1-26-6-4-14(5-7-26)27-11-24-17-3-2-13(10-18(17)27)25-20(28)19-15(22)8-12(21)9-16(19)23/h2-3,8-10,14,24H,4-7,11H2,1H3,(H,25,28)",BBYIBACYQLBDSC-UHFFFAOYSA-N,50156408,"2,4,6-Trifluoro-N-[3-(1-methyl-piperidin-4-yl)-2,3-dihydro-1H-benzoimidazol-5-yl]-benzamide::CHEMBL187581",5-hydroxytryptamine receptor 1F,Homo sapiens,
51227776,CCCCc1nc(Cl)c(CNC(=O)C(CS)Cc2ccc3ccccc3c2)n1Cc1ccc(cc1)-c1ccccc1C(O)=O,"InChI=1S/C36H36ClN3O3S/c1-2-3-12-33-39-34(37)32(21-38-35(41)29(23-44)20-25-15-16-26-8-4-5-9-28(26)19-25)40(33)22-24-13-17-27(18-14-24)30-10-6-7-11-31(30)36(42)43/h4-11,13-19,29,44H,2-3,12,20-23H2,1H3,(H,38,41)(H,42,43)",CHKOUVAKPRIMRS-UHFFFAOYSA-N,50503899,CHEMBL4471668,Neprilysin,, 398
50058703,CCOC(=O)C(=O)C1CCCN1C(=O)[C@@H]1CCCN1C(=O)CCCc1ccccc1,"InChI=1S/C23H30N2O5/c1-2-30-23(29)21(27)18-12-7-16-25(18)22(28)19-13-8-15-24(19)20(26)14-6-11-17-9-4-3-5-10-17/h3-5,9-10,18-19H,2,6-8,11-16H2,1H3/t18?,19-/m0/s1",LBLKMOXIRVMBGA-GGYWPGCISA-N,50037607,CHEMBL333638::Oxo-{1-[(S)-1-(4-phenyl-butyryl)-pyrrolidine-2-carbonyl]-pyrrolidin-2-yl}-acetic acid ethyl ester,Prolyl endopeptidase,, 10.3
50893588,Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1,"InChI=1S/C20H14FN3O/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(25)8-4-15/h1-12,25H,(H,23,24)",QHKYPYXTTXKZST-UHFFFAOYSA-N,13531,"4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole::4-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol::4-[4-(4-fluorophenyl)-5-(4-pyridyl)-4-imidazolin-2-ylidene]cyclohexa-2,5-dien-1-one::4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-yl]phenol::SB-202190::SB202190::biotinylated SB202190",Cyclin-dependent kinase 3,,
1039430,COCC1N(Cc2ccccc12)c1cn[nH]c(=O)c1Cl,,,431262,"US10550105, Example 207::US10870641, Example 207::US11014913, Example 207",Protein mono-ADP-ribosyltransferase TIPARP,,>1000
50314025,Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccc(F)cc4)cc3)c12,"InChI=1S/C22H20FN5O2/c1-14-12-24-21-19(14)20(25-13-26-21)15-2-6-17(7-3-15)27-22(30)28(10-11-29)18-8-4-16(23)5-9-18/h2-9,12-13,29H,10-11H2,1H3,(H,27,30)(H,24,25,26)",FCMRBYJIHLJQSI-UHFFFAOYSA-N,50072829,CHEMBL3410039,Mitogen-activated protein kinase 10,Homo sapiens,>10000
50594221,Cn1cc(Cc2cccc(n2)-c2cccc3OCOc23)c2cc(NC(=O)CC(C)(C)O)ccc12,"InChI=1S/C27H27N3O4/c1-27(2,32)14-25(31)29-19-10-11-23-21(13-19)17(15-30(23)3)12-18-6-4-8-22(28-18)20-7-5-9-24-26(20)34-16-33-24/h4-11,13,15,32H,12,14,16H2,1-3H3,(H,29,31)",VKKPZNVBRKYDRR-UHFFFAOYSA-N,50325894,"CHEMBL1224615::N-(3-((6-(benzo[d][1,3]dioxol-4-yl)pyridin-2-yl)methyl)-1-methyl-1H-indol-5-yl)-3-hydroxy-3-methylbutanamide",Cannabinoid receptor 1,Homo sapiens, 5
50547231,CC1(C)C(=O)N([C@H]2CCc3c2cccc3O)c2nc(Nc3ccccc3)ncc12,"InChI=1S/C23H22N4O2/c1-23(2)17-13-24-22(25-14-7-4-3-5-8-14)26-20(17)27(21(23)29)18-12-11-16-15(18)9-6-10-19(16)28/h3-10,13,18,28H,11-12H2,1-2H3,(H,24,25,26)/t18-/m0/s1",XLFNLJYGUOLEJS-SFHVURJKSA-N,50208911,CHEMBL3884319,Epidermal growth factor receptor,Homo sapiens, 10000
50253638,CCCCOC(=O)N1C[C@]2(C[C@H]1CNc1ncc[nH]1)CC(=NO2)C(=O)NC[C@H](NS(=O)(=O)c1c(C)cc(C)cc1C)C(O)=O,"InChI=1S/C28H39N7O8S/c1-5-6-9-42-27(39)35-16-28(12-20(35)14-32-26-29-7-8-30-26)13-21(33-43-28)24(36)31-15-22(25(37)38)34-44(40,41)23-18(3)10-17(2)11-19(23)4/h7-8,10-11,20,22,34H,5-6,9,12-16H2,1-4H3,(H,31,36)(H,37,38)(H2,29,30,32)/t20-,22-,28-/m0/s1",TZNXKIAIKROUOK-AHPZTNMXSA-N,50138306,"(5S,8S)-3-[(S)-2-Carboxy-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethylcarbamoyl]-8-[(1H-imidazol-2-ylamino)-methyl]-1-oxa-2,7-diaza-spiro[4.4]non-2-ene-7-carboxylic acid butyl ester::CHEMBL126983",Integrin alpha-V/beta-1,Homo sapiens, 130
763450,COc1ccc(OCC2N(CCc3cc(OC)cc(OC)c23)C(=O)c2cccc(Cl)c2)cc1,"InChI=1S/C26H26ClNO5/c1-30-20-7-9-21(10-8-20)33-16-23-25-17(14-22(31-2)15-24(25)32-3)11-12-28(23)26(29)18-5-4-6-19(27)13-18/h4-10,13-15,23H,11-12,16H2,1-3H3",DGEWNXLNJIUWQA-UHFFFAOYSA-N,50436105,"CHEMBL2397253::US10273214, Example 1180-20","Glutamate receptor ionotropic, NMDA 2C",Homo sapiens, 11000
51151319,CC(=O)NCCc1c[nH]c2ccc(F)cc12,"InChI=1S/C12H13FN2O/c1-8(16)14-5-4-9-7-15-12-3-2-10(13)6-11(9)12/h2-3,6-7,15H,4-5H2,1H3,(H,14,16)",UDLASALUJLTGJV-UHFFFAOYSA-N,50471827,CHEMBL284521,Melatonin receptor type 1A/1B,Homo sapiens,
50355089,C[C@H](NC(=O)[C@@H]1COC(=O)[C@H](Cc2ccc(cc2)[N+]([O-])=O)N1)c1ccccc1,"InChI=1S/C20H21N3O5/c1-13(15-5-3-2-4-6-15)21-19(24)18-12-28-20(25)17(22-18)11-14-7-9-16(10-8-14)23(26)27/h2-10,13,17-18,22H,11-12H2,1H3,(H,21,24)/t13-,17-,18-/m0/s1",SFJZUUDKNPCJAG-KKXDTOCCSA-N,50192095,CHEMBL215930::cis-5-(4-nitrobenzyl)-6-oxo-N-((S)-1-phenylethyl)morpholine-3-carboxamide,Voltage-dependent T-type calcium channel subunit alpha-1G,Homo sapiens, 2130
50761678,COc1cc2[nH]c3nc(N)nc(NCc4ccccc4)c3c2cc1O,"InChI=1S/C18H17N5O2/c1-25-14-8-12-11(7-13(14)24)15-16(22-18(19)23-17(15)21-12)20-9-10-5-3-2-4-6-10/h2-8,24H,9H2,1H3,(H4,19,20,21,22,23)",WYUMYTHSGQZLIP-UHFFFAOYSA-N,50242541,CHEMBL4073523,Epidermal growth factor receptor,Homo sapiens,
50122111,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)c1cc(O)ccc1O)C(=O)N[C@@H](CC)C(O)=O,"InChI=1S/C28H43N5O10/c1-4-15(3)23(27(41)30-18(5-2)28(42)43)33-26(40)20(10-12-22(36)37)32-25(39)19(8-6-7-13-29)31-24(38)17-14-16(34)9-11-21(17)35/h9,11,14-15,18-20,23,34-35H,4-8,10,12-13,29H2,1-3H3,(H,30,41)(H,31,38)(H,32,39)(H,33,40)(H,36,37)(H,42,43)/t15?,18?,19-,20-,23-/m0/s1",LNZLZVRFWYCKOF-MSMFUVKXSA-N,50070762,CHEMBL2372731::Nazumamide A (NAZA) analogue,Prothrombin,, 54000
51427462,CC(C)[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,,,50576610,CHEMBL4847494,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",Homo sapiens, 313
1035246,CO[C@H]1CC[C@@H](CC1)Nc1ncc(Cl)c(n1)-c1ccc2CN([C@H](C)C(=O)N[C@H](CO)c3cccc(C)c3)C(=O)c2c1,"InChI=1S/C31H36ClN5O4/c1-18-5-4-6-20(13-18)27(17-38)35-29(39)19(2)37-16-22-8-7-21(14-25(22)30(37)40)28-26(32)15-33-31(36-28)34-23-9-11-24(41-3)12-10-23/h4-8,13-15,19,23-24,27,38H,9-12,16-17H2,1-3H3,(H,35,39)(H,33,34,36)/t19-,23-,24-,27-/m1/s1",RESLBQNYLGHVCS-GVDONAMHSA-N,417964,"(2R)-2-[6-(5-chloro- 2-{[trans-4- methoxycyclohexyl] amino}pyrimidin-4-yl)- 1-oxo-2,3-dihydro- 1H-isoindol-2-yl]-N- [(1S)-2-hydroxy-1-(3- methylphenyl)ethyl] propanamide::US10457669, Example 629::US11001575, Example 629",Mitogen-activated protein kinase 1,Homo sapiens, 3.70
51019764,CCCCNCc1ccc(cc1)-c1nc(CN(C2CCCC2)S(=O)(=O)c2ccc(OC)c(OC)c2)cs1,"InChI=1S/C28H37N3O4S2/c1-4-5-16-29-18-21-10-12-22(13-11-21)28-30-23(20-36-28)19-31(24-8-6-7-9-24)37(32,33)25-14-15-26(34-2)27(17-25)35-3/h10-15,17,20,24,29H,4-9,16,18-19H2,1-3H3",YXZROCSVGRUEGS-UHFFFAOYSA-N,50417709,CHEMBL1643605,Vasopressin V1b receptor,,
50741388,OC(=O)CNC(=O)C1=CC2(CC1)CCN(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)c1ccccc1C2,"InChI=1S/C37H33N3O5/c41-33(42)24-38-34(43)28-18-19-37(23-28)20-21-40(32-13-7-4-10-27(32)22-37)36(45)26-14-16-29(17-15-26)39-35(44)31-12-6-5-11-30(31)25-8-2-1-3-9-25/h1-17,23H,18-22,24H2,(H,38,43)(H,39,44)(H,41,42)",JYKTYQLAXRWNPF-UHFFFAOYSA-N,50147231,"2-[1-[4-(2-phenylphenylcarboxamido)benzoyl]spiro[2,3,4,5-tetrahydro-1H-benzo[b]azepine-4,1'-(2'-cyclopentene)]-3-ylcarboxamido]acetic acid::CHEMBL419183",Vasopressin V2 receptor,, 350
50888283,COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,"InChI=1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)",IEDVJHCEMCRBQM-UHFFFAOYSA-N,18069,"5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine::CHEMBL22::TMP::Trimethoprim::Trimethoprim (TMP)::US10870625, Compound TMP",Dihydrofolate reductase,Pneumocystis carinii,
368730,COc1cc2nc([nH]c2cc1OC)-c1nc(sc1N1CCN([C@H](C)C1)C(=O)Cn1cnc2cccnc12)C(F)(F)F,"InChI=1S/C26H25F3N8O3S/c1-14-11-35(7-8-37(14)20(38)12-36-13-31-15-5-4-6-30-23(15)36)24-21(34-25(41-24)26(27,28)29)22-32-16-9-18(39-2)19(40-3)10-17(16)33-22/h4-6,9-10,13-14H,7-8,11-12H2,1-3H3,(H,32,33)/t14-/m1/s1",DQJDCGVYFWPJEV-CQSZACIVSA-N,208694,"US9266876, 161",C-X-C chemokine receptor type 3/Guanine nucleotide-binding protein subunit alpha-15,, 2
151536,CCOC(=O)c1c(NC(=S)NC(=O)N(C)C)scc1-c1ccc(C)o1,"InChI=1S/C16H19N3O4S2/c1-5-22-14(20)12-10(11-7-6-9(2)23-11)8-25-13(12)17-15(24)18-16(21)19(3)4/h6-8H,5H2,1-4H3,(H2,17,18,21,24)",YAHHFWGBZGKXKT-UHFFFAOYSA-N,65879,2-(dimethylcarbamoylthiocarbamoylamino)-4-(5-methyl-2-furyl)thiophene-3-carboxylic acid ethyl ester::2-[[[[dimethylamino(oxo)methyl]amino]-sulfanylidenemethyl]amino]-4-(5-methyl-2-furanyl)-3-thiophenecarboxylic acid ethyl ester::MLS000582162::SMR000200695::cid_1251205::ethyl 2-(dimethylcarbamoylcarbamothioylamino)-4-(5-methylfuran-2-yl)thiophene-3-carboxylate::ethyl 2-[({[(dimethylamino)carbonyl]amino}carbonothioyl)amino]-4-(5-methyl-2-furyl)-3-thiophenecarboxylate,C-C chemokine receptor type 6,, 47400
50496982,CCCCNC(=O)C1C(=O)N(O)C(=O)c2ccccc12,"InChI=1S/C14H16N2O4/c1-2-3-8-15-12(17)11-9-6-4-5-7-10(9)13(18)16(20)14(11)19/h4-7,11,20H,2-3,8H2,1H3,(H,15,17)",QQULFDYXVFUAMK-UHFFFAOYSA-N,50170912,CHEMBL3805930,Integrase,, 660
661572,CC(C)N(C)c1nc2CCN(CCc2c(Nc2ccc(nc2)C(F)(F)F)n1)c1ncccc1C(F)(F)F,"InChI=1S/C24H25F6N7/c1-14(2)36(3)22-34-18-9-12-37(21-17(23(25,26)27)5-4-10-31-21)11-8-16(18)20(35-22)33-15-6-7-19(32-13-15)24(28,29)30/h4-7,10,13-14H,8-9,11-12H2,1-3H3,(H,33,34,35)",QIKNKLZGIIGHNG-UHFFFAOYSA-N,245027,"US9422293, 266::US9738649, Example 266",Transient receptor potential cation channel subfamily V member 1,Homo sapiens, 120
865894,CC(C)c1c([nH]c2ccc(nc12)C1CCC(CC1)NCC(=O)N1CCOCC1)-c1cn2ncnc2c(C)c1C,"InChI=1S/C30H39N7O2/c1-18(2)27-28(23-16-37-30(32-17-33-37)20(4)19(23)3)35-25-10-9-24(34-29(25)27)21-5-7-22(8-6-21)31-15-26(38)36-11-13-39-14-12-36/h9-10,16-18,21-22,31,35H,5-8,11-15H2,1-4H3",ZCUIRECAFJFDEL-UHFFFAOYSA-N,428056,"US10544143, Example 490::US10730877, Example 490::US11053244, Example 490",Toll-like receptor 9,, 2127
50892144,CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,"InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1",BIIVYFLTOXDAOV-YVEFUNNKSA-N,5655,"2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-4H-chromen-4-one::CHEMBL428690::Flavopiridol::US10294218, Example Flavopiridol::US9617225, Flavopiridol",Death-associated protein kinase 1,Homo sapiens,
51187123,FC(F)(F)C(=O)CSCCc1ccccc1,"InChI=1S/C11H11F3OS/c12-11(13,14)10(15)8-16-7-6-9-4-2-1-3-5-9/h1-5H,6-8H2",UJAGOKUXPHIFEB-UHFFFAOYSA-N,50412689,CHEMBL460809,Liver carboxylesterase B-1,, 162
172919,O=C1NCN(c2ccccc2)C11CCN(CC2COc3ccccc3O2)CC1,"InChI=1S/C22H25N3O3/c26-21-22(25(16-23-21)17-6-2-1-3-7-17)10-12-24(13-11-22)14-18-15-27-19-8-4-5-9-20(19)28-18/h1-9,18H,10-16H2,(H,23,26)",JVGBTTIJPBFLTE-UHFFFAOYSA-N,50020192,"8-(2,3-Dihydro-benzo[1,4]dioxin-2-ylmethyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one::CHEMBL300555::Spiroxatrine",Alpha-2B adrenergic receptor,,
235817,Clc1ccc(cc1)-n1nc2c(cc1=O)[nH][nH]c2=O,"InChI=1S/C11H7ClN4O2/c12-6-1-3-7(4-2-6)16-9(17)5-8-10(15-16)11(18)14-13-8/h1-5,13H,(H,14,18)",BVWNEDJLGPEOJI-UHFFFAOYSA-N,52725,"5-(4-chlorophenyl)-1,2-dihydropyrazolo[4,3-c]pyridazine-3,6-dione::5-(4-chlorophenyl)-1,2-dihydropyrazolo[4,3-c]pyridazine-3,6-quinone::5-(4-chlorophenyl)-3-hydroxy-1,5-dihydro-6H-pyrazolo[4,3-c]pyridazin-6-one::MLS000755380::SMR000337771::cid_1475762",Disintegrin and metalloproteinase domain-containing protein 10,, 10075
51320165,Cn1c2nc3CN(CCn3c2c(=O)n(C)c1=O)[C@H]1CCc2ccccc12,"InChI=1S/C19H21N5O2/c1-21-17-16(18(25)22(2)19(21)26)24-10-9-23(11-15(24)20-17)14-8-7-12-5-3-4-6-13(12)14/h3-6,14H,7-11H2,1-2H3/t14-/m0/s1",RPKMNDYYVDIVKP-AWEZNQCLSA-N,50534194,CHEMBL4515367,Adenosine receptor A2b,Homo sapiens,
114065,CCOc1ccc(cc1)N1CSC2=C(C#N)C(CC(=O)N2C1)c1ccccc1Cl,"InChI=1S/C22H20ClN3O2S/c1-2-28-16-9-7-15(8-10-16)25-13-26-21(27)11-18(17-5-3-4-6-20(17)23)19(12-24)22(26)29-14-25/h3-10,18H,2,11,13-14H2,1H3",NHRWFZXWMCOFCE-UHFFFAOYSA-N,34523,"8-(2-chlorophenyl)-3-(4-ethoxyphenyl)-6-oxidanylidene-2,4,7,8-tetrahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile::8-(2-chlorophenyl)-3-(4-ethoxyphenyl)-6-oxo-2,4,7,8-tetrahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile::8-(2-chlorophenyl)-6-keto-3-p-phenetyl-2,4,7,8-tetrahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile::MLS000117274::SMR000094225::cid_5309663",Large T antigen,Simian virus 40, 17380
1162365,CC(C)[C@H]1COC(=O)N1c1ccnc(N[C@@H](C)c2cc(C)c(cn2)-c2ccnc(c2)C(F)(F)F)n1,"InChI=1S/C24H25F3N6O2/c1-13(2)19-12-35-23(34)33(19)21-6-8-29-22(32-21)31-15(4)18-9-14(3)17(11-30-18)16-5-7-28-20(10-16)24(25,26)27/h5-11,13,15,19H,12H2,1-4H3,(H,29,31,32)/t15-,19+/m0/s1",ARCBKTZOKAIYLK-HNAYVOBHSA-N,50279396,"CHEMBL4172087::US11311527, Cpd ID IDH305::US11376246, Cpd ID IDH305",Isocitrate dehydrogenase [NADP] cytoplasmic [R132C],, 4150
50623970,FC(F)c1nc2oc(=O)cc(CCCC3(CC3)c3ccccc3)c2c(=O)[nH]1,"InChI=1S/C20H18F2N2O3/c21-16(22)17-23-18(26)15-12(11-14(25)27-19(15)24-17)5-4-8-20(9-10-20)13-6-2-1-3-7-13/h1-3,6-7,11,16H,4-5,8-10H2,(H,23,24,26)",DKYRUKZCEHDDCS-UHFFFAOYSA-N,50337019,"2-(difluoromethyl)-5-(3-(1-phenylcyclopropyl)propyl)-3H-pyrano[2,3-d]pyrimidine-4,7-dione::CHEMBL1672643",Hydroxycarboxylic acid receptor 2,Homo sapiens,
450358,C[C@]1(CC2(CCC2)OC(N)=N1)c1cc(NC(=O)c2ncc(Cl)cc2F)ccc1F,"InChI=1S/C20H19ClF2N4O2/c1-19(10-20(5-2-6-20)29-18(24)27-19)13-8-12(3-4-14(13)22)26-17(28)16-15(23)7-11(21)9-25-16/h3-4,7-9H,2,5-6,10H2,1H3,(H2,24,27)(H,26,28)/t19-/m0/s1",MYVNXXFZPZMOFC-IBGZPJMESA-N,258290,"US9493485, 9-131",Beta-secretase 1,Homo sapiens, 87
50244697,Cc1ncc(n1CCOc1cccc(\C=N\Nc2nc(cs2)-c2ccc(Br)cc2)c1)[N+]([O-])=O,"InChI=1S/C22H19BrN6O3S/c1-15-24-13-21(29(30)31)28(15)9-10-32-19-4-2-3-16(11-19)12-25-27-22-26-20(14-33-22)17-5-7-18(23)8-6-17/h2-8,11-14H,9-10H2,1H3,(H,26,27)/b25-12+",LTSZWLXXTSHDQH-BRJLIKDPSA-N,50031293,CHEMBL3357058,3-oxoacyl-[acyl-carrier-protein] synthase 3,Escherichia coli, 20800
51192147,Cc1ccc(OCCn2ccc(=O)n(Cc3ccccc3)c2=O)cc1,"InChI=1S/C20H20N2O3/c1-16-7-9-18(10-8-16)25-14-13-21-12-11-19(23)22(20(21)24)15-17-5-3-2-4-6-17/h2-12H,13-15H2,1H3",DVSAGIGYEYXAET-UHFFFAOYSA-N,50490654,CHEMBL2337201,Reverse transcriptase,Human immunodeficiency virus 1,
50427504,O=C(Nc1ccn[nH]1)N1CCN(CC1)c1nc(ns1)-c1ccccc1,"InChI=1S/C16H17N7OS/c24-15(18-13-6-7-17-20-13)22-8-10-23(11-9-22)16-19-14(21-25-16)12-4-2-1-3-5-12/h1-7H,8-11H2,(H2,17,18,20,24)",RZQJFUXCPKGHDT-UHFFFAOYSA-N,50245067,"4-(3-phenyl-1,2,4-thiadiazol-5-yl)-N-(1H-pyrazol-5-yl)piperazine-1-carboxamide::CHEMBL488686",Fatty-acid amide hydrolase 1 [30-579],, 125
50092757,N[C@@H]1C[C@@H](NC(=O)c2ccc(O)cc2)[C@@H](C1)OC(=O)c1cc(O)c(C(=O)c2c(O)cccc2C(O)=O)c(O)c1,"InChI=1S/C27H24N2O10/c28-14-10-17(29-25(35)12-4-6-15(30)7-5-12)21(11-14)39-27(38)13-8-19(32)23(20(33)9-13)24(34)22-16(26(36)37)2-1-3-18(22)31/h1-9,14,17,21,30-33H,10-11,28H2,(H,29,35)(H,36,37)/t14-,17-,21-/m1/s1",FCVHMDURXUOCFY-SOIKWTOOSA-N,50055668,"4-(2-Carboxy-6-hydroxy-benzoyl)-3,5-dihydroxy-benzoic acid (1R,2R,4R)-4-amino-2-(4-hydroxy-benzoylamino)-cyclopentyl ester::CHEMBL432168",Protein kinase C zeta type,Homo sapiens, 1200
1135005,C[C@@H]1CN(CCO1)c1nc(C)cc(NC(=O)c2ccc(NS(=O)(=O)CF)cc2N2CCC3(CC3)CC2)n1,"InChI=1S/C25H33FN6O4S/c1-17-13-22(29-24(27-17)32-11-12-36-18(2)15-32)28-23(33)20-4-3-19(30-37(34,35)16-26)14-21(20)31-9-7-25(5-6-25)8-10-31/h3-4,13-14,18,30H,5-12,15-16H2,1-2H3,(H,27,28,29,33)/t18-/m1/s1",ZCQGLVASJYZJOU-GOSISDBHSA-N,535537,"(R)-4- ((Fluoromethyl)sulfonamido)- N-(6-methyl-2-(2- methylmorpholino)pyrimidin- 4-yl)-2-(6-azaspiro[2.5]octan- 6-yl)benzamide::US11236069, Example 6-3",Kinesin-like protein KIF18A [1-467],, 79.0
516365,CC(C)c1c([nH]c2ccc(cc12)C1CCN(CCC#N)CC1)-c1cc(c2ncnn2c1)C(C)(C)O,"InChI=1S/C28H34N6O/c1-18(2)25-22-14-20(19-8-12-33(13-9-19)11-5-10-29)6-7-24(22)32-26(25)21-15-23(28(3,4)35)27-30-17-31-34(27)16-21/h6-7,14-19,32,35H,5,8-9,11-13H2,1-4H3",GXECFFUJMBDDMR-UHFFFAOYSA-N,273428,"US10071079, Example 211::US10478424, Example 211",Toll-like receptor 8,, 212
1194977,OC(=O)[C@H](CCN(CCCCc1ccc2CCCNc2n1)CCC(F)F)Nc1ncc(cn1)C1CC1,"InChI=1S/C26H36F2N6O2/c27-23(28)11-15-34(13-2-1-5-21-9-8-19-4-3-12-29-24(19)32-21)14-10-22(25(35)36)33-26-30-16-20(17-31-26)18-6-7-18/h8-9,16-18,22-23H,1-7,10-15H2,(H,29,32)(H,35,36)(H,30,31,33)/t22-/m0/s1",WRAPGMNNYFJAFF-QFIPXVFZSA-N,465345,"US10793564, Compound 135::US11419869, Compound 135",Integrin alpha-V/beta-6,Homo sapiens, 150
431525,Cc1nc2c(OCc3c(F)cccc3F)cccn2c1C(=O)N[C@H]1[C@@H](Cc2ccccc12)C(O)=O,"InChI=1S/C26H21F2N3O4/c1-14-23(25(32)30-22-16-7-3-2-6-15(16)12-17(22)26(33)34)31-11-5-10-21(24(31)29-14)35-13-18-19(27)8-4-9-20(18)28/h2-11,17,22H,12-13H2,1H3,(H,30,32)(H,33,34)/t17-,22-/m1/s1",XMLVTBQYVNFTIZ-VGOFRKELSA-N,247306,"US9447090, 434",Guanylate cyclase soluble subunit alpha-1/beta-1,,
1004728,Nc1nccn2c(nc(-c3ccc(cc3)C(=O)Nc3cc(ccn3)C(F)(F)F)c12)[C@@H]1CCCCN1S(=O)(=O)C=C,"InChI=1S/C26H24F3N7O3S/c1-2-40(38,39)36-13-4-3-5-19(36)24-34-21(22-23(30)32-12-14-35(22)24)16-6-8-17(9-7-16)25(37)33-20-15-18(10-11-31-20)26(27,28)29/h2,6-12,14-15,19H,1,3-5,13H2,(H2,30,32)(H,31,33,37)/t19-/m0/s1",SSFQQODCTCCJNX-IBGZPJMESA-N,340131,"US10239883, Example 19::US10934296, Example 19::US9758524, Example 19",Tyrosine-protein kinase Lyn,Homo sapiens,
460048,Cn1ccc(COc2ccc3nc([C@@H]4[C@H](C(O)=O)C4(C)C)n(Cc4ccc(OC(F)(F)F)cc4)c3c2)n1,"InChI=1S/C26H25F3N4O4/c1-25(2)21(22(25)24(34)35)23-30-19-9-8-18(36-14-16-10-11-32(3)31-16)12-20(19)33(23)13-15-4-6-17(7-5-15)37-26(27,28)29/h4-12,21-22H,13-14H2,1-3H3,(H,34,35)/t21-,22+/m0/s1",HCBVSQDKTYZYKT-FCHUYYIVSA-N,145768,"US8952177, 122::US9089569, 122::US9695149, 122",Arachidonate 5-lipoxygenase-activating protein,Homo sapiens,
51203046,Oc1ccccc1\C=N\c1ccccc1\N=C\c1ccccc1O,"InChI=1S/C20H16N2O2/c23-19-11-5-1-7-15(19)13-21-17-9-3-4-10-18(17)22-14-16-8-2-6-12-20(16)24/h1-14,23-24H/b21-13+,22-14+",HXFYGSOGECBSOY-JFMUQQRKSA-N,50494678,CHEMBL1985188,Carbonic anhydrase 2,Homo sapiens,
50691026,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1,"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)",LHNIIDJUOCFXAP-UHFFFAOYSA-N,25028,"4-[2-(1H-indazol-4-yl)-6-[(4-methanesulfonylpiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine::GDC-0941::GDC0941::US10112932, pictilisib::US10851091, Compound pictilisib","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens,
51297514,CO[C@H]1C[C@@]2(C)C([C@H](O)C[C@H]3[C@@]4(C)CCC(=O)C(C)(C)[C@@H]4CC[C@]23C)=C1[C@H](C)C[C@H](O)[C@@H](OC(C)=O)C(C)(C)O,"InChI=1S/C33H54O7/c1-18(15-21(36)28(30(5,6)38)40-19(2)34)26-22(39-10)17-33(9)27(26)20(35)16-24-31(7)13-12-25(37)29(3,4)23(31)11-14-32(24,33)8/h18,20-24,28,35-36,38H,11-17H2,1-10H3/t18-,20-,21+,22+,23+,24+,28-,31+,32+,33+/m1/s1",MMSCSHVTCNYOAT-VWDUMGLQSA-N,50528851,CHEMBL4475517,Bile acid receptor,Homo sapiens,
198845,COc1ccc(nc1-c1cc(C)ncc1F)C(=O)N[C@@H](CC(O)=O)c1ccccc1C,"InChI=1S/C23H22FN3O4/c1-13-6-4-5-7-15(13)19(11-21(28)29)27-23(30)18-8-9-20(31-3)22(26-18)16-10-14(2)25-12-17(16)24/h4-10,12,19H,11H2,1-3H3,(H,27,30)(H,28,29)/t19-/m0/s1",MTSWQBRGBADNCL-IBGZPJMESA-N,47345,"US9029559, 470",Lysosomal protective protein,, 118.2
615572,COc1ccc(CN2CCCN(CC2)c2ccc(cn2)-c2cc(OCC(C)(C)O)cn3ncc(C#N)c23)cn1,"InChI=1S/C29H33N7O3/c1-29(2,37)20-39-24-13-25(28-23(14-30)17-33-36(28)19-24)22-6-7-26(31-16-22)35-10-4-9-34(11-12-35)18-21-5-8-27(38-3)32-15-21/h5-8,13,15-17,19,37H,4,9-12,18,20H2,1-3H3",XHFMRGOUXQOXJZ-UHFFFAOYSA-N,296804,"US10112942, Example 539::US10137124, Example 539::US10172851, Example 539::US10555944, Example 539::US10953005, Example 539","Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M]",, 250
50575376,O=C([C@H]1C[C@H](CN1)Oc1ccc(cc1)C#N)N1CCCN(CC1)C1CCC1,"InChI=1S/C21H28N4O2/c22-14-16-5-7-18(8-6-16)27-19-13-20(23-15-19)21(26)25-10-2-9-24(11-12-25)17-3-1-4-17/h5-8,17,19-20,23H,1-4,9-13,15H2/t19-,20-/m1/s1",DCLRBWCBZZADCC-WOJBJXKFSA-N,50317682,"4-((3R,5R)-5-(4-cyclobutyl-1,4-diazepane-1-carbonyl)pyrrolidin-3-yloxy)benzonitrile::CHEMBL1095011",Histamine H3 receptor,Homo sapiens,
50425195,COc1ccc(CC[C@@H](OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](C2CCCCC2)c2ccccc2)c2cccc(OCC(O)=O)c2)cc1OC,"InChI=1S/C39H47NO8/c1-45-34-22-20-27(24-35(34)46-2)19-21-33(30-16-11-17-31(25-30)47-26-36(41)42)48-39(44)32-18-9-10-23-40(32)38(43)37(28-12-5-3-6-13-28)29-14-7-4-8-15-29/h3,5-6,11-13,16-17,20,22,24-25,29,32-33,37H,4,7-10,14-15,18-19,21,23,26H2,1-2H3,(H,41,42)/t32-,33+,37+/m0/s1",POAFNNRQISTGEJ-QUBOUHRKSA-N,50125329,CHEMBL3623615,Peptidyl-prolyl cis-trans isomerase FKBP5,Homo sapiens,
677805,Cc1ccc(Oc2ccccn2)cc1-c1nccc2cc(ccc12)S(=O)(=O)Nc1ccncn1,"InChI=1S/C25H19N5O3S/c1-17-5-6-19(33-24-4-2-3-11-27-24)15-22(17)25-21-8-7-20(14-18(21)9-13-28-25)34(31,32)30-23-10-12-26-16-29-23/h2-16H,1H3,(H,26,29,30)",ANNMYRFWVOJSEY-UHFFFAOYSA-N,342948,"1-(2-methyl-5-(2-pyridinyloxy)phenyl)-N-4-pyrimidinyl-6-isoquinolinesulfonamide::US9776995, Example 40",Sodium channel protein type 9 subunit alpha,, 5690
349107,N=C1S\C(=C\c2ccco2)C(=O)N1c1nccs1,"InChI=1S/C11H7N3O2S2/c12-10-14(11-13-3-5-17-11)9(15)8(18-10)6-7-2-1-4-16-7/h1-6,12H/b8-6+,12-10?",RJHAJQSWEUEPCY-IIXGYHIASA-N,196158,"US9211296, Table 6, 12",DNA polymerase,, 32000
50777246,CCC1=C(OC(=O)N(C)C)c2cccn2-c2ccccc2O1,"InChI=1S/C17H18N2O3/c1-4-14-16(22-17(20)18(2)3)13-9-7-11-19(13)12-8-5-6-10-15(12)21-14/h5-11H,4H2,1-3H3",YGHGFQOXORJSOQ-UHFFFAOYSA-N,50052752,CHEMBL115704::Dimethyl-carbamic acid 5-ethyl-6-oxa-10b-aza-benzo[e]azulen-4-yl ester,Translocator protein,Rattus norvegicus,
945687,CC(C)(C)OC(=O)Nc1ccc2O[C@@H](CC(=O)NCCO)CN(c2c1)S(=O)(=O)c1cccc(c1)C(F)(F)F,"InChI=1S/C24H28F3N3O7S/c1-23(2,3)37-22(33)29-16-7-8-20-19(12-16)30(14-17(36-20)13-21(32)28-9-10-31)38(34,35)18-6-4-5-15(11-18)24(25,26)27/h4-8,11-12,17,31H,9-10,13-14H2,1-3H3,(H,28,32)(H,29,33)/t17-/m0/s1",MFGBKOWCPGDKEP-KRWDZBQOSA-N,352648,"(S)-tert-butyl (2-(2-((2- hydroxyethyl)amino)- 2-oxoethyl)-4-((3- (trifluoromethyl)phenyl) sulfonyl)-3,4- dihydro-2H- benzo[b][1,4]oxazin-6- yl)carbamate::US10745364, Example 37AJ::US9809561, 37AJ",Nuclear receptor ROR-gamma,, 5.73
50504723,Nc1ccc(cc1)-c1nc2ccccc2n2cccc12,"InChI=1S/C17H13N3/c18-13-9-7-12(8-10-13)17-16-6-3-11-20(16)15-5-2-1-4-14(15)19-17/h1-11H,18H2",DUTKRZVXBMKLQN-UHFFFAOYSA-N,50184319,CHEMBL3824080,DNA repair protein RAD51 homolog 1,Homo sapiens,>100000
454453,Nc1ncnc2n(cc(-c3ccc(Oc4c(F)c(F)cc(F)c4F)cc3F)c12)[C@@H]1CCN(C1)C#N,"InChI=1S/C23H15F5N6O/c24-15-5-12(35-21-19(27)16(25)6-17(26)20(21)28)1-2-13(15)14-8-34(11-3-4-33(7-11)9-29)23-18(14)22(30)31-10-32-23/h1-2,5-6,8,10-11H,3-4,7H2,(H2,30,31,32)/t11-/m1/s1",LDCONTUKJIBEOF-LLVKDONJSA-N,260644,"US10300066, Compound 118::US9532990, 118",Tyrosine-protein kinase BTK,Homo sapiens, 57
536761,CP(C)(=O)c1cc(cnc1F)-c1ccc2nc(oc2c1)-c1nc2ccccc2[nH]1,"InChI=1S/C21H16FN4O2P/c1-29(2,27)18-10-13(11-23-19(18)22)12-7-8-16-17(9-12)28-21(26-16)20-24-14-5-3-4-6-15(14)25-20/h3-11H,1-2H3,(H,24,25)",FGPOHRIUZZBAGW-UHFFFAOYSA-N,281546,"2-(1H-Benzo[d]imidazol-2-yl)-6-(5- (dimethylphosphoryl)pyridin-3- yl)benzo[d]oxazole bis(trifluoroacetate)::US10022387, Example 72","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens,<5000
484699,C[C@@H](Nc1nc(nc2nc(N(C)C3CCCC[C@@H]3O)n(C[C@H]3CC[C@H](C)CC3)c12)-c1noc(=O)[nH]1)C1CCC1,,,223706,"3-(6-{[(1r)-1- cyclobutylethyl]amino}- 8-{[(1r,2s)-2- hydroxycyclohexyl] (methyl)amino}-7- [(trans-4- methylcyclohexyl) methyl]-7h-purin-2- yl)-1,2,4-oxadiazol- 5(4h)-one::US9540377, 11.132::US9540377, 11.134",E3 ubiquitin-protein ligase Mdm2 [17-125],, 25.63
51211452,CC(=O)N[C@H](Cc1c[nH]c2ccc(Br)cc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O,"InChI=1S/C24H26BrN5O4/c1-14(31)29-21(10-16-12-27-19-8-7-17(25)11-18(16)19)24(34)30-20(23(33)28-13-22(26)32)9-15-5-3-2-4-6-15/h2-8,11-12,20-21,27H,9-10,13H2,1H3,(H2,26,32)(H,28,33)(H,29,31)(H,30,34)/t20-,21+/m0/s1",DXGRBXFKKUZQPR-LEWJYISDSA-N,50497851,CHEMBL3319087,Delta-type opioid receptor,Homo sapiens,
151695,Cc1ccc(c(C)c1)S(=O)(=O)N=C1C=C(Nc2cccc(c2)C(O)=O)C(=O)c2ccccc12,"InChI=1S/C25H20N2O5S/c1-15-10-11-23(16(2)12-15)33(31,32)27-21-14-22(24(28)20-9-4-3-8-19(20)21)26-18-7-5-6-17(13-18)25(29)30/h3-14,26H,1-2H3,(H,29,30)",RUWHEBZPTCVEMQ-UHFFFAOYSA-N,48039,"3-[[(4E)-4-(2,4-dimethylphenyl)sulfonylimino-1-keto-2-naphthyl]amino]benzoic acid::3-[[(4E)-4-(2,4-dimethylphenyl)sulfonylimino-1-oxidanylidene-naphthalen-2-yl]amino]benzoic acid::3-[[(4E)-4-(2,4-dimethylphenyl)sulfonylimino-1-oxo-2-naphthalenyl]amino]benzoic acid::3-[[(4E)-4-(2,4-dimethylphenyl)sulfonylimino-1-oxonaphthalen-2-yl]amino]benzoic acid::MLS000948061::SMR000620247::cid_5824726",C-C chemokine receptor type 6,, 39900
1164362,COc1cc2nc(N)n3nc(nc3c2cc1F)C1CCCN(c2cnn(CC(C)(C)O)c2)C1=O,"InChI=1S/C22H25FN8O3/c1-22(2,33)11-29-10-12(9-25-29)30-6-4-5-13(20(30)32)18-27-19-14-7-15(23)17(34-3)8-16(14)26-21(24)31(19)28-18/h7-10,13,33H,4-6,11H2,1-3H3,(H2,24,26)",XHUGNCIRTJIVJA-UHFFFAOYSA-N,551593,"US11312719, Example 139::rac-3-(5-amino-9-fluoro-8-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-2-yl)-1-(1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl)piperidin-2-one",Adenosine receptor A2b,Homo sapiens, 2824
50320156,COc1ccc2c(c1)N(CC1CC1)C(=O)C21CCN(CC2CCCCCCC2)CC1,"InChI=1S/C26H38N2O2/c1-30-22-11-12-23-24(17-22)28(19-21-9-10-21)25(29)26(23)13-15-27(16-14-26)18-20-7-5-3-2-4-6-8-20/h11-12,17,20-21H,2-10,13-16,18-19H2,1H3",VPULAKGHRZPYSW-UHFFFAOYSA-N,50173258,"1'-cyclooctylmethyl-1-cyclopropylmethyl-6-methoxyspiro[2,3-dihydro-1H-indole-3,4'-(hexahydropyridine)]-2-one::CHEMBL197959",Mu-type opioid receptor,Homo sapiens, 10000
50694073,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,"InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)",YCOYDOIWSSHVCK-UHFFFAOYSA-N,4851,(4-chlorophenyl)-[4-(4-pyridylmethyl)phthalazin-1-yl]amine::(A) PTK787::CGP 79787::CHEMBL101253::CHEMBL75232::N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)-1-phthalazinamine::N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine::PTK-787::PTK787::ZK222584::cid_151194,Proto-oncogene tyrosine-protein kinase Src,,
50207165,Cc1cc(C(=O)Nc2ccc(cc2)-c2ccccc2S(N)(=O)=O)n(n1)-c1cc2ccccc2cc1O,"InChI=1S/C27H22N4O4S/c1-17-14-24(31(30-17)23-15-19-6-2-3-7-20(19)16-25(23)32)27(33)29-21-12-10-18(11-13-21)22-8-4-5-9-26(22)36(28,34)35/h2-16,32H,1H3,(H,29,33)(H2,28,34,35)",FRKLXQVPIVHUTQ-UHFFFAOYSA-N,50114442,2-(3-Hydroxy-naphthalen-2-yl)-5-methyl-2H-pyrazole-3-carboxylic acid (2'-sulfamoyl-biphenyl-4-yl)-amide::CHEMBL431127,Coagulation factor X,Homo sapiens,>11000
50805912,CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O,"InChI=1S/C31H41N13O5/c1-17(45)41-25(10-19-13-35-15-39-19)29(48)44-26(11-20-14-36-16-40-20)30(49)42-23(7-4-8-37-31(33)34)28(47)43-24(27(32)46)9-18-12-38-22-6-3-2-5-21(18)22/h2-3,5-6,12-16,23-26,38H,4,7-11H2,1H3,(H2,32,46)(H,35,39)(H,36,40)(H,41,45)(H,42,49)(H,43,47)(H,44,48)(H4,33,34,37)/t23-,24-,25-,26-/m0/s1",ZACRQOAPRSMDDR-CQJMVLFOSA-N,50115383,2-[2-[2-Acetylamino-3-(3H-imidazol-4-yl)-propionylamino]-3-(3H-imidazol-4-yl)-propionylamino]-5-guanidino-pentanoic acid [1-carbamoyl-2-(1H-indol-3-yl)-ethyl]-amide::CHEMBL104010,Melanocortin receptor 3,Mus musculus,
283273,CC(C)[C@H]1COC(=O)N1c1ccnc(NC(C)c2nc(c(C)s2)-c2ccc(Cl)cc2)n1,"InChI=1S/C22H24ClN5O2S/c1-12(2)17-11-30-22(29)28(17)18-9-10-24-21(26-18)25-13(3)20-27-19(14(4)31-20)15-5-7-16(23)8-6-15/h5-10,12-13,17H,11H2,1-4H3,(H,24,25,26)/t13?,17-/m1/s1",GIRJNOHFFVVNAL-LRHAYUFXSA-N,146309,"US8957068, 411::US8957068, 412",Isocitrate dehydrogenase [NADP] cytoplasmic,, 2907
468901,Clc1ccc(CNc2cc(nn2C(=O)c2cccc3OCCOc23)-c2cccnc2=O)s1,,,162628,"US9687479, 108 3-(5-[(5-chlorothiophen-2-yl)methyl]amino-1-[(2,3-dihydro-1,4-benzodioxin-5-yl)carbonyl]-1H-pyrazol-3-yl)-1,2-dihydropyridin-2-one",Prothrombin,,<100
51393823,Clc1cncc(-c2cnn(Cc3ccccc3)c2)c1N1CCC2(CCNC2=O)CC1,"InChI=1S/C23H24ClN5O/c24-20-14-25-13-19(18-12-27-29(16-18)15-17-4-2-1-3-5-17)21(20)28-10-7-23(8-11-28)6-9-26-22(23)30/h1-5,12-14,16H,6-11,15H2,(H,26,30)",NHLXKIYNBUVQKH-UHFFFAOYSA-N,50563297,CHEMBL4788142,Cyclin-C,,
50775821,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,"InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1",BLJRIMJGRPQVNF-JTQLQIEISA-N,50292219,"(-)-3-morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole::(2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol::(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol::(S)-1-(1,1-(dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol::(S)-1-(tert-butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol::(S)-timolol::CHEMBL499::S-(-)-3-(3-tert-butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole::TIMOLOL",ATP-binding cassette sub-family C member 4,Homo sapiens, 133000
232476,CCc1ncnc(N2CCN(CC2)C(C)=O)c1C#Cc1ccc(N)nc1,"InChI=1S/C19H22N6O/c1-3-17-16(6-4-15-5-7-18(20)21-12-15)19(23-13-22-17)25-10-8-24(9-11-25)14(2)26/h5,7,12-13H,3,8-11H2,1-2H3,(H2,20,21)",GKROGJIGFRYBLZ-UHFFFAOYSA-N,111653,"US8618111, B-40",Serine/threonine-protein kinase mTOR,Homo sapiens, 32
719914,CC(C)(C)OC(=O)N1C[C@H](N(C(=O)C1)c1cc(ccn1)C#N)C(=O)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)c1cc(F)cc(F)c1,"InChI=1S/C34H31ClF4N6O5/c1-33(2,3)50-32(49)43-17-26(45(28(46)18-43)27-10-19(16-40)8-9-41-27)31(48)44(23-12-20(36)11-21(37)13-23)29(24-6-4-5-7-25(24)35)30(47)42-22-14-34(38,39)15-22/h4-13,22,26,29H,14-15,17-18H2,1-3H3,(H,42,47)/t26-,29-/m0/s1",NBBOZZYCTJIARB-WNJJXGMVSA-N,363608,"US10640534, Compound 97::US10689414, Compound 97::US10717764, Compound 97::US11021515, Compound 97::US9850277, Compound 97",Isocitrate dehydrogenase [NADP] cytoplasmic [R132C],,<500
50562451,CCCc1ccc(cc1)-c1oc(COc2ccc(OCC(O)=O)c(C)c2)nc1-c1ccc(OC)cc1,"InChI=1S/C29H29NO6/c1-4-5-20-6-8-22(9-7-20)29-28(21-10-12-23(33-3)13-11-21)30-26(36-29)17-34-24-14-15-25(19(2)16-24)35-18-27(31)32/h6-16H,4-5,17-18H2,1-3H3,(H,31,32)",XXWKUDASTWQWDH-UHFFFAOYSA-N,50312397,2-(4-((4-(4-Methoxyphenyl)-5-(4-propylphenyl)oxazol-2-yl)-methoxy)-2-methylphenoxy)acetic Acid::CHEMBL1079910,Peroxisome proliferator-activated receptor delta,,
1097546,CN1C(N)=NC(C1=O)(c1ccc(OC(F)F)c(C)c1)c1cc(F)c(F)c(F)c1,"InChI=1S/C18H14F5N3O2/c1-8-5-9(3-4-13(8)28-16(22)23)18(15(27)26(2)17(24)25-18)10-6-11(19)14(21)12(20)7-10/h3-7,16H,1-2H3,(H2,24,25)",BTHSYBYBUVFNRA-UHFFFAOYSA-N,519492,"US11142505, FAH-19",Beta-secretase 1,Homo sapiens, 960
51450102,CCc1cc(O)c(F)cc1-c1cc(NC2CCN(C)CC2)c2nc(N)ncc2c1,"InChI=1S/C22H26FN5O/c1-3-13-10-20(29)18(23)11-17(13)14-8-15-12-25-22(24)27-21(15)19(9-14)26-16-4-6-28(2)7-5-16/h8-12,16,26,29H,3-7H2,1-2H3,(H2,24,25,27)",USBPOYIQCXNWQH-UHFFFAOYSA-N,50585511,CHEMBL5077126,Non-receptor tyrosine-protein kinase TYK2/Tyrosine-protein kinase JAK1/Tyrosine-protein kinase JAK2,Homo sapiens, 16
720659,Cc1oc2CCCCc2c1NC(=O)C[C@H]1C[C@@H]2CC[C@H](C1)N2CC(=O)NC(C)(C)C,"InChI=1S/C24H37N3O3/c1-15-23(19-7-5-6-8-20(19)30-15)25-21(28)13-16-11-17-9-10-18(12-16)27(17)14-22(29)26-24(2,3)4/h16-18H,5-14H2,1-4H3,(H,25,28)(H,26,29)/t16-,17-,18+",ZCUFTQMRCLHCBO-NNZMDNLPSA-N,363979,"US9856250, 19",Voltage-dependent T-type calcium channel subunit alpha-1H,, 48.0
51046198,COc1ccc(cc1OC)C(=O)OCCCCN[C@H]1CCCc2[nH]c(=O)ccc12,"InChI=1S/C22H28N2O5/c1-27-19-10-8-15(14-20(19)28-2)22(26)29-13-4-3-12-23-17-6-5-7-18-16(17)9-11-21(25)24-18/h8-11,14,17,23H,3-7,12-13H2,1-2H3,(H,24,25)/t17-/m0/s1",NYKBSLRJTXLUOV-KRWDZBQOSA-N,50426926,CHEMBL2323716,Acetylcholinesterase,Rattus norvegicus, 4100
51429825,CNC(=O)c1cc(cs1)-n1ncc2cc(Nc3c(F)cccc3Cl)cnc12,"InChI=1S/C18H13ClFN5OS/c1-21-18(26)15-6-12(9-27-15)25-17-10(7-23-25)5-11(8-22-17)24-16-13(19)3-2-4-14(16)20/h2-9,24H,1H3,(H,21,26)",JOWZBTCWJHFAQE-UHFFFAOYSA-N,50577640,CHEMBL4857979,Mitogen-activated protein kinase 8,Homo sapiens, 213
593704,C[C@@H]1[C@@H](CCCN1c1cnc(C(N)=O)c(Nc2ccc(cc2)C2(CCCC2)C#N)n1)NC(=O)N(C)C,"InChI=1S/C26H34N8O2/c1-17-20(31-25(36)33(2)3)7-6-14-34(17)21-15-29-22(23(28)35)24(32-21)30-19-10-8-18(9-11-19)26(16-27)12-4-5-13-26/h8-11,15,17,20H,4-7,12-14H2,1-3H3,(H2,28,35)(H,30,32)(H,31,36)/t17-,20-/m1/s1",FWMLVTFHWBYRMT-YLJYHZDGSA-N,309779,"3-(4-(1-cyanocyclopentyl)phenylamino)-5-((2R,3R)-3-(3,3-dimethylureido)-2-methylpiperidin-1-yl)pyrazine-2-carboxamide::US9656988, Example 248",Tyrosine-protein kinase BTK,Homo sapiens,<10
1107530,N[C@@H]1C[C@H](N(C1)C(=O)c1cn2cc(Cl)ccc2n1)c1nc(cs1)C(=O)NCc1ncn2ccc(Cl)cc12,"InChI=1S/C24H20Cl2N8O2S/c25-13-3-4-32-12-29-16(19(32)5-13)7-28-22(35)18-11-37-23(31-18)20-6-15(27)9-34(20)24(36)17-10-33-8-14(26)1-2-21(33)30-17/h1-5,8,10-12,15,20H,6-7,9,27H2,(H,28,35)/t15-,20+/m1/s1",FKQMDAAKAOWPEB-QRWLVFNGSA-N,524403,"2-((2S,4R)-4-amino-1-(6- chloroimidazo[1,2-a]pyridine-2- carbonyl)pyrrolidin-2-yl)-N-((7- chloroimidazo[1,5-a]pyridin-1- yl)methyl)thiazole-4-carboxamide::US11168083, Example 55",Coagulation factor X,Homo sapiens,>10000
853028,O=C(NCc1ccccc1)Nc1ccc(cc1)C1CCNC1,"InChI=1S/C18H21N3O/c22-18(20-12-14-4-2-1-3-5-14)21-17-8-6-15(7-9-17)16-10-11-19-13-16/h1-9,16,19H,10-13H2,(H2,20,21,22)",WGWIXBVIMOHDAY-UHFFFAOYSA-N,250099,"US10501411, Example 9::US9452980, 9",Trace amine-associated receptor 1,Rattus norvegicus,
51425892,OC(c1cnn(c1C1CC1)-c1cccc(NS(=O)(=O)c2ccccc2)c1)C(F)(F)F,"InChI=1S/C20H18F3N3O3S/c21-20(22,23)19(27)17-12-24-26(18(17)13-9-10-13)15-6-4-5-14(11-15)25-30(28,29)16-7-2-1-3-8-16/h1-8,11-13,19,25,27H,9-10H2",VYKCMXSYCRPJNC-UHFFFAOYSA-N,50575968,CHEMBL4872323,Nuclear factor erythroid 2-related factor 2,,
50378437,Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1Nc1ncccc1-c1ccncn1,"InChI=1S/C24H18F3N5O/c1-15-7-8-18(31-23(33)16-4-2-5-17(12-16)24(25,26)27)13-21(15)32-22-19(6-3-10-29-22)20-9-11-28-14-30-20/h2-14H,1H3,(H,29,32)(H,31,33)",NESXBRNDMQUVNG-UHFFFAOYSA-N,50207861,CHEMBL245549::N-(4-methyl-3-(3-(pyrimidin-4-yl)pyridin-2-ylamino)phenyl)-3-(trifluoromethyl)benzamide::N-{4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]PHENYL}-3-(TRIFLUOROMETHYL)BENZAMIDE,Vascular endothelial growth factor receptor 2,Homo sapiens, 61
876621,Cn1nc(c2cccc(Cl)c12)C(C)(C)NC(=O)C1CNCCOC1,"InChI=1S/C17H23ClN4O2/c1-17(2,20-16(23)11-9-19-7-8-24-10-11)15-12-5-4-6-13(18)14(12)22(3)21-15/h4-6,11,19H,7-10H2,1-3H3,(H,20,23)",RHSMUJZGIDLNEM-UHFFFAOYSA-N,275969,"US10071974, Example 80::US10071974, Example 81::US10071974, Example 82::US10577336, Example 82",Somatostatin receptor type 4,,
50501582,COc1ccc(NC(=O)CSc2nc3ccccc3c(=O)n2CCc2ccccn2)cc1,"InChI=1S/C24H22N4O3S/c1-31-19-11-9-18(10-12-19)26-22(29)16-32-24-27-21-8-3-2-7-20(21)23(30)28(24)15-13-17-6-4-5-14-25-17/h2-12,14H,13,15-16H2,1H3,(H,26,29)",IEFZMSHPGLWDFW-UHFFFAOYSA-N,50180631,CHEMBL3813973,Prostaglandin G/H synthase 2,Ovis aries, 800
51095443,CC(C)Cc1c([nH]c2c(cccc12)[N+]([O-])=O)C(O)=O,"InChI=1S/C13H14N2O4/c1-7(2)6-9-8-4-3-5-10(15(18)19)11(8)14-12(9)13(16)17/h3-5,7,14H,6H2,1-2H3,(H,16,17)",HCEBMPIOXCOVPW-UHFFFAOYSA-N,50449196,CHEMBL3127751,"Fructose-1,6-bisphosphatase 1",, 10300
889892,Cc1cccc(Nc2nc(Nc3cccc(NC(=O)C(=C)Cn4cccn4)c3)ncc2F)c1,"InChI=1S/C24H22FN7O/c1-16-6-3-7-18(12-16)28-22-21(25)14-26-24(31-22)30-20-9-4-8-19(13-20)29-23(33)17(2)15-32-11-5-10-27-32/h3-14H,2,15H2,1H3,(H,29,33)(H2,26,28,30,31)",IGGMIWAUQDAFGD-UHFFFAOYSA-N,397309,"US10596172, Compound I-98::US10828300, Compound I-98::US11351168, Compound I-98::US9987276, Compound I-98",Tyrosine-protein kinase BTK,Homo sapiens, 550
959952,COc1cccc(COc2ccccc2CN(CC[C@@H](N)C(O)=O)Cc2ccccc2OCc2cccc(OC)c2)c1,"InChI=1S/C34H38N2O6/c1-39-29-13-7-9-25(19-29)23-41-32-15-5-3-11-27(32)21-36(18-17-31(35)34(37)38)22-28-12-4-6-16-33(28)42-24-26-10-8-14-30(20-26)40-2/h3-16,19-20,31H,17-18,21-24,35H2,1-2H3,(H,37,38)/t31-/m1/s1",DVPGIFOQXACXCT-WJOKGBTCSA-N,464408,"US10793514, Compound 12",Neutral amino acid transporter B(0),, 5100
51441962,Cc1cc(Br)ccc1NC(=O)COc1ccc2cc(\C=C3\SC(=O)NC3=O)ccc2c1,"InChI=1S/C23H17BrN2O4S/c1-13-8-17(24)5-7-19(13)25-21(27)12-30-18-6-4-15-9-14(2-3-16(15)11-18)10-20-22(28)26-23(29)31-20/h2-11H,12H2,1H3,(H,25,27)(H,26,28,29)/b20-10+",OVYVATCIVXIUCL-KEBDBYFISA-N,50582535,CHEMBL5087514,Histone deacetylase 4,Homo sapiens, 550
50474794,[Na+].[Na+].[Na+].[Na+].CC(C)=CCC\C(C)=C\CC(Cc1cn(CCC=C(C)C)nn1)(P([O-])([O-])=O)P([O-])([O-])=O,"InChI=1S/C20H35N3O6P2.4Na/c1-16(2)8-6-10-18(5)11-12-20(30(24,25)26,31(27,28)29)14-19-15-23(22-21-19)13-7-9-17(3)4;;;;/h8-9,11,15H,6-7,10,12-14H2,1-5H3,(H2,24,25,26)(H2,27,28,29);;;;/q;4*+1/p-4/b18-11+;;;;",SPTJYBFALOMEBK-HSEBTKBPSA-J,50151852,CHEMBL3775694,Geranylgeranyl pyrophosphate synthase,Homo sapiens, 380
1078869,CC(C)N(C)C(=O)c1cn(CC2(O)CCN(CC2)C(=O)C[C@@H](C)c2ccccc2)c(=O)cc1-c1ccc(C)cc1,"InChI=1S/C33H41N3O4/c1-23(2)34(5)32(39)29-21-36(31(38)20-28(29)27-13-11-24(3)12-14-27)22-33(40)15-17-35(18-16-33)30(37)19-25(4)26-9-7-6-8-10-26/h6-14,20-21,23,25,40H,15-19,22H2,1-5H3/t25-/m1/s1",BOAGDSFECJZRPO-RUZDIDTESA-N,514353,"US11053213, Example 96",Ubiquitin carboxyl-terminal hydrolase 19,, 27500
50462731,Oc1ccc(CN=Nc2ccc(Br)cc2)c(O)c1,"InChI=1S/C13H11BrN2O2/c14-10-2-4-11(5-3-10)16-15-8-9-1-6-12(17)7-13(9)18/h1-7,17-18H,8H2",SGMBOFMCHLWMIY-UHFFFAOYSA-N,50279925,"4-[(4-Bromo-phenyl)-hydrazonomethyl]-benzene-1,3-diol::CHEMBL68327",Tyrosine-protein kinase Lck,, 521000
50980969,CNS(=O)(=O)c1ccc2c(c[nH]c(=O)c2c1)C(=O)NC[C@@H](O)CN1CCC(CC1)Oc1ccc(Cl)c(Cl)c1,"InChI=1S/C25H28Cl2N4O6S/c1-28-38(35,36)18-3-4-19-20(11-18)24(33)30-13-21(19)25(34)29-12-15(32)14-31-8-6-16(7-9-31)37-17-2-5-22(26)23(27)10-17/h2-5,10-11,13,15-16,28,32H,6-9,12,14H2,1H3,(H,29,34)(H,30,33)/t15-/m1/s1",AMEQLQYPRVOFMB-OAHLLOKOSA-N,50402117,CHEMBL2207284,C-C chemokine receptor type 3,Homo sapiens,
451567,CC(C)[C@]1(C)C(=N)N[C@@](C)(CS1(=O)=O)c1cc(N)ccc1F,"InChI=1S/C15H22FN3O2S/c1-9(2)15(4)13(18)19-14(3,8-22(15,20)21)11-7-10(17)5-6-12(11)16/h5-7,9H,8,17H2,1-4H3,(H2,18,19)/t14-,15+/m0/s1",ASLNFVWKKHRNQF-LSDHHAIUSA-N,259241,"US9499502, Table A: Entry 28",Beta-secretase 1,Homo sapiens,
50711806,COC[C@H]1CN(C(=O)O1)c1ccc(OCC[C@@H](O)C(F)(F)F)cc1,"InChI=1S/C15H18F3NO5/c1-22-9-12-8-19(14(21)24-12)10-2-4-11(5-3-10)23-7-6-13(20)15(16,17)18/h2-5,12-13,20H,6-9H2,1H3/t12-,13-/m1/s1",IALVDLPLCLFBCF-CHWSQXEVSA-N,50361617,BEFLOXATONE,Amine oxidase [flavin-containing] B,Bos taurus,
50049285,NC(N)=NCCCCN=C(N)N,"InChI=1S/C6H16N6/c7-5(8)11-3-1-2-4-12-6(9)10/h1-4H2,(H4,7,8,11)(H4,9,10,12)",HGMDNMBBCKDWTQ-UHFFFAOYSA-N,86165,Arcaine::CAS_2227::CHEMBL102740::NSC_2227,Deoxyhypusine synthase,Rattus norvegicus, 179000
956877,Nc1nn(Cc2ccc(cc2)C(=O)N2CCCC2)cc1C(=O)NCCOc1cccc(Cl)c1,"InChI=1S/C24H26ClN5O3/c25-19-4-3-5-20(14-19)33-13-10-27-23(31)21-16-30(28-22(21)26)15-17-6-8-18(9-7-17)24(32)29-11-1-2-12-29/h3-9,14,16H,1-2,10-13,15H2,(H2,26,28)(H,27,31)",SMHRRWCCPUBJDL-UHFFFAOYSA-N,463373,"3-amino-N-[2-(3-chlorophenoxy)ethyl]-1-({4-[(pyrrolidin-1-::US10781181, Example 51",Plasma kallikrein,, 427
50715279,CCCCC#Cc1nc(N)c2ncn([C@@H]3OC[C@@H](O)[C@H]3O)c2n1,"InChI=1S/C15H19N5O3/c1-2-3-4-5-6-10-18-13(16)11-14(19-10)20(8-17-11)15-12(22)9(21)7-23-15/h8-9,12,15,21-22H,2-4,7H2,1H3,(H2,16,18,19)/t9-,12-,15-/m1/s1",KVSBFXTVPHRJRK-DDHOLCJHSA-N,50363168,CHEMBL1945563,Adenosine receptor A2a,Homo sapiens,
50507304,O=C(NC1CCCCC1)c1ccc(nc1)C#Cc1ccccc1,"InChI=1S/C20H20N2O/c23-20(22-19-9-5-2-6-10-19)17-12-14-18(21-15-17)13-11-16-7-3-1-4-8-16/h1,3-4,7-8,12,14-15,19H,2,5-6,9-10H2,(H,22,23)",UVQBVTGQRSXVAW-UHFFFAOYSA-N,50293644,CHEMBL550624::N-cyclohexyl-6-(2-phenylethynyl)nicotinamide,Metabotropic glutamate receptor 5,Homo sapiens,
945898,CC(C[C@H]1CN(c2cc(NC(=O)OC(C)(C)C(F)(F)F)ccc2O1)S(=O)(=O)c1cccc(c1)C(F)(F)F)C(=O)NS(=O)(=O)C1CC1,"InChI=1S/C27H29F6N3O8S2/c1-15(23(37)35-45(39,40)19-8-9-19)11-18-14-36(46(41,42)20-6-4-5-16(12-20)26(28,29)30)21-13-17(7-10-22(21)43-18)34-24(38)44-25(2,3)27(31,32)33/h4-7,10,12-13,15,18-19H,8-9,11,14H2,1-3H3,(H,34,38)(H,35,37)/t15?,18-/m0/s1",VSGFMXADRZZHBV-PKHIMPSTSA-N,352868,"1,1,1-trifluoro-2-methylpropan-2-yl ((S)-2-((R and S)-3- (cyclopropanesulfonamido)-2-methyl- 3-oxopropyl)-4-((3- (trifluoromethyl)phenyl)sulfonyl)-3,4- dihydro-2H-benzo[b][1,4]oxazin-6- yl)carbamate::US10745364, Example 98D::US9809561, 98D",Nuclear receptor ROR-gamma,, 29.7
1260357,O=C(N1CCC2(C1)CCC(=O)NC2=O)c1ccc2ncsc2c1,"InChI=1S/C16H15N3O3S/c20-13-3-4-16(15(22)18-13)5-6-19(8-16)14(21)10-1-2-11-12(7-10)23-9-17-11/h1-2,7,9H,3-6,8H2,(H,18,20,22)",JWJJQVYGSHTVAA-UHFFFAOYSA-N,594658,"2-(Benzo[d]thiazole-6-carbonyl)-2,7-diazaspiro[4.5]decane-6,8-dione::US11584748, Example 25::US11584748, Example 56",Protein cereblon,,
50084600,C[C@H](c1ccccc1)n1c(C)c(C)c2c1nc([nH]c2=O)-c1ccc(Cl)cc1,"InChI=1S/C22H20ClN3O/c1-13-14(2)26(15(3)16-7-5-4-6-8-16)21-19(13)22(27)25-20(24-21)17-9-11-18(23)12-10-17/h4-12,15H,1-3H3,(H,24,25,27)/t15-/m1/s1",DYWXNZMNTJKRLH-OAHLLOKOSA-N,50051663,"2-(4-Chloro-phenyl)-5,6-dimethyl-7-((R)-1-phenyl-ethyl)-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one::CHEMBL84368",Adenosine receptor A1,Rattus norvegicus,
1726,CCN1c2nc(ccc2N(C)C(=O)c2cccnc12)-c1cccs1,"InChI=1S/C18H16N4OS/c1-3-22-16-12(6-4-10-19-16)18(23)21(2)14-9-8-13(20-17(14)22)15-7-5-11-24-15/h4-11H,3H2,1-2H3",YFEJBNCFMFTPFP-UHFFFAOYSA-N,1555,"2-ethyl-9-methyl-5-(thiophen-2-yl)-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one::Dipyridodiazepinone deriv. 44","Gag-Pol polyprotein [600-1027,Y780C]/[600-1155,Y780C]",Human immunodeficiency virus 1, 420
411264,Cc1nc(-c2cnc(C)cn2)n(n1)-c1cc(nc(C)n1)N1CC(C1)c1nc2ccccc2n1C,"InChI=1S/C24H24N10/c1-14-10-26-19(11-25-14)24-29-16(3)31-34(24)22-9-21(27-15(2)28-22)33-12-17(13-33)23-30-18-7-5-6-8-20(18)32(23)4/h5-11,17H,12-13H2,1-4H3",JOXPFBFNJLVXON-UHFFFAOYSA-N,236015,"US9365562, 53","Isoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)",,
51436495,Nc1nc2n(CCc3ccc(NC(=O)CCCCCCC(=O)NO)cc3)ncc2c2nc(nn12)-c1ccco1,"InChI=1S/C26H29N9O4/c27-26-31-24-19(25-30-23(32-35(25)26)20-6-5-15-39-20)16-28-34(24)14-13-17-9-11-18(12-10-17)29-21(36)7-3-1-2-4-8-22(37)33-38/h5-6,9-12,15-16,38H,1-4,7-8,13-14H2,(H2,27,31)(H,29,36)(H,33,37)",GDORGFVYOGNYSG-UHFFFAOYSA-N,50580296,CHEMBL5093149,Histone deacetylase 1,Homo sapiens, 8.0
195610,COc1ccc(OC)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2C)c1,"InChI=1S/C17H20N2O4/c1-9-15(11(3)20)10(2)18-16(9)17(21)19-13-8-12(22-4)6-7-14(13)23-5/h6-8,18H,1-5H3,(H,19,21)",VMSBWVMXFXIZAZ-UHFFFAOYSA-N,89636,"4-acetyl-N-(2,5-dimethoxyphenyl)-3,5-dimethyl-1H-pyrrole-2-carboxamide::MLS000053898::N-(2,5-dimethoxyphenyl)-4-ethanoyl-3,5-dimethyl-1H-pyrrole-2-carboxamide::SMR000064307::cid_867000",Corticotropin-releasing factor-binding protein,Homo sapiens,
50329926,Cn1cc(cn1)[C@H]1C[C@H]2CSC(N)=N[C@]2(CO1)c1ccc(F)cc1F,"InChI=1S/C19H15F6N5O/c20-12-3-13(21)18(23)17(22)11(12)7-29-6-10(5-26-29)27-16(31)8-30-15(19(24)25)4-14(28-30)9-1-2-9/h3-6,9,19H,1-2,7-8H2,(H,27,31)",JBVZPXHGLQAXRZ-UHFFFAOYSA-N,41536,"US8865706, 15",Beta-secretase 1,Homo sapiens, 4.0
1148832,Cc1cccc(c1)-c1c(sc(c1-c1ccncc1)-c1ccc(F)cc1)C#CCCO,"InChI=1S/C26H20FNOS/c1-18-5-4-6-21(17-18)24-23(7-2-3-16-29)30-26(20-8-10-22(27)11-9-20)25(24)19-12-14-28-15-13-19/h4-6,8-15,17,29H,3,16H2,1H3",QFDJKEPSCQYTSU-UHFFFAOYSA-N,542044,"US11273153, Compound 3.48",Mitogen-activated protein kinase 14,Homo sapiens,
189680,Brc1ccc(Oc2ccc(C#N)c(c2)C#N)cc1,InChI=1S/C14H7BrN2O/c15-12-2-5-13(6-3-12)18-14-4-1-10(8-16)11(7-14)9-17/h1-7H,ZHWODKAGCZSVQP-UHFFFAOYSA-N,86778,"Phthalonitrile analogue, 4g",Amine oxidase [flavin-containing] A,, 1.92e+4
51406594,OC(=O)c1ccc(Cl)cc1-c1cccc2n(CCCOc3cccc4ccccc34)ccc12,"InChI=1S/C28H22ClNO3/c29-20-12-13-24(28(31)32)25(18-20)22-9-4-10-26-23(22)14-16-30(26)15-5-17-33-27-11-3-7-19-6-1-2-8-21(19)27/h1-4,6-14,16,18H,5,15,17H2,(H,31,32)",KGDQVKRMGYAUAI-UHFFFAOYSA-N,50568324,CHEMBL4860820,Bcl-2-like protein 1,Homo sapiens,
1066242,COc1ncc(cn1)-c1ccc(cc1Cl)C(=O)N1[C@@H](CC[C@@H]1c1ccccc1Cl)C(O)=O,"InChI=1S/C23H19Cl2N3O4/c1-32-23-26-11-14(12-27-23)15-7-6-13(10-18(15)25)21(29)28-19(8-9-20(28)22(30)31)16-4-2-3-5-17(16)24/h2-7,10-12,19-20H,8-9H2,1H3,(H,30,31)/t19-,20+/m1/s1",IUEWEZIMIOSGAE-UXHICEINSA-N,404159,"(2S,5R)-1-(3-chloro-4-(2-methoxypyrimidin-5-yl)benzoyl)-5-(2-chlorophenyl)pyrrolidine-2-carboxylic acid::US10017468, Compound 329::US10781171, Compound 329::US11072582, Compound 329",Free fatty acid receptor 2,Homo sapiens,
51449025,NS(=O)(=O)c1ccc(CNc2nc(Nc3cccc(NC(=O)N4CCCC4)c3)ncc2Br)cc1,"InChI=1S/C22H24BrN7O3S/c23-19-14-26-21(29-20(19)25-13-15-6-8-18(9-7-15)34(24,32)33)27-16-4-3-5-17(12-16)28-22(31)30-10-1-2-11-30/h3-9,12,14H,1-2,10-11,13H2,(H,28,31)(H2,24,32,33)(H2,25,26,27,29)",OEZHSZIDGUKBRK-UHFFFAOYSA-N,50585191,CHEMBL5079149,Non-receptor tyrosine-protein kinase TYK2,Homo sapiens, 48
665820,CCS(=O)(=O)Cc1ccccc1-c1ccc(c(F)c1)-c1cnc(N)cn1,"InChI=1S/C19H18FN3O2S/c1-2-26(24,25)12-14-5-3-4-6-15(14)13-7-8-16(17(20)9-13)18-10-23-19(21)11-22-18/h3-11H,2,12H2,1H3,(H2,21,23)",GOGOLDJIHLAMNI-UHFFFAOYSA-N,169344,"US9079866, 749::US9745328, Compound 749::US9884878, Compound 749",Flap endonuclease 1,Homo sapiens,
51089452,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@]2([C@H]1c1cccc(Cl)c1F)C(=O)Nc1cc(Cl)sc21)C(O)=O,"InChI=1S/C29H28Cl2FN3O5S/c1-28(2,3)12-19-29(24-17(34-27(29)39)11-20(31)41-24)21(14-6-5-7-15(30)22(14)32)23(35-19)25(36)33-16-9-8-13(26(37)38)10-18(16)40-4/h5-11,19,21,23,35H,12H2,1-4H3,(H,33,36)(H,34,39)(H,37,38)/t19-,21-,23+,29+/m0/s1",YXQHJKFKRZDXHV-HNXAPSNLSA-N,50446196,CHEMBL3109041,E3 ubiquitin-protein ligase Mdm2,Homo sapiens, 7.0
50793987,CN1CCN(CC1)c1nc2ccccc2c2-c3ccsc3CCc12,"InChI=1S/C20H21N3S/c1-22-9-11-23(12-10-22)20-16-6-7-18-15(8-13-24-18)19(16)14-4-2-3-5-17(14)21-20/h2-5,8,13H,6-7,9-12H2,1H3",UQLASFOWQSFVMZ-UHFFFAOYSA-N,50076402,"6-(4-Methyl-piperazin-1-yl)-4,5-dihydro-3-thia-7-aza-cyclopenta[c]phenanthrene::CHEMBL288069",5-hydroxytryptamine receptor 2C,,
50124443,CCn1cc(C(=O)CC(=O)C(=O)OC)c2ccccc12,"InChI=1S/C15H15NO4/c1-3-16-9-11(10-6-4-5-7-12(10)16)13(17)8-14(18)15(19)20-2/h4-7,9H,3,8H2,1-2H3",CLULSGGUQBPYDX-UHFFFAOYSA-N,50154403,"4-(1-Ethyl-1H-indol-3-yl)-2,4-dioxo-butyric acid methyl ester::CHEMBL364097::Methyl 4-(1-Ethyl-1H-indol-3-yl)-2-hydroxy-4-oxo-but-2-enoate",Integrase,Human immunodeficiency virus 1,>100000
555420,C[C@@H]1C[C@H](N)CN(C1)c1ccncc1NC(=O)c1ccc2ccc(cc2n1)N1CC(C)(C)C1,"InChI=1S/C26H32N6O/c1-17-10-19(27)14-31(13-17)24-8-9-28-12-23(24)30-25(33)21-7-5-18-4-6-20(11-22(18)29-21)32-15-26(2,3)16-32/h4-9,11-12,17,19H,10,13-16,27H2,1-3H3,(H,30,33)/t17-,19+/m1/s1",UURNQJRXOUIRSZ-MJGOQNOKSA-N,291213,"N-{4-[(3S,5R)-3-Amino-5-methylpiperidin-1-yl]pyridin-3-yl}-7-(3,3-dimethylazetidin-1-yl)quinoline-2-carboxamide::US9580418, Example 33::US9890162, Example 33",Serine/threonine-protein kinase pim-1,,<10
50701907,Ic1ccc(CSc2nnc(o2)-c2ccc3OCCOc3c2)cc1,"InChI=1S/C17H13IN2O3S/c18-13-4-1-11(2-5-13)10-24-17-20-19-16(23-17)12-3-6-14-15(9-12)22-8-7-21-14/h1-6,9H,7-8,10H2",JEKRLGMLAOGKSA-UHFFFAOYSA-N,50357376,CHEMBL1917267,Telomerase reverse transcriptase,Homo sapiens, 3660
51121262,C1CC(C1)c1ccnc2N3CCNC[C@H]3CCc12,"InChI=1S/C15H21N3/c1-2-11(3-1)13-6-7-17-15-14(13)5-4-12-10-16-8-9-18(12)15/h6-7,11-12,16H,1-5,8-10H2/t12-/m1/s1",QRFXLVHUVBURRJ-GFCCVEGCSA-N,50459714,"CHEMBL4204710::US10836764, Compound 149",5-hydroxytryptamine receptor 2C,Homo sapiens,
51187013,Nc1n[nH]c2nccc(-c3ccc(NC(=O)Nc4cccc(c4)C(F)(F)F)cc3)c12,"InChI=1S/C20H15F3N6O/c21-20(22,23)12-2-1-3-14(10-12)27-19(30)26-13-6-4-11(5-7-13)15-8-9-25-18-16(15)17(24)28-29-18/h1-10H,(H2,26,27,30)(H3,24,25,28,29)",LYHXSDWIWVVZPB-UHFFFAOYSA-N,50372153,CHEMBL255955,Vascular endothelial growth factor receptor 2,Homo sapiens, 1.7
50480708,CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,"InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1",IZTQOLKUZKXIRV-YRVFCXMDSA-N,21147,(3S)-3-[(2S)-2-[(2S)-2-{2-[(2S)-2-[(2S)-2-[(3S)-3-amino-3-formamidopropanoic acid]-3-[4-(sulfooxy)phenyl]propanamido]-4-(methylsulfanyl)butanamido]acetamido}-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-{[(1S)-1-carbamoyl-2-phenylethyl]carbamoyl}propanoic acid::CCK-8::CCK-8(SO3)::CHEMBL1121::H-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2::SINCALIDE::Syncalide::[125I]CCK-8,Gastrin/cholecystokinin type B receptor,Homo sapiens, 1.2
213503,COc1ccc(\C=C(\C(=O)NCc2ccc(cc2)C(=O)Nc2ccccc2N)c2ccc(C)cc2)cc1OC,"InChI=1S/C32H31N3O4/c1-21-8-13-24(14-9-21)26(18-23-12-17-29(38-2)30(19-23)39-3)32(37)34-20-22-10-15-25(16-11-22)31(36)35-28-7-5-4-6-27(28)33/h4-19H,20,33H2,1-3H3,(H,34,37)(H,35,36)/b26-18+",KEAXYLKXZYDTTP-NLRVBDNBSA-N,97686,"US8476255, 29",Histone deacetylase 1,Mus musculus, 57
50478202,COc1ccc(\C=C2/CC(C)OC2=O)cc1,"InChI=1S/C13H14O3/c1-9-7-11(13(14)16-9)8-10-3-5-12(15-2)6-4-10/h3-6,8-9H,7H2,1-2H3/b11-8+",ONYWBNVSVNXDNV-DHZHZOJOSA-N,50154356,CHEMBL3775969,Dual specificity tyrosine-phosphorylation-regulated kinase 1B,, 10500
39448,CCCc1cc(ccc1OCCCOc1ccc2[C@H](CC(O)=O)CCc2c1)-c1nc2OCCCc2s1,"InChI=1S/C29H33NO5S/c1-2-5-21-16-22(29-30-28-26(36-29)6-3-13-35-28)9-12-25(21)34-15-4-14-33-23-10-11-24-19(17-23)7-8-20(24)18-27(31)32/h9-12,16-17,20H,2-8,13-15,18H2,1H3,(H,31,32)/t20-/m0/s1",DDAMWXQFEJPURM-FQEVSTJZSA-N,21803,"2-[(1S)-5-[3-(2-propyl-4-{5H,6H,7H-pyrano[2,3-d][1,3]thiazol-2-yl}phenoxy)propoxy]-2,3-dihydro-1H-inden-1-yl]acetic acid::Indanylacetic Acid Analog, 34r",Peroxisome proliferator-activated receptor delta,,
787796,CC(C)(C)c1nc(cc(n1)C(F)(F)F)N1CCN(CCCCNC(=O)N2CCN(C(=O)C2)c2ccccc2)CC1,"InChI=1S/C28H38F3N7O2/c1-27(2,3)25-33-22(28(29,30)31)19-23(34-25)36-15-13-35(14-16-36)12-8-7-11-32-26(40)37-17-18-38(24(39)20-37)21-9-5-4-6-10-21/h4-6,9-10,19H,7-8,11-18,20H2,1-3H3,(H,32,40)",UGRUVQBETHORJS-UHFFFAOYSA-N,301917," N-(4-(4-(2-(tert-Butyl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)butyl)-3-oxo-4-phenylpiperazine-1-carboxamide ::US9598387, Compound 102::US9969743, 102",D(3) dopamine receptor,,
124777,Cc1ccc(cc1)C(=O)CNc1cccc(Cl)c1,"InChI=1S/C15H14ClNO/c1-11-5-7-12(8-6-11)15(18)10-17-14-4-2-3-13(16)9-14/h2-9,17H,10H2,1H3",VSOAYRFQTKQDCE-UHFFFAOYSA-N,67225,2-(3-Chloro-phenylamino)-1-p-tolyl-ethanone::2-(3-chloroanilino)-1-(4-methylphenyl)ethanone::2-(3-chloroanilino)-1-(p-tolyl)ethanone::2-[(3-chlorophenyl)amino]-1-(4-methylphenyl)ethanone::MLS000561352::SMR000177334::cid_788408,Apelin receptor,Homo sapiens, 4130
56742,CC(C)CNC(=O)c1ccc(c(c1)C(O)=O)-c1ccc(cc1C(=O)Nc1ccc(cc1)C(N)=N)-c1ccsc1CO,"InChI=1S/C31H30N4O5S/c1-17(2)15-34-29(37)20-6-10-24(26(14-20)31(39)40)23-9-5-19(22-11-12-41-27(22)16-36)13-25(23)30(38)35-21-7-3-18(4-8-21)28(32)33/h3-14,17,36H,15-16H2,1-2H3,(H3,32,33)(H,34,37)(H,35,38)(H,39,40)",REKBLSLNDZXMEV-UHFFFAOYSA-N,31495,"substituted biphenyl derivative, 36ai",Coagulation factor X,Homo sapiens, 450
808908,Cc1ccc(CC(=O)Nc2cn(CCCCn3cc(nn3)C(=O)NCc3cccnc3)nn2)cn1,"InChI=1S/C23H26N10O2/c1-17-6-7-18(13-25-17)11-22(34)27-21-16-33(31-29-21)10-3-2-9-32-15-20(28-30-32)23(35)26-14-19-5-4-8-24-12-19/h4-8,12-13,15-16H,2-3,9-11,14H2,1H3,(H,26,35)(H,27,34)",NZGOGFLFOHRLCQ-UHFFFAOYSA-N,404978,"1-(4-{4-[2-(6-methylpyridin-3- yl)acetamido]-1H-1,2,3-triazol-1- yl}butyl)-N-(pyridin-3-ylmethyl)- 1H-1,2,3-triazole-4-carboxamide::US10344025, Example 322::US11370786, Example 322","Glutaminase kidney isoform, mitochondrial",Homo sapiens, 300
50647120,CN(CCCNC(=O)c1ccc2c(c1)N(Cc1ccc(C)cc1C)C(=O)c1ccccc1S2=O)C1CCCCC1,"InChI=1S/C33H39N3O3S/c1-23-14-15-26(24(2)20-23)22-36-29-21-25(32(37)34-18-9-19-35(3)27-10-5-4-6-11-27)16-17-31(29)40(39)30-13-8-7-12-28(30)33(36)38/h7-8,12-17,20-21,27H,4-6,9-11,18-19,22H2,1-3H3,(H,34,37)",ZJRYVYSMLLTUKI-UHFFFAOYSA-N,50347282,CHEMBL1796130,L-cysteine:1D-myo-inositol 2-amino-2-deoxy-alpha-D-glucopyranoside ligase,Mycobacterium tuberculosis, 2000000
264644,COc1cc(ccn1)N1CCN(C1=O)c1cnccc1C,"InChI=1S/C15H16N4O2/c1-11-3-5-16-10-13(11)19-8-7-18(15(19)20)12-4-6-17-14(9-12)21-2/h3-6,9-10H,7-8H2,1-2H3",AOBJYZSGNJYOIH-UHFFFAOYSA-N,132138,"USRE45173, 72A","Steroid 17-alpha-hydroxylase/17,20 lyase",Homo sapiens, 9.4
808128,CN1CCC(CC1)Oc1ccc(nc1)-c1cnc2c(cnn2c1)-c1cccc2nc(C)ccc12,"InChI=1S/C27H26N6O/c1-18-6-8-23-22(4-3-5-26(23)31-18)24-16-30-33-17-19(14-29-27(24)33)25-9-7-21(15-28-25)34-20-10-12-32(2)13-11-20/h3-9,14-17,20H,10-13H2,1-2H3",ILUYOBAWAMCPBZ-UHFFFAOYSA-N,161928,"US10017516, Compound 60::US9682983, 60",Activin receptor type-1,Homo sapiens, 155
678355,Cc1cc2c(ccc3nnc(C)n23)n1Cc1ccccn1,"InChI=1S/C16H15N5/c1-11-9-15-14(6-7-16-19-18-12(2)21(15)16)20(11)10-13-5-3-4-8-17-13/h3-9H,10H2,1-2H3",ZFYQTIVFJMZMOL-UHFFFAOYSA-N,343408,"US10442803, Example 7::US11091484, Example 7::US9777003, Example 7",Bromodomain-containing protein 4 [42-168],, 550
1185753,COc1ccc(OCCN2CCNC(=O)C2)cc1Nc1ncc(Cl)c(Nc2ccc3ccccc3c2P(C)(C)=O)n1,"InChI=1S/C29H32ClN6O4P/c1-39-25-11-9-20(40-15-14-36-13-12-31-26(37)18-36)16-24(25)34-29-32-17-22(30)28(35-29)33-23-10-8-19-6-4-5-7-21(19)27(23)41(2,3)38/h4-11,16-17H,12-15,18H2,1-3H3,(H,31,37)(H2,32,33,34,35)",DRXIRBQDBFODMM-UHFFFAOYSA-N,561452,"US11390625, Compound 28::US11390625, Example 28","Epidermal growth factor receptor [1-18,20-1210,T790M,C797S]",, 185
50597191,CC(=O)OCc1cc(ccc1C\N=C(/S)NCc1ccc(NS(C)(=O)=O)cc1)C(C)(C)C,"InChI=1S/C23H31N3O4S2/c1-16(27)30-15-19-12-20(23(2,3)4)9-8-18(19)14-25-22(31)24-13-17-6-10-21(11-7-17)26-32(5,28)29/h6-12,26H,13-15H2,1-5H3,(H2,24,25,31)",KFHFJFSHOSPKIS-UHFFFAOYSA-N,50224194,CHEMBL47473,Transient receptor potential cation channel subfamily V member 1/2/4,Rattus norvegicus, 580
51434799,COc1ncc-2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCc1cncc(c1)-c1ncnc3c(C)c-2sc13,"InChI=1S/C26H20N6O4S2/c1-14-21-24-22(31-13-30-21)17-6-15(9-27-11-17)10-28-25(33)16-4-3-5-19(7-16)38(34,35)32-20-8-18(23(14)37-24)12-29-26(20)36-2/h3-9,11-13,32H,10H2,1-2H3,(H,28,33)",CWLUZOJADRKJSM-UHFFFAOYSA-N,50579635,CHEMBL4868512,Serine/threonine-protein kinase pim-1,, 43
51002378,Cn1c2cc([nH]c2c(=O)n(C)c1=O)-c1ccc(OCC(=O)Nc2nc3ccccc3[nH]2)cc1,"InChI=1S/C23H20N6O4/c1-28-18-11-17(24-20(18)21(31)29(2)23(28)32)13-7-9-14(10-8-13)33-12-19(30)27-22-25-15-5-3-4-6-16(15)26-22/h3-11,24H,12H2,1-2H3,(H2,25,26,27,30)",RHXRPAQOUNYAHJ-UHFFFAOYSA-N,50410777,CHEMBL203043,Adenosine receptor A2b,Homo sapiens,
50084863,CC(C)(C)CC[C@@H](N1C(=O)C(=N[C@@]11CC[C@@H](CC1)C(C)(C)C)c1cc(F)cc(F)c1)c1ccc(cc1)C(=O)NCc1nn[nH]n1,"InChI=1S/C34H43F2N7O2/c1-32(2,3)14-13-27(21-7-9-22(10-8-21)30(44)37-20-28-39-41-42-40-28)43-31(45)29(23-17-25(35)19-26(36)18-23)38-34(43)15-11-24(12-16-34)33(4,5)6/h7-10,17-19,24,27H,11-16,20H2,1-6H3,(H,37,44)(H,39,40,41,42)/t24-,27-,34-/m1/s1",UMDCPMLQYQJRGI-OWWAFECUSA-N,50007225,CHEMBL3238217,Glucagon receptor,, 110
743165,CN([C@H]1CCN(Cc2nc(C)oc2C(F)(F)F)C1)c1cc(F)c(cc1C)S(=O)(=O)Nc1cscn1,"InChI=1S/C21H23F4N5O3S2/c1-12-6-18(35(31,32)28-19-10-34-11-26-19)15(22)7-17(12)29(3)14-4-5-30(8-14)9-16-20(21(23,24)25)33-13(2)27-16/h6-7,10-11,14,28H,4-5,8-9H2,1-3H3/t14-/m0/s1",ODMSQVRRGMVXCI-AWEZNQCLSA-N,373887,"(S)-2-fluoro-5-methyl-4-(methyl(1-((2-methyl-5-(trifluoromethyl)oxazol-4-yl)methyl)pyrrolidin-3-yl)amino)-N-(thiazol-4-yl)benzenesulfonamide::US10246453, Example 154",Sodium channel protein type 1 subunit alpha,, 16556
841333,CN1CCN(CC1)S(=O)(=O)N(Cc1ccc(cn1)-c1nnc(o1)C(F)F)c1ccccc1,"InChI=1S/C20H22F2N6O3S/c1-26-9-11-27(12-10-26)32(29,30)28(17-5-3-2-4-6-17)14-16-8-7-15(13-23-16)19-24-25-20(31-19)18(21)22/h2-8,13,18H,9-12,14H2,1H3",TZZYLOQLBZNTEZ-UHFFFAOYSA-N,419605,"US10464911, Example 33",Histone deacetylase 1,Homo sapiens, 15.0
259072,CN(C)CCNc1ccc(CO)c2oc3ccc(O)cc3c(=O)c12,"InChI=1S/C18H20N2O4/c1-20(2)8-7-19-14-5-3-11(10-21)18-16(14)17(23)13-9-12(22)4-6-15(13)24-18/h3-6,9,19,21-22H,7-8,10H2,1-2H3",BOTXZPXSICDQHE-UHFFFAOYSA-N,94854,"1-[2-(dimethylamino)ethylamino]-4-(hydroxymethyl)-7-oxidanyl-xanthen-9-one::1-[2-(dimethylamino)ethylamino]-7-hydroxy-4-(hydroxymethyl)-9-xanthenone::1-[2-(dimethylamino)ethylamino]-7-hydroxy-4-(hydroxymethyl)xanthen-9-one::1-[2-(dimethylamino)ethylamino]-7-hydroxy-4-methylol-xanthone::9H-Xanthen-9-one, 1-[[2-(dimethylamino)ethyl]amino]- 7-hydroxy-4-(hydroxymethyl)-::MLS002702888::SMR001566706::cid_337396",Transthyretin,,>55162
50971540,CC#CCO[C@@H]1C[C@H]2[C@@H]3CCC(=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)C=CC(=O)C=C12,"InChI=1S/C23H28O3/c1-4-5-12-26-20-14-16-17-6-7-21(25)23(17,3)11-9-18(16)22(2)10-8-15(24)13-19(20)22/h8,10,13,16-18,20H,6-7,9,11-12,14H2,1-3H3/t16-,17-,18-,20+,22+,23-/m0/s1",GNDYBZKXORBCFO-KVAKACLVSA-N,50398453,CHEMBL2179109,Aromatase,Homo sapiens, 112.3
50767796,CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1Cc2ccccc2CN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N)C(N)=O,"InChI=1S/C64H98N18O13S/c1-37(2)32-46(57(89)75-42(54(69)86)26-31-96-3)74-53(85)35-73-55(87)47(33-38-14-5-4-6-15-38)79-60(92)50-34-39-16-7-8-17-40(39)36-82(50)63(95)45(23-25-52(68)84)77-56(88)43(22-24-51(67)83)76-58(90)49-21-13-30-81(49)62(94)44(19-9-10-27-65)78-59(91)48-20-12-29-80(48)61(93)41(66)18-11-28-72-64(70)71/h4-8,14-17,37,41-50H,9-13,18-36,65-66H2,1-3H3,(H2,67,83)(H2,68,84)(H2,69,86)(H,73,87)(H,74,85)(H,75,89)(H,76,90)(H,77,88)(H,78,91)(H,79,92)(H4,70,71,72)/t41-,42-,43-,44-,45-,46-,47-,48-,49-,50-/m0/s1",XIUBIMRSCFRWTN-SARDKLJWSA-N,50030165,Arg-Pro-Lys-Pro-Gln-Gln-Tic-Phe-Gly-Leu-Met::CHEMBL2372444,Substance-K receptor,, 520
6435,Cc1c(O)cccc1C(=O)N[C@@H](Cc1ccccc1)[C@H](O)C(=O)N1C[C@@H](Cl)C[C@H]1C(=O)NC(C)(C)C,"InChI=1S/C27H34ClN3O5/c1-16-19(11-8-12-22(16)32)24(34)29-20(13-17-9-6-5-7-10-17)23(33)26(36)31-15-18(28)14-21(31)25(35)30-27(2,3)4/h5-12,18,20-21,23,32-33H,13-15H2,1-4H3,(H,29,34)(H,30,35)/t18-,20-,21-,23-/m0/s1",SAFCQBPFQXDREG-ROQCDXFCSA-N,4124,"(2S,4S)-N-tert-butyl-4-chloro-1-[(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-phenylbutanoyl]pyrrolidine-2-carboxamide::(3-Hydroxy-2-methylbenzoyl)-(2(S)-hydroxy-3(S)-amino-phenylbutanoyl)-4(S)-Cl-Pro-NH-t-Bu::AHPBA deriv. 9::CHEMBL113958",Dimer of Gag-Pol polyprotein [489-587],Human immunodeficiency virus 1, 0.8
50218577,CC(=O)CNc1nc(nc2nc(C)cn12)-c1ccccc1,"InChI=1S/C15H15N5O/c1-10-9-20-14(16-8-11(2)21)18-13(19-15(20)17-10)12-6-4-3-5-7-12/h3-7,9H,8H2,1-2H3,(H,16,17,18,19)",VGUQKUXXKQGMDW-UHFFFAOYSA-N,50120765,"1-(7-Methyl-2-phenyl-imidazo[1,2-a][1,3,5]triazin-4-ylamino)-propan-2-one::CHEMBL146234",Adenosine receptor A1,Bos taurus,
50745886,OC(=O)C(CCC\C=C(/c1ccccc1)c1cccnc1)Sc1ccccc1,"InChI=1S/C24H23NO2S/c26-24(27)23(28-21-13-5-2-6-14-21)16-8-7-15-22(19-10-3-1-4-11-19)20-12-9-17-25-18-20/h1-6,9-15,17-18,23H,7-8,16H2,(H,26,27)/b22-15+",NXOOOQXFKKSYNW-PXLXIMEGSA-N,50026528,7-Phenyl-2-phenylsulfanyl-7-pyridin-3-yl-hept-6-enoic acid::CHEMBL329064,Thromboxane-A synthase,Homo sapiens, 33
50078772,C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1c1ccc(F)cc1C)NC1CC1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,"InChI=1S/C27H30F7N3O/c1-15-10-20(28)4-7-23(15)24-14-22(35-21-5-6-21)8-9-37(24)25(38)36(3)16(2)17-11-18(26(29,30)31)13-19(12-17)27(32,33)34/h4,7,10-13,16,21-22,24,35H,5-6,8-9,14H2,1-3H3/t16-,22+,24-/m1/s1",VPSGABLRZGFPPI-CFJRQAHESA-N,50417975,CHEMBL1672057,Substance-P receptor,Homo sapiens,
947318,C[C@H](O)CNC(=O)c1cnn2ccc(nc12)N1CCCC1c1cncc(F)c1,"InChI=1S/C19H21FN6O2/c1-12(27)8-22-19(28)15-11-23-26-6-4-17(24-18(15)26)25-5-2-3-16(25)13-7-14(20)10-21-9-13/h4,6-7,9-12,16,27H,2-3,5,8H2,1H3,(H,22,28)/t12-,16?/m0/s1",CUAZXICLJJKGFD-HKALDPMFSA-N,127736,"US10251889, Example 109::US10758542, Example 109::US8791123, 109::US9782415, Example 109::US9796724, Example 109",Tyrosine-protein kinase JAK2 [808-1132],,>1000
803127,C[C@@H]1CC[C@H](CN1C(=O)c1ccccc1OC(F)(F)F)n1nc(C)c(n1)C(C)(C)O,"InChI=1S/C20H25F3N4O3/c1-12-9-10-14(27-24-13(2)17(25-27)19(3,4)29)11-26(12)18(28)15-7-5-6-8-16(15)30-20(21,22)23/h5-8,12,14,29H,9-11H2,1-4H3/t12-,14-/m1/s1",NSAJAKGXXXKIQN-TZMCWYRMSA-N,401851,"2-{5-Methyl-2-[(3R,6R)-6- methyl-1-{[2- (trifluoromethoxy)phenyl] carbonyl}piperidin-3-yl]-2H- 1,2,3-triazol-4-yl}propan-2-ol::US10010539, 67",Orexin/Hypocretin receptor type 1,Rattus norvegicus, 10.1
1089756,C[C@H](CO)Nc1n[nH]c2nccc(Oc3ccc(NC(=O)c4cc(nn(-c5ccc(F)cc5)c4=O)C(C)C)cc3F)c12,,,517036,"(R)-N-(3-fluoro-4-((3- ((1-hydroxypropan-2- yl)amino)-1H- pyrazolo[3,4-b]pyridin- 4-yl)oxy)phenyl)-2-(4- fluorophenyl)-6- isopropyl-3-oxo-2,3- dihydropyridazine-4- carboxamide::US11104676, Example 106",Hepatocyte growth factor receptor [Y1230H],, 6.40
1130067,CO[C@]1(CN2CCN3CCCC[C@@H]3C2)\C=C\C[C@H](C)[C@@H](CCO[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)S(=O)(=O)NC(=O)c2ccc3OC[C@]4(CCCc5cc(Cl)ccc45)CN(C[C@@H]4CC[C@@H]14)c3c2,"InChI=1S/C59H77ClN4O6SSi/c1-43-16-14-31-59(68-5,41-62-33-34-63-32-13-12-18-48(63)39-62)52-26-23-46(52)38-64-40-58(30-15-17-44-36-47(60)25-27-51(44)58)42-69-54-28-24-45(37-53(54)64)56(65)61-71(66,67)55(43)29-35-70-72(57(2,3)4,49-19-8-6-9-20-49)50-21-10-7-11-22-50/h6-11,14,19-22,24-25,27-28,31,36-37,43,46,48,52,55H,12-13,15-18,23,26,29-30,32-35,38-42H2,1-5H3,(H,61,65)/b31-14+/t43-,46-,48+,52+,55+,58-,59-/m0/s1",SVKPJASVOYHCTB-BIYQAEMBSA-N,533904,"US11224601, Example 359",Bcl-2-like protein 11 [51-76]/Induced myeloid leukemia cell differentiation protein Mcl-1 [171-327],, 2.08
890766,OCC1CCc2c1c(ccc2Oc1cc(F)cc(F)c1)S(=O)(=O)C(F)F,"InChI=1S/C17H14F4O4S/c18-10-5-11(19)7-12(6-10)25-14-3-4-15(26(23,24)17(20)21)16-9(8-22)1-2-13(14)16/h3-7,9,17,22H,1-2,8H2",DGRCYAWGQLKYNI-UHFFFAOYSA-N,437736,"US10597366, Compound 24",Endothelial PAS domain-containing protein 1,Homo sapiens, 920
50663578,Cc1cn2c(cnc2c(Nc2ccc(C(=O)N3CCOCC3)c(Cl)c2)n1)-c1cn[nH]c1,"InChI=1S/C21H20ClN7O2/c1-13-12-29-18(14-9-24-25-10-14)11-23-20(29)19(26-13)27-15-2-3-16(17(22)8-15)21(30)28-4-6-31-7-5-28/h2-3,8-12H,4-7H2,1H3,(H,24,25)(H,26,27)",AXMMFQYWZDPEFR-UHFFFAOYSA-N,50354445,CHEMBL1836810,Tyrosine-protein kinase Lck,, 2000
50401956,OC[C@@H](N1CCCn2cc(cc2C1=O)-c1ccnc(NC2CC3(COC3)C2)n1)c1ccccc1,"InChI=1S/C26H29N5O3/c32-15-23(18-5-2-1-3-6-18)31-10-4-9-30-14-19(11-22(30)24(31)33)21-7-8-27-25(29-21)28-20-12-26(13-20)16-34-17-26/h1-3,5-8,11,14,20,23,32H,4,9-10,12-13,15-17H2,(H,27,28,29)/t23-/m1/s1",OWPUQESWKHKBDC-HSZRJFAPSA-N,50115396,CHEMBL3608463,Mitogen-activated protein kinase 1,Homo sapiens, 0.040000
737236,Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1cc(N2CCOCC2)c(=O)n(CCC#N)c1,"InChI=1S/C27H27F2N5O3/c1-18-4-5-21(32-25(35)19-6-8-31-24(15-19)27(2,28)29)16-22(18)20-14-23(33-10-12-37-13-11-33)26(36)34(17-20)9-3-7-30/h4-6,8,14-17H,3,9-13H2,1-2H3,(H,32,35)",KARKXYOHJUTQHZ-UHFFFAOYSA-N,77892,"US10245267, Example 334::US10709712, Example 334::US9694016, 334",Serine/threonine-protein kinase B-raf [V600E],, 2.30
50233817,COc1cc2CCN(Cc3cnc(N)nc3N)[C@H](C)c2c2OCOc12,"InChI=1S/C17H21N5O3/c1-9-13-10(5-12(23-2)14-15(13)25-8-24-14)3-4-22(9)7-11-6-20-17(19)21-16(11)18/h5-6,9H,3-4,7-8H2,1-2H3,(H4,18,19,20,21)/t9-/m1/s1",NTMLNTRPMUIDQA-SECBINFHSA-N,50128535,"5-(4-Methoxy-9-methyl-6,9-dihydro-7H-[1,3]dioxolo[4,5-h]isoquinolin-8-ylmethyl)-pyrimidine-2,4-diamine::CHEMBL310468",Dihydrofolate reductase,Homo sapiens, 9.8
51142303,C\C=C(\C)C(=O)OCC1(C)[C@@H]2C[C@@H](C)[C@@]34C=C(C)[C@H](OC(=O)C(\C)=C/C)[C@@]3(O)[C@H](O)C(C)=C[C@@H]([C@H]12)C4=O,"InChI=1S/C30H40O7/c1-9-15(3)26(33)36-14-28(8)21-12-19(7)29-13-18(6)25(37-27(34)16(4)10-2)30(29,35)23(31)17(5)11-20(22(21)28)24(29)32/h9-11,13,19-23,25,31,35H,12,14H2,1-8H3/b15-9-,16-10-/t19-,20+,21-,22+,23-,25+,28?,29-,30+/m1/s1",IMQVWZKEFSFWCH-FRTLHQRBSA-N,50468103,CHEMBL4295025,G protein-activated inward rectifier potassium channel 4,Homo sapiens, 1450
50512025,NCCCOc1ccccc1C(=O)Nc1nc2ccc(Oc3ccccc3)cc2s1,"InChI=1S/C23H21N3O3S/c24-13-6-14-28-20-10-5-4-9-18(20)22(27)26-23-25-19-12-11-17(15-21(19)30-23)29-16-7-2-1-3-8-16/h1-5,7-12,15H,6,13-14,24H2,(H,25,26,27)",GYBCZPSNDNTEHI-UHFFFAOYSA-N,50295698,2-(3-Amino-propoxy)-N-(6-phenoxy-benzothiazol-2-yl)-benzamide::CHEMBL563655,Voltage-dependent N-type calcium channel subunit alpha-1B,,
754826,C[C@@H]1C[C@H](N)CN(C1)c1c2CC[C@H](O)c2ncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(cc1F)C(C)(C)O,"InChI=1S/C29H32F3N5O3/c1-14-8-16(33)13-37(12-14)27-17-4-7-23(38)25(17)34-11-22(27)36-28(39)21-6-5-18(30)26(35-21)24-19(31)9-15(10-20(24)32)29(2,3)40/h5-6,9-11,14,16,23,38,40H,4,7-8,12-13,33H2,1-3H3,(H,36,39)/t14-,16+,23+/m1/s1",AFSHCISYYIAZAH-WREIHNQOSA-N,377237,"N-{4-[(3S,5R)-3-Amino-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-[2,6-difluoro-4-(1-hydroxy-1-methylethyl)phenyl]-5-fluoropyridine-2-carboxamide::US10265307, Example 67-1::US10517858, Example 67 (Diastereoisomer 1)::US10828290, Example 67 (Diastereoisomer 1)::US11229631, Example 67 Diastereoisomer 1",Serine/threonine-protein kinase pim-2,Homo sapiens,<100
50404923,OP(O)(=O)C(F)(Cc1cccnc1)P(O)(O)=O,"InChI=1S/C7H10FNO6P2/c8-7(16(10,11)12,17(13,14)15)4-6-2-1-3-9-5-6/h1-3,5H,4H2,(H2,10,11,12)(H2,13,14,15)",HHDUHWLBPDOLIL-UHFFFAOYSA-N,50225999,"1-fluoro-2-(3-pyridinyl)-ethylidene-1,1-bisphosphonic acid::CHEMBL437758",Farnesyl pyrophosphate synthase,Homo sapiens, 16.4
50786350,CN(C)c1cc(Nc2nn(cc2C(N)=O)[C@H]2COCC[C@@H]2C#N)cc(F)n1,"InChI=1S/C17H20FN7O2/c1-24(2)15-6-11(5-14(18)22-15)21-17-12(16(20)26)8-25(23-17)13-9-27-4-3-10(13)7-19/h5-6,8,10,13H,3-4,9H2,1-2H3,(H2,20,26)(H,21,22,23)/t10-,13+/m1/s1",AHHGVSZRWGXENV-MFKMUULPSA-N,50250928,CHEMBL4092626,Tyrosine-protein kinase JAK1,Homo sapiens, 0.180000
872103,CCOc1cc(-c2ccc(nc2)N2CCN(CC2)C(=O)[C@@H](O)C(C)C)c2c(cnn2c1)C#N,"InChI=1S/C24H28N6O3/c1-4-33-19-11-20(22-18(12-25)14-27-30(22)15-19)17-5-6-21(26-13-17)28-7-9-29(10-8-28)24(32)23(31)16(2)3/h5-6,11,13-16,23,31H,4,7-10H2,1-3H3/t23-/m0/s1",MTEJEZLZCRERST-QHCPKHFHSA-N,296231,"US10112942, Example 38::US10137124, Example 38::US10172851, Example 38::US10555944, Example 38::US10953005, Example 38",Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114],, 353
575570,CC(N1CC2CCC(C1)O2)C(=O)Nc1cc(ccc1OC(F)(F)F)C(=O)Nc1ccc(nc1)-c1cccc(F)c1,"InChI=1S/C28H26F4N4O4/c1-16(36-14-21-7-8-22(15-36)39-21)26(37)35-24-12-18(5-10-25(24)40-28(30,31)32)27(38)34-20-6-9-23(33-13-20)17-3-2-4-19(29)11-17/h2-6,9-13,16,21-22H,7-8,14-15H2,1H3,(H,34,38)(H,35,37)",XTYSNFAOAGFDBE-UHFFFAOYSA-N,300500,"N-[6-(3-fluorophenyl)pyridin-3-yl]-3-{[2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)propanoyl]amino}-4-(trifluoromethoxy)benzamide::US10130633, Example 70",Protein Wnt-3a,Homo sapiens, 6300
1002000,O=C(N1CCCC1c1cnccn1)c1cc(on1)-c1ccc2OCOc2c1,"InChI=1S/C19H16N4O4/c24-19(23-7-1-2-15(23)14-10-20-5-6-21-14)13-9-17(27-22-13)12-3-4-16-18(8-12)26-11-25-16/h3-6,8-10,15H,1-2,7,11H2",QSINZVQQPUJCJD-UHFFFAOYSA-N,483269,"US10919885, Compound No. 418",Stearoyl-CoA desaturase,,>45000
475193,COc1cc2c(cc1-c1c(C)noc1C)[nH]c1nc(C)nc(-c3ccc(NC(=O)N4CCN(C)CC4)c4ccccc34)c21,"InChI=1S/C33H33N7O3/c1-18-29(19(2)43-38-18)25-16-27-24(17-28(25)42-5)30-31(34-20(3)35-32(30)36-27)23-10-11-26(22-9-7-6-8-21(22)23)37-33(41)40-14-12-39(4)13-15-40/h6-11,16-17H,12-15H2,1-5H3,(H,37,41)(H,34,35,36)",YPXANNJXRXDMDY-UHFFFAOYSA-N,179633,"US9675697, Cpd. No. 316",Bromodomain-containing protein 2 [364-436],,
50694298,CN(C)CC(=O)N1CCC(CC1)c1ccc(NC(=O)c2ncc([nH]2)C#N)c(c1)C1=CCCCC1,"InChI=1S/C26H32N6O2/c1-31(2)17-24(33)32-12-10-18(11-13-32)20-8-9-23(22(14-20)19-6-4-3-5-7-19)30-26(34)25-28-16-21(15-27)29-25/h6,8-9,14,16,18H,3-5,7,10-13,17H2,1-2H3,(H,28,29)(H,30,34)",GUBJNPWVIUFSTR-UHFFFAOYSA-N,50355499,CHEMBL1908395::CHEMBL1908842,Dual specificity tyrosine-phosphorylation-regulated kinase 1B,,
627970,Cn1cc(cn1)-c1cc(-c2ccc(nc2)N2[C@H]3CC[C@@H]2C[C@H](O)C3)c2c(cnn2c1)C#N,"InChI=1S/C24H23N7O/c1-29-13-18(12-27-29)16-6-22(24-17(9-25)11-28-30(24)14-16)15-2-5-23(26-10-15)31-19-3-4-20(31)8-21(32)7-19/h2,5-6,10-14,19-21,32H,3-4,7-8H2,1H3/t19-,20+,21+",DGXBVCAOSZHHAK-AERCQKQUSA-N,284189,"US10023570, Example 199::US10174028, Example 199",Proto-oncogene tyrosine-protein kinase receptor Ret [V804M],, 34.8
51177762,Br.OC(=O)CCCn1nc(ccc1=N)-c1ccc(OCc2cccc(c2)[N+]([O-])=O)cc1,"InChI=1S/C21H20N4O5/c22-20-11-10-19(23-24(20)12-2-5-21(26)27)16-6-8-18(9-7-16)30-14-15-3-1-4-17(13-15)25(28)29/h1,3-4,6-11,13,22H,2,5,12,14H2,(H,26,27)",LZTHAJBUMOQDLU-UHFFFAOYSA-N,50483961,CHEMBL1795561,Gamma-aminobutyric acid receptor subunit alpha-1/beta-2/gamma-2,Homo sapiens, 3.0
227146,O=C(CC#N)N[C@H]1CC[C@H](CCN2CCC(CC2)c2cccc3OCOc23)CC1,"InChI=1S/C23H31N3O3/c24-12-8-22(27)25-19-6-4-17(5-7-19)9-13-26-14-10-18(11-15-26)20-2-1-3-21-23(20)29-16-28-21/h1-3,17-19H,4-11,13-16H2,(H,25,27)/t17-,19-",ZJUQDFIINDCGDS-UAPYVXQJSA-N,107517,"US8598357, 20",D(2) dopamine receptor,Homo sapiens,
50349810,COc1cc2c(cc1-c1c(C)noc1C)[nH]c1ccnc(-c3c(C)noc3C)c21,"InChI=1S/C22H20N4O3/c1-10-19(12(3)28-25-10)15-8-17-14(9-18(15)27-5)21-16(24-17)6-7-23-22(21)20-11(2)26-29-13(20)4/h6-9,24H,1-5H3",ZBKQIKDKLUJFMK-UHFFFAOYSA-N,50092324,"CHEMBL3581655::US9675697, Cpd. No. 1",Bromodomain-containing protein 4,,
167870,CCOc1ccc(NC(=O)CN(C)C(=O)c2ccc(COc3ccccc3)cc2)cc1OCC,"InChI=1S/C27H30N2O5/c1-4-32-24-16-15-22(17-25(24)33-5-2)28-26(30)18-29(3)27(31)21-13-11-20(12-14-21)19-34-23-9-7-6-8-10-23/h6-17H,4-5,18-19H2,1-3H3,(H,28,30)",BFPKIYUTYPMKDV-UHFFFAOYSA-N,83977,"MLS002180496::N-[2-(3,4-diethoxyanilino)-2-keto-ethyl]-N-methyl-4-(phenoxymethyl)benzamide::N-[2-(3,4-diethoxyanilino)-2-oxoethyl]-N-methyl-4-(phenoxymethyl)benzamide::N-[2-[(3,4-diethoxyphenyl)amino]-2-oxidanylidene-ethyl]-N-methyl-4-(phenoxymethyl)benzamide::SMR001269526::cid_25161676",Apoptotic protease-activating factor 1,Homo sapiens,>100000
50517107,Cc1cc(C)c2nc(S)n(CCc3ccc(cc3)S(N)(=O)=O)c(=O)c2c1,"InChI=1S/C18H19N3O3S2/c1-11-9-12(2)16-15(10-11)17(22)21(18(25)20-16)8-7-13-3-5-14(6-4-13)26(19,23)24/h3-6,9-10H,7-8H2,1-2H3,(H,20,25)(H2,19,23,24)",HBHWKYQYGWPPBR-UHFFFAOYSA-N,50190138,CHEMBL3828605,Carbonic anhydrase 1,Homo sapiens,
51047878,Clc1ccc(cc1)N(C[C@@H]1CNC[C@H]1Cc1ccccc1)c1ccccc1,"InChI=1S/C24H25ClN2/c25-22-11-13-24(14-12-22)27(23-9-5-2-6-10-23)18-21-17-26-16-20(21)15-19-7-3-1-4-8-19/h1-14,20-21,26H,15-18H2/t20-,21+/m1/s1",FCWGSUKXROLTNW-RTWAWAEBSA-N,50427565,CHEMBL2322896,Renin,Homo sapiens, 14000
50477532,Cc1cccc(NC(=O)NC2N=C(c3ccccc3)c3ccccc3N(CC(=O)NCCSCc3csc(N=C(N)N)n3)C2=O)c1,"InChI=1S/C32H33N9O3S2/c1-20-8-7-11-22(16-20)36-31(44)39-28-29(43)41(25-13-6-5-12-24(25)27(38-28)21-9-3-2-4-10-21)17-26(42)35-14-15-45-18-23-19-46-32(37-23)40-30(33)34/h2-13,16,19,28H,14-15,17-18H2,1H3,(H,35,42)(H2,36,39,44)(H4,33,34,37,40)",TYYIQPKNUREZGD-UHFFFAOYSA-N,50287241,"CHEMBL285746::N-[2-(2-Guanidino-thiazol-4-ylmethylsulfanyl)-ethyl]-2-[2-oxo-5-phenyl-3-(3-m-tolyl-ureido)-2,3-dihydro-benzo[e][1,4]diazepin-1-yl]-acetamide",Gastrin/cholecystokinin type B receptor,Mus musculus, 35
50679149,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,"InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+",JWNPDZNEKVCWMY-VQHVLOKHSA-N,50161957,"4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide::CHEMBL180022::HKI-272::N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide::N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)butanamide::NERATINIB::US10822334, Compound Neratinib",Maternal embryonic leucine zipper kinase,,
624480,Clc1ccccc1Cn1cnc(c1)-c1cc(ccn1)-c1c[nH]nn1,"InChI=1S/C17H13ClN6/c18-14-4-2-1-3-13(14)9-24-10-17(20-11-24)15-7-12(5-6-19-15)16-8-21-23-22-16/h1-8,10-11H,9H2,(H,21,22,23)",FEAWGCOCHKJAAI-UHFFFAOYSA-N,276040,"2-[1-[(2-chlorophenyl)methyl]imidazol-4-yl]-4-(1H-triazol-4-yl)pyridine::US10071984, Example 2::US10174003, Example 2::US9896436, Example 2",Lysine-specific demethylase 2B,,<100
51238264,CN(C)Cc1ccc(COc2ccc3c(CO)cc(=O)oc3c2)cc1,"InChI=1S/C20H21NO4/c1-21(2)11-14-3-5-15(6-4-14)13-24-17-7-8-18-16(12-22)9-20(23)25-19(18)10-17/h3-10,22H,11-13H2,1-2H3",PWCTXLAYYMUQLL-UHFFFAOYSA-N,50506795,CHEMBL4457458,Amine oxidase [flavin-containing] B,, 78
281734,CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCC(F)(F)CC4)c(c3)[N+]([O-])=O)c(Oc3cc4cc[nH]c4cc3F)c2)=C(C1)c1ccc(Cl)cc1,"InChI=1S/C47H50ClF3N6O6S/c1-46(2)15-13-33(38(27-46)31-3-5-34(48)6-4-31)29-55-19-21-56(22-20-55)35-7-9-37(43(24-35)63-44-23-32-14-18-52-41(32)26-39(44)49)45(58)54-64(61,62)36-8-10-40(42(25-36)57(59)60)53-28-30-11-16-47(50,51)17-12-30/h3-10,14,18,23-26,30,52-53H,11-13,15-17,19-22,27-29H2,1-2H3,(H,54,58)",MCEJBRBKHBZOAK-UHFFFAOYSA-N,145220,"US8952157, 411::US9303025, 411",Apoptosis regulator Bcl-2,,
50801547,NC(=O)c1ccc(N[C@H]2CCCNC2)c2cc([nH]c12)-c1cccc(F)c1,"InChI=1S/C20H21FN4O/c21-13-4-1-3-12(9-13)18-10-16-17(24-14-5-2-8-23-11-14)7-6-15(20(22)26)19(16)25-18/h1,3-4,6-7,9-10,14,23-25H,2,5,8,11H2,(H2,22,26)/t14-/m0/s1",KCXSHSRRSKFOQP-AWEZNQCLSA-N,50255163,CHEMBL4067770,Serine/threonine-protein kinase Chk1,Homo sapiens, 9
50662600,COc1ccc(CC(=O)NS(=O)(=O)c2ccc(Br)cc2)cc1,"InChI=1S/C15H14BrNO4S/c1-21-13-6-2-11(3-7-13)10-15(18)17-22(19,20)14-8-4-12(16)5-9-14/h2-9H,10H2,1H3,(H,17,18)",LOLCZXRSTYWMQO-UHFFFAOYSA-N,50353984,CHEMBL1828884,Epidermal growth factor receptor,Homo sapiens, 24150
864442,CC(C)c1c([nH]c2ccc(nc12)N1CC(C1)NC1CCOCC1)-c1cn2ncnc2c(C)c1C,"InChI=1S/C26H33N7O/c1-15(2)23-24(20-13-33-26(27-14-28-33)17(4)16(20)3)30-21-5-6-22(31-25(21)23)32-11-19(12-32)29-18-7-9-34-10-8-18/h5-6,13-15,18-19,29-30H,7-12H2,1-4H3",UNASQJNJFFQFCW-UHFFFAOYSA-N,427563,"1-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-pyrrolo[3,2-b]pyridin-5-yl)-N-(tetrahydro-2H-pyran-4-yl)azetidin-3-amine::US10544143, Example 1::US10730877, Example 1::US11053244, Example 1",Toll-like receptor 7,, 20.0
50573135,Cc1cn(Cc2ccc(cc2)C(N)=O)c2cc(ccc12)C(=O)Nc1c(Cl)cncc1Cl,"InChI=1S/C23H18Cl2N4O2/c1-13-11-29(12-14-2-4-15(5-3-14)22(26)30)20-8-16(6-7-17(13)20)23(31)28-21-18(24)9-27-10-19(21)25/h2-11H,12H2,1H3,(H2,26,30)(H,27,28,31)",LYQNYINZEXWAQG-UHFFFAOYSA-N,50215939,CHEMBL56406,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A/4B/4C/4D",,
175390,COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F,"InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+",CJOFXWAVKWHTFT-XSFVSMFZSA-N,50028091,(1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime::CHEMBL814::FLUVOXAMINE,Sodium-dependent noradrenaline transporter,Homo sapiens,
33492,CN(Cc1ccc2nc(C)[nH]c(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,"InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1",IVTVGDXNLFLDRM-HNNXBMFYSA-N,18795,"(2S)-2-[(5-{methyl[(2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl]amino}thiophen-2-yl)formamido]pentanedioic acid::CHEMBL225071::RTX::Raltitrexed::Tomudex::ZD1694",Dihydrofolate reductase,Escherichia coli, 23000
831879,CCOc1cc(-c2ccc(nc2)N2CC[C@@H](NC(=O)OC(C)(C)C)[C@@H](O)C2)c2c(cnn2c1)C#N,"InChI=1S/C25H30N6O4/c1-5-34-18-10-19(23-17(11-26)13-28-31(23)14-18)16-6-7-22(27-12-16)30-9-8-20(21(32)15-30)29-24(33)35-25(2,3)4/h6-7,10,12-14,20-21,32H,5,8-9,15H2,1-4H3,(H,29,33)/t20-,21+/m1/s1",QIEZJVPZOIWZGE-RTWAWAEBSA-N,305498,"US10144734, Example 515::US10172845, Example 515::US10441581, Example 515::US10881652, Example 515::tert-butyl ((3S,4R)-1- (5-(3-cyano-6- ethoxypyrazolo[1,5- a]pyridin-4-yl)pyridin- 2-yl)-3- hydroxypiperidin-4- yl)carbamate",Proto-oncogene tyrosine-protein kinase receptor Ret [V804M],, 2392
50312882,Cc1ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c(N)c1-c1ccc2nc(sc2c1)C(F)(F)F,"InChI=1S/C32H23F3N4O2S/c1-18-13-15-22(27(36)25(18)20-14-16-23-24(17-20)42-31(37-23)32(33,34)35)29(40)26-28(19-9-5-3-6-10-19)38(2)39(30(26)41)21-11-7-4-8-12-21/h3-17H,36H2,1-2H3",DRQQNHJHIDNZOM-UHFFFAOYSA-N,50072035,CHEMBL3407861,Eukaryotic translation initiation factor 2-alpha kinase 3,, 88
50487791,OC(=O)[C@H](CNC(=O)c1ccc(OCCC2CCNCC2)cc1)NS(=O)(=O)c1ccccc1,"InChI=1S/C23H29N3O6S/c27-22(18-6-8-19(9-7-18)32-15-12-17-10-13-24-14-11-17)25-16-21(23(28)29)26-33(30,31)20-4-2-1-3-5-20/h1-9,17,21,24,26H,10-16H2,(H,25,27)(H,28,29)/t21-/m0/s1",UIJBJQDAZCEJGM-NRFANRHFSA-N,50091737,(S)-2-Benzenesulfonylamino-3-[4-(2-piperidin-4-yl-ethoxy)-benzoylamino]-propionic acid::2-((S)-Benzenesulfonylamino)-3-[4-(2-piperidin-4-yl-ethoxy)-benzoylamino]-propionic acid::2-Benzenesulfonylamino-3-[4-(2-piperidin-4-yl-ethoxy)-benzoylamino]-propionic acid::CHEMBL59562,Integrin alpha-IIb/beta-3,, 13
50827536,CN1CCC(C(CSCC(=O)N2CCCCC2)C1)c1ccc(Cl)cc1,"InChI=1S/C20H29ClN2OS/c1-22-12-9-19(16-5-7-18(21)8-6-16)17(13-22)14-25-15-20(24)23-10-3-2-4-11-23/h5-8,17,19H,2-4,9-15H2,1H3",VXDYZTDYUKVXNJ-UHFFFAOYSA-N,50156052,2-[4-(4-Chloro-phenyl)-1-methyl-piperidin-3-ylmethylsulfanyl]-1-piperidin-1-yl-ethanone::CHEMBL191330,Transporter,Rattus norvegicus,
50690790,Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F,"InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)",GFMMXOIFOQCCGU-UHFFFAOYSA-N,50132260,"2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide::2-(2-chloro-4-iodophenylamino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide::CHEMBL105442::CI-1040::PD-18435::PD-184352::US8575391, 341",Platelet-derived growth factor receptor alpha,Homo sapiens,
51416417,COc1ccc(cc1)-c1cc(=O)c2c(O)c(OC)c(OC)c(OC)c2o1,"InChI=1S/C19H18O7/c1-22-11-7-5-10(6-8-11)13-9-12(20)14-15(21)17(23-2)19(25-4)18(24-3)16(14)26-13/h5-9,21H,1-4H3",LXEVSYZNYDZSOB-UHFFFAOYSA-N,50060925,CHEBI:79628::GARDENIN B,Peroxisome proliferator-activated receptor gamma,Homo sapiens, 2500
50281823,CCOc1cccc(c1)-c1cc(ccc1C#CC(O)(c1cncn1C)c1ccc(cc1)C#N)C#N,"InChI=1S/C29H22N4O2/c1-3-35-26-6-4-5-24(16-26)27-15-22(18-31)7-10-23(27)13-14-29(34,28-19-32-20-33(28)2)25-11-8-21(17-30)9-12-25/h4-12,15-16,19-20,34H,3H2,1-2H3",QYLBZDCYGRTUQE-UHFFFAOYSA-N,50126036,6-[3-(4-Cyano-phenyl)-3-hydroxy-3-(3-methyl-3H-imidazol-4-yl)-prop-1-ynyl]-3''-ethoxy-biphenyl-3-carbonitrile::6-[3-(4-Cyano-phenyl)-3-hydroxy-3-(3-methyl-3H-imidazol-4-yl)-prop-1-ynyl]-3'-ethoxy-biphenyl-3-carbonitrile::CHEMBL24043,Geranylgeranyl transferase type-1 subunit beta/Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha,, 2400
127494,Fc1ccccc1NC(=O)CN1C(=O)c2ccccc2C1=O,"InChI=1S/C16H11FN2O3/c17-12-7-3-4-8-13(12)18-14(20)9-19-15(21)10-5-1-2-6-11(10)16(19)22/h1-8H,9H2,(H,18,20)",LXBMTSUDKRFZND-UHFFFAOYSA-N,68639,"2-(1,3-dioxo-2-isoindolyl)-N-(2-fluorophenyl)acetamide::2-(1,3-dioxoisoindol-2-yl)-N-(2-fluorophenyl)acetamide::2-[1,3-bis(oxidanylidene)isoindol-2-yl]-N-(2-fluorophenyl)ethanamide::MLS000109631::N-(2-fluorophenyl)-2-phthalimido-acetamide::SMR000105571::cid_723287",Glycogen synthase kinase-3 beta,Homo sapiens,
822024,FC(F)(F)Oc1cccc(c1)-c1cnc2ccc(N[C@H]3CC[C@@H](CC3)C#N)nn12,"InChI=1S/C20H18F3N5O/c21-20(22,23)29-16-3-1-2-14(10-16)17-12-25-19-9-8-18(27-28(17)19)26-15-6-4-13(11-24)5-7-15/h1-3,8-10,12-13,15H,4-7H2,(H,26,27)/t13-,15-",PKHSKJFGAUOKTM-CTYIDZIISA-N,242403,"US10392392, Example 8-86::US10875864, EX. 8-86::US9416132, 8-86",Serine/threonine-protein kinase pim-1,, 14.0
50252764,Cc1cccc(CNC(=O)c2cccc(c2)-c2ccc(cc2)S(=O)(=O)CC(O)=O)c1,"InChI=1S/C23H21NO5S/c1-16-4-2-5-17(12-16)14-24-23(27)20-7-3-6-19(13-20)18-8-10-21(11-9-18)30(28,29)15-22(25)26/h2-13H,14-15H2,1H3,(H,24,27)(H,25,26)",JZSGKCNSPZBKTO-UHFFFAOYSA-N,50137899,CHEMBL175280::[3'-(3-methyl-benzylcarbamoyl)-biphenyl-4-sulfonyl]-acetic acid,Replication protein E1,Human papillomavirus type 11, 27
50500521,COC(=O)[C@@H]1CCCN1C(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)C[C@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)N(C)C(=O)[C@@H](NC(=O)[C@H](C)O)C(C)C,"InChI=1S/C50H74N8O12/c1-29(2)25-36(45(64)52-31(5)47(66)57(8)39(27-34-19-14-11-15-20-34)48(67)58-24-16-21-38(58)50(69)70-9)53-42(62)28-40(60)35(26-33-17-12-10-13-18-33)54-46(65)37(22-23-41(51)61)56(7)49(68)43(30(3)4)55-44(63)32(6)59/h10-15,17-20,29-32,35-40,43,59-60H,16,21-28H2,1-9H3,(H2,51,61)(H,52,64)(H,53,62)(H,54,65)(H,55,63)/t31-,32-,35-,36-,37-,38-,39+,40-,43-/m0/s1",WFMVRFNXMBGKEW-HVGQEOIXSA-N,50400221,CHEMBL2181015,Cathepsin D,Homo sapiens, 50
567010,Clc1nccc(C(=O)N2CCc3c(C2)[nH]nc3-c2ccccc2)c1Cl,"InChI=1S/C18H14Cl2N4O/c19-15-13(6-8-21-17(15)20)18(25)24-9-7-12-14(10-24)22-23-16(12)11-4-2-1-3-5-11/h1-6,8H,7,9-10H2,(H,22,23)",UQHVENMLNXEZOV-UHFFFAOYSA-N,254219,"US10112937, Example 104::US10150765, Example 104::US10703749, Example 104::US9464084, 104",P2X purinoceptor 7,, 205
187165,COCc1cc(NC(=O)c2ccc(F)cc2)cc(c1)C1(C)CCSC(N)=N1,"InChI=1S/C20H22FN3O2S/c1-20(7-8-27-19(22)24-20)15-9-13(12-26-2)10-17(11-15)23-18(25)14-3-5-16(21)6-4-14/h3-6,9-11H,7-8,12H2,1-2H3,(H2,22,24)(H,23,25)",KCEVQICKCKDJAP-UHFFFAOYSA-N,35281,"US8546380, 896::US8633188, 896",Beta-secretase 1,Homo sapiens, 8497
910216,CCc1c([nH]c2ccc(cc12)C1CCN(CC(O)=O)CC1)-c1ccnc(C)c1,"InChI=1S/C23H27N3O2/c1-3-19-20-13-17(16-7-10-26(11-8-16)14-22(27)28)4-5-21(20)25-23(19)18-6-9-24-15(2)12-18/h4-6,9,12-13,16,25H,3,7-8,10-11,14H2,1-2H3,(H,27,28)",UPCMEHSVCKAHGV-UHFFFAOYSA-N,444286,"US10660877, Example 876",Toll-like receptor 7,, 958
51112516,CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,"InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)",NDDAHWYSQHTHNT-UHFFFAOYSA-N,25901,"4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)-3-sulfamoylbenzamide::Indaflex::Indapamide::Indapamide (2)::Lozol::Noranat",Carbonic anhydrase 2,Homo sapiens,
598729,C[C@H](Nc1nn(C)c(=O)c2cccnc12)[C@@H](N(C)C)c1ccc(cc1)C(O)=O,"InChI=1S/C20H23N5O3/c1-12(17(24(2)3)13-7-9-14(10-8-13)20(27)28)22-18-16-15(6-5-11-21-16)19(26)25(4)23-18/h5-12,17H,1-4H3,(H,22,23)(H,27,28)/t12-,17+/m0/s1",BFQWSEXKEXWINT-YVEFUNNKSA-N,311506,"US10155764, Example 81",Histone acetyltransferase KAT2B [719-832],, 98.0
274656,CC(Nc1ncc(cn1)C(=O)NO)c1ccncc1,"InChI=1S/C12H13N5O2/c1-8(9-2-4-13-5-3-9)16-12-14-6-10(7-15-12)11(18)17-19/h2-8,19H,1H3,(H,17,18)(H,14,15,16)",UYQRPBKIKYLDGQ-UHFFFAOYSA-N,139307,"US8614223, 85",Histone deacetylase 6,Homo sapiens, 4
51259351,CN(C\C=C\c1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(cc2)C2CC2)c1C)C(=O)C=C,"InChI=1S/C28H28FN5O2/c1-4-25(35)34(3)13-5-6-22-26(31-16-32-27(22)30)23-14-21(29)15-24(17(23)2)33-28(36)20-11-9-19(10-12-20)18-7-8-18/h4-6,9-12,14-16,18H,1,7-8,13H2,2-3H3,(H,33,36)(H2,30,31,32)/b6-5+",QGWYFFMAGYSPLU-AATRIKPKSA-N,50514635,CHEMBL4559123,Tyrosine-protein kinase BTK,Homo sapiens, 3.8
385103,Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CC[C@@H](CC1)NC(=O)\C=C\CN1CCOCC1,"InChI=1S/C31H35N7O3/c32-30-28-29(22-8-14-26(15-9-22)41-25-5-2-1-3-6-25)36-38(31(28)34-21-33-30)24-12-10-23(11-13-24)35-27(39)7-4-16-37-17-19-40-20-18-37/h1-9,14-15,21,23-24H,10-13,16-20H2,(H,35,39)(H2,32,33,34)/b7-4+/t23-,24+",QWEKIGQOBHAQDZ-WWBGYUKBSA-N,191629,"US9181263, 25::US9278100, 25",Epidermal growth factor receptor,Homo sapiens, 272.9
51127955,CCCCCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)B(O)O,"InChI=1S/C20H33BN2O4/c1-4-5-7-12-19(24)22-17(14-16-10-8-6-9-11-16)20(25)23-18(21(26)27)13-15(2)3/h6,8-11,15,17-18,26-27H,4-5,7,12-14H2,1-3H3,(H,22,24)(H,23,25)/t17-,18-/m0/s1",UESZADMGJTUSQM-ROUUACIJSA-N,50462612,CHEMBL4246480,Proteasome subunit beta type-5,Homo sapiens, 2.3
51402534,Cc1cc(no1)[C@H](C1CCOCC1)n1c2cc(ccc2c2ncc(cc12)-c1c(C)nnn1C)C(C)(C)O,"InChI=1S/C28H32N6O3/c1-16-12-22(31-37-16)27(18-8-10-36-11-9-18)34-23-14-20(28(3,4)35)6-7-21(23)25-24(34)13-19(15-29-25)26-17(2)30-32-33(26)5/h6-7,12-15,18,27,35H,8-11H2,1-5H3/t27-/m0/s1",WFFRALIRWDMZPW-MHZLTWQESA-N,50566610,CHEMBL4857742,Bromodomain-containing protein 4,, 2.8
468741,CN(C)C(=O)c1cncc(Nc2snc(C)c2C(=O)Nc2ccc(F)c(F)c2)n1,"InChI=1S/C18H16F2N6O2S/c1-9-15(16(27)22-10-4-5-11(19)12(20)6-10)17(29-25-9)24-14-8-21-7-13(23-14)18(28)26(2)3/h4-8H,1-3H3,(H,22,27)(H,23,24)",HFGYZXREESJJSR-UHFFFAOYSA-N,162206,"US9682995, 104",Dual specificity protein kinase TTK,Homo sapiens,>20000
568049,CCOc1cc(-c2ccc(nc2)N2CCN(CC2)C(=O)Cc2ccc(F)cn2)c2c(cnn2c1)C#N,"InChI=1S/C26H24FN7O2/c1-2-36-22-12-23(26-19(13-28)15-31-34(26)17-22)18-3-6-24(30-14-18)32-7-9-33(10-8-32)25(35)11-21-5-4-20(27)16-29-21/h3-6,12,14-17H,2,7-11H2,1H3",BDOMYACNYFLEKA-UHFFFAOYSA-N,296224,"US10112942, Example 31::US10137124, Example 31::US10172851, Example 31::US10555944, Example 31::US10953005, Example 31",Proto-oncogene tyrosine-protein kinase receptor Ret,Homo sapiens, 13.5
51453242,C[C@]1(CO[C@](C)(C(N)=N1)C(F)(F)F)c1nc(NC(=O)c2ncc(cc2N)C(F)(F)F)ccc1F,"InChI=1S/C19H17F7N6O2/c1-16(7-34-17(2,15(28)32-16)19(24,25)26)13-9(20)3-4-11(30-13)31-14(33)12-10(27)5-8(6-29-12)18(21,22)23/h3-6H,7,27H2,1-2H3,(H2,28,32)(H,30,31,33)/t16-,17+/m0/s1",RNLNFTQJIYFRSH-DLBZAZTESA-N,50586755,CHEMBL5070669,Beta-secretase 2,, 182
528285,CC1(C)CN(C[C@H](F)[C@@H]1Oc1ccc(cc1C#N)-c1ncnc(Nc2ccc(cc2)N2CCN(CC2)C2COC2)n1)C(=O)CO,"InChI=1S/C32H37FN8O4/c1-32(2)19-41(28(43)16-42)15-26(33)29(32)45-27-8-3-21(13-22(27)14-34)30-35-20-36-31(38-30)37-23-4-6-24(7-5-23)39-9-11-40(12-10-39)25-17-44-18-25/h3-8,13,20,25-26,29,42H,9-12,15-19H2,1-2H3,(H,35,36,37,38)/t26-,29-/m0/s1",ZWIZDCQAFLVPFU-WNJJXGMVSA-N,277956,"2-(((4R,5S)-5-fluoro-1-(2- hydroxyacetyl)-3,3- dimethylpiperidin-4- yl)oxy)-5-(4-((4-(4-(oxetan- 3-yl)piperazin-1- yl)phenyl)amino)-1,3,5- triazin-2-yl)benzonitrile::US10040781, Example 178::US10253019, Example 178",Serine/threonine-protein kinase TBK1,, 2000
346950,C(Sc1ccccc1)c1ccc(CSc2ccccc2)cc1,"InChI=1S/C20H18S2/c1-3-7-19(8-4-1)21-15-17-11-13-18(14-12-17)16-22-20-9-5-2-6-10-20/h1-14H,15-16H2",TTWDUMRLHQJUFV-UHFFFAOYSA-N,194577,"US9205085, MSX- 211",C-X-C chemokine receptor type 4,, 1000
50475301,CCCN1c2ccccc2C(=N[C@H](NC(=O)Nc2cccc(C)c2)C1=O)N1CCN(C)CC1,"InChI=1S/C25H32N6O2/c1-4-12-31-21-11-6-5-10-20(21)23(30-15-13-29(3)14-16-30)27-22(24(31)32)28-25(33)26-19-9-7-8-18(2)17-19/h5-11,17,22H,4,12-16H2,1-3H3,(H2,26,28,33)/t22-/m1/s1",HIDXDIXMVZDVNO-JOCHJYFZSA-N,50286122,"1-[(S)-5-(4-Methyl-piperazin-1-yl)-2-oxo-1-propyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-m-tolyl-urea::CHEMBL319180",Cholecystokinin receptor type A,Rattus, 1900
462668,CS(=O)(=O)N1CCC(CC1)Nc1n[nH]c2ccc(cc12)C(c1ccc(Cl)cc1)c1ccc(Cl)cc1,"InChI=1S/C26H26Cl2N4O2S/c1-35(33,34)32-14-12-22(13-15-32)29-26-23-16-19(6-11-24(23)30-31-26)25(17-2-7-20(27)8-3-17)18-4-9-21(28)10-5-18/h2-11,16,22,25H,12-15H2,1H3,(H2,29,30,31)",QKENPAWWACETES-UHFFFAOYSA-N,115796,"US9682940, 125",Cannabinoid receptor 1,Homo sapiens,
198673,COc1cc(cc(OC)c1OC)C1=C(C(=O)NC1=O)c1cn(CCCO)c2ccccc12,"InChI=1S/C24H24N2O6/c1-30-18-11-14(12-19(31-2)22(18)32-3)20-21(24(29)25-23(20)28)16-13-26(9-6-10-27)17-8-5-4-7-15(16)17/h4-5,7-8,11-13,27H,6,9-10H2,1-3H3,(H,25,28,29)",IFUKBECSYNPLCY-UHFFFAOYSA-N,47165,"US8957103, C1::US9364459, I",Glycogen synthase kinase-3 beta,Homo sapiens, 3386
259364,NCC=CC(=N)c1ccn2c(cnc2c1)-c1cccc(NC(=O)NCC(F)(F)F)c1,"InChI=1S/C20H19F3N6O/c21-20(22,23)12-27-19(30)28-15-4-1-3-14(9-15)17-11-26-18-10-13(6-8-29(17)18)16(25)5-2-7-24/h1-6,8-11,25H,7,12,24H2,(H2,27,28,30)",HOVGKFRLRAHOTJ-UHFFFAOYSA-N,128430,"US8796244, 9",Fibroblast growth factor receptor 3,Homo sapiens, 4
50229929,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,"InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1",BMGQWWVMWDBQGC-IIFHNQTCSA-N,50326053,CHEMBL608533::PKC-412,Calcium/calmodulin-dependent protein kinase type II subunit gamma,,
51090329,COc1cc2nc(C)oc2c(C[C@]2(C)[C@@H](C)CC[C@]3(C)[C@H]2CCC=C3C)c1O,"InChI=1S/C24H33NO3/c1-14-8-7-9-20-23(14,4)11-10-15(2)24(20,5)13-17-21(26)19(27-6)12-18-22(17)28-16(3)25-18/h8,12,15,20,26H,7,9-11,13H2,1-6H3/t15-,20+,23-,24+/m0/s1",ATQVAIUSAHRLDF-KSVBPBMVSA-N,50446565,CHEMBL3109402,Aurora kinase B,Homo sapiens,>100000
50853671,CC(C)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC(C)(C)C#N,"InChI=1S/C25H30F3N3O3S/c1-16(2)14-21(23(32)31-24(3,4)15-29)30-22(25(26,27)28)19-8-6-17(7-9-19)18-10-12-20(13-11-18)35(5,33)34/h6-13,16,21-22,30H,14H2,1-5H3,(H,31,32)/t21-,22-/m0/s1",MQLWDLYYNYALHH-VXKWHMMOSA-N,50233035,"(S)-4-methyl-2-[(S)-2,2,2-trifluoro-1-(4'-methanesulfonyl-biphenyl-4-yl)-ethylamino]-pentanoic acid (cyano-dimethyl-methyl)-amide::CHEMBL428417",Cathepsin B,Homo sapiens,>10000
1050348,CCOc1cccnc1Oc1cncc(c1)-c1ncc(cn1)C(=O)N[C@]1(CO)CCOC1,"InChI=1S/C22H23N5O5/c1-2-31-18-4-3-6-24-21(18)32-17-8-15(9-23-12-17)19-25-10-16(11-26-19)20(29)27-22(13-28)5-7-30-14-22/h3-4,6,8-12,28H,2,5,7,13-14H2,1H3,(H,27,29)/t22-/m0/s1",DFNKRIPGDXQUEM-QFIPXVFZSA-N,276761,"(S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(3-(hydroxymethyl)tetrahydrofuran-3-yl)pyrimidine-5-carboxamide::US10071992, Example 6b::US11034678, Example 6b::US11065249, WO2018033832-Ex.-6a::WO2018033832, Ex. 6a",Diacylglycerol O-acyltransferase 2,Homo sapiens, 23.2
51160230,CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2[C@@H]3Oc4c6c(C[C@H]7N(C)CC[C@@]36[C@@]7(O)Cc12)ccc4O)ccc5O,"InChI=1S/C34H35N3O6/c1-36-9-7-31-23-15-3-5-19(38)27(23)42-29(31)25-17(13-33(31,40)21(36)11-15)18-14-34(41)22-12-16-4-6-20(39)28-24(16)32(34,8-10-37(22)2)30(43-28)26(18)35-25/h3-6,21-22,29-30,35,38-41H,7-14H2,1-2H3/t21-,22-,29+,30+,31+,32+,33-,34-/m1/s1",ASOVJVGZJDVADR-UCDXVGGRSA-N,50475336,CHEMBL606959,Delta-type opioid receptor,Rattus norvegicus,
482341,Cc1nc2ccccc2n2c(nnc12)-c1cc(OCC(=O)c2ccccn2)ccc1Cl,"InChI=1S/C23H16ClN5O2/c1-14-22-27-28-23(29(22)20-8-3-2-6-18(20)26-14)16-12-15(9-10-17(16)24)31-13-21(30)19-7-4-5-11-25-19/h2-12H,13H2,1H3",AJCFLJFPXFEKEH-UHFFFAOYSA-N,204695,"2-[4-chloro-3-(4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)-phenoxy]-1-pyridin-2-yl-ethanone::US9540379, 93","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens,>1000
90480,CC(C)Nc1ncnc2n(ncc12)-c1ccc(Cl)cc1,"InChI=1S/C14H14ClN5/c1-9(2)19-13-12-7-18-20(14(12)17-8-16-13)11-5-3-10(15)4-6-11/h3-9H,1-2H3,(H,16,17,19)",DJYPPKXJBSHHDF-UHFFFAOYSA-N,48165,"1-(4-chlorophenyl)-N-propan-2-yl-4-pyrazolo[3,4-d]pyrimidinamine::1-(4-chlorophenyl)-N-propan-2-yl-pyrazolo[3,4-d]pyrimidin-4-amine::1-(4-chlorophenyl)-N-propan-2-ylpyrazolo[3,4-d]pyrimidin-4-amine::MLS000100781::SMR000017466::[1-(4-chlorophenyl)pyrazolo[3,4-d]pyrimidin-4-yl]-isopropyl-amine::cid_866407",Matrix metalloproteinase-14 [1-36],Homo sapiens,
50627808,COC(=O)CC(NCC1CN=C(c2ccccc2F)c2ccccc2N1C)c1ccccc1,"InChI=1S/C27H28FN3O2/c1-31-20(17-29-24(16-26(32)33-2)19-10-4-3-5-11-19)18-30-27(21-12-6-8-14-23(21)28)22-13-7-9-15-25(22)31/h3-15,20,24,29H,16-18H2,1-2H3",COAZJQLEWBNTGL-UHFFFAOYSA-N,50013191,"3-{[5-(2-Fluoro-phenyl)-1-methyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-2-ylmethyl]-amino}-3-phenyl-propionic acid methyl ester::CHEMBL141629",Delta-type opioid receptor/Kappa-type opioid receptor/Mu-type opioid receptor/Sigma non-opioid intracellular receptor 1,Rattus, 18
51030325,CC(C)N1CCN(CC1)C(=S)SCCOc1ccc2c(C)cc(=O)oc2c1,"InChI=1S/C20H26N2O3S2/c1-14(2)21-6-8-22(9-7-21)20(26)27-11-10-24-16-4-5-17-15(3)12-19(23)25-18(17)13-16/h4-5,12-14H,6-11H2,1-3H3",AYCMSQHGVRSOEG-UHFFFAOYSA-N,50295322,CHEMBL4167973,Acetylcholinesterase,Homo sapiens, 1990
50420751,CC(C)(C)c1ccc(CS(=O)(=O)CC(=O)N=c2scc(CC(O)=O)n2O)cc1,"InChI=1S/C18H22N2O6S2/c1-18(2,3)13-6-4-12(5-7-13)10-28(25,26)11-15(21)19-17-20(24)14(9-27-17)8-16(22)23/h4-7,9,24H,8,10-11H2,1-3H3,(H,22,23)",POIZOEYDEHXVML-UHFFFAOYSA-N,50251959,"2-(2-(2-(4-tert-butylbenzylsulfonyl)acetamido)-3-hydroxy-2,3-dihydrothiazol-4-yl)acetic acid::CHEMBL520935",Egl nine homolog 1,Homo sapiens, 3
50220032,COc1ccc(C[C@H](NC(C)=O)[C@H](O)CN[C@H]2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc23)cc1OC,"InChI=1S/C30H43N3O5/c1-19(34)33-23(13-20-8-9-26(36-5)27(14-20)37-6)25(35)18-31-24-16-30(10-7-11-30)38-28-22(24)12-21(17-32-28)15-29(2,3)4/h8-9,12,14,17,23-25,31,35H,7,10-11,13,15-16,18H2,1-6H3,(H,33,34)/t23-,24-,25+/m0/s1",UVODFPUSJFFSKE-CCDWMCETSA-N,50397684,CHEMBL2181885,Beta-secretase 1,Homo sapiens, 18
355704,CCC(CC)(Cc1ccc(s1)C(=O)Oc1ccc(cc1F)C(N)=N)C(=O)N[C@@H](Cc1nn[nH]n1)C(O)=O,,,199976,"US9227949, 86",Serine protease 1,Homo sapiens,
51258255,OCC1OC2(CCN(CCc3ccccc3)CC2)CN(C1=O)c1ccccc1,"InChI=1S/C23H28N2O3/c26-17-21-22(27)25(20-9-5-2-6-10-20)18-23(28-21)12-15-24(16-13-23)14-11-19-7-3-1-4-8-19/h1-10,21,26H,11-18H2",QGQRUYNHBMRUGE-UHFFFAOYSA-N,50514266,CHEMBL4459117,Mu-type opioid receptor,Homo sapiens,
1002713,OC(=O)c1ccn(n1)C(=O)N1C[C@@H]2C[C@H](C[C@@H]2C1)OCc1ccccc1Cl,"InChI=1S/C19H20ClN3O4/c20-16-4-2-1-3-12(16)11-27-15-7-13-9-22(10-14(13)8-15)19(26)23-6-5-17(21-23)18(24)25/h1-6,13-15H,7-11H2,(H,24,25)/t13-,14+,15+",LFQHZMFSAFLVBM-FICVDOATSA-N,483642,"US10927105, Ex 15",Monoglyceride lipase,Homo sapiens, 550
50765691,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1,"InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2",QWCRAEMEVRGPNT-UHFFFAOYSA-N,50001859,"(buspirone) 8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione::8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione : (Hydrochloride)::8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione; Hydrochloride(Buspirone)::8-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione::BUSPAR::BUSPIRONE::CHEMBL49::US10562853, Compound Buspirone",5-hydroxytryptamine receptor 1A,Rattus norvegicus,
75925,COc1ccc(CN2CCN(CC2)c2ccccc2F)c(OC)c1,"InChI=1S/C19H23FN2O2/c1-23-16-8-7-15(19(13-16)24-2)14-21-9-11-22(12-10-21)18-6-4-3-5-17(18)20/h3-8,13H,9-12,14H2,1-2H3",FTXHIWXQEQZCKC-UHFFFAOYSA-N,31037,"1-(2,4-dimethoxybenzyl)-4-(2-fluorophenyl)piperazine::1-[(2,4-dimethoxyphenyl)methyl]-4-(2-fluorophenyl)piperazine::MLS000105278::SMR000102159::cid_2173523",Sphingosine 1-phosphate receptor 3,Homo sapiens,
1187122,CNS(=O)(=O)N1CCC(CC1)Nc1ncc2ccc(=O)n(C3CCCC3)c2n1,"InChI=1S/C18H26N6O3S/c1-19-28(26,27)23-10-8-14(9-11-23)21-18-20-12-13-6-7-16(25)24(17(13)22-18)15-4-2-3-5-15/h6-7,12,14-15,19H,2-5,8-11H2,1H3,(H,20,21,22)",CGZPQEKNAAVWHA-UHFFFAOYSA-N,370122,"US10233188, Example 11::US10800783, Example 11::US11396512, Example 11",Cyclin-dependent kinase 2/G1/S-specific cyclin-E1,Homo sapiens,
617667,COc1cccc(n1)-c1nc(N[C@H](C)C2CC2)nc(N[C@H](C)C2CC2)n1,"InChI=1S/C19H26N6O/c1-11(13-7-8-13)20-18-23-17(15-5-4-6-16(22-15)26-3)24-19(25-18)21-12(2)14-9-10-14/h4-6,11-14H,7-10H2,1-3H3,(H2,20,21,23,24,25)/t11-,12-/m1/s1",WYXMPHFGDDGKSR-VXGBXAGGSA-N,280141,"US10028961, Compound 294::US10172864, Compound 294::US10946023, Compound 294",Isocitrate dehydrogenase [NADP] cytoplasmic [R132H],, 550
51062722,CC(C)n1ncnc1-c1nc-2c(CCOc3cc(ccc-23)-c2cnn(CC(C)(C)O)c2)s1,"InChI=1S/C23H26N6O2S/c1-14(2)29-21(24-13-26-29)22-27-20-17-6-5-15(9-18(17)31-8-7-19(20)32-22)16-10-25-28(11-16)12-23(3,4)30/h5-6,9-11,13-14,30H,7-8,12H2,1-4H3",XJCBJODXECFWKL-UHFFFAOYSA-N,50433535,CHEMBL2381374,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 47
356868,Cc1c(NC(=O)c2ccc(cc2)C2CC2)cc(F)cc1-c1ncnc2[nH]c(cc12)C1=CCN(CC1)C(=O)N1CCCC1,"InChI=1S/C33H33FN6O2/c1-20-26(16-25(34)17-28(20)38-32(41)24-8-6-22(7-9-24)21-4-5-21)30-27-18-29(37-31(27)36-19-35-30)23-10-14-40(15-11-23)33(42)39-12-2-3-13-39/h6-10,16-19,21H,2-5,11-15H2,1H3,(H,38,41)(H,35,36,37)",UZQDYTBAPMZXKM-UHFFFAOYSA-N,200816,"US9233111, 30",Tyrosine-protein kinase BTK,Homo sapiens, 6
977083,N[C@H]1CCCN(C1)c1c(NC(=O)c2nc(c(F)cc2N)-c2c(F)cccc2F)cnc2NCCCc12,"InChI=1S/C25H26F3N7O/c26-15-6-1-7-16(27)20(15)21-17(28)10-18(30)22(34-21)25(36)33-19-11-32-24-14(5-2-8-31-24)23(19)35-9-3-4-13(29)12-35/h1,6-7,10-11,13H,2-5,8-9,12,29-30H2,(H,31,32)(H,33,36)/t13-/m0/s1",KCVZUSUTNUFEER-ZDUSSCGKSA-N,377182,"3-Amino-N-{4-[(3S)-3-aminopiperidin-1-yl]-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide::US10265307, Example 32::US10517858, Example 32::US10828290, Example 32::US11229631, Example 32",Serine/threonine-protein kinase pim-3,Homo sapiens,<100
50763914,CCOP(O)(=O)CCC(NC(=O)c1ccc(NCc2cnc3nc(N)[nH]c(=O)c3c2)cc1)C(O)=O,"InChI=1S/C21H25N6O7P/c1-2-34-35(32,33)8-7-16(20(30)31)25-18(28)13-3-5-14(6-4-13)23-10-12-9-15-17(24-11-12)26-21(22)27-19(15)29/h3-6,9,11,16,23H,2,7-8,10H2,1H3,(H,25,28)(H,30,31)(H,32,33)(H3,22,24,26,27,29)",FBRKPFQSNPGVGM-UHFFFAOYSA-N,50005866,"2-{4-[(2-Amino-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-6-ylmethyl)-amino]-benzoylamino}-4-(ethoxy-hydroxy-phosphoryl)-butyric acid::CHEMBL294973",Thymidylate synthase,Homo sapiens, 100000
50554037,CO[P@@]1(=O)CC[C@H]2COC(=O)C2=C(C)O1,"InChI=1S/C9H13O5P/c1-6-8-7(5-13-9(8)10)3-4-15(11,12-2)14-6/h7H,3-5H2,1-2H3/t7-,15-/m0/s1",JBANMOPKOHITOL-ZIDLFYJRSA-N,50308513,"(3R,8aR)-3-Methoxy-5-methyl-3-oxo-8,8a-dihydro-1H-3lambda*5*-furo[3,4-e][1,3,2]dioxaphosphepin-6-one::CHEMBL590031",Acetylcholinesterase,Homo sapiens, 30000
50437618,CN(Cc1ccccc1)C(=O)c1ccc(s1)C(=O)C(F)(F)F,"InChI=1S/C15H12F3NO2S/c1-19(9-10-5-3-2-4-6-10)14(21)12-8-7-11(22-12)13(20)15(16,17)18/h2-8H,9H2,1H3",CEBFXUYKCDHZEP-UHFFFAOYSA-N,25157,"CHEMBL462209::N-benzyl-N-methyl-5-(2,2,2-trifluoroacetyl)thiophene-2-carboxamide::thiophene derivative, 3c",Histone deacetylase 3,Homo sapiens, 560
50524383,C[C@@H](NC(=O)c1nn(c2c1CN(C\C2=C/c1ccc(F)cc1)C(=O)c1nc[nH]n1)-c1ccc(Cl)cc1Cl)c1ccccc1,"InChI=1S/C31H24Cl2FN7O2/c1-18(20-5-3-2-4-6-20)37-30(42)27-24-16-40(31(43)29-35-17-36-38-29)15-21(13-19-7-10-23(34)11-8-19)28(24)41(39-27)26-12-9-22(32)14-25(26)33/h2-14,17-18H,15-16H2,1H3,(H,37,42)(H,35,36,38)/b21-13+/t18-/m1/s1",MBEMYKYSBQQXMT-KOMLCTQHSA-N,50198735,CHEMBL3960011,Cannabinoid receptor 2,Homo sapiens,
1074466,FC1(F)CCC(CC1)NC(=O)C(N(C(=O)CCl)c1cccc2n(ccc12)C1CC1)c1cncnc1,"InChI=1S/C25H26ClF2N5O2/c26-12-22(34)33(21-3-1-2-20-19(21)8-11-32(20)18-4-5-18)23(16-13-29-15-30-14-16)24(35)31-17-6-9-25(27,28)10-7-17/h1-3,8,11,13-15,17-18,23H,4-7,9-10,12H2,(H,31,35)",PVKXIGIDEVPQHN-UHFFFAOYSA-N,512649,"WO2021219089, INSCoV-557A",Replicase polyprotein 1ab,,>25000
51065594,CC(C)COc1nc(ccc1CNC(=O)C(C)c1ccc(NS(C)(=O)=O)c(F)c1)C(F)(F)F,"InChI=1S/C21H25F4N3O4S/c1-12(2)11-32-20-15(6-8-18(27-20)21(23,24)25)10-26-19(29)13(3)14-5-7-17(16(22)9-14)28-33(4,30)31/h5-9,12-13,28H,10-11H2,1-4H3,(H,26,29)",YYYUBLPWJUJOSR-UHFFFAOYSA-N,50434932,CHEMBL2385408,Transient receptor potential cation channel subfamily V member 1,Homo sapiens, 68
50625051,CC[C@H]1COCC[C@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCN(CC1)c1cccc(c1)C(F)(F)F,"InChI=1S/C27H40F3N3O2/c1-4-20-18-35-15-9-24(20)31-22-8-10-26(17-22,19(2)3)25(34)33-13-11-32(12-14-33)23-7-5-6-21(16-23)27(28,29)30/h5-7,16,19-20,22,24,31H,4,8-15,17-18H2,1-3H3/t20-,22+,24+,26-/m0/s1",DNPRHSLKGYTIJX-RXDHMRHRSA-N,50337609,"CHEMBL1683064::cis-((1S,3R)-3-(3-ethyl-tetrahydro-2H-pyran-4-ylamino)-1-isopropylcyclopentyl)(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)methanone",C-C chemokine receptor type 5,, 312
992426,CCN1[C@H]2Cc3n(nc4cc(ccc34)C(=O)NCCN(C)C)[C@H]2[C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12,"InChI=1S/C32H31Cl2FN6O2/c1-4-40-26-16-25-19-10-8-17(30(42)36-12-13-39(2)3)14-23(19)38-41(25)29(26)27(20-6-5-7-22(34)28(20)35)32(40)21-11-9-18(33)15-24(21)37-31(32)43/h5-11,14-15,26-27,29H,4,12-13,16H2,1-3H3,(H,36,42)(H,37,43)/t26-,27-,29+,32+/m0/s1",GUZFCPUHQQRKAS-MRFOFCOLSA-N,454391,"US10717742, Example Ia-51::US10882866, Example Ia-51",E3 ubiquitin-protein ligase Mdm2 [23-117],, 7.00
50277333,N[C@@H](C1CC[C@@H](CC1)NS(=O)(=O)c1ccc(NS(=O)(=O)CC(F)(F)F)cc1)C(=O)N1CCCC1,"InChI=1S/C20H29F3N4O5S2/c21-20(22,23)13-33(29,30)25-15-7-9-17(10-8-15)34(31,32)26-16-5-3-14(4-6-16)18(24)19(28)27-11-1-2-12-27/h7-10,14,16,18,25-26H,1-6,11-13,24H2/t14?,16-,18-/m0/s1",ADSYCQHXJJBMGD-CMTKHDEESA-N,50137266,"CHEMBL140577::N-[4-((S)-1-Amino-2-oxo-2-pyrrolidin-1-yl-ethyl)-cyclohexyl]-4-(2,2,2-trifluoro-ethanesulfonylamino)-benzenesulfonamide::N-[4-(1-Amino-2-oxo-2-pyrrolidin-1-yl-ethyl)-cyclohexyl]-4-(2,2,2-trifluoro-ethanesulfonylamino)-benzenesulfonamide",Dipeptidyl peptidase 4,Homo sapiens, 2.6
51425671,COc1cccc(c1)-c1oc(CCC(O)=O)nc1-c1ccccc1,"InChI=1S/C19H17NO4/c1-23-15-9-5-8-14(12-15)19-18(13-6-3-2-4-7-13)20-16(24-19)10-11-17(21)22/h2-9,12H,10-11H2,1H3,(H,21,22)",JLLYLYAWTGEXCF-UHFFFAOYSA-N,50575857,CHEMBL4864263,Retinoic acid receptor RXR-beta,Homo sapiens,
50642757,CC(C)(C)C(=O)Nc1ccc(cc1)S(N)(=O)=O,"InChI=1S/C11H16N2O3S/c1-11(2,3)10(14)13-8-4-6-9(7-5-8)17(12,15)16/h4-7H,1-3H3,(H,13,14)(H2,12,15,16)",KGBTVIQRHXYTRQ-UHFFFAOYSA-N,16649,"2,2-dimethyl-N-(4-sulfamoylphenyl)propanamide::4-Pivaloylamido-benzenesulfonamide::CHEMBL23285::aromatic sulfonamide compound 14",Carbonic anhydrase 1,Homo sapiens,
50085536,CN1CCN2[C@H]3CCN(CCCC(=O)c4ccncc4)C[C@H]3c3cccc1c23,"InChI=1S/C23H28N4O/c1-25-14-15-27-20-9-13-26(12-3-6-22(28)17-7-10-24-11-8-17)16-19(20)18-4-2-5-21(25)23(18)27/h2,4-5,7-8,10-11,19-20H,3,6,9,12-16H2,1H3/t19-,20-/m0/s1",GCOQAARUFVDXHC-PMACEKPBSA-N,50007678,CHEMBL3233407,D(2) dopamine receptor,Rattus norvegicus,
629598,CC(c1ccc(C(F)F)c(F)c1)n1nc(CF)c2c1nc([nH]c2=O)N(C)C,,,320791,"(R)- or (S)-1-(1-(4-(Difluoromethyl)-3- fluorophenyl)ethyl)-6-(dimethylamino)-3- (fluoromethyl)-1H-pyrazolo[3,4- d]pyrimidin-4(5H)-one::US10174037, Example 196::US10174037, Example 197","cGMP-dependent 3',5'-cyclic phosphodiesterase",,
51040361,OC(=O)\C=C\C(O)=O,"InChI=1S/C4H4O4/c5-3(6)1-2-4(7)8/h1-2H,(H,5,6)(H,7,8)/b2-1+",VZCYOOQTPOCHFL-OWOJBTEDSA-N,26122,"(2E)-but-2-enedioic acid::FUMARIC ACID::Fumarate::fumarate, 10",Egl nine homolog 1,Homo sapiens,
50643282,O=C(NCc1ccccc1)c1cccnc1OC1CC2CCC1C2,"InChI=1S/C20H22N2O2/c23-19(22-13-14-5-2-1-3-6-14)17-7-4-10-21-20(17)24-18-12-15-8-9-16(18)11-15/h1-7,10,15-16,18H,8-9,11-13H2,(H,22,23)",YRADNWKOQRRDFI-UHFFFAOYSA-N,50228862,CHEMBL171141,"cAMP-specific 3',5'-cyclic phosphodiesterase 4C",, 220
87329,CCOC(=O)c1ccc(cc1)-n1sc2ccccc2c1=O,"InChI=1S/C16H13NO3S/c1-2-20-16(19)11-7-9-12(10-8-11)17-15(18)13-5-3-4-6-14(13)21-17/h3-10H,2H2,1H3",YICDSLBAVQXFOF-UHFFFAOYSA-N,46038,"4-(3-keto-1,2-benzothiazol-2-yl)benzoic acid ethyl ester::4-(3-oxo-1,2-benzothiazol-2-yl)benzoic acid ethyl ester::MLS-0315808.0001::cid_2467794::ethyl 4-(3-oxidanylidene-1,2-benzothiazol-2-yl)benzoate::ethyl 4-(3-oxo-1,2-benzothiazol-2-yl)benzoate",Mannose-6-phosphate isomerase,Homo sapiens, 23600
50391617,ONC(=O)\C=C\c1ccc2CN(Cc3ccc(cc3)-c3ccncc3)C(=O)c2c1,"InChI=1S/C23H19N3O3/c27-22(25-29)8-4-16-1-7-20-15-26(23(28)21(20)13-16)14-17-2-5-18(6-3-17)19-9-11-24-12-10-19/h1-13,29H,14-15H2,(H,25,27)/b8-4+",IFRRSKDLVRTGSJ-XBXARRHUSA-N,50216516,3-(2-(4-(pyridin-4-yl)benzyl)-3-oxoisoindolin-5-yl)-N-hydroxyacrylamide::CHEMBL246199,Histone deacetylase 4,Homo sapiens, 2100
50423057,CSc1ccccc1CN([C@H]1CCNC1)S(C)(=O)=O,"InChI=1S/C13H20N2O2S2/c1-18-13-6-4-3-5-11(13)10-15(19(2,16)17)12-7-8-14-9-12/h3-6,12,14H,7-10H2,1-2H3/t12-/m0/s1",BUJVJHVEEOZSIE-LBPRGKRZSA-N,50262682,CHEMBL477572::N-(2-Methylsulfanyl-benzyl)-N-(S)-pyrrolidin-3-yl-methanesulfonamide,Sodium-dependent dopamine transporter,Homo sapiens,
1116761,COCc1nnc(NS(=O)(=O)[C@@H](C)[C@H](C)c2cnc(C)cn2)n1-c1c(OC)ncnc1OC,"InChI=1S/C19H26N8O5S/c1-11-7-21-14(8-20-11)12(2)13(3)33(28,29)26-19-25-24-15(9-30-4)27(19)16-17(31-5)22-10-23-18(16)32-6/h7-8,10,12-13H,9H2,1-6H3,(H,25,26)/t12-,13-/m0/s1",YFWNWWXQUBQHPV-STQMWFEESA-N,528366,"US11191762, Example 9.0",Apelin receptor,Homo sapiens,
51125443,CCCCCCOc1c2CN(C(=O)c2c(OCCCCCC)c2ccccc12)c1ccc(CC(O)=O)cc1,"InChI=1S/C32H39NO5/c1-3-5-7-11-19-37-30-25-13-9-10-14-26(25)31(38-20-12-8-6-4-2)29-27(30)22-33(32(29)36)24-17-15-23(16-18-24)21-28(34)35/h9-10,13-18H,3-8,11-12,19-22H2,1-2H3,(H,34,35)",DKAJTTJQVGYKHG-UHFFFAOYSA-N,50461456,CHEMBL4228095,Prostaglandin E2 receptor EP4 subtype,Homo sapiens,
50402775,CC(C)[C@H](NC(=O)CCN(C)C)c1cc(C)ccc1N1CCN(CC1)C(=O)[C@H](C)Cc1ccc(Cl)cc1,"InChI=1S/C30H43ClN4O2/c1-21(2)29(32-28(36)13-14-33(5)6)26-19-22(3)7-12-27(26)34-15-17-35(18-16-34)30(37)23(4)20-24-8-10-25(31)11-9-24/h7-12,19,21,23,29H,13-18,20H2,1-6H3,(H,32,36)/t23-,29+/m1/s1",FRHBHVROLQSPMW-BTYSJIOQSA-N,50224181,1-{2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl}-4-[(2R)-methyl-3-(4-chlorophenyl)propionyl]piperazine::CHEMBL427860::N-((S)-1-(2-(4-((R)-3-(4-chlorophenyl)-2-methylpropanoyl)piperazin-1-yl)-5-methylphenyl)-2-methylpropyl)-3-(dimethylamino)propanamide,Cytochrome P450 2C9,Homo sapiens,>10000
50525501,OC[C@@]12C[C@@H]1[C@H]([C@H](O)[C@@H]2O)n1cnc2c(NC(C3CC3)C3CC3)nc(Cl)nc12,"InChI=1S/C19H24ClN5O3/c20-18-23-16(22-11(8-1-2-8)9-3-4-9)12-17(24-18)25(7-21-12)13-10-5-19(10,6-26)15(28)14(13)27/h7-11,13-15,26-28H,1-6H2,(H,22,23,24)/t10-,13-,14+,15+,19+/m1/s1",HOGXFHNYQVRCAK-DRYZDSLUSA-N,50199464,CHEMBL3923870,Adenosine receptor A1,Homo sapiens,
1033647,ClCC(=O)N1CC2CC1CN2Cc1cccc(Cl)c1,"InChI=1S/C14H16Cl2N2O/c15-6-14(19)18-9-12-5-13(18)8-17(12)7-10-2-1-3-11(16)4-10/h1-4,12-13H,5-9H2",VSKDLORAYNFUSV-UHFFFAOYSA-N,496766,DAN-LON-a5fc619e-8,Replicase polyprotein 1ab,, 2170
1104992,Cc1ncc2nc3COP(S)(=O)O[C@@H]4[C@@H](F)[C@@H](COP(S)(=O)OCCn3c2n1)O[C@H]4n1cnc2c1nc(N)[nH]c2=O,,,523187,"US11161864, Example 11D",Stimulator of interferon genes protein [154-378],,<1000
50328983,COc1cc(OC2CCN(C)CC2)ccc1Nc1nccc(n1)-c1c[nH]c2cnccc12,"InChI=1S/C24H26N6O2/c1-30-11-7-16(8-12-30)32-17-3-4-21(23(13-17)31-2)29-24-26-10-6-20(28-24)19-14-27-22-15-25-9-5-18(19)22/h3-6,9-10,13-16,27H,7-8,11-12H2,1-2H3,(H,26,28,29)",FTZQWKAIKYEWPM-UHFFFAOYSA-N,50081173,CHEMBL3421972,Dual specificity protein kinase TTK,Homo sapiens, 20
51064023,Clc1ccc2[nH]c(=O)ccc2c1,"InChI=1S/C9H6ClNO/c10-7-2-3-8-6(5-7)1-4-9(12)11-8/h1-5H,(H,11,12)",OJEBWFGRUPIVSD-UHFFFAOYSA-N,50197522,CHEMBL3929492,Coagulation factor XI,Homo sapiens, 140000
748102,CS(=N)(=O)c1ccc(Nc2ncnc(n2)-c2ccc(O[C@H]3CCN(CC3(F)F)C=O)c(c2)C#N)cc1,"InChI=1S/C23H21F2N7O3S/c1-36(27,34)18-5-3-17(4-6-18)30-22-29-13-28-21(31-22)15-2-7-19(16(10-15)11-26)35-20-8-9-32(14-33)12-23(20,24)25/h2-7,10,13-14,20,27H,8-9,12H2,1H3,(H,28,29,30,31)/t20-,36?/m0/s1",VBVBCPLRKQJABM-PIPNLDLUSA-N,278260,"2-(((S)-3,3-difluoro-1-formylpiperidin-4-yl)oxy)-5-(4-((4-(S-methylsulfonimidoyl)phenyl)amino)-1,3,5-triazin-2-yl)benzonitrile::US10040781, Example 482::US10253019, Example 482",Tyrosine-protein kinase JAK2,Homo sapiens, 221
51400312,CC1CCCc2sc(NC(=S)Nc3ccccc3)c(C(N)=O)c12,"InChI=1S/C17H19N3OS2/c1-10-6-5-9-12-13(10)14(15(18)21)16(23-12)20-17(22)19-11-7-3-2-4-8-11/h2-4,7-8,10H,5-6,9H2,1H3,(H2,18,21)(H2,19,20,22)",XEWOCORPFIZSQN-UHFFFAOYSA-N,50565662,CHEMBL4777482,C-X-C chemokine receptor type 4,,>10000
51230631,NS(=O)(=O)c1cc(C(=O)NCCO)c(cc1Br)[S+]([O-])c1ccccc1,"InChI=1S/C15H15BrN2O5S2/c16-12-9-13(24(21)10-4-2-1-3-5-10)11(15(20)18-6-7-19)8-14(12)25(17,22)23/h1-5,8-9,19H,6-7H2,(H,18,20)(H2,17,22,23)",WMAKPMGOFNHAFL-UHFFFAOYSA-N,50504908,CHEMBL4566236,Carbonic anhydrase 14,Homo sapiens,
50966804,Fc1ccccc1\C=C1/Sc2ccc(cc2NC1=O)C(=O)NCCN1CCCC1,"InChI=1S/C22H22FN3O2S/c23-17-6-2-1-5-15(17)14-20-22(28)25-18-13-16(7-8-19(18)29-20)21(27)24-9-12-26-10-3-4-11-26/h1-2,5-8,13-14H,3-4,9-12H2,(H,24,27)(H,25,28)/b20-14-",WVZWNOATQPTBMX-ZHZULCJRSA-N,50396502,CHEMBL2170912,Glucose-6-phosphate dehydrogenase,Plasmodium falciparum, 11000
50573797,COc1ccc(Cn2c(nc3ccccc23)C2CCCN(C2)C2CCOCC2)cc1,"InChI=1S/C25H31N3O2/c1-29-22-10-8-19(9-11-22)17-28-24-7-3-2-6-23(24)26-25(28)20-5-4-14-27(18-20)21-12-15-30-16-13-21/h2-3,6-11,20-21H,4-5,12-18H2,1H3",WLXTZKAROJEVMI-UHFFFAOYSA-N,50316927,1-(4-methoxybenzyl)-2-(1-(tetrahydro-2H-pyran-4-yl)piperidin-3-yl)-1H-benzo[d]imidazole::CHEMBL1094852,Potassium voltage-gated channel subfamily H member 2,Homo sapiens,
50644887,C[C@@H]1NC(=N[C@@]1(c1ccc(F)cc1)c1ccc(F)nc1)c1ccc(=O)n(c1)C(F)F,"InChI=1S/C21H16F4N4O/c1-12-21(14-3-6-16(22)7-4-14,15-5-8-17(23)26-10-15)28-19(27-12)13-2-9-18(30)29(11-13)20(24)25/h2-12,20H,1H3,(H,27,28)/t12-,21-/m0/s1",MUTOQFPGGSSVLM-QKVFXAPYSA-N,50346228,"1-(Difluoromethyl)-5-[(4S,5S)-4-(4-fluorophenyl)-4-(6-fluoropyridin-3-yl)-5-methyl-4,5-dihydro-1H-imidazol-2-yl]pyridin-2(1H)-one::CHEMBL1784130",Potassium voltage-gated channel subfamily H member 2,Homo sapiens,>10
1092813,CCNc1nc(Nc2cc(nn2CC)C(C)(C)n2nccn2)ncc1C(F)(F)F,"InChI=1S/C17H22F3N9/c1-5-21-14-11(17(18,19)20)10-22-15(26-14)25-13-9-12(27-28(13)6-2)16(3,4)29-23-7-8-24-29/h7-10H,5-6H2,1-4H3,(H2,21,22,25,26)",BQJLGQQNMBGURT-UHFFFAOYSA-N,384402,"US10590114, No. 129::US11111235, No. 88::US9932325, Example 129::US9932325, Example 88",Leucine-rich repeat serine/threonine-protein kinase 2 [G2019S],,<30
50608950,CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34,"InChI=1S/C25H31NO/c1-24(2,3)25(27)13-14-26-16-21-19-9-5-4-7-17(19)11-12-18-8-6-10-20(23(18)21)22(26)15-25/h4-10,21-22,27H,11-16H2,1-3H3/t21-,22-,25-/m0/s1",ZZJYIKPMDIWRSN-HWBMXIPRSA-N,50008735,"(+)-3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::(+)-butaclamol::(+/-)-3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::(S)-(-)-3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol ((+)-butaclamol)::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol((+)-butaclamol)::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol(Butaclamol)::BUTACLAMOL::BUTACLAMOL, (-)::BUTACLAMOL,(+)::BUTACLAMOL,d-::CHEMBL8514::d-Butaclamol",Sodium channel protein type 1/2/3 subunit alpha,, 3600
51004805,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C,"InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1",VKHAHZOOUSRJNA-GCNJZUOMSA-N,18627,"(10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one::Mifeprex::Mifepristone::RU-486::RU486 (tetramethyl-rhodamine conjugated)",Glucocorticoid receptor,,
397182,Cn1ncc(NC(=O)c2csc(n2)-c2cnc3cccnc3c2)c1[C@@H]1CC[C@@H](N)[C@H](F)CO1,"InChI=1S/C22H22FN7O2S/c1-30-20(19-5-4-14(24)13(23)10-32-19)17(9-27-30)28-21(31)18-11-33-22(29-18)12-7-16-15(26-8-12)3-2-6-25-16/h2-3,6-9,11,13-14,19H,4-5,10,24H2,1H3,(H,28,31)/t13-,14-,19+/m1/s1",KWXNSGZERGSWJP-LPMFXHHGSA-N,227446,"US9328106, 399",Serine/threonine-protein kinase pim-1,,
51352288,Cc1ccc(\C=C\c2cccc(c2)-c2nn(c(CC3CC3)c2Cc2ccc(c(F)c2)S(N)(=O)=O)-c2nc(cs2)C(O)=O)s1,"InChI=1S/C31H27FN4O4S3/c1-18-5-10-23(42-18)11-8-19-3-2-4-22(13-19)29-24(14-21-9-12-28(25(32)15-21)43(33,39)40)27(16-20-6-7-20)36(35-29)31-34-26(17-41-31)30(37)38/h2-5,8-13,15,17,20H,6-7,14,16H2,1H3,(H,37,38)(H2,33,39,40)/b11-8+",FBYATYKNYYAWRX-DHZHZOJOSA-N,50465091,CHEMBL4294999,L-lactate dehydrogenase A chain,Homo sapiens, 52
50877872,Clc1ccccc1[C@@H]1CC[C@@H](CC1)N1CCN(CC1)c1ccccn1,"InChI=1S/C21H26ClN3/c22-20-6-2-1-5-19(20)17-8-10-18(11-9-17)24-13-15-25(16-14-24)21-7-3-4-12-23-21/h1-7,12,17-18H,8-11,13-16H2/t17-,18+",QSUQNNQRYGZRHL-HDICACEKSA-N,50274944,CHEMBL458802::cis-4-[4-(2-Chlorophenyl)cyclohexyl]-1-(2-pyridinyl)piperazine,Sigma non-opioid intracellular receptor 1,Cavia porcellus,
482888,FC(F)Oc1ccccc1-n1nnnc1-c1ccccc1-c1ccccc1F,"InChI=1S/C20H13F3N4O/c21-16-10-4-3-8-14(16)13-7-1-2-9-15(13)19-24-25-26-27(19)17-11-5-6-12-18(17)28-20(22)23/h1-12,20H",SPCBWVUNUOIDHK-UHFFFAOYSA-N,205078,"US9556132, 58::process for preparing 1-[2-(difluoromethoxy)phenyl]-5-[2-(2-fluorophenyl)phenyl]-1h-1,2,3,4-tetrazole ",Intermediate conductance calcium-activated potassium channel protein 4,Homo sapiens, 1100
50925168,Cc1ccccc1NC(=O)Nc1cccc(c1)[N+]([O-])=O,"InChI=1S/C14H13N3O3/c1-10-5-2-3-8-13(10)16-14(18)15-11-6-4-7-12(9-11)17(19)20/h2-9H,1H3,(H2,15,16,18)",MSBVHIWAXMMCPU-UHFFFAOYSA-N,50379302,CHEMBL2011807,ATP-dependent RNA helicase DDX3X,Homo sapiens, 1000
810924,OC(=O)c1ccncc1Nc1nn(C2CCOCC2)c2ccc(F)cc12,"InChI=1S/C18H17FN4O3/c19-11-1-2-16-14(9-11)17(22-23(16)12-4-7-26-8-5-12)21-15-10-20-6-3-13(15)18(24)25/h1-3,6,9-10,12H,4-5,7-8H2,(H,21,22)(H,24,25)",YFWMMWXAAXINTP-UHFFFAOYSA-N,277765,"3-{[5-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-indazol-3-yl]amino}pyridine-4-carboxylic acid::US10040779, Example 62::US10336727, Example 62::US9617242, Example 62",Lysine-specific demethylase 4C,, 550
706368,CSc1c(-c2ccc(C)s2)c(nn1C[C@@H]1CC[C@H](COCC(O)=O)CC1)-c1ccccc1,"InChI=1S/C25H30N2O3S2/c1-17-8-13-21(32-17)23-24(20-6-4-3-5-7-20)26-27(25(23)31-2)14-18-9-11-19(12-10-18)15-30-16-22(28)29/h3-8,13,18-19H,9-12,14-16H2,1-2H3,(H,28,29)/t18-,19+",ZMROZIDRJCRQLR-KDURUIRLSA-N,357270,"2-(((1s,4s)-4-((5- (methylthio)-4-(5- methylthiophen-2-yl)-3- phenyl-1H-pyrazol-1- yl)methyl)cyclohexyl) methoxy)acetic acid::US10214518, Compound 111::US11098034, Compound 111",Major prion protein,Homo sapiens, 28.0
465772,OCCNC(=O)COc1nc(NCc2cccc(c2)C(F)(F)F)c2cc(ccc2n1)C(c1ccc(Cl)cc1)c1ccc(Cl)cc1,"InChI=1S/C33H27Cl2F3N4O3/c34-25-9-4-21(5-10-25)30(22-6-11-26(35)12-7-22)23-8-13-28-27(17-23)31(42-32(41-28)45-19-29(44)39-14-15-43)40-18-20-2-1-3-24(16-20)33(36,37)38/h1-13,16-17,30,43H,14-15,18-19H2,(H,39,44)(H,40,41,42)",YMRAMJXPOJXMAC-UHFFFAOYSA-N,143565,"US9682955, 40",Cannabinoid receptor 1,Homo sapiens,
50023995,CCCCN(CCCC)[C@H]1CCc2cccc(O)c2C1,"InChI=1S/C18H29NO/c1-3-5-12-19(13-6-4-2)16-11-10-15-8-7-9-18(20)17(15)14-16/h7-9,16,20H,3-6,10-14H2,1-2H3/t16-/m0/s1",SYSODJPJTHIXAV-INIZCTEOSA-N,50016775,"7-Dibutylamino-5,6,7,8-tetrahydro-naphthalen-1-ol::CHEMBL423987",5-hydroxytryptamine receptor 1A,Rattus norvegicus, 46
50884774,O=C(Oc1ccc2ccccc2c1)N1CCN2CCC1CC2,"InChI=1S/C18H20N2O2/c21-18(20-12-11-19-9-7-16(20)8-10-19)22-17-6-5-14-3-1-2-4-15(14)13-17/h1-6,13,16H,7-12H2",MQZFLDZRBIKMGM-UHFFFAOYSA-N,50296748,"CHEMBL564850::naphthalen-2-yl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate",Neuronal acetylcholine receptor subunit alpha-3,Homo sapiens, 4910
50878757,CC(C)Oc1ccccc1\C=C(/CC([O-])=O)c1nc2ccccc2s1,"InChI=1S/C20H19NO3S/c1-13(2)24-17-9-5-3-7-14(17)11-15(12-19(22)23)20-21-16-8-4-6-10-18(16)25-20/h3-11,13H,12H2,1-2H3,(H,22,23)/p-1/b15-11+",QIBUPJYJYNFVEA-RVDMUPIBSA-M,50266386,3-(benzo[d]thiazol-2-yl)-4-(2-isopropoxyphenyl)but-3-enoate,Trans-sialidase,Trypanosoma cruzi, 290000
716238,Cc1cc(C(=O)NCc2ccc(CN)cc2)c(C)n1Cc1csc(n1)-c1ccncc1,"InChI=1S/C24H25N5OS/c1-16-11-22(23(30)27-13-19-5-3-18(12-25)4-6-19)17(2)29(16)14-21-15-31-24(28-21)20-7-9-26-10-8-20/h3-11,15H,12-14,25H2,1-2H3,(H,27,30)",ROUDVONQVMIJDR-UHFFFAOYSA-N,186866,"US9670157, 32 2,5-Dimethyl-1-(2-pyridin-4-yl-thiazol-4-ylmethyl)-1H-pyrrole-3-carboxylic acid 4-aminomethyl-benzylamide::US9834513, 32",Kallikrein-1,, 10000
1198131,[O-][N+](=O)c1cc(ccc1NC[C@@H]1COCCO1)S(=O)(=O)NC(=O)c1ccc(cc1Oc1cnc2[nH]ccc2c1)N1CCC2(CC(C2)N2CCC[C@H]2c2ccccc2C2CC2)CC1,,,567671,"US11420968, Example F38",Bcl-2-like protein 1,Homo sapiens, 38.0
296936,Cc1cc(ccn1)-c1n[nH]c2ccc(cc12)C(=O)N[C@@H]1CCCN(Cc2ccncn2)C1,,,154704,"US8999957, Table 2, Compound 41",Mitogen-activated protein kinase 1,Mus musculus, 506.7
51188776,COc1cc2CC(Oc3cccc(CN4CCN(C)CC4)c3)C(=O)c2cc1OC,"InChI=1S/C23H28N2O4/c1-24-7-9-25(10-8-24)15-16-5-4-6-18(11-16)29-22-13-17-12-20(27-2)21(28-3)14-19(17)23(22)26/h4-6,11-12,14,22H,7-10,13,15H2,1-3H3",UNRGUOAZKUZHRW-UHFFFAOYSA-N,50169862,"5,6-Dimethoxy-2-[3-(4-methyl-piperazin-1-ylmethyl)-phenoxy]-indan-1-one::CHEMBL264242",Acetylcholinesterase,Rattus norvegicus, 6400
51096658,CNC(=O)c1nnc2ccc(cc2c1N[C@@H](C)C1CCOCC1)-c1ccc(OCCCN(C)C)nc1,"InChI=1S/C27H36N6O3/c1-18(19-10-14-35-15-11-19)30-25-22-16-20(6-8-23(22)31-32-26(25)27(34)28-2)21-7-9-24(29-17-21)36-13-5-12-33(3)4/h6-9,16-19H,5,10-15H2,1-4H3,(H,28,34)(H,30,31)/t18-/m0/s1",SJOFSBIUJPEXTG-SFHVURJKSA-N,50459003,CHEMBL4218854,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 3800
51262924,Nc1ccc2n(CC(=O)c3ccc4ccccc4c3)c(=O)sc2c1,"InChI=1S/C19H14N2O2S/c20-15-7-8-16-18(10-15)24-19(23)21(16)11-17(22)14-6-5-12-3-1-2-4-13(12)9-14/h1-10H,11,20H2",SBCCWBKAQIYKKV-UHFFFAOYSA-N,50515889,CHEMBL4514325,Chromodomain Y-like protein 2,,
699322,COc1cc(OC)c(F)c(N2Cc3cnc(cc3C3(CC3)C2=O)-c2ccnc(NC(=O)C=C)c2)c1F,"InChI=1S/C26H22F2N4O4/c1-4-21(33)31-20-9-14(5-8-29-20)17-10-16-15(12-30-17)13-32(25(34)26(16)6-7-26)24-22(27)18(35-2)11-19(36-3)23(24)28/h4-5,8-12H,1,6-7,13H2,2-3H3,(H,29,31,33)",UGROMKOQSBRWOA-UHFFFAOYSA-N,291236,"N-(4-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,7]naphthyridine]-6'-yl)pyridin-2-yl)acrylamide::US10016438, Example 4::US9580423, Example 4::US9801889, Example 4",Fibroblast growth factor receptor 3,Homo sapiens, 20
51158266,CC(C)N(CCC1=C(C(C)c2ccccn2)c2ccccc2C1)C(C)C,"InChI=1S/C24H32N2/c1-17(2)26(18(3)4)15-13-21-16-20-10-6-7-11-22(20)24(21)19(5)23-12-8-9-14-25-23/h6-12,14,17-19H,13,15-16H2,1-5H3",HBRHULDGKNIFGB-UHFFFAOYSA-N,50474492,CHEMBL352375,Muscarinic acetylcholine receptor M1,,
891282,c1sc(nc1-c1cccc(c1)-c1ccccc1)-c1ccc2ccccc2c1,InChI=1S/C25H17NS/c1-2-7-18(8-3-1)21-11-6-12-22(15-21)24-17-27-25(26-24)23-14-13-19-9-4-5-10-20(19)16-23/h1-17H,RYZFPVXUVVKWOK-UHFFFAOYSA-N,393742,"US10597367, Example 32::US9969726, Example 32",Metabotropic glutamate receptor 5,Rattus norvegicus,
50426550,Nc1nccc(\C=C\c2c(nc3sccn23)-c2ccccc2)n1,"InChI=1S/C17H13N5S/c18-16-19-9-8-13(20-16)6-7-14-15(12-4-2-1-3-5-12)21-17-22(14)10-11-23-17/h1-11H,(H2,18,19,20)/b7-6+",GOJZHNWOESVAEU-VOTSOKGWSA-N,50272586,"(E/Z)-4-(2-(6-phenylimidazo[2,1-b]thiazol-5-yl)vinyl)pyrimidin-2-amine::CHEMBL497114",Vascular endothelial growth factor receptor 1,Homo sapiens, 30000
710241,COc1cccc(OC)c1-n1c(NS(=O)(=O)[C@H](C)[C@@H](OC(C)C)c2ncc(C)cn2)nnc1-c1cccnc1,"InChI=1S/C26H31N7O5S/c1-16(2)38-23(24-28-13-17(3)14-29-24)18(4)39(34,35)32-26-31-30-25(19-9-8-12-27-15-19)33(26)22-20(36-5)10-7-11-21(22)37-6/h7-16,18,23H,1-6H3,(H,31,32)/t18-,23-/m1/s1",TTWYRZCYYPCYSL-WZONZLPQSA-N,270058,"(1S,2R)-N-(4-(2,6-dimethoxyphenyl)-5-(3-pyridinyl)-4H-1,2,4-triazol-3-yl)-1-(1-methylethoxy)-1-(5-methyl-2-pyrimidinyl)-2-propanesulfonamide, (1R,2S)-N-(4-(2,6-dimethoxyphenyl)-5-(3-pyridinyl)-4H-1,2,4-triazol-3-yl)-1-(1-methylethoxy)-1-(5-methyl-2-pyrimidinyl)-2-propanesulfonamide::US10058550, Example 624.0::US10058550, Example 626.0::US10221162, Example 626.0::US9845310, Example 626.0",Apelin receptor,Homo sapiens,
733668,Cn1c(=O)n(Cc2nccs2)c2ccc(cc2c1=O)S(=O)(=O)NC1(C)CC1,"InChI=1S/C17H18N4O4S2/c1-17(5-6-17)19-27(24,25)11-3-4-13-12(9-11)15(22)20(2)16(23)21(13)10-14-18-7-8-26-14/h3-4,7-9,19H,5-6,10H2,1-2H3",FFQXXBIOWSDRGH-UHFFFAOYSA-N,371039,"US10239843, Example 146",Poly(ADP-ribose) glycohydrolase,, 671
50399415,CN1C(=O)c2ccc(OC(=O)CCc3ccc(N)nc3)cc2C1=O,"InChI=1S/C17H15N3O4/c1-20-16(22)12-5-4-11(8-13(12)17(20)23)24-15(21)7-3-10-2-6-14(18)19-9-10/h2,4-6,8-9H,3,7H2,1H3,(H2,18,19)",OSPQCZJJZMQHLM-UHFFFAOYSA-N,50322033,"2-Methylisoindole-1,3-dione-5-yl 3-(6-aminopyridin-3-yl)propionate::CHEMBL1171655",Tryptase beta-2/delta/gamma,Homo sapiens, 190
183137,CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(N)=O)C(N)=O,"InChI=1S/C147H238N44O42S/c1-18-75(12)115(143(231)182-97(56-72(6)7)131(219)174-94(118(156)206)61-108(153)199)189-140(228)106(68-193)186-135(223)102(63-110(155)201)179-132(220)96(55-71(4)5)176-133(221)98(58-81-37-41-84(196)42-38-81)177-126(214)88(33-23-26-49-149)168-124(212)89(34-24-27-50-150)172-141(229)113(73(8)9)187-119(207)76(13)165-122(210)93(47-53-234-17)171-128(216)92(45-46-107(152)198)170-123(211)87(32-22-25-48-148)167-125(213)90(35-28-51-162-146(157)158)169-130(218)95(54-70(2)3)175-127(215)91(36-29-52-163-147(159)160)173-144(232)116(78(15)194)190-137(225)99(59-82-39-43-85(197)44-40-82)178-134(222)101(62-109(154)200)180-136(224)104(65-112(204)205)184-145(233)117(79(16)195)191-138(226)100(57-80-30-20-19-21-31-80)183-142(230)114(74(10)11)188-120(208)77(14)166-129(217)103(64-111(202)203)181-139(227)105(67-192)185-121(209)86(151)60-83-66-161-69-164-83/h19-21,30-31,37-44,66,69-79,86-106,113-117,192-197H,18,22-29,32-36,45-65,67-68,148-151H2,1-17H3,(H2,152,198)(H2,153,199)(H2,154,200)(H2,155,201)(H2,156,206)(H,161,164)(H,165,210)(H,166,217)(H,167,213)(H,168,212)(H,169,218)(H,170,211)(H,171,216)(H,172,229)(H,173,232)(H,174,219)(H,175,215)(H,176,221)(H,177,214)(H,178,222)(H,179,220)(H,180,224)(H,181,227)(H,182,231)(H,183,230)(H,184,233)(H,185,209)(H,186,223)(H,187,207)(H,188,208)(H,189,228)(H,190,225)(H,191,226)(H,202,203)(H,204,205)(H4,157,158,162)(H4,159,160,163)/t75-,76-,77-,78+,79+,86-,87-,88-,89-,90-,91-,92-,93-,94+,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,113-,114-,115-,116?,117-/m0/s1",HEOYHMUESMJFDC-CWQDQJDSSA-N,85877,VIP [D- Asn28]::VIP [D-Asn28],VIP peptides,Rattus,
277234,O=C(CC1COCCO1)N[C@H]1CC[C@H](CCN2CCC(CC2)c2coc3ccccc23)CC1,"InChI=1S/C27H38N2O4/c30-27(17-23-18-31-15-16-32-23)28-22-7-5-20(6-8-22)9-12-29-13-10-21(11-14-29)25-19-33-26-4-2-1-3-24(25)26/h1-4,19-23H,5-18H2,(H,28,30)/t20-,22-,23?",CQUFCEROSHHDTD-YEMPIKNUSA-N,141766,"US8921397, 8",D(3) dopamine receptor,,
928421,CCOCCOc1ccc(cn1)-c1cc(=O)[nH]c(n1)-c1c(F)ccc(CNC(=O)C(C)C)c1Cl,"InChI=1S/C24H26ClFN4O4/c1-4-33-9-10-34-20-8-6-15(12-27-20)18-11-19(31)30-23(29-18)21-17(26)7-5-16(22(21)25)13-28-24(32)14(2)3/h5-8,11-12,14H,4,9-10,13H2,1-3H3,(H,28,32)(H,29,30,31)",ZXMWDPUUYWCASI-UHFFFAOYSA-N,451585,"US10710967, Example 185",Prostaglandin E synthase,Homo sapiens, 52.0
50729383,CCCCCCCN1C(=O)NC(C1=O)(c1ccc(Br)cc1)c1ccc(Br)cc1,"InChI=1S/C22H24Br2N2O2/c1-2-3-4-5-6-15-26-20(27)22(25-21(26)28,16-7-11-18(23)12-8-16)17-9-13-19(24)14-10-17/h7-14H,2-6,15H2,1H3,(H,25,28)",DARDHNGWORIPGS-UHFFFAOYSA-N,50080104,"5,5-Bis-(4-bromo-phenyl)-3-heptyl-imidazolidine-2,4-dione::5,5-bis(4-bromophenyl)-3-heptylimidazolidine-2,4-dione::CHEMBL49407",Cannabinoid receptor 1,Homo sapiens,
50085841,CCC(=O)Nc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)C1,"InChI=1S/C22H26ClN3O3/c1-3-21(27)25-19-12-20(29-2)17(11-18(19)23)22(28)24-16-9-10-26(14-16)13-15-7-5-4-6-8-15/h4-8,11-12,16H,3,9-10,13-14H2,1-2H3,(H,24,28)(H,25,27)/t16-/m0/s1",APTCMKUWYITAOW-INIZCTEOSA-N,50052195,CHEMBL93198::N-((S)-1-Benzyl-pyrrolidin-3-yl)-5-chloro-2-methoxy-4-propionylamino-benzamide,D(2) dopamine receptor,Rattus norvegicus,
1147067,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@](O)(CF)CC[C@H]34)[C@@H]1CC[C@@H]2C(=O)Cn1nnc2cnccc12,"InChI=1S/C26H35FN4O2/c1-25-9-6-18-17-7-10-26(33,15-27)12-16(17)2-3-19(18)20(25)4-5-21(25)24(32)14-31-23-8-11-28-13-22(23)29-30-31/h8,11,13,16-21,33H,2-7,9-10,12,14-15H2,1H3/t16-,17-,18+,19+,20-,21+,25-,26+/m0/s1",FTZYVQGZJNKUFA-NMAPPNDSSA-N,540772,"US11261211, Compound SB-14",Gamma-aminobutyric acid receptor subunit alpha-1,,>500
50642832,CCCC(C)C(=O)Nc1ccc(cc1)S(N)(=O)=O,"InChI=1S/C12H18N2O3S/c1-3-4-9(2)12(15)14-10-5-7-11(8-6-10)18(13,16)17/h5-9H,3-4H2,1-2H3,(H,14,15)(H2,13,16,17)",QSFJQYWMTFBTCD-UHFFFAOYSA-N,50345210,2-methyl-N-(4-sulfamoylphenyl)pentanamide::CHEMBL1085095,Carbonic anhydrase 14,Homo sapiens,
1018336,CN([C@@H]1C[C@@H](C1)NS(=O)(=O)c1cnc(C)s1)c1ncnc2[nH]ccc12,,,159788,"US10966980, Example 38::US9035074, 38",Non-receptor tyrosine-protein kinase TYK2,Homo sapiens, 546
448064,NC(=O)CC(NC(=O)C1(N)CCN(CC1)c1ncnc2[nH]ccc12)c1ccc(Cl)cc1,,,256870,"US10654855, Example 66::US11236095, Example 66::US9492453, 66",RAC-alpha serine/threonine-protein kinase,, 6.6
738404,CC(C)Oc1ncc(cc1N1CCOCC1)-c1cc(NC(=O)c2cc(ccn2)C(C)(C)F)cnc1C,"InChI=1S/C27H32FN5O3/c1-17(2)36-26-24(33-8-10-35-11-9-33)12-19(15-31-26)22-14-21(16-30-18(22)3)32-25(34)23-13-20(6-7-29-23)27(4,5)28/h6-7,12-17H,8-11H2,1-5H3,(H,32,34)",NFDIQKBIDWDWPV-UHFFFAOYSA-N,87928,"US10245267, Example 957::US10709712, Example 957::US9694016, 957",Serine/threonine-protein kinase B-raf [V600E],, 6.23
1080633,COc1ccc(nc1)-c1nc2c(ccnc2[nH]1)-c1ccc(CN2CCOc3cc(cc(F)c3C2=O)C2CC2)c(F)c1,"InChI=1S/C31H25F2N5O3/c1-40-21-6-7-25(35-15-21)29-36-28-22(8-9-34-30(28)37-29)18-4-5-19(23(32)12-18)16-38-10-11-41-26-14-20(17-2-3-17)13-24(33)27(26)31(38)39/h4-9,12-15,17H,2-3,10-11,16H2,1H3,(H,34,36,37)",OSIUMCUMOLRQBT-UHFFFAOYSA-N,514816,"US11098041, Example 40",Tyrosine-protein kinase BTK [328-659],,<100
299114,COc1ccc(nc1-c1cccc(c1)-c1nnc(C)o1)C(=O)N[C@@H](CC(O)=O)c1ccc(C)cc1,"InChI=1S/C26H24N4O5/c1-15-7-9-17(10-8-15)21(14-23(31)32)28-25(33)20-11-12-22(34-3)24(27-20)18-5-4-6-19(13-18)26-30-29-16(2)35-26/h4-13,21H,14H2,1-3H3,(H,28,33)(H,31,32)/t21-/m0/s1",NBHBYESMGRRQLP-NRFANRHFSA-N,156817,"US9029559, 249",Lysosomal protective protein,, 8710
50463232,O[C@H]1C[C@@H](CP(O)(O)=O)C[C@](O)(C1)C(O)=O,"InChI=1S/C8H15O7P/c9-6-1-5(4-16(13,14)15)2-8(12,3-6)7(10)11/h5-6,9,12H,1-4H2,(H,10,11)(H2,13,14,15)/t5-,6+,8+/m1/s1",SWEXPEKCRDSBSH-CHKWXVPMSA-N,50028883,"(1S,3S,5R)-1,3-Dihydroxy-5-phosphonomethyl-cyclohexanecarboxylic acid::CHEMBL178075",3-dehydroquinate synthase,Escherichia coli,
621543,CN(C)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(cc2)C2(CC2)[N+]#[C-])c1F,"InChI=1S/C26H21F2N5O3S/c1-29-26(10-11-26)17-6-4-15(5-7-17)16-12-18-19(14-31-25(18)30-13-16)24(34)22-20(27)8-9-21(23(22)28)32-37(35,36)33(2)3/h4-9,12-14,32H,10-11H2,2-3H3,(H,30,31)",ZLMCSJGIOXHDRP-UHFFFAOYSA-N,317741,"US9624213, Compound P-0237",Serine/threonine-protein kinase B-raf [V600E],,<100.0
50327501,CNCc1csc(n1)-c1ccc(cc1)N1C[C@H](CNC(=O)c2ccc(Cl)s2)OC1=O,"InChI=1S/C20H19ClN4O3S2/c1-22-8-13-11-29-19(24-13)12-2-4-14(5-3-12)25-10-15(28-20(25)27)9-23-18(26)16-6-7-17(21)30-16/h2-7,11,15,22H,8-10H2,1H3,(H,23,26)/t15-/m0/s1",ITZHMNIHOLLIFO-HNNXBMFYSA-N,50080099,CHEMBL3415995,Coagulation factor X,Oryctolagus cuniculus, 1910
50737442,Cc1nc(Cn2cnc3c2C(=O)C=CC3=O)cs1,"InChI=1S/C12H9N3O2S/c1-7-14-8(5-18-7)4-15-6-13-11-9(16)2-3-10(17)12(11)15/h2-3,5-6H,4H2,1H3",VLDBWVXKOHLFNZ-UHFFFAOYSA-N,50112053,"1-(2-Methyl-thiazol-4-ylmethyl)-1H-benzoimidazole-4,7-dione::CHEMBL177325",Purine nucleoside phosphorylase,Homo sapiens,
441786,CNC(C)C(=O)Nc1ccc(-c2c(nc3cc(C)ccn23)-c2ccncc2)c(n1)C#Cc1ccc(cc1)-c1ccon1,"InChI=1S/C33H27N7O2/c1-21-14-18-40-30(20-21)38-31(25-12-16-35-17-13-25)32(40)26-9-11-29(37-33(41)22(2)34-3)36-28(26)10-6-23-4-7-24(8-5-23)27-15-19-42-39-27/h4-5,7-9,11-20,22,34H,1-3H3,(H,36,37,41)",FWYXNWZPJQXBSF-UHFFFAOYSA-N,253988,"US9481673, 82",Cytochrome P450 3A4,Homo sapiens, 2300
50490834,CC(C)(C)c1cc(=O)[nH]c(SCC(=O)c2ccc(cc2)S(N)(=O)=O)n1,"InChI=1S/C16H19N3O4S2/c1-16(2,3)13-8-14(21)19-15(18-13)24-9-12(20)10-4-6-11(7-5-10)25(17,22)23/h4-8H,9H2,1-3H3,(H2,17,22,23)(H,18,19,21)",OMYTZYUGUKDESE-UHFFFAOYSA-N,50380144,"CHEMBL2010994::carbonic anhydrase (CA) inhibitors, benzenesulphonamide ligand, 8",Carbonic anhydrase 9,Homo sapiens,
50834158,COc1ccc2c(CCCN3CCCCC3)cccc2c1,"InChI=1S/C19H25NO/c1-21-18-10-11-19-16(7-5-8-17(19)15-18)9-6-14-20-12-3-2-4-13-20/h5,7-8,10-11,15H,2-4,6,9,12-14H2,1H3",KUKSPSOQFDNBNK-UHFFFAOYSA-N,50179279,1-(3-(6-methoxynaphthalen-1-yl)propyl)piperidine hydrochloride::CHEMBL553091,Sigma non-opioid intracellular receptor 1,Cavia porcellus,
513944,CC(C)(C)n1c(=O)[nH]\c(=N/c2ccc(Oc3cccc(n3)C(N)=O)cc2)n(Cc2ccc(Cl)cc2)c1=O,"InChI=1S/C26H25ClN6O4/c1-26(2,3)33-24(35)31-23(32(25(33)36)15-16-7-9-17(27)10-8-16)29-18-11-13-19(14-12-18)37-21-6-4-5-20(30-21)22(28)34/h4-14H,15H2,1-3H3,(H2,28,34)(H,29,31,35)",PYPJFXASTVCJMD-UHFFFAOYSA-N,271917,"US10065941, Compound R-233::US9732060, Compound R-233",P2X purinoceptor 3,Homo sapiens, 318
50392361,Nc1ccc(Oc2cccc(c2)N(CC(O)C(F)(F)F)Cc2cccc(OC(F)(F)C(F)F)c2)cc1,"InChI=1S/C24H21F7N2O3/c25-22(26)24(30,31)36-20-6-1-3-15(11-20)13-33(14-21(34)23(27,28)29)17-4-2-5-19(12-17)35-18-9-7-16(32)8-10-18/h1-12,21-22,34H,13-14,32H2",OIJCKALHPUHDSY-UHFFFAOYSA-N,50128151,"3-((3-(1,1,2,2-tetrafluoroethoxy)benzyl)(3-(4-aminophenoxy)phenyl)amino)-1,1,1-trifluoropropan-2-ol::3-((3-(4-aminophenoxy)phenyl)(3-(1,1,2,2-tetrafluoroethoxy)benzyl)amino)-1,1,1-trifluoropropan-2-ol::3-{[3-(4-Amino-phenoxy)-phenyl]-[3-(1,1,2,2-tetrafluoro-ethoxy)-benzyl]-amino}-1,1,1-trifluoro-propan-2-ol::CHEMBL69170",Cholesteryl ester transfer protein,Homo sapiens, 700
259305,COC(=O)c1cccc(c1)-c1sc(NC(=O)c2c(F)cccc2F)cc1C,"InChI=1S/C20H15F2NO3S/c1-11-9-16(23-19(24)17-14(21)7-4-8-15(17)22)27-18(11)12-5-3-6-13(10-12)20(25)26-2/h3-10H,1-2H3,(H,23,24)",WQSDCURSTYANJT-UHFFFAOYSA-N,128391,"US8802721, 120",Interleukin-2,, 87
51154982,COc1ccc(cc1OC)-c1nnc(O)c2ccccc12,"InChI=1S/C16H14N2O3/c1-20-13-8-7-10(9-14(13)21-2)15-11-5-3-4-6-12(11)16(19)18-17-15/h3-9H,1-2H3,(H,18,19)",IIVDYPOZZPVJAU-UHFFFAOYSA-N,50473333,CHEMBL84860,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A/4B/4C/4D",, 1585
50055352,CC1=CC(C)(C)Nc2ccc3-c4cc(Cl)ccc4OC(c4ccc(F)c(C)c4)c3c12,"InChI=1S/C26H23ClFNO/c1-14-11-16(5-8-20(14)28)25-24-18(19-12-17(27)6-10-22(19)30-25)7-9-21-23(24)15(2)13-26(3,4)29-21/h5-13,25,29H,1-4H3",JSHHKDQSFNGJMA-UHFFFAOYSA-N,50062434,"9-Chloro-5-(4-fluoro-3-methyl-phenyl)-2,2,4-trimethyl-2,5-dihydro-1H-6-oxa-1-aza-chrysene::CHEMBL104347",Progesterone receptor,,
459189,Cc1ccc(NC(=O)c2ccnc(c2)C(C)(C)O)cc1-c1cc(OC2CCOCC2)nc(c1)N1CCOCC1,"InChI=1S/C30H36N4O5/c1-20-4-5-23(32-29(35)21-6-9-31-26(16-21)30(2,3)36)19-25(20)22-17-27(34-10-14-38-15-11-34)33-28(18-22)39-24-7-12-37-13-8-24/h4-6,9,16-19,24,36H,7-8,10-15H2,1-3H3,(H,32,35)",BYXXBDVYEKKNKK-UHFFFAOYSA-N,88113,"US10245267, Example 1150::US10709712, Example 1150::US9694016, 1150",Serine/threonine-protein kinase B-raf [V600E],, 1.60
1083069,Cc1cccc2CN(CCc12)C(=O)c1cn(CC(=O)NC2CN(C2)C(=O)C=C)c2c(Cl)cc(Cl)cc12,"InChI=1S/C27H26Cl2N4O3/c1-3-25(35)32-12-19(13-32)30-24(34)15-33-14-22(21-9-18(28)10-23(29)26(21)33)27(36)31-8-7-20-16(2)5-4-6-17(20)11-31/h3-6,9-10,14,19H,1,7-8,11-13,15H2,2H3,(H,30,34)",FYQASLIOYJFNFY-UHFFFAOYSA-N,515984,"US11053226, Example 74","GTPase KRas [1-169,G12C,C118A]",, 170.00
50084067,Cc1c(-c2ccc(=O)n(CC(F)(F)F)c2)c2cc(F)ccc2n1CC(O)=O,"InChI=1S/C18H14F4N2O3/c1-10-17(11-2-5-15(25)23(7-11)9-18(20,21)22)13-6-12(19)3-4-14(13)24(10)8-16(26)27/h2-7H,8-9H2,1H3,(H,26,27)",SQRSFLBXXPFBHA-UHFFFAOYSA-N,50006833,CHEMBL3237236,Prostaglandin D2 receptor 2,Homo sapiens, 84
50724372,CC(C)[C@H](NCP(O)(O)=O)C(=O)N[C@@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N1C[C@H](O)C[C@H]1C(O)=O,"InChI=1S/C26H34N3O8P/c1-16(2)23(27-15-38(35,36)37)24(31)28-21(25(32)29-14-20(30)13-22(29)26(33)34)12-17-8-10-19(11-9-17)18-6-4-3-5-7-18/h3-11,16,20-23,27,30H,12-15H2,1-2H3,(H,28,31)(H,33,34)(H2,35,36,37)/t20-,21+,22+,23+/m1/s1",HKDDPXBAKXLRGJ-LDVJMBRRSA-N,50283653,1-{(S)-3-Biphenyl-4-yl-2-[(S)-3-methyl-1-oxo-2-(phosphonomethyl-amino)-butylamino]-propionyl}-4-hydroxy-pyrrolidine-2-carboxylic acid::CHEMBL329372,Neprilysin,, 12
332598,CC(C)(CO)c1cc(NC(=O)c2ccc3cc4C(=O)NCCCn4c3c2)on1,"InChI=1S/C20H22N4O4/c1-20(2,11-25)16-10-17(28-23-16)22-18(26)13-5-4-12-8-15-19(27)21-6-3-7-24(15)14(12)9-13/h4-5,8-10,25H,3,6-7,11H2,1-2H3,(H,21,27)(H,22,26)",INAKAFWEISWUGV-UHFFFAOYSA-N,184327,"US9150577, 208",Ribosomal protein S6 kinase alpha-2,Homo sapiens, 96
50529399,CS(=O)(=O)c1ccc2n(nc(Oc3c(Cl)cccc3Cl)c2c1)-c1ccc(cc1)C(O)=O,"InChI=1S/C21H14Cl2N2O5S/c1-31(28,29)14-9-10-18-15(11-14)20(30-19-16(22)3-2-4-17(19)23)24-25(18)13-7-5-12(6-8-13)21(26)27/h2-11H,1H3,(H,26,27)",FVZXPOMEZHOAJF-UHFFFAOYSA-N,50203499,CHEMBL3947885,Retinoic acid receptor gamma,Homo sapiens, 4500
109531,NNc1nc(Nc2ccccc2)nc(Nc2ccccc2)n1,"InChI=1S/C15H15N7/c16-22-15-20-13(17-11-7-3-1-4-8-11)19-14(21-15)18-12-9-5-2-6-10-12/h1-10H,16H2,(H3,17,18,19,20,21,22)",LUFLTVHAAVPJCI-UHFFFAOYSA-N,57906,"(4-anilino-6-hydrazino-s-triazin-2-yl)-phenyl-amine::6-diazanyl-N2,N4-diphenyl-1,3,5-triazine-2,4-diamine::6-hydrazinyl-2-N,4-N-diphenyl-1,3,5-triazine-2,4-diamine::6-hydrazinyl-N2,N4-diphenyl-1,3,5-triazine-2,4-diamine::MLS000687381::SMR000285105::cid_253501",Streptokinase A,Streptococcus pyogenes M1 GAS,
122128,Fc1ccc(CSc2nnc(-c3ccccn3)n2Cc2cccs2)c(F)c1,"InChI=1S/C19H14F2N4S2/c20-14-7-6-13(16(21)10-14)12-27-19-24-23-18(17-5-1-2-8-22-17)25(19)11-15-4-3-9-26-15/h1-10H,11-12H2",FLFDFOZJEHKPGG-UHFFFAOYSA-N,65825,"2-[5-[(2,4-difluorobenzyl)thio]-4-(2-thenyl)-1,2,4-triazol-3-yl]pyridine::2-[5-[(2,4-difluorophenyl)methylsulfanyl]-4-(thiophen-2-ylmethyl)-1,2,4-triazol-3-yl]pyridine::2-[5-[(2,4-difluorophenyl)methylthio]-4-(thiophen-2-ylmethyl)-1,2,4-triazol-3-yl]pyridine::2-[5-[[2,4-bis(fluoranyl)phenyl]methylsulfanyl]-4-(thiophen-2-ylmethyl)-1,2,4-triazol-3-yl]pyridine::KSC-5-247E::KUC103901N::cid_44601468",Kappa-type opioid receptor,Homo sapiens,
477459,COCCOC(=O)N1C(C2=C(CCC2=O)N(C1=O)c1cccc(c1)C(F)(F)F)c1ccc(cc1)C#N,"InChI=1S/C25H20F3N3O5/c1-35-11-12-36-24(34)31-22(16-7-5-15(14-29)6-8-16)21-19(9-10-20(21)32)30(23(31)33)18-4-2-3-17(13-18)25(26,27)28/h2-8,13,22H,9-12H2,1H3",RXSNNPCNRZNENR-UHFFFAOYSA-N,211816,"US9290459, 31.2::US9670166, 31.2",Neutrophil elastase,Homo sapiens, 6.70
1013187,CC(C)C(=O)N1C2CC1CN(C2)c1ccc(cn1)-c1cc(OCC(C)(C)O)cn2ncc(C#N)c12,"InChI=1S/C26H30N6O3/c1-16(2)25(33)32-19-7-20(32)13-30(12-19)23-6-5-17(10-28-23)22-8-21(35-15-26(3,4)34)14-31-24(22)18(9-27)11-29-31/h5-6,8,10-11,14,16,19-20,34H,7,12-13,15H2,1-4H3",XGBWRVJYZBZAFX-UHFFFAOYSA-N,296621,"US10112942, Example 355::US10137124, Example 355::US10172851, Example 355::US10555944, Example 355::US10953005, Example 355","Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M]",, 5473
51081873,NCCN(CCNC(=O)CCC(=O)NCCOCCOCCNC(=O)NC(=N)NCCC[C@@H](NC(=O)C(c1ccccc1)c1ccccc1)C(=O)NCc1ccc(CNC(N)=O)cc1)CCNC(=O)CCC(=O)NCCOCCOCCNC(=O)NC(N)=NCCC[C@@H](NC(=O)C(c1ccccc1)c1ccccc1)C(=O)NCc1ccc(CNC(N)=O)cc1,"InChI=1S/C86H120N22O16/c87-37-46-108(47-40-92-71(109)33-35-73(111)94-42-49-121-53-55-123-51-44-98-85(119)106-81(88)96-38-13-23-69(77(113)100-57-61-25-29-63(30-26-61)59-102-83(90)117)104-79(115)75(65-15-5-1-6-16-65)66-17-7-2-8-18-66)48-41-93-72(110)34-36-74(112)95-43-50-122-54-56-124-52-45-99-86(120)107-82(89)97-39-14-24-70(78(114)101-58-62-27-31-64(32-28-62)60-103-84(91)118)105-80(116)76(67-19-9-3-10-20-67)68-21-11-4-12-22-68/h1-12,15-22,25-32,69-70,75-76H,13-14,23-24,33-60,87H2,(H,92,109)(H,93,110)(H,94,111)(H,95,112)(H,100,113)(H,101,114)(H,104,115)(H,105,116)(H3,90,102,117)(H3,91,103,118)(H4,88,96,98,106,119)(H4,89,97,99,107,120)/t69-,70-/m1/s1",IEUJAGBMWVPDJC-FAECOVEHSA-N,50442573,CHEMBL2440911,Neuropeptide Y receptor type 5,,
57440,COc1ccc(NC(=O)c2ccc(Nc3nc(Nc4ccc(O)cc4)ncc3F)cc2)cc1,"InChI=1S/C24H20FN5O3/c1-33-20-12-8-17(9-13-20)28-23(32)15-2-4-16(5-3-15)27-22-21(25)14-26-24(30-22)29-18-6-10-19(31)11-7-18/h2-14,31H,1H3,(H,28,32)(H2,26,27,29,30)",VLEHOZCAQJNQPI-UHFFFAOYSA-N,31876,"2,4-Bisanilinopyrimidine, 42",Aurora kinase A,Homo sapiens, 14
50880905,O=C(NCCc1nccs1)c1ccc2c(SSc3cccc4nc(ccc34)C(=O)NCCc3nccs3)cccc2n1,"InChI=1S/C30H24N6O2S4/c37-29(33-13-11-27-31-15-17-39-27)23-9-7-19-21(35-23)3-1-5-25(19)41-42-26-6-2-4-22-20(26)8-10-24(36-22)30(38)34-14-12-28-32-16-18-40-28/h1-10,15-18H,11-14H2,(H,33,37)(H,34,38)",ZZWWQLNFHHEYRR-UHFFFAOYSA-N,50264500,CHEMBL4103114,STAM-binding protein,,>100000
50102659,Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1,"InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3",JOGKUKXHTYWRGZ-UHFFFAOYSA-N,92862,"US9284315, BEZ-235::mTOR Inhibitor, BEZ235",Serine/threonine-protein kinase mTOR,Homo sapiens, 5.0
51275123,Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12,"InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)",NQDJXKOVJZTUJA-UHFFFAOYSA-N,1434,"11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2 ,3 -e][1,4]diazepin-6-one::2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one::BI-RG-587::CHEMBL57::Nevirapine::Nevirapine (NVP)::US11420959, Example NVP::Viramune",Reverse transcriptase,Human immunodeficiency virus 1, 181
50223676,Cc1cc(CN(c2ccc(cc2)-c2ccccc2S(N)(=O)=O)S(C)(=O)=O)n(n1)-c1cccc(c1)C(N)=N,"InChI=1S/C25H26N6O4S2/c1-17-14-22(31(29-17)21-7-5-6-19(15-21)25(26)27)16-30(36(2,32)33)20-12-10-18(11-13-20)23-8-3-4-9-24(23)37(28,34)35/h3-15H,16H2,1-2H3,(H3,26,27)(H2,28,34,35)",JXBHOVKAQIVYJP-UHFFFAOYSA-N,50123434,3-(5-{[Methanesulfonyl-(2'-sulfamoyl-biphenyl-4-yl)-amino]-methyl}-3-methyl-pyrazol-1-yl)-benzamidine::CHEMBL356416,Coagulation factor X,Homo sapiens, 500
50502413,CN1CCC(CC1)S(=O)(=O)c1c(Cl)ccc(NC(=O)Nc2cccc(Cl)c2Cl)c1O,"InChI=1S/C19H20Cl3N3O4S/c1-25-9-7-11(8-10-25)30(28,29)18-13(21)5-6-15(17(18)26)24-19(27)23-14-4-2-3-12(20)16(14)22/h2-6,11,26H,7-10H2,1H3,(H2,23,24,27)",ITIUSBGOKOUQFX-UHFFFAOYSA-N,50182250,CHEMBL3819521,C-X-C chemokine receptor type 2,Homo sapiens, 1.6
50286794,CN([C@@H]1CCCC[C@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,"InChI=1S/C19H26Cl2N2O/c1-22(19(24)13-14-8-9-15(20)16(21)12-14)17-6-2-3-7-18(17)23-10-4-5-11-23/h8-9,12,17-18H,2-7,10-11,13H2,1H3/t17-,18-/m1/s1",VQLPLYSROCPWFF-QZTJIDSGSA-N,50000296,"CHEMBL441765::CHEMBL482811::U-50488H::US11492374, ID 1",Kappa-type opioid receptor,Homo sapiens, 0.300000
867302,CC(C)c1c([nH]c2ccc(nc12)N1C[C@@H](C)N(C[C@@H]1C)C(=O)CCN1CCC(F)(F)C1)-c1cn2ncnc2c(C)c1C,,,428526,"US10544143, Example 962::US10730877, Example 962::US11053244, Example 962",Toll-like receptor 8,, 17.0
13449,CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](COCc1ccc(Br)cc1)NC(=O)c1c(F)cc(F)cc1F)C(N)=O,"InChI=1S/C28H34BrF3N4O6/c1-14(2)8-21(26(33)39)35-27(40)15(3)34-24(38)11-23(37)22(13-42-12-16-4-6-17(29)7-5-16)36-28(41)25-19(31)9-18(30)10-20(25)32/h4-7,9-10,14-15,21-23,37H,8,11-13H2,1-3H3,(H2,33,39)(H,34,38)(H,35,40)(H,36,41)/t15-,21-,22-,23-/m0/s1",BTVFEHHDPWMSER-OBAATPRFSA-N,7988,"(3S,4S)-5-[(4-bromophenyl)methoxy]-N-[(1S)-1-{[(1S)-1-carbamoyl-3-methylbutyl]carbamoyl}ethyl]-3-hydroxy-4-[(2,4,6-trifluorophenyl)formamido]pentanamide::CHEMBL113331::N-{(1S,2S)-1-(4-Bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl}-2,4,6-trifluorobenzamide::Statine-like inhibitor 27",Cathepsin D,Homo sapiens,
51213206,OC(=O)c1ccnc(c1)-c1cn(CCc2ccccc2)nn1,"InChI=1S/C16H14N4O2/c21-16(22)13-6-8-17-14(10-13)15-11-20(19-18-15)9-7-12-4-2-1-3-5-12/h1-6,8,10-11H,7,9H2,(H,21,22)",WJDRQPCTXDWIML-UHFFFAOYSA-N,50498689,CHEMBL3621857,Lysine-specific demethylase 5C,Homo sapiens, 7943
50895747,O[C@]1(Cc2cc(on2)-c2cn[nH]c2)CC[C@H](Cc2ccc(OC(F)(F)F)cc2)CC1,"InChI=1S/C21H22F3N3O3/c22-21(23,24)29-18-3-1-14(2-4-18)9-15-5-7-20(28,8-6-15)11-17-10-19(30-27-17)16-12-25-26-13-16/h1-4,10,12-13,15,28H,5-9,11H2,(H,25,26)/t15-,20+",ZAYUGTUDYGNQFR-GSXCWMCISA-N,50269760,CHEMBL4101281,"Glutamate receptor ionotropic, NMDA 2B",, 25
51023860,Cc1cc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)cc(NC(N)=O)c1,"InChI=1S/C27H41N3O5/c1-20-14-21(16-24(15-20)30-27(28)34)8-4-7-13-35-12-6-3-2-5-11-29-18-26(33)22-9-10-25(32)23(17-22)19-31/h9-10,14-17,26,29,31-33H,2-8,11-13,18-19H2,1H3,(H3,28,30,34)/t26-/m0/s1",DBESJEGRRAZRSW-SANMLTNESA-N,50419312,CHEMBL1835862,Beta-1 adrenergic receptor,Homo sapiens,
174280,CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](Cc1cccc2ccccc12)C(N)=O,"InChI=1S/C71H81N11O9/c1-44(2)63(71(91)81-61(39-47-23-10-5-11-24-47)67(87)77-58(64(74)84)41-50-27-18-26-49-25-12-13-28-53(49)50)82-66(86)57(31-16-17-36-72)76-70(90)62(42-51-43-75-56-30-15-14-29-54(51)56)80-69(89)60(40-48-32-34-52(83)35-33-48)79-68(88)59(38-46-21-8-4-9-22-46)78-65(85)55(73)37-45-19-6-3-7-20-45/h3-15,18-30,32-35,43-44,55,57-63,75,83H,16-17,31,36-42,72-73H2,1-2H3,(H2,74,84)(H,76,90)(H,77,87)(H,78,85)(H,79,88)(H,80,89)(H,81,91)(H,82,86)/t55-,57+,58-,59+,60+,61+,62-,63+/m1/s1",AWRMNKFDOAUSCG-OOSWLFMASA-N,84629,BIM 23056,Somatostatin receptor type 5,Rattus,
493162,COc1c(cc(Cl)c(C#N)c1C1CN(CC2CC2)C1)C(C)n1nc(C)c2c(N)ncnc12,"InChI=1S/C23H26ClN7O/c1-12-19-22(26)27-11-28-23(19)31(29-12)13(2)16-6-18(24)17(7-25)20(21(16)32-3)15-9-30(10-15)8-14-4-5-14/h6,11,13-15H,4-5,8-10H2,1-3H3,(H2,26,27,28)",DHMAUKKOJFKQKU-UHFFFAOYSA-N,261243,"US10092570, Example 266::US10376513, Example 266::US10646492, Example 266::US11433071, Example 266::US9707233, 266::US9730939, Example 266","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta/delta isoform",Homo sapiens,<10
854647,CNc1cc(Nc2cc(C)nc(c2)N2CCCC2)nc2c(cnn12)C(N)=O,"InChI=1S/C18H22N8O/c1-11-7-12(8-16(22-11)25-5-3-4-6-25)23-14-9-15(20-2)26-18(24-14)13(10-21-26)17(19)27/h7-10,20H,3-6H2,1-2H3,(H2,19,27)(H,22,23,24)",FNMUPMJVQYXXLO-UHFFFAOYSA-N,423572,"US10508120, Compound I-27::US10577373, Compound I-27::US11046698, Compound I-27",Non-receptor tyrosine-protein kinase TYK2 [556-888],,
50165383,CC(C)c1cccc(C(C)C)c1N1CCN(CCC2CCN(CC3COc4ccccc4O3)CC2)C1=O,"InChI=1S/C31H43N3O3/c1-22(2)26-8-7-9-27(23(3)4)30(26)34-19-18-33(31(34)35)17-14-24-12-15-32(16-13-24)20-25-21-36-28-10-5-6-11-29(28)37-25/h5-11,22-25H,12-21H2,1-4H3",PBTGVANSAJOWQK-UHFFFAOYSA-N,50092417,"1-{2-[1-(2,3-Dihydro-benzo[1,4]dioxin-2-ylmethyl)-piperidin-4-yl]-ethyl}-3-(2,6-diisopropyl-phenyl)-imidazolidin-2-one::CHEMBL124288",D(2) dopamine receptor,Rattus norvegicus, 480
51086626,CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)c1ccc(CN(CC)CC)o1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O,"InChI=1S/C37H58N8O7/c1-7-24(6)31(35(49)43-29(36(50)51)21-25-14-11-10-12-15-25)44-33(47)28(20-23(4)5)42-32(46)27(16-13-19-40-37(38)39)41-34(48)30-18-17-26(52-30)22-45(8-2)9-3/h10-12,14-15,17-18,23-24,27-29,31H,7-9,13,16,19-22H2,1-6H3,(H,41,48)(H,42,46)(H,43,49)(H,44,47)(H,50,51)(H4,38,39,40)/t24-,27-,28-,29-,31-/m0/s1",VZVWPRUVQREUEM-LRLYEUBCSA-N,50444666,CHEMBL3098663,Cyclin-dependent kinase 4/G1/S-specific cyclin-D1,Homo sapiens, 41900
50137290,CC(=O)Nc1ccc(cc1)C#CCCCN1CCC(Cc2ccccc2)CC1,"InChI=1S/C25H30N2O/c1-21(28)26-25-13-11-22(12-14-25)8-6-3-7-17-27-18-15-24(16-19-27)20-23-9-4-2-5-10-23/h2,4-5,9-14,24H,3,7,15-20H2,1H3,(H,26,28)",SXHFOZMDNMIMRF-UHFFFAOYSA-N,50078484,CHEMBL81204::N-{4-[5-(4-Benzyl-piperidin-1-yl)-pent-1-ynyl]-phenyl}-acetamide,"Glutamate receptor ionotropic, NMDA 1/2B",Rattus, 1400
50390661,CC(C)CCN(CCC(C)C)C(=O)c1ccc2nc(Nc3ccc(cc3)C(C)=O)n(CCCNC(=O)OC(C)(C)C)c2c1,"InChI=1S/C34H49N5O4/c1-23(2)16-20-38(21-17-24(3)4)31(41)27-12-15-29-30(22-27)39(19-9-18-35-33(42)43-34(6,7)8)32(37-29)36-28-13-10-26(11-14-28)25(5)40/h10-15,22-24H,9,16-21H2,1-8H3,(H,35,42)(H,36,37)",RFFNBJUWAPQMDZ-UHFFFAOYSA-N,50215818,CHEMBL397140::tert-butyl 3-(2-(4-acetylphenylamino)-6-(diisopentylcarbamoyl)-1H-benzo[d]imidazol-1-yl)propylcarbamate,Melanocortin receptor 4,,
741383,C[C@@H]1CCCN([C@@H]1CNc1ccc(cn1)C(F)(F)F)C(=O)c1nc(C)ccc1-c1ccccn1,"InChI=1S/C25H26F3N5O/c1-16-6-5-13-33(21(16)15-31-22-11-9-18(14-30-22)25(26,27)28)24(34)23-19(10-8-17(2)32-23)20-7-3-4-12-29-20/h3-4,7-12,14,16,21H,5-6,13,15H2,1-2H3,(H,30,31)/t16-,21-/m1/s1",DLPSCLMVTPZXRV-IIBYNOLFSA-N,373455,"((2S,3R)-3-Methyl-2-(((5-(trifluoromethyl)pyridin-2-yl)amino)methyl)piperidin-1-yl)(6&#8242;-methyl-[2,3&#8242;-bipyridin]-2&#8242;-yl)methanone::US9896452, Ex. A217",Orexin/Hypocretin receptor type 1,Homo sapiens, 150
51250533,CCc1ccc(cc1-c1cccc(c1)-c1cnc2cnccn12)C(=O)Nc1ccc(cc1)C(F)(F)F,"InChI=1S/C28H21F3N4O/c1-2-18-6-7-21(27(36)34-23-10-8-22(9-11-23)28(29,30)31)15-24(18)19-4-3-5-20(14-19)25-16-33-26-17-32-12-13-35(25)26/h3-17H,2H2,1H3,(H,34,36)",KULCILVQAXSMEP-UHFFFAOYSA-N,50511480,CHEMBL4575992,Discoidin domain-containing receptor 2,Homo sapiens,>10000
51431805,CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1,"InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)/t16-,17-",KPWSJANDNDDRMB-QAQDUYKDSA-N,50443101,Cariprazine::RGH-188,5-hydroxytryptamine receptor 1A,,
450252,Cn1nccc1[C@H]1CCCC[C@@H]1Oc1cc(F)c(cc1Cl)S(=O)(=O)Nc1ccnc(=O)[nH]1,,,258245,"US9493448, 153::US9845313, Example 153",Sodium channel protein type 9 subunit alpha,,>100000
50418431,O=c1[nH]c(nc(NC2CCNCC2)c1-c1nc2ccccc2s1)N1CCOCC1,"InChI=1S/C20H24N6O2S/c27-18-16(19-23-14-3-1-2-4-15(14)29-19)17(22-13-5-7-21-8-6-13)24-20(25-18)26-9-11-28-12-10-26/h1-4,13,21H,5-12H2,(H2,22,24,25,27)",OKBLGUODEJGUAX-UHFFFAOYSA-N,203531,"US9221809, 88",Interleukin-1 receptor-associated kinase 4,Homo sapiens, 121
166663,COc1ccccc1\C=C1\SC(=S)N(CCC(=O)Nc2cccnc2)C1=O,"InChI=1S/C19H17N3O3S2/c1-25-15-7-3-2-5-13(15)11-16-18(24)22(19(26)27-16)10-8-17(23)21-14-6-4-9-20-12-14/h2-7,9,11-12H,8,10H2,1H3,(H,21,23)/b16-11+",TXSKTJXLPVVKOR-LFIBNONCSA-N,53300,"3-[(5E)-4-keto-5-o-anisylidene-2-thioxo-thiazolidin-3-yl]-N-(3-pyridyl)propionamide::3-[(5E)-5-[(2-methoxyphenyl)methylidene]-4-oxidanylidene-2-sulfanylidene-1,3-thiazolidin-3-yl]-N-pyridin-3-yl-propanamide::3-[(5E)-5-[(2-methoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]-N-pyridin-3-ylpropanamide::3-[(5E)-5-[(2-methoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-3-thiazolidinyl]-N-(3-pyridinyl)propanamide::MLS001031537::SMR000664927::cid_2286451",Endoribonuclease toxin MazF,Escherichia coli str. K-12 substr. MG1655,
323775,COC(=O)c1nnc(Nc2ccccc2N2CC3(CCN(CC(C)(C)C)CC3)c3c2c(O)ccc3Cl)s1,"InChI=1S/C27H32ClN5O3S/c1-26(2,3)15-32-13-11-27(12-14-32)16-33(22-20(34)10-9-17(28)21(22)27)19-8-6-5-7-18(19)29-25-31-30-23(37-25)24(35)36-4/h5-10,34H,11-16H2,1-4H3,(H,29,31)",HBCBRIKFLXFWHF-UHFFFAOYSA-N,177977,"US9120798, 17",P2Y purinoceptor 1,, 48
51358682,Fc1cc2[nH]c3CCCc4n[nH]c(=O)c(c1)c2c34,"InChI=1S/C13H10FN3O/c14-6-4-7-11-10(5-6)15-8-2-1-3-9(12(8)11)16-17-13(7)18/h4-5,15H,1-3H2,(H,17,18)",YKIBUJVDRWECHV-UHFFFAOYSA-N,207562,"US10501467, Example 7::US9260440, 7::US9617273, Example 7",Poly [ADP-ribose] polymerase 1,, 6.0
50040175,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12,"InChI=1S/C12H16N6O4/c1-2-14-11(21)8-6(19)7(20)12(22-8)18-4-17-5-9(13)15-3-16-10(5)18/h3-4,6-8,12,19-20H,2H2,1H3,(H,14,21)(H2,13,15,16)/t6-,7+,8-,12+/m0/s1",JADDQZYHOWSFJD-FLNNQWSLSA-N,21220,"(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide::Adenosine analog, 3::Adenosine, N6-Ethyl-carboxamido::Adenosine-5-(N-ethylcarboxamide)::CHEMBL464859::N-Ethylcarboxamidoadenosine::NECA",Adenosine receptor A1,Rattus norvegicus,
50486833,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1,"InChI=1S/C27H29N5O/c28-26-25-24(21-8-4-9-23(14-21)33-17-19-6-2-1-3-7-19)16-32(27(25)30-18-29-26)22-12-20(13-22)15-31-10-5-11-31/h1-4,6-9,14,16,18,20,22H,5,10-13,15,17H2,(H2,28,29,30)/t20-,22+",AECDBHGVIIRMOI-GRGXKFILSA-N,50157879,CHEMBL1614712,Mast/stem cell growth factor receptor Kit,, 6300
51403712,CN(C)c1nccc(n1)-c1cnc2ncccn12,"InChI=1S/C12H12N6/c1-17(2)12-14-6-4-9(16-12)10-8-15-11-13-5-3-7-18(10)11/h3-8H,1-2H3",UYXOVPJCCPREHU-UHFFFAOYSA-N,50567081,CHEMBL4872408,Dual specificity tyrosine-phosphorylation-regulated kinase 1A,Homo sapiens, 158
50818813,CN(C)c1cccc(CNCc2ccc3ccc(N)nc3c2)c1,"InChI=1S/C19H22N4/c1-23(2)17-5-3-4-14(10-17)12-21-13-15-6-7-16-8-9-19(20)22-18(16)11-15/h3-11,21H,12-13H2,1-2H3,(H2,20,22)",SOVIURHDFSQRNW-UHFFFAOYSA-N,50258724,CHEMBL4096369,"Nitric oxide synthase, endothelial",Bos taurus,
51067676,O=C(CN1CCN(CCCOc2ccc3c(cc(=O)oc3c2)-c2ccccc2)CC1)Nc1c2CCCCc2nc2ccccc12,"InChI=1S/C37H38N4O4/c42-35(39-37-29-11-4-6-13-32(29)38-33-14-7-5-12-30(33)37)25-41-20-18-40(19-21-41)17-8-22-44-27-15-16-28-31(26-9-2-1-3-10-26)24-36(43)45-34(28)23-27/h1-4,6,9-11,13,15-16,23-24H,5,7-8,12,14,17-22,25H2,(H,38,39,42)",LIGXGSONOCBWSR-UHFFFAOYSA-N,50435945,CHEMBL2391479,Cholinesterase,, 3160
50132891,COc1ccc(CCOc2ccc3c(c2)oc(cc3=O)N2CCOCC2)cc1,"InChI=1S/C22H23NO5/c1-25-17-4-2-16(3-5-17)8-11-27-18-6-7-19-20(24)15-22(28-21(19)14-18)23-9-12-26-13-10-23/h2-7,14-15H,8-13H2,1H3",GWRGBNRVPQOEAV-UHFFFAOYSA-N,50178112,7-(4-methoxyphenylethoxy)-2-morpholin-4-yl-chromen-4-one::CHEMBL197108,DNA-dependent protein kinase catalytic subunit,Homo sapiens, 3100
50945681,CCCCCCCCCCc1c(C)c(CCCCCCCCCC)c2CCCC[n+]2c1C,"InChI=1S/C31H56N/c1-5-7-9-11-13-15-17-19-23-29-27(3)30(24-20-18-16-14-12-10-8-6-2)31-25-21-22-26-32(31)28(29)4/h5-26H2,1-4H3/q+1",MNUFBGVKCOWOIH-UHFFFAOYSA-N,50351148,CHEMBL1817913::CHEMBL2057818,C-C chemokine receptor type 5,, 15200
212519,COC(=O)c1ccc2nc(cn2c1)-c1cccc(N)c1,"InChI=1S/C15H13N3O2/c1-20-15(19)11-5-6-14-17-13(9-18(14)8-11)10-3-2-4-12(16)7-10/h2-9H,16H2,1H3",NPXMRZXPVGXVFP-UHFFFAOYSA-N,97222,"2-(3-aminophenyl)-6-imidazo[1,2-a]pyridinecarboxylic acid methyl ester::2-(3-aminophenyl)imidazo[1,2-a]pyridine-6-carboxylic acid methyl ester::MLS000696517::SMR000336620::cid_3845864::methyl 2-(3-aminophenyl)imidazo[1,2-a]pyridine-6-carboxylate",Nuclear receptor subfamily 0 group B member 1,Homo sapiens,>833.59
557792,NC[C@H]1CCCCN1C(=O)c1cc(ncc1Cl)-c1cnn2ccc(nc12)-c1ccccc1,"InChI=1S/C24H23ClN6O/c25-20-15-27-22(12-18(20)24(32)30-10-5-4-8-17(30)13-26)19-14-28-31-11-9-21(29-23(19)31)16-6-2-1-3-7-16/h1-3,6-7,9,11-12,14-15,17H,4-5,8,10,13,26H2/t17-/m1/s1",JJDCMRWUAYERPG-QGZVFWFLSA-N,292481,"(R)-(2-(aminomethyl)piperidin-1-yl)(5-chloro-2-(5-phenylpyrazolo[1,5-a]pyrimidin-3-yl)pyridin-4-yl)methanone::US10100058, Example 137",Calcium/calmodulin-dependent protein kinase type II subunit delta,, 1.82
51080455,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(cc2)S(C)(=O)=O)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O,"InChI=1S/C33H33BrN4O6S/c1-20(35-2)31(39)36-27-19-38(32(40)21-9-13-24(14-10-21)45(4,42)43)29-8-6-5-7-28(29)37(33(27)41)18-26-25-15-12-23(34)17-22(25)11-16-30(26)44-3/h5-17,20,27,35H,18-19H2,1-4H3,(H,36,39)/t20-,27-/m0/s1",ODNRMXZHMWXBTG-DCFHFQCYSA-N,50441832,"CHEMBL2436205::US10053431, 90d",E3 ubiquitin-protein ligase XIAP,, 25700
1194155,CNc1ccc(-c2cc(NC)n3ncc(C(=O)N[C@@H]4CC[C@H]4OC)c3n2)n2ccnc12,"InChI=1S/C21H24N8O2/c1-22-14-4-6-16(28-9-8-24-20(14)28)15-10-18(23-2)29-19(26-15)12(11-25-29)21(30)27-13-5-7-17(13)31-3/h4,6,8-11,13,17,22-23H,5,7H2,1-3H3,(H,27,30)/t13-,17-/m1/s1",ADDCOWJHSHCQCP-CXAGYDPISA-N,565922,"US11414431, Compound I-490",Non-receptor tyrosine-protein kinase TYK2 [556-888],,
50613706,COc1cc2CCCO[C@@H](CCCCCC(=O)NO)C(=O)Nc3ccccc3OCc(c2)c1,"InChI=1S/C25H32N2O6/c1-31-20-15-18-8-7-13-32-23(11-3-2-4-12-24(28)27-30)25(29)26-21-9-5-6-10-22(21)33-17-19(14-18)16-20/h5-6,9-10,14-16,23,30H,2-4,7-8,11-13,17H2,1H3,(H,26,29)(H,27,28)/t23-/m0/s1",HIEFOIISQBSAEQ-QHCPKHFHSA-N,50333093,"(S)-6-(19-Methoxy-11-oxo-3,13-dioxa-10-azatricyclo[15.3.1.04,9]henicosa-1(21),4(9),5,7,17,19-hexaen-12-yl)hexanoic acid hydroxyamide::CHEMBL1631917",Histone deacetylase 3,Homo sapiens, 94
332131,C[C@@H]1CN([C@H](Cc2cccc(c2)-n2nccn2)CO1)C(=O)c1ccccc1-n1nccn1,"InChI=1S/C23H23N7O2/c1-17-15-28(23(31)21-7-2-3-8-22(21)30-26-11-12-27-30)20(16-32-17)14-18-5-4-6-19(13-18)29-24-9-10-25-29/h2-13,17,20H,14-16H2,1H3/t17-,20-/m1/s1",QWFXFQGJPGRBQR-YLJYHZDGSA-N,184062,"US9150566, 100",Orexin receptor type 2,Homo sapiens, 289
519521,Cc1nc(c(-c2ccc3nc(NC(=O)c4ccnc(F)c4)cn3n2)n1C1CCN(CCCF)CC1)-c1ccc(F)cc1,"InChI=1S/C30H29F3N8O/c1-19-35-28(20-3-5-22(32)6-4-20)29(41(19)23-10-15-39(16-11-23)14-2-12-31)24-7-8-27-36-26(18-40(27)38-24)37-30(42)21-9-13-34-25(33)17-21/h3-9,13,17-18,23H,2,10-12,14-16H2,1H3,(H,37,42)",UWFIHPBPGRXLEZ-UHFFFAOYSA-N,274568,"2-fluoro-N-(6-(4-(4-fluorophenyl)-1-(1-(3-fluoropropyl)piperidin-4-yl)-2-methyl-1H-imidazol-5-yl)imidazo[1,2-b]pyridazin-2-yl)isonicotinamide::US9556179, Compound 140",Casein kinase I isoform delta,, 2.29
50032983,Oc1ccc2CC3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2c(Br)cccc2c1C[C@@]35O,"InChI=1S/C26H25BrN2O3/c27-17-3-1-2-15-16-11-26(31)19-10-14-6-7-18(30)23-20(14)25(26,8-9-29(19)12-13-4-5-13)24(32-23)22(16)28-21(15)17/h1-3,6-7,13,19,24,28,30-31H,4-5,8-12H2/t19?,24-,25-,26+/m0/s1",KXQMACNKPIFADJ-VCCHHJRHSA-N,50013623,"9-bromo-22-cyclopropylmethyl-(2S,13R)-14-oxa-11,22-diazaheptacyclo[13.9.1.01,13.02,21.04,12.05,10.019,25]pentacosa-4(12),5(10),6,8,15(25),16,18-heptaene-2,16-diol",Mu-type opioid receptor,Cavia cutleri,
50978667,Cc1nc(N)nc(n1)-c1cccnc1Nc1cnc(Cl)c(NS(=O)(=O)c2ccc(F)cc2)c1,"InChI=1S/C20H16ClFN8O2S/c1-11-26-19(29-20(23)27-11)15-3-2-8-24-18(15)28-13-9-16(17(21)25-10-13)30-33(31,32)14-6-4-12(22)5-7-14/h2-10,30H,1H3,(H,24,28)(H2,23,26,27,29)",MUNMOKXVNKEMSH-UHFFFAOYSA-N,50401270,"CHEMBL2206912::US8772480, 264","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens,
51302620,COc1cc(Cl)cc(c1)-c1nn(cc1-c1ccncc1)-c1cccc(NC(=O)Nc2cccc(c2)C(F)(F)F)c1,"InChI=1S/C29H21ClF3N5O2/c1-40-25-13-19(12-21(30)15-25)27-26(18-8-10-34-11-9-18)17-38(37-27)24-7-3-6-23(16-24)36-28(39)35-22-5-2-4-20(14-22)29(31,32)33/h2-17H,1H3,(H2,35,36,39)",DUJZSUKPBRZVOV-UHFFFAOYSA-N,50530157,CHEMBL4468905,Serine/threonine-protein kinase B-raf,Homo sapiens, 475
50853677,CC(C)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC(C)(C)C#N,"InChI=1S/C25H30F3N3O3S/c1-16(2)14-21(23(32)31-24(3,4)15-29)30-22(25(26,27)28)19-8-6-17(7-9-19)18-10-12-20(13-11-18)35(5,33)34/h6-13,16,21-22,30H,14H2,1-5H3,(H,31,32)/t21-,22-/m0/s1",MQLWDLYYNYALHH-VXKWHMMOSA-N,50233035,"(S)-4-methyl-2-[(S)-2,2,2-trifluoro-1-(4'-methanesulfonyl-biphenyl-4-yl)-ethylamino]-pentanoic acid (cyano-dimethyl-methyl)-amide::CHEMBL428417",Cathepsin K,Homo sapiens, 4
50821329,CN(C)C(=O)C1CN(C)CC[C@@H]1c1ccc(Cl)cc1,"InChI=1S/C15H21ClN2O/c1-17(2)15(19)14-10-18(3)9-8-13(14)11-4-6-12(16)7-5-11/h4-7,13-14H,8-10H2,1-3H3/t13-,14?/m1/s1",DMWLTIQYONJIPM-KWCCSABGSA-N,50147836,(S)-4-(4-Chloro-phenyl)-1-methyl-piperidine-3-carboxylic acid dimethylamide::CHEMBL102861,Sodium-dependent dopamine transporter,Rattus norvegicus,
51273363,CCOc1cccc2cc(-c3ccc(OC)c(OC)c3)c(=O)oc12,"InChI=1S/C19H18O5/c1-4-23-16-7-5-6-13-10-14(19(20)24-18(13)16)12-8-9-15(21-2)17(11-12)22-3/h5-11H,4H2,1-3H3",BSBXLVLZEWGUGJ-UHFFFAOYSA-N,50519749,CHEMBL4552685,Adenosine receptor A3,Homo sapiens,
347237,Fc1cc(OCCCN2CCN(CC2)c2cccc3sccc23)cc2CCC(=O)Nc12,"InChI=1S/C24H26FN3O2S/c25-20-16-18(15-17-5-6-23(29)26-24(17)20)30-13-2-8-27-9-11-28(12-10-27)21-3-1-4-22-19(21)7-14-31-22/h1,3-4,7,14-16H,2,5-6,8-13H2,(H,26,29)",VGMMKAWLAFTFHD-UHFFFAOYSA-N,194767,"US9206167, 116",5-hydroxytryptamine receptor 2A,Rattus norvegicus,
50572264,COc1cc2ncc3c(N)nc(cc3c2cc1OC)-c1cncc(OC[C@H](N)CC(C)C)c1,"InChI=1S/C25H29N5O3/c1-14(2)5-16(26)13-33-17-6-15(10-28-11-17)21-7-18-19-8-23(31-3)24(32-4)9-22(19)29-12-20(18)25(27)30-21/h6-12,14,16H,5,13,26H2,1-4H3,(H2,27,30)/t16-/m1/s1",YPVWKNICBVIRFI-MRXNPFEDSA-N,50316348,"2-(5-{[(2R)-2-Amino-4-methylpentyl]oxy}pyridin-3-yl)-8,9-dimethoxybenzo[c]-2,7-naphthyridin-4-amine::CHEMBL1094637",RAC-alpha serine/threonine-protein kinase,, 1395
50375273,O=C(Nc1ccc2nc(-c3ccccc3)c(nc2c1)-c1ccccc1)N1CCCC(C1)C(=O)N1CCCCC1,"InChI=1S/C32H33N5O2/c38-31(36-18-8-3-9-19-36)25-15-10-20-37(22-25)32(39)33-26-16-17-27-28(21-26)35-30(24-13-6-2-7-14-24)29(34-27)23-11-4-1-5-12-23/h1-2,4-7,11-14,16-17,21,25H,3,8-10,15,18-20,22H2,(H,33,39)",LNCQHPBMIVTJJH-UHFFFAOYSA-N,50205435,"CHEMBL389107::N-(2,3-diphenylquinoxalin-6-yl)-3-(piperidine-1-carbonyl)piperidine-1-carboxamide",Dual specificity protein phosphatase 22,Homo sapiens,>40000
573761,Clc1ccc(cc1)C(CNC(=O)c1cc(ccc1Cl)C#N)N1CCOCC1,"InChI=1S/C20H19Cl2N3O2/c21-16-4-2-15(3-5-16)19(25-7-9-27-10-8-25)13-24-20(26)17-11-14(12-23)1-6-18(17)22/h1-6,11,19H,7-10,13H2,(H,24,26)",JLJUTXSVZMZSOR-UHFFFAOYSA-N,242067,"US9415055, (+)2-chloro-N-[2-(4-chlorophenyl)-2-morpholino-ethyl]-5-cyano-benzamide::US9593105, 69",P2X purinoceptor 7,, 23
50516253,Cc1ccc2C(N=O)C(=O)N(Cc3cc(F)cc4COCOc34)c2c1,"InChI=1S/C18H15FN2O4/c1-10-2-3-14-15(4-10)21(18(22)16(14)20-23)7-11-5-13(19)6-12-8-24-9-25-17(11)12/h2-6,16H,7-9H2,1H3",CEFHLBGJHWUOBZ-UHFFFAOYSA-N,50297455,"1-((6-fluoro-4H-benzo[d][1,3]dioxin-8-yl)methyl)-3-(hydroxyimino)-6-methylindolin-2-one::CHEMBL551140",Mitogen-activated protein kinase 14,Homo sapiens,
126309,CC(C)(C)c1ccc(Oc2ccc(N)cc2)cc1,"InChI=1S/C16H19NO/c1-16(2,3)12-4-8-14(9-5-12)18-15-10-6-13(17)7-11-15/h4-11H,17H2,1-3H3",FHOZTGQNSUZCIN-UHFFFAOYSA-N,68082,4-(4-tert-butylphenoxy)aniline::MLS000686543::SMR000268191::[4-(4-tert-butylphenoxy)phenyl]amine::cid_82498,DNA damage-inducible transcript 3 protein,Mus musculus, 6900
489518,CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CS(C)(=O)=O)c2cc(ccc2N(Cc2c(OC)ccc3c(Br)cccc23)C1=O)C#N,"InChI=1S/C29H30BrN5O6S/c1-17(32-2)28(37)33-23-15-34(27(36)16-42(4,39)40)25-12-18(13-31)8-10-24(25)35(29(23)38)14-21-19-6-5-7-22(30)20(19)9-11-26(21)41-3/h5-12,17,23,32H,14-16H2,1-4H3,(H,33,37)/t17-,23-/m0/s1",WEPCTAAUSDCYCZ-SBUREZEXSA-N,242675,"(S)-N-((S)-1-((5-bromo-2- methoxynaphthalen-1-yl)methyl)-7- cyano-5-(2-(methylsulfonyl)acetyl)-2- oxo-2,3,4,5-tetrahydro-1H- benzo[b][1,4]diazepin-3-yl)-2- (methylamino)propanamide hydrochloride::US10053431, 160",E3 ubiquitin-protein ligase XIAP [241-356],,>54800
50676283,Cn1nnc2c(ncn2c1=O)C(=O)NOS(N)(=O)=O,"InChI=1S/C6H7N7O5S/c1-12-6(15)13-2-8-3(4(13)9-11-12)5(14)10-18-19(7,16)17/h2H,1H3,(H,10,14)(H2,7,16,17)",UJNHBHKVLXJTPG-UHFFFAOYSA-N,50226856,CHEMBL4091278,Carbonic anhydrase 2,Homo sapiens,
50509192,Nc1nc(cc(n1)-c1ccco1)C(=O)NCc1ccccc1Cl,"InChI=1S/C16H13ClN4O2/c17-11-5-2-1-4-10(11)9-19-15(22)13-8-12(20-16(18)21-13)14-6-3-7-23-14/h1-8H,9H2,(H,19,22)(H2,18,20,21)",ZVWNHOGZGKJOCZ-UHFFFAOYSA-N,50294505,2-amino-N-(2-chlorobenzyl)-6-(furan-2-yl)pyrimidine-4-carboxamide::CHEMBL560904,Adenosine receptor A2a,Homo sapiens,
697506,CC[C@@H]1N(C[C@@H]2CC[C@H](OC2)C(F)(F)F)Cc2cc(cnc12)C(=O)N[C@@H](CO)c1ccc(cn1)S(=O)(=O)CC,"InChI=1S/C26H33F3N4O5S/c1-3-22-24-18(13-33(22)12-16-5-8-23(38-15-16)26(27,28)29)9-17(10-31-24)25(35)32-21(14-34)20-7-6-19(11-30-20)39(36,37)4-2/h6-7,9-11,16,21-23,34H,3-5,8,12-15H2,1-2H3,(H,32,35)/t16-,21-,22-,23-/m0/s1",ACAKRMFKIXEPKR-KKPKCPPISA-N,351604,"US9796710, Compound 6",Nuclear receptor ROR-gamma,,
1106697,CC(C)C(Cn1ccc2cnc(Nc3cnn(CC(=O)OCCO)c3)nc12)C(C)C,"InChI=1S/C21H30N6O3/c1-14(2)18(15(3)4)12-26-6-5-16-9-22-21(25-20(16)26)24-17-10-23-27(11-17)13-19(29)30-8-7-28/h5-6,9-11,14-15,18,28H,7-8,12-13H2,1-4H3,(H,22,24,25)",BHVQTTAUOBLHMV-UHFFFAOYSA-N,523977,"2-hydroxyethyl 2-(4-((7- (2-isopropyl-3- methylbutyl)-7H- pyrrolo[2,3-d]pyrimidin- 2-yl)amino)-1H-pyrazol- 1-yl)acetate::US11136329, Compound 88",Tyrosine-protein kinase JAK3,Homo sapiens,<100
51391813,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,50436459,CHEMBL2396661,"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 18
51185835,CCc1nc(Cl)c([nH]1)C1C(C(=O)OCC(C)C)=C(C)NC(C)=C1C(=O)OCC(C)C,"InChI=1S/C22H32ClN3O4/c1-8-15-25-19(20(23)26-15)18-16(21(27)29-9-11(2)3)13(6)24-14(7)17(18)22(28)30-10-12(4)5/h11-12,18,24H,8-10H2,1-7H3,(H,25,26)",LJILYATXUDXMDR-UHFFFAOYSA-N,50487602,CHEMBL2261185,Voltage-dependent L-type calcium channel subunit alpha-1C,, 2.6
18879,NS(=O)(=O)c1ccc(CCO)cc1,"InChI=1S/C8H11NO3S/c9-13(11,12)8-3-1-7(2-4-8)5-6-10/h1-4,10H,5-6H2,(H2,9,11,12)",RYKHXKKLCRPAJP-UHFFFAOYSA-N,10877,4-(2-hydroxyethyl)benzene-1-sulfonamide::CHEMBL6784::JMC522226 Compound 21::JMC523116 Compound 21::aromatic/heteroaromatic sulfonamide 22,"Carbonic anhydrase 5A, mitochondrial",Homo sapiens,
50712109,C(Cc1ccccc1)N1CCCCC1,"InChI=1S/C13H19N/c1-3-7-13(8-4-1)9-12-14-10-5-2-6-11-14/h1,3-4,7-8H,2,5-6,9-12H2",DBDVAKGHPZJLTH-UHFFFAOYSA-N,50109389,1-Phenethyl-piperidine::1-phenethylpiperidine::CHEMBL75228::N-(2-phenylethyl)piperidine::N-phenethylpiperidine,Amine oxidase [flavin-containing] A,, 757300
50324988,COC(=O)C1C2CCC(CC1c1ccc(cc1)-c1nccs1)N2C,"InChI=1S/C19H22N2O2S/c1-21-14-7-8-16(21)17(19(22)23-2)15(11-14)12-3-5-13(6-4-12)18-20-9-10-24-18/h3-6,9-10,14-17H,7-8,11H2,1-2H3",XUJAZHYZOMZFOS-UHFFFAOYSA-N,50175647,CHEMBL382943::methyl 8-methyl-3-(4-(thiazol-2-yl)phenyl)-8-aza-bicyclo[3.2.1]octane-2-carboxylate,Sodium-dependent dopamine transporter,Rattus norvegicus,
506687,CCNC(=O)c1noc(c1-c1ccc(CN2CCN(C)CC2)cc1)-c1cc(CC)c(O)cc1O,"InChI=1S/C26H32N4O4/c1-4-18-14-20(22(32)15-21(18)31)25-23(24(28-34-25)26(33)27-5-2)19-8-6-17(7-9-19)16-30-12-10-29(3)11-13-30/h6-9,14-15,31-32H,4-5,10-13,16H2,1-3H3,(H,27,33)",NAIOWGXKMUYTEJ-UHFFFAOYSA-N,265161,"US10413550, Example 57::US11234987, Example 57::US9718793, 57",Heat shock protein HSP 90-alpha,Homo sapiens,<10000
50253298,OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(cc1)C(F)(F)F)c1ncc(Cl)cc1Cl,"InChI=1S/C20H13Cl2F3N2O4S/c21-15-9-17(22)18(26-10-15)27(11-12-1-5-14(6-2-12)20(23,24)25)32(30,31)16-7-3-13(4-8-16)19(28)29/h1-10H,11H2,(H,28,29)",CMSUMMIXTLRWFY-UHFFFAOYSA-N,50036554,CHEMBL3353609,Transient receptor potential cation channel subfamily M member 8,, 11
50529098,C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N,"InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1",UJLAWZDWDVHWOW-YPMHNXCESA-N,50193995,"3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile::3-(4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile::3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile::CHEMBL221959::CP-690550::TOFACITINIB CITRATE::Tofacitinib::Tofacitinib citrate (1)::US10112907, Example 00035::US10399979, Compound Tofacitinib::US10766894, Compound TABLE 1.20::US10875847, Compound Tofacitinib::US11078206, Example Tofacitinib::US11203595, TABLE 1.20::US11339167, Example Tofacitinib",Tyrosine-protein kinase JAK3,Mus musculus, 156
50277308,CN(CCOc1ccc(Cc2sc(=O)[nH]c2O)cc1)c1ccccn1,"InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,22H,10-12H2,1H3,(H,20,23)",FLDPBMANMDLQTH-UHFFFAOYSA-N,28681,"5-[(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione::Avandia::BRL 49653::Brl-49653::CHEMBL121::ROSIGLITAZONE MALEATE::[3H]rosiglitazone::cid_5281055::rosiglitazone",Peroxisome proliferator-activated receptor gamma,Homo sapiens,
50075765,CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1)C(C)(C)O,"InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)",UQGKUQLKSCSZGY-UHFFFAOYSA-N,50442892,Benicar::CS-866::OLMESARTAN MEDOXOMIL,Solute carrier organic anion transporter family member 1B3,, 977
665476,CC(C)S(=O)(=O)c1ncccc1-c1ccc(c(F)c1)-c1cnc(N)cn1,"InChI=1S/C18H17FN4O2S/c1-11(2)26(24,25)18-13(4-3-7-21-18)12-5-6-14(15(19)8-12)16-9-23-17(20)10-22-16/h3-11H,1-2H3,(H2,20,23)",AUZBYTWULTYYKP-UHFFFAOYSA-N,168994,"US9079866, 395::US9745328, Compound 395::US9884878, Compound 395",Flap endonuclease 1,Homo sapiens,
285913,NC(=O)c1cn(nc1Nc1ccc(F)cc1)C1CC[C@@H](C[C@@H]1C#N)OC(=O)NC1CCCCC1,"InChI=1S/C24H29FN6O3/c25-16-6-8-18(9-7-16)28-23-20(22(27)32)14-31(30-23)21-11-10-19(12-15(21)13-26)34-24(33)29-17-4-2-1-3-5-17/h6-9,14-15,17,19,21H,1-5,10-12H2,(H2,27,32)(H,28,30)(H,29,33)/t15-,19+,21?/m1/s1",JRXLXONTPFENPI-GAKLZJQJSA-N,147979,"US8962608, 34-2",Tyrosine-protein kinase JAK2,Homo sapiens, 164
50357559,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(C[C@@H]1F)c1ccc(cn1)C#N,"InChI=1S/C15H23N5O5/c1-2-4-24-5-3-9-18-13(16)10-14(19-9)20(7-17-10)15-12(23)11(22)8(6-21)25-15/h7-8,11-12,15,21-23H,2-6H2,1H3,(H2,16,18,19)/t8-,11+,12+,15?/m1/s1",QZIQXTJSJONATN-ZCUDWAKFSA-N,50095952,CHEMBL3593777,Potassium voltage-gated channel subfamily H member 2,Homo sapiens,>100000
844379,COc1cccc2[nH]c(cc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)CO,"InChI=1S/C24H32N4O6/c1-13(2)9-18(23(32)27-17(20(30)12-29)10-14-7-8-25-22(14)31)28-24(33)19-11-15-16(26-19)5-4-6-21(15)34-3/h4-6,11,13-14,17-18,26,29H,7-10,12H2,1-3H3,(H,25,31)(H,27,32)(H,28,33)/t14-,17-,18-/m0/s1",QDIMHKWNHMVDJB-WBAXXEDZSA-N,420298,"PF-00835231::PF-0835231::US11524940, Compound 741::WO2005113580-Ex-02::WO2021205298, Compound 1::cmdc.202100576, 6b",Replicase polyprotein 1ab,,
51202343,Cl.CCN1CCN(CC1)c1nc(C)nc2n(CC3CCOCC3)c(nc12)-c1ccccc1Cl,"InChI=1S/C24H31ClN6O/c1-3-29-10-12-30(13-11-29)23-21-24(27-17(2)26-23)31(16-18-8-14-32-15-9-18)22(28-21)19-6-4-5-7-20(19)25/h4-7,18H,3,8-16H2,1-2H3",PGBKYWIIHKALFL-UHFFFAOYSA-N,50494513,CHEMBL3092900,Cannabinoid receptor 2,,
50132761,CCCCCCC\C=C\CCCCCCCC[C@@H]1OC[C@@H](COP(O)([O-])=S)O1,"InChI=1S/C21H41O5PS/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21-24-18-20(26-21)19-25-27(22,23)28/h8-9,20-21H,2-7,10-19H2,1H3,(H2,22,23,28)/p-1/b9-8+/t20-,21+/m0/s1",GPCDCYBCUTWZFV-FIKIWUFISA-M,50177333,"CHEMBL200003::potassium O-((2R,4S)-2-(heptadec-9-enyl)-1,3-dioxolan-4-yl)methyl O-hydrogenphosphorothioate",Ectonucleotide pyrophosphatase/phosphodiesterase family member 2,, 363
340379,CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O,"InChI=1S/C30H36N6O2/c1-18(2)36-17-20(4)28-24(29(37)33-16-25-19(3)12-21(5)34-30(25)38)13-23(14-26(28)36)22-6-7-27(32-15-22)35-10-8-31-9-11-35/h6-7,12-15,17-18,31H,8-11,16H2,1-5H3,(H,33,37)(H,34,38)",OCWAKUTWRJNZGR-UHFFFAOYSA-N,190197,"EPZ008278::US9175331, 26",Histone-lysine N-methyltransferase EZH2 [A677G],, 9.3
51447500,CN(C)C(=O)[C@H]1CSCc2c(cccc2C(=O)OC[C@@H](NC(=O)[C@@H]2CCCN2C(C)=O)C(=O)N1)-c1ccc(cc1)C(O)=O,"InChI=1S/C30H34N4O8S/c1-17(35)34-13-5-8-25(34)27(37)31-23-14-42-30(41)21-7-4-6-20(18-9-11-19(12-10-18)29(39)40)22(21)15-43-16-24(32-26(23)36)28(38)33(2)3/h4,6-7,9-12,23-25H,5,8,13-16H2,1-3H3,(H,31,37)(H,32,36)(H,39,40)/t23-,24-,25+/m1/s1",RNGXYARCEQWNBD-SDHSZQHLSA-N,50584822,CHEMBL5092602,Kelch-like ECH-associated protein 1,,
50696736,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,50331096,"4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline::CHEMBL491473::Cediranib::US10464902, Cediranib::ZD-2171",Cyclin-dependent kinase 13,Homo sapiens,
50150899,COc1cccc(\C=C\c2nc3n(CCCO)c(=O)n(CC#C)c(=O)c3n2C)c1,"InChI=1S/C21H22N4O4/c1-4-11-25-20(27)18-19(24(21(25)28)12-6-13-26)22-17(23(18)2)10-9-15-7-5-8-16(14-15)29-3/h1,5,7-10,14,26H,6,11-13H2,2-3H3/b10-9+",FWLDDFYHEQMIGG-MDZDMXLPSA-N,50084860,"3-(3-Hydroxy-propyl)-8-[2-(3-methoxy-phenyl)-vinyl]-7-methyl-1-prop-2-ynyl-3,7-dihydro-purine-2,6-dione(MSX-2)::CHEMBL413079",Adenosine receptor A1,Rattus norvegicus,
42281,COc1cc(COc2cc(O)c3c(c2)oc(cc3=O)C(O)=O)ccc1NC(=O)C(O)=O,"InChI=1S/C20H15NO10/c1-29-14-4-9(2-3-11(14)21-18(24)20(27)28)8-30-10-5-12(22)17-13(23)7-16(19(25)26)31-15(17)6-10/h2-7,22H,8H2,1H3,(H,21,24)(H,25,26)(H,27,28)",VPQTWQRHEYLDMH-UHFFFAOYSA-N,23224,"7-{[4-(formamidoformic acid)-3-methoxyphenyl]methoxy}-5-hydroxy-4-oxo-4H-chromene-2-carboxylic acid::Oxamic acid derivative, 1",L-lactate dehydrogenase,Plasmodium falciparum, 48300
51103321,Cc1ccc(NC(=O)c2ccccc2NC(=O)C2CCCCC2)cc1,"InChI=1S/C21H24N2O2/c1-15-11-13-17(14-12-15)22-21(25)18-9-5-6-10-19(18)23-20(24)16-7-3-2-4-8-16/h5-6,9-14,16H,2-4,7-8H2,1H3,(H,22,25)(H,23,24)",RQHMBOSMNJPRFL-UHFFFAOYSA-N,50449866,CHEMBL3716352,Relaxin receptor 1,Homo sapiens,
50157991,COc1cc2CCN(CCc3ccc(NC(=O)c4ccccc4[N+]([O-])=O)cc3)Cc2cc1OC,"InChI=1S/C26H27N3O5/c1-33-24-15-19-12-14-28(17-20(19)16-25(24)34-2)13-11-18-7-9-21(10-8-18)27-26(30)22-5-3-4-6-23(22)29(31)32/h3-10,15-16H,11-14,17H2,1-2H3,(H,27,30)",OPEFHOQGDRRMFK-UHFFFAOYSA-N,50241472,"CHEMBL442464::N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2-nitrobenzamide::N-{4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl}-2-nitrobenzamide",Broad substrate specificity ATP-binding cassette transporter ABCG2,Homo sapiens, 40000
50456401,Cc1ccc2[nH]cc(CCN(CC=C)CC=C)c2c1,"InChI=1S/C17H22N2/c1-4-9-19(10-5-2)11-8-15-13-18-17-7-6-14(3)12-16(15)17/h4-7,12-13,18H,1-2,8-11H2,3H3",HTDIOUCPOHFDQH-UHFFFAOYSA-N,50140056,CHEMBL3753318,5-hydroxytryptamine receptor 2A,,
1142072,CNc1cc(nn1C)-c1cc2ncccc2c(n1)-c1ccn(n1)C1(CC#N)CC(C1)C#N,"InChI=1S/C23H21N9/c1-26-21-11-20(29-31(21)2)19-10-18-16(4-3-8-27-18)22(28-19)17-5-9-32(30-17)23(6-7-24)12-15(13-23)14-25/h3-5,8-11,15,26H,6,12-13H2,1-2H3",GKMFFKTVZSDFEU-UHFFFAOYSA-N,538729,"US11254668, Example 69::US11254668, Example 70",Tyrosine-protein kinase JAK3,Homo sapiens,>10000
1249938,CCn1c(c2CC(C)(C)COC(=O)[C@@H]3CCCN(N3)C(=O)[C@H](Cc3cc(O)cc(c3)-c3ccc1c2c3)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CCN(C1)C(=O)C=C)-c1cnccc1COC,"InChI=1S/C50H63N7O8/c1-9-43(59)55-19-16-33(27-55)47(61)54(7)44(30(3)4)46(60)52-41-22-31-20-35(23-36(58)21-31)32-13-14-42-37(24-32)38(45(56(42)10-2)39-26-51-17-15-34(39)28-64-8)25-50(5,6)29-65-49(63)40-12-11-18-57(53-40)48(41)62/h9,13-15,17,20-21,23-24,26,30,33,40-41,44,53,58H,1,10-12,16,18-19,22,25,27-29H2,2-8H3,(H,52,60)/t33-,40-,41-,44-/m0/s1",KEDIJZKZFGWOMJ-MQSPAOBUSA-N,591350,"Synthesis of (2S)-N-[(8S,14S)-22-ethyl-4-hydroxy-21-[4-(methoxymethyl)pyridin-3-yl]-18,18-dimethyl-9,15-dioxo-16-oxa-10,22,28-triazapentacyclo[18.5.2.1{circumflex over (&#8195;)}[2,6].1{circumflex over (&#8195;)}[10,14].0{circumflex over (&#8195;)}[23,27]]nonacosa-1(26),2,4,6(29),20,23::US11566007, Example A28::US11566007, Example A91",GTPase KRas [G13C],, 550
909531,COc1cc(ccn1)-c1[nH]c2ccc(cc2c1C(C)C)C1CCN(C)CC1,"InChI=1S/C23H29N3O/c1-15(2)22-19-13-17(16-8-11-26(3)12-9-16)5-6-20(19)25-23(22)18-7-10-24-21(14-18)27-4/h5-7,10,13-16,25H,8-9,11-12H2,1-4H3",BSQLAHUSYWMOHV-UHFFFAOYSA-N,444049,"US10660877, Example 638",Toll-like receptor 8,, 55.1
51165880,CCC(=O)NCCC[C@@H](C)N(c1cc(Cl)ccc1CO)S(=O)(=O)c1ccc(Cl)cc1,"InChI=1S/C21H26Cl2N2O4S/c1-3-21(27)24-12-4-5-15(2)25(20-13-18(23)7-6-16(20)14-26)30(28,29)19-10-8-17(22)9-11-19/h6-11,13,15,26H,3-5,12,14H2,1-2H3,(H,24,27)/t15-/m1/s1",UUSHJHKKWMREIS-OAHLLOKOSA-N,50477941,CHEMBL403841,Presenilin-1,, 13
50115669,COc1ccc(cc1)C(=O)Nc1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl,"InChI=1S/C23H16ClNO6/c1-30-13-8-6-12(7-9-13)23(29)25-21-18(28)10-16(26)20-17(27)11-19(31-22(20)21)14-4-2-3-5-15(14)24/h2-11,26,28H,1H3,(H,25,29)",HDOFRSOUPSLNLW-UHFFFAOYSA-N,50199022,"CHEMBL224666::N-[2-(2-chlorophenyl)-5,7-dihydroxy-4-oxo-4Hchromen-8-yl]-4-methoxybenzamide",Cyclin-A1/Cyclin-A2/Cyclin-dependent kinase 2,Homo sapiens, 54000
50580049,COc1ccc(cc1OC1CCCC1)S(=O)(=O)C(CCCC(=O)N1CCCc2ccccc12)CC(=O)NO,"InChI=1S/C28H36N2O7S/c1-36-25-16-15-23(18-26(25)37-21-10-3-4-11-21)38(34,35)22(19-27(31)29-33)12-6-14-28(32)30-17-7-9-20-8-2-5-13-24(20)30/h2,5,8,13,15-16,18,21-22,33H,3-4,6-7,9-12,14,17,19H2,1H3,(H,29,31)",GSXKMMPZFVRZAU-UHFFFAOYSA-N,50090381,"3-(3-Cyclopentyloxy-4-methoxy-benzenesulfonyl)-7-(3,4-dihydro-2H-quinolin-1-yl)-7-oxo-heptanoic acid hydroxyamide::CHEMBL418443","cAMP-specific 3',5'-cyclic phosphodiesterase 4A/4B/4C/4D",, 36
50625394,CC1(C)C2CC[C@]1(CS(=O)(=O)Nc1ccc(cc1)S(N)(=O)=O)C(=O)C2,"InChI=1S/C16H22N2O5S2/c1-15(2)11-7-8-16(15,14(19)9-11)10-24(20,21)18-12-3-5-13(6-4-12)25(17,22)23/h3-6,11,18H,7-10H2,1-2H3,(H2,17,22,23)/t11?,16-/m0/s1",FSXHELJSQFRYHW-NBFOKTCDSA-N,50337746,"4-(((1R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methylsulfonamido)benzenesulfonamide::CHEMBL1683466","Carbonic anhydrase 5B, mitochondrial",Homo sapiens,
227955,OCC1OC(Oc2cc3c(cc(O)cc3=[OH+])oc2-c2ccc(O)cc2)C(O)C(O)C1O,"InChI=1S/C21H20O10/c22-8-16-17(26)18(27)19(28)21(31-16)30-15-7-12-13(25)5-11(24)6-14(12)29-20(15)9-1-3-10(23)4-2-9/h1-7,16-19,21-24,26-28H,8H2/p+1",NVBLGZSVOCZYSB-UHFFFAOYSA-O,108034,"5,7&#8208;dihydroxy&#8208;2&#8208;(4&#8208;hydroxyphenyl)&#8208;3&#8208; {[(2S,3R,4S,5S,6R)&#8208;3,4,5&#8208;trihydroxy&#8208;6&#8208; (hydroxymethyl)oxan&#8208;2&#8208;yl]oxy}&#8208;1&#955;&#8308;&#8208;chromen&#8208;1&#8208;ylium::Pelargonidin-3-glucoside (M9)",Alpha-glucosidase MAL12,Saccharomyces cerevisiae, 1.982e+5
918296,Fc1cc(cc(c1)-c1ccc(cc1F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12)C#N,"InChI=1S/C33H27F2N9O/c34-25-12-21(15-37)11-23(13-25)27-2-1-22(14-29(27)35)32(45)42-9-4-26(5-10-42)43-18-33(19-43,6-7-36)44-17-24(16-41-44)30-28-3-8-38-31(28)40-20-39-30/h1-3,8,11-14,16-17,20,26H,4-6,9-10,18-19H2,(H,38,39,40)",HPXDUENAACWXMF-UHFFFAOYSA-N,400374,"US10695337, Example 128::US11285140, Example 128::US9999619, Example 129",Tyrosine-protein kinase JAK2 [828-1132],, 30.0
51073637,COc1ccc2ccc(-c3cccnc3)c(F)c2c1,"InChI=1S/C16H12FNO/c1-19-13-6-4-11-5-7-14(16(17)15(11)9-13)12-3-2-8-18-10-12/h2-10H,1H3",NVRWXGKJXOBEQC-UHFFFAOYSA-N,50439002,CHEMBL2420675,"Steroid 17-alpha-hydroxylase/17,20 lyase",Homo sapiens, 106
51079143,CCOC(=O)c1c(O)coc1Nc1cnc2ccccc2c1,"InChI=1S/C16H14N2O4/c1-2-21-16(20)14-13(19)9-22-15(14)18-11-7-10-5-3-4-6-12(10)17-8-11/h3-9,18-19H,2H2,1H3",UKHMSTFAVQLBQF-UHFFFAOYSA-N,50441251,CHEMBL2431498,"Dihydroorotate dehydrogenase (quinone), mitochondrial",Homo sapiens,>50000
973127,CN([C@H]1CCN(Cc2csc(C)n2)C1)c1cc(F)c(cc1C)S(=O)(=O)Nc1cscn1,"InChI=1S/C20H24FN5O2S3/c1-13-6-19(31(27,28)24-20-11-29-12-22-20)17(21)7-18(13)25(3)16-4-5-26(9-16)8-15-10-30-14(2)23-15/h6-7,10-12,16,24H,4-5,8-9H2,1-3H3/t16-/m0/s1",GQMCCWCTLXZEJF-INIZCTEOSA-N,373843,"(S)-2-fluoro-5-methyl-4-(methyl(1-((2-methylthiazol-4-yl)methyl)pyrrolidin-3-yl)amino)-N-(thiazol-4-yl)benzenesulfonamide formate::US10246453, Example 110::US10815229, Example 110",Sodium channel protein type 1 subunit alpha,,>30000
51415433,O=Cc1ccc2c(c1)[nH]c1c(NC(=O)C3CC3)nccc21,"InChI=1S/C16H13N3O2/c20-8-9-1-4-11-12-5-6-17-15(14(12)18-13(11)7-9)19-16(21)10-2-3-10/h1,4-8,10,18H,2-3H2,(H,17,19,21)",PQSDMIBFNQMFIW-UHFFFAOYSA-N,50571743,CHEMBL4873680,Glycogen synthase kinase-3 beta,Homo sapiens, 400
182851,COc1ccc(c(OC)c1)S(=O)(=O)N1C(=O)[C@@](N2C[C@H](O)C[C@H]2C(=O)N(C)C)(c2cc(Cl)ccc12)c1ccccc1OC,"InChI=1S/C30H32ClN3O8S/c1-32(2)28(36)24-15-19(35)17-33(24)30(21-8-6-7-9-25(21)41-4)22-14-18(31)10-12-23(22)34(29(30)37)43(38,39)27-13-11-20(40-3)16-26(27)42-5/h6-14,16,19,24,35H,15,17H2,1-5H3/t19-,24+,30+/m1/s1",NJXZWIIMWNEOGJ-WEWKHQNJSA-N,50299343,"(2S,4R)-1-((R)-5-chloro-1-(2,4-dimethoxyphenylsulfonyl)-3-(2-methoxyphenyl)-2-oxoindolin-3-yl)-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide::(2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,Ndimethyl-2-pyrrolidine carboxamide::CHEMBL582857::SR-149415::SSR149415",Vasopressin V1b receptor,,
50226482,Cc1cccnc1C1CCN(CC1)C(=O)Nc1ccc(cc1)C(F)(F)F,"InChI=1S/C19H20F3N3O/c1-13-3-2-10-23-17(13)14-8-11-25(12-9-14)18(26)24-16-6-4-15(5-7-16)19(20,21)22/h2-7,10,14H,8-9,11-12H2,1H3,(H,24,26)",DOUBDNJQWXEMSU-UHFFFAOYSA-N,50163220,"3-Methyl-3'',4'',5'',6''-tetrahydro-2''H-[2,4'']bipyridinyl-1''-carboxylic acid (4-trifluoromethyl-phenyl)-amide::CHEMBL175383",Transient receptor potential cation channel subfamily V member 1,Rattus norvegicus,
50472650,CN1C2=N[C@@H]3CCC[C@@H]3N2C2N(Cc3ccc(cc3)-c3ccc(F)cc3)NC(Nc3ccccc3)=C2C1=O,"InChI=1S/C30H29FN6O/c1-35-29(38)26-27(32-23-6-3-2-4-7-23)34-36(28(26)37-25-9-5-8-24(25)33-30(35)37)18-19-10-12-20(13-11-19)21-14-16-22(31)17-15-21/h2-4,6-7,10-17,24-25,28,32,34H,5,8-9,18H2,1H3/t24-,25+,28?/m1/s1",FLQCKSZQICZFTJ-CRWLQCRJSA-N,50150261,CHEMBL3771172,"cAMP-specific 3',5'-cyclic phosphodiesterase 4A",Homo sapiens,
50299077,COc1cc(NCc2cnc3nc(N)nc(N)c3c2C)cc(OC)c1OC,"InChI=1S/C18H22N6O3/c1-9-10(8-22-17-14(9)16(19)23-18(20)24-17)7-21-11-5-12(25-2)15(27-4)13(6-11)26-3/h5-6,8,21H,7H2,1-4H3,(H4,19,20,22,23,24)",LRANACXXEDNIGR-UHFFFAOYSA-N,50029772,"5-Methyl-6-[(3,4,5-trimethoxy-phenylamino)-methyl]-pyrido[2,3-d]pyrimidine-2,4-diamine::CHEMBL23532",Dihydrofolate reductase,Rattus norvegicus, 2.1
50056014,Clc1ccc2nc(Nc3ccccc3I)oc(=O)c2c1,"InChI=1S/C14H8ClIN2O2/c15-8-5-6-11-9(7-8)13(19)20-14(17-11)18-12-4-2-1-3-10(12)16/h1-7H,(H,17,18)",BXNYJWKBNDSIMR-UHFFFAOYSA-N,50063714,"6-Chloro-2-(2-iodo-phenylamino)-benzo[d][1,3]oxazin-4-one::CHEMBL10246",Complement C1r subcomponent,Homo sapiens, 4000
50275471,Fc1cc2CCCOc2c(OCCNCCc2c[nH]c3ccccc23)c1,"InChI=1S/C21H23FN2O2/c22-17-12-15-4-3-10-26-21(15)20(13-17)25-11-9-23-8-7-16-14-24-19-6-2-1-5-18(16)19/h1-2,5-6,12-14,23-24H,3-4,7-11H2",ISBIUGFQLVFPNK-UHFFFAOYSA-N,50150106,CHEMBL124638::[2-(6-Fluoro-chroman-8-yloxy)-ethyl]-[2-(1H-indol-3-yl)-ethyl]-amine,Sodium-dependent serotonin transporter,Homo sapiens, 42.2
763575,Cn1cnc(c1-c1ccc2cc[nH]c2c1)-c1cc(ccn1)C(O)=O,"InChI=1S/C18H14N4O2/c1-22-10-21-16(15-9-13(18(23)24)5-7-20-15)17(22)12-3-2-11-4-6-19-14(11)8-12/h2-10,19H,1H3,(H,23,24)",YSKDANZJZJAOHN-UHFFFAOYSA-N,381950,"2-[5-(1H-indol-6-yl)-1-methyl- 1H-imidazol-4-yl]pyridine-4- carboxylic acid::US10273222, Example 22",Lysine-specific demethylase 5B,,<100
50553752,COc1cc2C\C(=C/c3ccc(cc3)N3CCN(CC3)c3ccccc3)C(=O)c2cc1OC,"InChI=1S/C28H28N2O3/c1-32-26-18-21-17-22(28(31)25(21)19-27(26)33-2)16-20-8-10-24(11-9-20)30-14-12-29(13-15-30)23-6-4-3-5-7-23/h3-11,16,18-19H,12-15,17H2,1-2H3/b22-16+",IFPARRBNOVWNHQ-CJLVFECKSA-N,50210839,CHEMBL3965447,Cholinesterase,, 5980
51304461,Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,50357312,"IBRUTINIB::PCI-32765::US10124003, Ref. Ex. Compound 1::US10711006, Compound Ibrutinib::US10793575, Example ibrutinib::US10835536, Ref. Ex. Comp 1::US10919899, Ibrutinib::US11078206, Example Ibrutinib::US11186578, Example Ibrutinib::US11339167, Example Ibrutinib::US11407754, Example Ibrutinib::US9108973, Ref 1::US9181263, 1::US9278100, 1",Tyrosine-protein kinase ITK/TSK,Homo sapiens, 77
50542425,O=C(C1CCCC1)c1cn(CCN2CCOCC2)c2ccccc12,"InChI=1S/C20H26N2O2/c23-20(16-5-1-2-6-16)18-15-22(19-8-4-3-7-17(18)19)10-9-21-11-13-24-14-12-21/h3-4,7-8,15-16H,1-2,5-6,9-14H2",HMSJDERPEWZRIU-UHFFFAOYSA-N,50303521,CHEMBL584534::Cyclopentyl(1-(2-morpholinoethyl)-1H-indol-3-yl)methanone,Cannabinoid receptor 2,Homo sapiens,
50644050,C[C@H](Cc1ccccc1)N(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C,"InChI=1S/C21H28N2O2/c1-16(14-18-10-7-6-8-11-18)23(5)21(24)25-20-13-9-12-19(15-20)17(2)22(3)4/h6-13,15-17H,14H2,1-5H3/t16-,17+/m1/s1",QGKSWUZOCNWHHA-SJORKVTESA-N,50345812,3-((S)-1-(dimethylamino)ethyl)phenylmethyl((R)-1-phenylpropan-2-yl)carbamate hydrochloride::CHEMBL1784958,Acetylcholinesterase,Homo sapiens, 302
50129705,CN1C[C@H]2CC[C@@H]1[C@@H](C2)C(=O)N[C@H](Cc1ccc(F)cc1)C(=O)N1CCC(CC1)(C1CCCCC1)C(=O)NC(C)(C)C,"InChI=1S/C34H51FN4O3/c1-33(2,3)37-32(42)34(25-8-6-5-7-9-25)16-18-39(19-17-34)31(41)28(21-23-10-13-26(35)14-11-23)36-30(40)27-20-24-12-15-29(27)38(4)22-24/h10-11,13-14,24-25,27-29H,5-9,12,15-22H2,1-4H3,(H,36,40)(H,37,42)/t24-,27+,28+,29+/m0/s1",ARFBDECCXOFCBN-HOLBEBDISA-N,50169442,"(1R,4S,6R)-2-Methyl-2-aza-bicyclo[2.2.2]octane-6-carboxylic acid [(R)-2-(4-tert-butylcarbamoyl-4-cyclohexyl-piperidin-1-yl)-1-(4-fluoro-benzyl)-2-oxo-ethyl]-amide::CHEMBL364346",Melanocortin receptor 4,,
50659598,CCN(CC)c1ccc2c(Oc3cc(ccc3C22N(CCc3ccc(cc3)S(N)(=O)=O)C(=O)c3ccccc23)N(CC)CC)c1,"InChI=1S/C36H40N4O4S/c1-5-38(6-2)26-15-19-31-33(23-26)44-34-24-27(39(7-3)8-4)16-20-32(34)36(31)30-12-10-9-11-29(30)35(41)40(36)22-21-25-13-17-28(18-14-25)45(37,42)43/h9-20,23-24H,5-8,21-22H2,1-4H3,(H2,37,42,43)",AXVQXDKRGPCGGE-UHFFFAOYSA-N,50352646,CHEMBL1822702,Carbonic anhydrase 9,Homo sapiens,
1022588,CC(C)(O)CNC(=O)c1nc(C(=O)N2CCC(F)CC2)c(s1)-c1cnc(NCCC(F)(F)F)cc1C(F)(F)F,"InChI=1S/C23H26F7N5O3S/c1-21(2,38)11-33-18(36)19-34-16(20(37)35-7-3-12(24)4-8-35)17(39-19)13-10-32-15(9-14(13)23(28,29)30)31-6-5-22(25,26)27/h9-10,12,38H,3-8,11H2,1-2H3,(H,31,32)(H,33,36)",QANVZUVYUBTVPS-UHFFFAOYSA-N,491870,"4-(4-Fluoropiperidine-1-carbonyl)-N-(2-hydroxy-2-methylpropyl)-5-(4-(trifluoromethyl)-6-((3,3,3-trifluoropropyl)amino)pyridin-3-yl)thiazole-2-carboxamide::US10975068, Example 8",Nuclear receptor ROR-gamma,,
981461,COc1cc(CNC(=O)c2cc(Cn3ccn(C)c3=N)cc(c2F)-c2ccc(F)cc2C(F)(F)F)cc(OC)c1,"InChI=1S/C28H25F5N4O3/c1-36-6-7-37(27(36)34)15-17-10-22(21-5-4-18(29)12-24(21)28(31,32)33)25(30)23(11-17)26(38)35-14-16-8-19(39-2)13-20(9-16)40-3/h4-13,34H,14-15H2,1-3H3,(H,35,38)",VWZAGEVGWUQNJL-UHFFFAOYSA-N,473256,"US10844044, Example 108",WD repeat-containing protein 5,,
77879,COc1ccc2c(C)n[nH]c3cccc1c23,"InChI=1S/C13H12N2O/c1-8-9-6-7-12(16-2)10-4-3-5-11(13(9)10)15-14-8/h3-7,15H,1-2H3",MXCNJRIUQVTTPS-UHFFFAOYSA-N,31997,6-Methoxy-3-methyl-1H-benzo[de]cinnoline::MLS000027089::SMR000010302::cid_644992,Serine/threonine-protein kinase PLK1,Homo sapiens,
395522,CCOC(=O)C1Cc2cc(C(=O)c3ccccc3F)c(O)c(O)c2O1,"InChI=1S/C18H15FO6/c1-2-24-18(23)13-8-9-7-11(15(21)16(22)17(9)25-13)14(20)10-5-3-4-6-12(10)19/h3-7,13,21-22H,2,8H2,1H3",HEDTVMHUBDAJRX-UHFFFAOYSA-N,225836,hsp90_127,Heat shock protein HSP 90-beta,Homo sapiens, 50000
51272703,Cc1nc(cs1)C(=O)Nc1cccc(NC(=O)COc2ccc3c(c2)occc3=O)c1,"InChI=1S/C22H17N3O5S/c1-13-23-18(12-31-13)22(28)25-15-4-2-3-14(9-15)24-21(27)11-30-16-5-6-17-19(26)7-8-29-20(17)10-16/h2-10,12H,11H2,1H3,(H,24,27)(H,25,28)",VGJUQZDOYBBMLP-UHFFFAOYSA-N,50519671,CHEMBL4470778,Rho-associated protein kinase 1,Homo sapiens, 473
805882,CCOC(=O)c1cnc(s1)N1CCCC(COc2cc(OC)cc3oc(cc23)-c2cn3nc(OC)sc3n2)C1,"InChI=1S/C26H27N5O6S2/c1-4-35-23(32)22-11-27-24(38-22)30-7-5-6-15(12-30)14-36-19-8-16(33-2)9-20-17(19)10-21(37-20)18-13-31-25(28-18)39-26(29-31)34-3/h8-11,13,15H,4-7,12,14H2,1-3H3",NGYWCXFVNBJHSX-UHFFFAOYSA-N,403314,"US10329307, Example 61",PRKC apoptosis WT1 regulator protein,, 1500
50605426,Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12,"InChI=1S/C29H30ClN5O2S/c1-21-25(30)13-8-14-27(21)38(36,37)34-28-24-20-35(19-23-11-6-3-7-12-23)18-16-26(24)32-29(33-28)31-17-15-22-9-4-2-5-10-22/h2-14H,15-20H2,1H3,(H2,31,32,33,34)",LGUUETDTMQTHML-UHFFFAOYSA-N,50329499,"CHEMBL1270331::N-(6-benzyl-2-(phenethylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)-3-chloro-2-methylbenzenesulfonamide",Calcium/calmodulin-dependent protein kinase type IV,Homo sapiens,>60000
51405561,Cc1ccc(cc1)-n1nc(nc1CNc1ccc(cc1)C(=O)NO)-c1ccccc1,"InChI=1S/C23H21N5O2/c1-16-7-13-20(14-8-16)28-21(25-22(26-28)17-5-3-2-4-6-17)15-24-19-11-9-18(10-12-19)23(29)27-30/h2-14,24,30H,15H2,1H3,(H,27,29)",FHXKGVZDSDZEEF-UHFFFAOYSA-N,50567888,CHEMBL4862349,Histone deacetylase 6,Homo sapiens, 310
51160199,C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)CNC(=O)CNC[C@@H](N)Cc1ccccc1)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(=O)N(N)N)C(=O)NN,"InChI=1S/C82H142FN35O20/c1-44(104-63(123)42-103-79(138)66(46(3)120)116-76(135)58(37-48-24-26-49(83)27-25-48)106-64(124)41-102-62(122)40-98-39-50(87)36-47-16-5-4-6-17-47)67(126)107-54(21-13-33-99-80(89)90)70(129)111-53(20-9-12-32-86)74(133)115-60(43-119)77(136)105-45(2)68(127)108-55(22-14-34-100-81(91)92)71(130)109-51(18-7-10-30-84)69(128)112-56(23-15-35-101-82(93)94)72(131)110-52(19-8-11-31-85)73(132)114-59(38-61(88)121)75(134)113-57(78(137)117-95)28-29-65(125)118(96)97/h4-6,16-17,24-27,44-46,50-60,66,98,119-120H,7-15,18-23,28-43,84-87,95-97H2,1-3H3,(H2,88,121)(H,102,122)(H,103,138)(H,104,123)(H,105,136)(H,106,124)(H,107,126)(H,108,127)(H,109,130)(H,110,131)(H,111,129)(H,112,128)(H,113,134)(H,114,132)(H,115,133)(H,116,135)(H,117,137)(H4,89,90,99)(H4,91,92,100)(H4,93,94,101)/t44-,45-,46+,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,66-/m0/s1",RONPEYBYZVADRG-OJQBRUKQSA-N,50475330,CHEMBL442297,Nociceptin receptor,Homo sapiens,
50456686,COc1ccc(CCN2CCC(CC2)C(O)c2cccc(OCCF)c2OC)cc1,"InChI=1S/C24H32FNO4/c1-28-20-8-6-18(7-9-20)10-14-26-15-11-19(12-16-26)23(27)21-4-3-5-22(24(21)29-2)30-17-13-25/h3-9,19,23,27H,10-17H2,1-2H3",YTQJBBJHLKKOLR-UHFFFAOYSA-N,50267555,(3-(2-Fluoroethoxy)-2-methoxyphenyl)-(1-(2-p-methoxyphenylethyl)-piperidine-4-yl)-methanol::CHEMBL490633,5-hydroxytryptamine receptor 2A,Rattus norvegicus,
798783,CN(C(C)=O)c1cnn(c1)C(=O)N1CC2CN(Cc3cc(cc(c3)C(F)(F)F)N3CCOCC3)CC2C1,"InChI=1S/C25H31F3N6O3/c1-17(35)30(2)23-10-29-34(16-23)24(36)33-14-19-12-31(13-20(19)15-33)11-18-7-21(25(26,27)28)9-22(8-18)32-3-5-37-6-4-32/h7-10,16,19-20H,3-6,11-15H2,1-2H3",VWEVJBUMBJLFAO-UHFFFAOYSA-N,399828,"N-methyl-N-(1-(5-(3-morpholino-5- (trifluoromethyl)benzyl)octahydropyrrolo [3,4-c]pyrrole-2-carbonyl)-1H-pyrazol- 4-yl)acetamide::US10323038, Example 114",Fatty-acid amide hydrolase 1,Mus musculus,<100
465664,Cc1cc(cnc1N)C(=O)NC1CCC(CC1)=Cc1cccc(Oc2ccc(Cl)c(C)n2)c1,"InChI=1S/C26H27ClN4O2/c1-16-12-20(15-29-25(16)28)26(32)31-21-8-6-18(7-9-21)13-19-4-3-5-22(14-19)33-24-11-10-23(27)17(2)30-24/h3-5,10-15,21H,6-9H2,1-2H3,(H2,28,29)(H,31,32)/b18-13-",FOEPYDRNMKOTOW-AQTBWJFISA-N,143288,"US9682953, 2.E-25",Fatty-acid amide hydrolase 1 [30-579],, 32
50626789,N[C@H](Cc1cc(F)ccc1F)C1CCN(CC1)c1ccc(F)nc1,"InChI=1S/C18H20F3N3/c19-14-1-3-16(20)13(9-14)10-17(22)12-5-7-24(8-6-12)15-2-4-18(21)23-11-15/h1-4,9,11-12,17H,5-8,10,22H2/t17-/m1/s1",QQVUXENLUIUCMJ-QGZVFWFLSA-N,50338430,"(R)-2-(2,5-difluorophenyl)-1-(1-(6-fluoropyridin-3-yl)piperidin-4-yl)ethanamine::CHEMBL1683136",Dipeptidyl peptidase 2,Homo sapiens, 52000
524944,CNc1nc(OCc2cn(nn2)-c2ccc(F)c(c2)C(C)(F)F)ncc1C,"InChI=1S/C17H17F3N6O/c1-10-7-22-16(23-15(10)21-3)27-9-11-8-26(25-24-11)12-4-5-14(18)13(6-12)17(2,19)20/h4-8H,9H2,1-3H3,(H,21,22,23)",VUOWLVQOWAMXQW-UHFFFAOYSA-N,276637,"2-[[1-[3-(1,1-Difluoroethyl)-4-fluoro-phenyl]triazol-4-yl]methoxy]-N,5-::US10071988, Example 577::US10233173, Example 577",Retinoic acid receptor RXR-alpha,Homo sapiens, 128
50206169,CC(C)NCC(O)c1ccc(O)c(O)c1,"InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3",JWZZKOKVBUJMES-UHFFFAOYSA-N,25392,"4-[1-hydroxy-2-(isopropylamino)ethyl]pyrocatechol;hydrochloride::4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol::4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol, 2::CHEMBL434::ISOPROTERONOL::Isoprenaline::Isoproterenol::Isoproterenol (-)::Isoproterenol,(+)::Isoproterenol-l::Norisodrine::Novodrin",Beta-1 adrenergic receptor,Homo sapiens,
172462,COc1cc(N)c(Cl)cc1C(=O)NC1CCN2CCCC1C2,"InChI=1S/C16H22ClN3O2/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-14-4-6-20-5-2-3-10(14)9-20/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21)",GZSKEXSLDPEFPT-UHFFFAOYSA-N,82422,CAS_109872-41-5::NSC_3035240::RENZAPRIDE,5-hydroxytryptamine receptor 4,,
50280686,Cc1ccc(cc1)C1=N[C@@H](Sc2ccccc2)[C@@H](O1)C=C,"InChI=1S/C18H17NOS/c1-3-16-18(21-15-7-5-4-6-8-15)19-17(20-16)14-11-9-13(2)10-12-14/h3-12,16,18H,1H2,2H3/t16-,18-/m0/s1",HMMHUOOBBQHGHE-WMZOPIPTSA-N,50152630,"(4S,5S)-4-Phenylsulfanyl-2-p-tolyl-5-vinyl-4,5-dihydro-oxazole::CHEMBL184472",Interstitial collagenase,,
51108174,Fc1ccc(Cn2ccc(NC(=O)Cc3ccc4[nH]ccc4c3)n2)cc1F,"InChI=1S/C20H16F2N4O/c21-16-3-1-14(10-17(16)22)12-26-8-6-19(25-26)24-20(27)11-13-2-4-18-15(9-13)5-7-23-18/h1-10,23H,11-12H2,(H,24,25,27)",SHDZUWIULZBHDM-UHFFFAOYSA-N,50452290,CHEMBL4207159,Voltage-dependent T-type calcium channel subunit alpha-1H,, 14
347922,COC1CCC2(Cc3ccc(CCC4CC4)cc3C22N=C(N)N(Cc3ccc(cc3)C#N)C2=O)CC1,"InChI=1S/C30H34N4O2/c1-36-25-12-14-29(15-13-25)17-24-11-10-21(5-4-20-2-3-20)16-26(24)30(29)27(35)34(28(32)33-30)19-23-8-6-22(18-31)7-9-23/h6-11,16,20,25H,2-5,12-15,17,19H2,1H3,(H2,32,33)",FEASUUSJHPORHM-UHFFFAOYSA-N,195477,"US9212153, 387,Ex. 329",Beta-secretase 1 [1-458],, 15.5
426974,CSc1ccc(Nc2nc(nc3CCN(CCc23)c2ncccc2C(F)(F)F)N2CCCCC2)cc1,"InChI=1S/C26H29F3N6S/c1-36-19-9-7-18(8-10-19)31-23-20-11-16-34(24-21(26(27,28)29)6-5-13-30-24)17-12-22(20)32-25(33-23)35-14-3-2-4-15-35/h5-10,13H,2-4,11-12,14-17H2,1H3,(H,31,32,33)",SRBRGADEBFLEFC-UHFFFAOYSA-N,244932,"US9422293, 160::US9738649, Example 160",Transient receptor potential cation channel subfamily V member 1,Rattus norvegicus, 100
846297,C[C@@H](O)CC(=O)N1CCC(CC1)c1ccc2[nH]c(c(CC(F)F)c2c1)-c1ccc2nc(C)nn2c1,,,273871,"US10071079, Example 657::US10478424, Example 657",Toll-like receptor 7,, 416
136454,[O-][N+](=O)c1cccc(c1)C(=O)COC(=O)CN1C(=O)C2C3CCC(C3)C2C1=O,"InChI=1S/C19H18N2O7/c22-14(10-2-1-3-13(7-10)21(26)27)9-28-15(23)8-20-18(24)16-11-4-5-12(6-11)17(16)19(20)25/h1-3,7,11-12,16-17H,4-6,8-9H2",TWJKYCDAQQTRKJ-UHFFFAOYSA-N,67222,"(3,5-Dioxo-4-aza-tricyclo[5.2.1.0*2,6*]dec-4-yl)-acetic acid 2-(3-nitro-phenyl)-2-oxo-ethyl ester::MLS000566901::SMR000175979::cid_3118009",Type-1 angiotensin II receptor,Homo sapiens, 26310
1152796,CC(C)c1nccc(C)c1-n1c2nc(c(F)cc2c(nc1=O)N1C[C@@H](C)N(C[C@@H]1C)C(=O)C=C)-c1ccccc1CO,"InChI=1S/C32H35FN6O3/c1-7-26(41)37-15-21(6)38(16-20(37)5)30-24-14-25(33)28(23-11-9-8-10-22(23)17-40)35-31(24)39(32(42)36-30)29-19(4)12-13-34-27(29)18(2)3/h7-14,18,20-21,40H,1,15-17H2,2-6H3/t20-,21+/m1/s1",XDAKAEMHDVNNBC-RTWAWAEBSA-N,544121,"(M)-4-[(2S,5R)- 2,5-dimethyl-4- prop-2-enoyl- piperazin-1-yl]- 6-fluoro-7-[2- (hydroxymethyl) phenyl]-1-(2- isopropyl-4- methyl-3- pyridyl)pyrido [2,3- d]pyrimidin-2- one::US11285156, Ex.# 94-2","GTPase KRas [1-169,G12C,C118A]",, 322
50485689,COc1ccc(cc1)N1CCN(CC1)C(=O)Nc1ccc(OC)c(c1)N1CCN(C)CC1,"InChI=1S/C24H33N5O3/c1-26-10-12-28(13-11-26)22-18-19(4-9-23(22)32-3)25-24(30)29-16-14-27(15-17-29)20-5-7-21(31-2)8-6-20/h4-9,18H,10-17H2,1-3H3,(H,25,30)",HCTBJYWMGCQPOS-UHFFFAOYSA-N,50290919,4-(4-Methoxy-phenyl)-piperazine-1-carboxylic acid [4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]-amide; compound with (E)-but-2-enedioic acid::CHEMBL108645,5-hydroxytryptamine receptor 1D,Homo sapiens,
50354440,CCN1C(=S)N2CCCC2c2c1nc(-c1cccc(OC)c1)c(C#N)c2N1CCOCC1,"InChI=1S/C22H21N3O/c26-22-19-15-24(13-16-7-2-1-3-8-16)20-12-5-4-11-18(20)21(19)23-25(22)14-17-9-6-10-17/h1-5,7-8,11-12,15,17H,6,9-10,13-14H2",ZXIGHFLRSGWDLS-UHFFFAOYSA-N,50094947,CHEMBL3589376,Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta,Homo sapiens, 9760
51439068,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@H](NC1=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N(C)[C@@H](CCCNC(N)=N)C(=O)N(C)[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)[C@@H](C)O)[C@@H](C)CC,,,50581301,CHEMBL5093939,Melanocortin receptor 4,,
50065221,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12,"InChI=1S/C20H15N3O2/c24-19-15-11-17(21-13-7-3-1-4-8-13)18(12-16(15)20(25)23-19)22-14-9-5-2-6-10-14/h1-12,21-22H,(H,23,24,25)",AAALVYBICLMAMA-UHFFFAOYSA-N,50040929,"4,5-dianilinophthalimide::5,6-bis(phenylamino)-1H-isoindole-1,3(2H)-dione::CHEMBL268868::Cgp 52411",Proto-oncogene tyrosine-protein kinase Src,, 16000
50844159,COc1ccc(OC[C@@H]2CC[C@H]3CN(CCN3C2)c2nc(N)n3nc(nc3n2)-c2ccco2)cc1,"InChI=1S/C24H28N8O3/c1-33-18-6-8-19(9-7-18)35-15-16-4-5-17-14-31(11-10-30(17)13-16)23-27-22(25)32-24(28-23)26-21(29-32)20-3-2-12-34-20/h2-3,6-9,12,16-17H,4-5,10-11,13-15H2,1H3,(H2,25,26,27,28,29)/t16-,17+/m1/s1",DHWRYELCNPJLRF-SJORKVTESA-N,50156641,"(7RS,9aSR)-2-furan-2-yl-5-[7-(4-methoxy-phenoxymethyl)-octahydro-pyrido[1,2-a]pyrazin-2-yl]-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-ylamine::CHEMBL387327",Adenosine receptor A1,Rattus norvegicus,
50646512,CN1CCC(CC1)NC(=O)c1ccc(cc1)-c1ccc(cc1C)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1,"InChI=1S/C41H35N5O2/c1-26-21-34(13-14-35(26)27-7-9-28(10-8-27)41(48)44-33-17-19-45(2)20-18-33)46-39(47)16-12-31-24-43-38-15-11-29(23-36(38)40(31)46)32-22-30-5-3-4-6-37(30)42-25-32/h3-16,21-25,33H,17-20H2,1-2H3,(H,44,48)",OQNZFXCQVQSQDF-UHFFFAOYSA-N,50346970,CHEMBL1795884,Serine/threonine-protein kinase mTOR,,
50720262,CC(C)n1cc2OC3(CCN(CC3)C(=O)c3cc(C)c4[nH]nc(C)c4c3)CC(=O)c2n1,"InChI=1S/C23H27N5O3/c1-13(2)28-12-19-21(26-28)18(29)11-23(31-19)5-7-27(8-6-23)22(30)16-9-14(3)20-17(10-16)15(4)24-25-20/h9-10,12-13H,5-8,11H2,1-4H3,(H,24,25)",POQBAOOHSSEVOU-UHFFFAOYSA-N,50365290,CHEMBL1958371,Acetyl-CoA carboxylase 1,Rattus norvegicus, 12
51001776,Fc1ccc(C(=O)NC(=O)Nc2ccc3CCCNc3c2)c(Cl)c1,"InChI=1S/C17H15ClFN3O2/c18-14-8-11(19)4-6-13(14)16(23)22-17(24)21-12-5-3-10-2-1-7-20-15(10)9-12/h3-6,8-9,20H,1-2,7H2,(H2,21,22,23,24)",XGMNIMNOWWRWSJ-UHFFFAOYSA-N,50174402,"1-(2-Chloro-4-fluoro-benzoyl)-3-(1,2,3,4-tetrahydro-quinolin-7-yl)-urea::CHEMBL198770","Glycogen phosphorylase, liver form",Homo sapiens, 3467.37
50491806,COc1nc(nc(C)c1F)N1C[C@H]2C(=O)N(C)C(N)=N[C@]2(C1)c1c(F)ccc(F)c1F,"InChI=1S/C19H18F4N6O2/c1-8-13(22)15(31-3)26-18(25-8)29-6-9-16(30)28(2)17(24)27-19(9,7-29)12-10(20)4-5-11(21)14(12)23/h4-5,9H,6-7H2,1-3H3,(H2,24,27)/t9-,19-/m0/s1",VRRVVCOABSEJKG-UGZDLDLSSA-N,102969,"US8541427, 40",Cytochrome P450 3A4,Homo sapiens,>20000
50671587,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,"InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)",UHTHHESEBZOYNR-UHFFFAOYSA-N,21,"6-[(4R,5S,6S,7R)-4,7-dibenzyl-3-(5-carboxypentyl)-5,6-dihydroxy-2-oxo-1,3-diazepan-1-yl]hexanoic acid::CHEMBL24828::DMPC Cyclic Urea 1::N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine::VANDETANIB::ZD-6474::ZD6474::cid_3081361",Serine/threonine-protein kinase 16,,
50484933,C(COc1nc(nc2CCCCc12)-c1ccccc1)CN1CCCCC1,"InChI=1S/C22H29N3O/c1-3-10-18(11-4-1)21-23-20-13-6-5-12-19(20)22(24-21)26-17-9-16-25-14-7-2-8-15-25/h1,3-4,10-11H,2,5-9,12-17H2",WYWPQLUAZPOYCP-UHFFFAOYSA-N,50034165,CHEMBL3359233,Sigma non-opioid intracellular receptor 1,Cavia porcellus,
51119657,O[C@@H]1CCN(C1)c1ncc(cc1-c1[nH]ncc1F)C(=O)Nc1ccc(OC(F)(F)Cl)cc1,"InChI=1S/C20H17ClF3N5O3/c21-20(23,24)32-14-3-1-12(2-4-14)27-19(31)11-7-15(17-16(22)9-26-28-17)18(25-8-11)29-6-5-13(30)10-29/h1-4,7-9,13,30H,5-6,10H2,(H,26,28)(H,27,31)/t13-/m1/s1",NAXNSUPRCUTVTP-CYBMUJFWSA-N,50459090,CHEMBL4213152,"1,3-beta-glucan synthase component GSC2",Saccharomyces cerevisiae,>30000
932029,CC(C)(C)CNC(=O)COc1cccc(c1)-c1nc2COCc2c(Nc2ccc(cc2)-c2cn[nH]c2)n1,"InChI=1S/C28H30N6O3/c1-28(2,3)17-29-25(35)16-37-22-6-4-5-19(11-22)26-33-24-15-36-14-23(24)27(34-26)32-21-9-7-18(8-10-21)20-12-30-31-13-20/h4-13H,14-17H2,1-3H3,(H,29,35)(H,30,31)(H,32,33,34)",XKSKWJHTUPYWCG-UHFFFAOYSA-N,453245,"2-(3-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)-5,7-dihydrofuro[3,4-d]pyrimidin-2-yl)phenoxy)-N-neopentylacetamide::US10729691, Example 30",Putative sugar transporter,Plasmodium falciparum, 175
158701,CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34,"InChI=1S/C25H31NO/c1-24(2,3)25(27)13-14-26-16-21-19-9-5-4-7-17(19)11-12-18-8-6-10-20(23(18)21)22(26)15-25/h4-10,21-22,27H,11-16H2,1-3H3/t21-,22-,25-/m0/s1",ZZJYIKPMDIWRSN-HWBMXIPRSA-N,50008735,"(+)-3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::(+)-butaclamol::(+/-)-3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::(S)-(-)-3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol ((+)-butaclamol)::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[4,5]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol((+)-butaclamol)::3-(tert-butyl)-(3S,4aS,13bS)-2,3,4,4a,8,9,13b,14-octahydro-1H-benzo[6,7]cyclohepta[de]pyrido[2,1-a]isoquinolin-3-ol(Butaclamol)::BUTACLAMOL::BUTACLAMOL, (-)::BUTACLAMOL,(+)::BUTACLAMOL,d-::CHEMBL8514::d-Butaclamol",Sigma non-opioid intracellular receptor 1,Rattus,
1022857,C[C@H]1CCCN1C(=O)c1nc(sc1-c1cnc(N[C@@H]2CCCC2(F)F)cc1C(F)(F)F)C(=O)NCC(C)(C)O,"InChI=1S/C25H30F5N5O3S/c1-13-6-5-9-35(13)22(37)18-19(39-21(34-18)20(36)32-12-23(2,3)38)14-11-31-17(10-15(14)25(28,29)30)33-16-7-4-8-24(16,26)27/h10-11,13,16,38H,4-9,12H2,1-3H3,(H,31,33)(H,32,36)/t13-,16+/m0/s1",UMEOAYCBDSHQBY-XJKSGUPXSA-N,492139,"5-(6-(((R*)-2,2-Difluorocyclopentyl)amino)-4-(trifluoromethyl)pyridin-3-yl)-N-(2-hydroxy-2-methylpropyl)-4-((S)-2-methylpyrrolidine-1-carbonyl)thiazole-2-carboxamide::US10975068, Example 280",Nuclear receptor ROR-gamma,,
1216210,CC(C)n1nc(-c2noc(C3CC3)c2-c2ccccn2)c2c(N)ncc(Cl)c12,"InChI=1S/C20H19ClN6O/c1-10(2)27-18-12(21)9-24-20(22)15(18)16(25-27)17-14(13-5-3-4-8-23-13)19(28-26-17)11-6-7-11/h3-5,8-11H,6-7H2,1-2H3,(H2,22,24)",GWDRQXMAYBMTEO-UHFFFAOYSA-N,576988,"US11472802, Example 8",Proto-oncogene tyrosine-protein kinase receptor Ret [V804M],, 0.017
51381513,OS(=O)(=O)C(C(=O)Nc1cnc2ccccc2c1)c1ccccc1,"InChI=1S/C17H14N2O4S/c20-17(16(24(21,22)23)12-6-2-1-3-7-12)19-14-10-13-8-4-5-9-15(13)18-11-14/h1-11,16H,(H,19,20)(H,21,22,23)",BDHSZYAVPQKKIY-UHFFFAOYSA-N,50558483,CHEMBL4778085,Tyrosine-protein phosphatase non-receptor type 2,Homo sapiens,>200000
50721323,NS(=O)(=O)c1ccc(cc1)-n1nnnc1-c1ccc(cc1)C(F)(F)F,"InChI=1S/C14H10F3N5O2S/c15-14(16,17)10-3-1-9(2-4-10)13-19-20-21-22(13)11-5-7-12(8-6-11)25(18,23)24/h1-8H,(H2,18,23,24)",HDGAMZKNYZRNRU-UHFFFAOYSA-N,50365758,CHEMBL1956386,Prostaglandin G/H synthase 2,Homo sapiens,>100000
50500071,COCCOc1nc(-c2cccc(c2)C(F)(F)F)n(n1)-c1ccc(NC(=O)CCl)cc1,"InChI=1S/C20H18ClF3N4O3/c1-30-9-10-31-19-26-18(13-3-2-4-14(11-13)20(22,23)24)28(27-19)16-7-5-15(6-8-16)25-17(29)12-21/h2-8,11H,9-10,12H2,1H3,(H,25,29)",YNPCFQRRZGAJJP-UHFFFAOYSA-N,50177227,CHEMBL3814547,Mucosa-associated lymphoid tissue lymphoma translocation protein 1,, 93000
78832,Cc1c(C)c(O)c(C=CCCC#CCCCC#CCO)c(C)c1O,"InChI=1S/C21H26O3/c1-16-17(2)21(24)19(18(3)20(16)23)14-12-10-8-6-4-5-7-9-11-13-15-22/h12,14,22-24H,5,7-10,15H2,1-3H3",YJJCOKZDOWPHHH-UHFFFAOYSA-N,50006811,"2-(12-Hydroxy-5,10-dodecadiynyl)-3,5,6-trimethyl-p-benzoquinone::2-(12-hydroxydodeca-5,10-diyn-1-yl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione::2-(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoquinone::AA861::CHEMBL304818::cid_1967::docebenone",Tyrosine-protein phosphatase YopH,Yersinia enterocolitica,>50000
788924,O[C@@H](CNC(=O)c1ccnc(NC2CCCC2)c1)CN1CCc2ccccc2C1,"InChI=1S/C23H30N4O2/c28-21(16-27-12-10-17-5-1-2-6-19(17)15-27)14-25-23(29)18-9-11-24-22(13-18)26-20-7-3-4-8-20/h1-2,5-6,9,11,13,20-21,28H,3-4,7-8,10,12,14-16H2,(H,24,26)(H,25,29)/t21-/m0/s1",GDMQNDHVTFHNKD-NRFANRHFSA-N,179439,"US10307413, Compound 334::US10391089, Compound 334::US10980794, Cmpd No 334::US9675614, 334",Protein arginine N-methyltransferase 5,,<100
50488611,CCNCC(=O)N1N=C(CC1c1ccccc1)c1cc2ccccc2oc1=O,"InChI=1S/C22H21N3O3/c1-2-23-14-21(26)25-19(15-8-4-3-5-9-15)13-18(24-25)17-12-16-10-6-7-11-20(16)28-22(17)27/h3-12,19,23H,2,13-14H2,1H3",CAVZUUOEKYFUDX-UHFFFAOYSA-N,50160395,CHEMBL3786821,Telomerase reverse transcriptase,Homo sapiens, 6680
465190,CC1CN(CCO1)C1CN(C1)c1cnc2ccc(nc2n1)-c1ccc2oc(N)nc2c1,"InChI=1S/C22H23N7O2/c1-13-10-28(6-7-30-13)15-11-29(12-15)20-9-24-17-4-3-16(25-21(17)27-20)14-2-5-19-18(8-14)26-22(23)31-19/h2-5,8-9,13,15H,6-7,10-12H2,1H3,(H2,23,26)",IDOCBOMLGZNLKU-UHFFFAOYSA-N,141974,"US9682141, 547","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens,>10000
18244,CC(Cc1cccc(OC(=O)N(C)C2CCCCC2)c1)N(C)CC#C,"InChI=1S/C21H30N2O2/c1-5-14-22(3)17(2)15-18-10-9-13-20(16-18)25-21(24)23(4)19-11-7-6-8-12-19/h1,9-10,13,16-17,19H,6-8,11-12,14-15H2,2-4H3",FTMQGFFVKGHYEQ-UHFFFAOYSA-N,10829,"3-(N-Methyl,Ncyclohexylcarbamyloxy)-N-methyl-N-propargylphenylpropylamine Mesylate::3-{2-[methyl(prop-2-yn-1-yl)amino]propyl}phenyl N-cyclohexyl-N-methylcarbamate; methanesulfonic acid::Phenethylamine deriv. 53e",Acetylcholinesterase,Homo sapiens, 8670
452959,NC(=O)C(=C\c1ccc2cn[nH]c2c1)\C#N,"InChI=1S/C11H8N4O/c12-5-9(11(13)16)3-7-1-2-8-6-14-15-10(8)4-7/h1-4,6H,(H2,13,16)(H,14,15)/b9-3+",XLGYCNBBWHAJDG-YCRREMRBSA-N,259815,"US9505766, 15",Serine/threonine-protein kinase Nek2 [C22A],,>10000
50962415,CCCCCCCCCN[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1OC,"InChI=1S/C16H33NO5/c1-3-4-5-6-7-8-9-10-17-11-12(18)13(19)14(20)15(21)16(11)22-2/h11-21H,3-10H2,1-2H3/t11-,12-,13+,14-,15+,16-/m0/s1",XIVQQGYSZPSBSE-KLOLGFOXSA-N,50394825,CHEMBL2164230,Lysosomal acid glucosylceramidase,Homo sapiens,
627972,CO[C@@H]1C[C@@H]2CC[C@H](C1)N2c1ccc(cn1)-c1cc(cn2ncc(C#N)c12)-c1cnn(C)c1,"InChI=1S/C25H25N7O/c1-30-14-19(13-28-30)17-7-23(25-18(10-26)12-29-31(25)15-17)16-3-6-24(27-11-16)32-20-4-5-21(32)9-22(8-20)33-2/h3,6-7,11-15,20-22H,4-5,8-9H2,1-2H3/t20-,21+,22+",DJCMPYFVTZZCKJ-ZBYYUNFXSA-N,284190,"US10023570, Example 200::US10174028, Example 200",Proto-oncogene tyrosine-protein kinase receptor Ret [V804M],, 50.7
50542741,CC(C)COC(=O)[C@@H](Cn1cncn1)NC(=O)c1ccc(cc1)-c1ccccc1F,"InChI=1S/C22H23FN4O3/c1-15(2)12-30-22(29)20(11-27-14-24-13-25-27)26-21(28)17-9-7-16(8-10-17)18-5-3-4-6-19(18)23/h3-10,13-15,20H,11-12H2,1-2H3,(H,26,28)/t20-/m1/s1",YIJUYZNEIGFWAF-HXUWFJFHSA-N,50207552,CHEMBL3892576,Cytochrome P450 2C19,Homo sapiens, 1890
50285629,CCCCCc1cc(O)cc(OCCCCCCCCCCCCNC2CC2)c1,"InChI=1S/C26H45NO2/c1-2-3-12-15-23-20-25(28)22-26(21-23)29-19-14-11-9-7-5-4-6-8-10-13-18-27-24-16-17-24/h20-22,24,27-28H,2-19H2,1H3",IRCVQHMAPOVLBT-UHFFFAOYSA-N,50055435,CHEMBL3321781,Cannabinoid receptor 1,Homo sapiens,
50930513,Nc1c2CCCCc2nc2cccc(N3CCN(CCCCc4c[nH]c5ccccc45)CC3)c12,"InChI=1S/C29H35N5/c30-29-23-10-2-4-12-25(23)32-26-13-7-14-27(28(26)29)34-18-16-33(17-19-34)15-6-5-8-21-20-31-24-11-3-1-9-22(21)24/h1,3,7,9,11,13-14,20,31H,2,4-6,8,10,12,15-19H2,(H2,30,32)",QJVGHNGLGSOMNC-UHFFFAOYSA-N,50272685,CHEMBL4126818,5-hydroxytryptamine receptor 1A,,
58525,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CC[C@H](C)[C@H]1C(=O)Nc1cc(C)nn1-c1ccccc1,"InChI=1S/C28H40N6O3/c1-18-15-16-33(28(37)24(21-11-7-5-8-12-21)31-26(35)20(3)29-4)25(18)27(36)30-23-17-19(2)32-34(23)22-13-9-6-10-14-22/h6,9-10,13-14,17-18,20-21,24-25,29H,5,7-8,11-12,15-16H2,1-4H3,(H,30,36)(H,31,35)/t18-,20-,24-,25-/m0/s1",IBBHIZXRMBKKII-IYNDAXALSA-N,32578,CS-1,Baculoviral IAP repeat-containing protein 2 [269-336],Homo sapiens,
401508,CNC(=O)c1cccc(Nc2ncnc(n2)N2CC(C2)Oc2cc(Cl)ccc2Cl)c1,"InChI=1S/C20H18Cl2N6O2/c1-23-18(29)12-3-2-4-14(7-12)26-19-24-11-25-20(27-19)28-9-15(10-28)30-17-8-13(21)5-6-16(17)22/h2-8,11,15H,9-10H2,1H3,(H,23,29)(H,24,25,26,27)",CQGIHNRCGNJXCT-UHFFFAOYSA-N,229691,"US9334269, 18",Sodium channel protein type 9 subunit alpha,, 310
151938,OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O,"InChI=1S/C14H14O4S2/c15-5-7-19-13-11(17)9-3-1-2-4-10(9)12(18)14(13)20-8-6-16/h1-4,15-16H,5-8H2",MAASHDQFQDDECQ-UHFFFAOYSA-N,50208827,"2,3-bis(2-hydroxyethylthio)naphthalene-1,4-dione::CHEMBL429095::N1786 (NSC95397)::NSC 9539::NSC 95397::NSC-95397::cid_262093",Hexokinase HKDC1 [W721R],Homo sapiens, 3150
544214,CC[C@H](NS(=O)(=O)c1ccc(-c2sc(nc2CC2CCCC2)-c2nnc(CC(C)(C)C(O)=O)o2)c(F)c1C(F)F)C(F)(F)F,"InChI=1S/C27H30F6N4O5S2/c1-4-17(27(31,32)33)37-44(40,41)16-10-9-14(20(28)19(16)22(29)30)21-15(11-13-7-5-6-8-13)34-24(43-21)23-36-35-18(42-23)12-26(2,3)25(38)39/h9-10,13,17,22,37H,4-8,11-12H2,1-3H3,(H,38,39)/t17-/m0/s1",BECOVIMMPUELIN-KRWDZBQOSA-N,285774,"US10080744, Example 3/41",Nuclear receptor ROR-gamma,,
239102,C(N=Nc1nc2ccccc2s1)c1ccc2OCOc2c1,"InChI=1S/C15H11N3O2S/c1-2-4-14-11(3-1)17-15(21-14)18-16-8-10-5-6-12-13(7-10)20-9-19-12/h1-7H,8-9H2",FLPXBDSAMCYBMJ-UHFFFAOYSA-N,114847,"1,3-benzodioxole-5-carbaldehyde 1,3-benzothiazol-2-ylhydrazone::1,3-benzothiazol-2-yl-[(E)-piperonylideneamino]amine::MLS000576981::N-[(E)-1,3-benzodioxol-5-ylmethylideneamino]-1,3-benzothiazol-2-amine::SMR000186009::cid_9561228",Oxysterols receptor LXR-beta,, 67521
50336609,FC(F)(F)c1cccc(Nc2ncnc3ccc(cc23)-c2cncs2)c1,"InChI=1S/C18H11F3N4S/c19-18(20,21)12-2-1-3-13(7-12)25-17-14-6-11(16-8-22-10-26-16)4-5-15(14)23-9-24-17/h1-10H,(H,23,24,25)",GDJPSUNLWNVYIH-UHFFFAOYSA-N,50086410,CHEMBL3426080,ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,Homo sapiens, 2150
51096239,OC(=O)CCc1c([nH]c2cc(ccc12)-c1ccccc1)C(O)=O,"InChI=1S/C18H15NO4/c20-16(21)9-8-14-13-7-6-12(11-4-2-1-3-5-11)10-15(13)19-17(14)18(22)23/h1-7,10,19H,8-9H2,(H,20,21)(H,22,23)",GDRVFNVJBQRHAM-UHFFFAOYSA-N,50458867,CHEMBL3968577,Uracil nucleotide/cysteinyl leukotriene receptor,Homo sapiens,
1034804,CC(C)(C)OC(=O)CN1CCc2ccc(cc2C1=O)-c1nc(NC2CCOCC2)ncc1Cl,"InChI=1S/C24H29ClN4O4/c1-24(2,3)33-20(30)14-29-9-6-15-4-5-16(12-18(15)22(29)31)21-19(25)13-26-23(28-21)27-17-7-10-32-11-8-17/h4-5,12-13,17H,6-11,14H2,1-3H3,(H,26,27,28)",CJYOOBJKGKQVSI-UHFFFAOYSA-N,417526,"US10457669, Example 140::US11001575, Example 140",Mitogen-activated protein kinase 1,Homo sapiens, 120
50626442,CCO\N=C\c1c(cc(C)c2NC(C)(C)[C@H](O)[C@@H](C)c12)-c1cccc2cc[nH]c12,"InChI=1S/C24H29N3O2/c1-6-29-26-13-19-18(17-9-7-8-16-10-11-25-22(16)17)12-14(2)21-20(19)15(3)23(28)24(4,5)27-21/h7-13,15,23,25,27-28H,6H2,1-5H3/b26-13+/t15-,23+/m0/s1",RVNWJSHHOWQTNT-SYWQUHTRSA-N,50338317,"(+/-)-3-hydroxy-6-(1H-indol-7-yl)-2,2,4,8-tetramethyl-1,2,3,4-tetrahydroquinoline-5-carbaldehyde O-ethyl oxime::CHEMBL1682424",Glucocorticoid receptor,, 0.9
51048729,Cc1ccc(Cc2cc[n+](C)c(COc3ccc(C)cc3)c2)cc1,"InChI=1S/C22H24NO/c1-17-4-8-19(9-5-17)14-20-12-13-23(3)21(15-20)16-24-22-10-6-18(2)7-11-22/h4-13,15H,14,16H2,1-3H3/q+1",VDNDCWISAWQFKI-UHFFFAOYSA-N,50427980,CHEMBL2324261,Potassium voltage-gated channel subfamily H member 2,Homo sapiens, 346
50160965,Cc1ccc(cc1C)-c1ccc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2)cc1,"InChI=1S/C23H20N2O4S/c1-14-7-8-17(13-15(14)2)16-9-11-18(12-10-16)24-23(27)21-22(26)19-5-3-4-6-20(19)30(28,29)25-21/h3-13,25-26H,1-2H3,(H,24,27)",ATLCLKVCFGVILG-UHFFFAOYSA-N,50313223,"4-Hydroxy-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid(3',4'-dimethyl-biphenyl-4-yl)-amide::CHEMBL1086884",Prostaglandin E synthase,Homo sapiens,<26
50168722,CN1C(N)=N[C@](C1=O)(c1ccc(OC(F)F)cc1)c1cccc(c1)C#CCCF,"InChI=1S/C21H18F3N3O2/c1-27-18(28)21(26-20(27)25,15-8-10-17(11-9-15)29-19(23)24)16-7-4-6-14(13-16)5-2-3-12-22/h4,6-11,13,19H,3,12H2,1H3,(H2,25,26)/t21-/m1/s1",ONIZYHRXWWCZPM-OAQYLSRUSA-N,50329547,(R)-2-amino-4-(4-(difluoromethoxy)phenyl)-4-(3-(4-fluorobut-1-ynyl)phenyl)-1-methyl-1H-imidazol-5(4H)-one::CHEMBL1271141,Beta-secretase 1,Homo sapiens, 10
51347652,C[C@]1(CCC(F)(F)C(N)=N1)c1cc(NC(=O)c2cnc(OCF)cn2)ccc1F,"InChI=1S/C18H17F4N5O2/c1-17(4-5-18(21,22)16(23)27-17)11-6-10(2-3-12(11)20)26-15(28)13-7-25-14(8-24-13)29-9-19/h2-3,6-8H,4-5,9H2,1H3,(H2,23,27)(H,26,28)/t17-/m0/s1",HMMWZIDNPYYZHM-KRWDZBQOSA-N,50545174,CHEMBL4637181,Cytochrome P450 2D6,, 1000
208466,CSc1ccc(\C=C\c2ccc3cccc(O)c3n2)cc1,"InChI=1S/C18H15NOS/c1-21-16-11-6-13(7-12-16)5-9-15-10-8-14-3-2-4-17(20)18(14)19-15/h2-12,20H,1H3/b9-5+",ZTZFBDBMJQSZBB-WEVVVXLNSA-N,49979,2-[(E)-2-(4-methylsulfanylphenyl)ethenyl]quinolin-8-ol::2-[(E)-2-[4-(methylthio)phenyl]ethenyl]-8-quinolinol::2-[(E)-2-[4-(methylthio)phenyl]vinyl]quinolin-8-ol::MLS000760781::SMR000370890::cid_5731689,Tumor necrosis factor receptor superfamily member 10B,,
121634,CC1CCN(CC1)c1nc(C)nc2sc(C(=O)Nc3cc(F)ccc3C)c(C)c12,"InChI=1S/C22H25FN4OS/c1-12-7-9-27(10-8-12)20-18-14(3)19(29-22(18)25-15(4)24-20)21(28)26-17-11-16(23)6-5-13(17)2/h5-6,11-12H,7-10H2,1-4H3,(H,26,28)",MRWFWRKWPIFMJW-UHFFFAOYSA-N,59528,"MLS000682667::N-(5-fluoranyl-2-methyl-phenyl)-2,5-dimethyl-4-(4-methylpiperidin-1-yl)thieno[2,3-d]pyrimidine-6-carboxamide::N-(5-fluoro-2-methyl-phenyl)-2,5-dimethyl-4-(4-methylpiperidino)thieno[2,3-d]pyrimidine-6-carboxamide::N-(5-fluoro-2-methylphenyl)-2,5-dimethyl-4-(4-methyl-1-piperidinyl)-6-thieno[2,3-d]pyrimidinecarboxamide::N-(5-fluoro-2-methylphenyl)-2,5-dimethyl-4-(4-methylpiperidin-1-yl)thieno[2,3-d]pyrimidine-6-carboxamide::SMR000312024::cid_4137230",Tumor necrosis factor,Homo sapiens, 20000
51334795,CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12,"InChI=1S/C18H21IN6O2S/c1-10(2)21-4-3-5-25-17-15(16(20)22-8-23-17)24-18(25)28-14-7-13-12(6-11(14)19)26-9-27-13/h6-8,10,21H,3-5,9H2,1-2H3,(H2,20,22,23)",SUPVGFZUWFMATN-UHFFFAOYSA-N,50180302,"8-(6-iodo-benzo[1,3]dioxol-5-ylsulfanyl)-9-(3-isopropylamino-propyl)adenine::8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9-(3-(isopropylamino)propyl)-9H-purin-6-amine::8-[(6-IODO-1,3-BENZODIOXOL-5-YL)THIO]-9-[3-(ISOPROPYLAMINO)PROPYL]-9H-PURIN-6-AMINE::CHEMBL200102::US10336757, Compound PU-H71::US10676476, Example 9",Endoplasmin,, 301
51063480,CCOc1cc2c(n[nH]c2cc1-c1cnn(CC(C)C)c1)-c1cccc(c1)S(N)(=O)=O,"InChI=1S/C22H25N5O3S/c1-4-30-21-10-19-20(9-18(21)16-11-24-27(13-16)12-14(2)3)25-26-22(19)15-6-5-7-17(8-15)31(23,28)29/h5-11,13-14H,4,12H2,1-3H3,(H,25,26)(H2,23,28,29)",DCQJOTPFAGUJNC-UHFFFAOYSA-N,50433905,CHEMBL2380584,Dual specificity protein kinase TTK,Homo sapiens, 119
515173,CC(NC(=O)c1c(N)nn2cccnc12)c1cc(Cl)c2cncn2c1N1CCOCC1,"InChI=1S/C20H21ClN8O2/c1-12(25-19(30)16-17(22)26-29-4-2-3-24-18(16)29)13-9-14(21)15-10-23-11-28(15)20(13)27-5-7-31-8-6-27/h2-4,9-12H,5-8H2,1H3,(H2,22,26)(H,25,30)",XOYXKQWCTZWZQW-UHFFFAOYSA-N,272744,"2-Amino-N-[1-(8-chloro-5-morpholin-4- ylimidazo[1,5-a]pyridin-6-yl)ethyl]pyrazolo[1,5- a]pyrimidine-3-carboxamide trifluoroacetate salt (racemic mixture prepared)::US10065963, Example 145","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform",Homo sapiens,<100
50032593,Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1,"InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1",AHOUBRCZNHFOSL-YOEHRIQHSA-N,22416,"(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine::(3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine::CHEMBL490::PAROXETINE::US09969700, Paroxetine::US9944618, Compound ID No. 182::[3H]Paroxetine",Sodium-dependent dopamine transporter,Mus musculus,
724061,CN(C1CCN(C)CC1)C(=O)c1ccc(Nc2nc3c(cccn3n2)N2CCC(C)(CC2)NC(C)=O)cc1,"InChI=1S/C28H38N8O2/c1-20(37)31-28(2)13-18-35(19-14-28)24-6-5-15-36-25(24)30-27(32-36)29-22-9-7-21(8-10-22)26(38)34(4)23-11-16-33(3)17-12-23/h5-10,15,23H,11-14,16-19H2,1-4H3,(H,29,32)(H,31,37)",CINFXIQWPMFKMW-UHFFFAOYSA-N,366663,"4-[[8-(4-acetamido-4- methyl-1-piperidyl)- [1,2,4]triazolo[1,5- a]pyridin-2-yl]amino]- N-methyl-N-(1- methyl-4- piperidyl)benzamide::US9873709, Example 1-260",Tyrosine-protein kinase JAK2,Homo sapiens,
50165621,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,"InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1",UIARLYUEJFELEN-LROUJFHJSA-N,50308060,"16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8(13),9,11,20(25),21,23-nonaen-3-one::CEP-701::CHEMBL603469::US11370779, Compound CEP-701","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Homo sapiens,
50861837,CC(C)[C@H](NC(=O)c1ccc(cc1)C(=O)NS(=O)(=O)c1ccc(Cl)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)c1nc2ccccc2o1,"InChI=1S/C36H38ClN5O8S/c1-20(2)29(31(43)35-38-26-8-5-6-10-28(26)50-35)39-34(46)27-9-7-19-42(27)36(47)30(21(3)4)40-32(44)22-11-13-23(14-12-22)33(45)41-51(48,49)25-17-15-24(37)16-18-25/h5-6,8,10-18,20-21,27,29-30H,7,9,19H2,1-4H3,(H,39,46)(H,40,44)(H,41,45)/t27-,29-,30-/m0/s1",AUBRXLUUCXRHAM-BKHJTQGXSA-N,50031209,(S)-1-{(S)-2-[4-(4-Chloro-benzenesulfonylaminocarbonyl)-benzoylamino]-3-methyl-butyryl}-pyrrolidine-2-carboxylic acid [(S)-1-(benzooxazole-2-carbonyl)-2-methyl-propyl]-amide::CHEMBL127714::N1-((S)-1-((S)-2-(((S)-1-(benzo[d]oxazol-2-yl)-3-methyl-1-oxobutan-2-yl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)-N4-(4-chlorophenylsulfonyl)terephthalamide,Neutrophil elastase,Homo sapiens,
51090691,CCOc1cc(ccc1OC(C)C)C(Nc1ccc2c(N)nccc2c1)C(=O)NCc1cccc(c1)N(C)C(C)=O,"InChI=1S/C32H37N5O4/c1-6-40-29-18-24(10-13-28(29)41-20(2)3)30(36-25-11-12-27-23(17-25)14-15-34-31(27)33)32(39)35-19-22-8-7-9-26(16-22)37(5)21(4)38/h7-18,20,30,36H,6,19H2,1-5H3,(H2,33,34)(H,35,39)",LCUIJLFLRNXHCD-UHFFFAOYSA-N,50446796,CHEMBL3114839,Coagulation factor XI,Homo sapiens,
50304979,CC(C)C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN1CCC=CC1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](C)N)[C@H](C)O)[C@H](C)O)[C@H](C)O)C(=O)N[C@@H](C)C(O)=O,"InChI=1S/C99H178N36O28/c1-51(2)47-68(89(155)119-55(6)96(162)163)129-86(152)66(33-35-71(104)140)125-81(147)60(26-12-16-38-101)123-84(150)64(30-22-41-113-98(108)109)127-91(157)70-32-24-46-135(70)95(161)54(5)118-80(146)59(25-11-15-37-100)120-74(143)49-115-73(142)48-116-92(158)75(56(7)137)131-90(156)69(50-136)130-85(151)61(28-14-20-45-134-43-18-10-19-44-134)124-83(149)63(29-21-40-112-97(106)107)122-79(145)53(4)117-93(159)76(57(8)138)132-88(154)67(34-36-72(105)141)126-82(148)62(27-13-17-39-102)128-94(160)77(58(9)139)133-87(153)65(121-78(144)52(3)103)31-23-42-114-99(110)111/h10,18,51-70,75-77,136-139H,11-17,19-50,100-103H2,1-9H3,(H2,104,140)(H2,105,141)(H,115,142)(H,116,158)(H,117,159)(H,118,146)(H,119,155)(H,120,143)(H,121,144)(H,122,145)(H,123,150)(H,124,149)(H,125,147)(H,126,148)(H,127,157)(H,128,160)(H,129,152)(H,130,151)(H,131,156)(H,132,154)(H,133,153)(H,162,163)(H4,106,107,112)(H4,108,109,113)(H4,110,111,114)/t52-,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68+,69+,70+,75+,76+,77+/m1/s1",PEBZIKCSRGTWSC-SDODRVGOSA-N,50067548,CHEMBL3402051,Amine oxidase [flavin-containing] B,,>100000
365012,ONC(=O)CCCCCCC(=O)Nc1ccccc1,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,19149,"CHEMBL98::N-hydroxy-N'-phenyloctanediamide::SAHA::US10011611, SAHA::US10188756, Compound SAHA::US11207431, SAHA::US11505523, Compound SAHA::US9115116, SAHA::US9353061, SAHA::US9428447, SAHA::US9695181, Vorinostat::Vorinostat::Zolinza::cid_5311::suberoylanilide hydroxamic acid",Histone deacetylase 1/11/4/6/8,Homo sapiens, 131
93899,CC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(c1)-c1cnc2ccccc2n1,"InChI=1S/C23H18N4O2/c1-15(28)25-18-11-9-16(10-12-18)23(29)26-19-6-4-5-17(13-19)22-14-24-20-7-2-3-8-21(20)27-22/h2-14H,1H3,(H,25,28)(H,26,29)",MVAPFNCEPCNHIN-UHFFFAOYSA-N,48787,4-(acetylamino)-N-[3-(2-quinoxalinyl)phenyl]benzamide::4-acetamido-N-(3-quinoxalin-2-ylphenyl)benzamide::4-acetamido-N-[3-(2-quinoxalinyl)phenyl]benzamide::MLS000672627::SMR000295483::cid_2221462,Induced myeloid leukemia cell differentiation protein Mcl-1,Homo sapiens, 25477.02018
583656,CC(C)[C@@H]1CN(CCN1c1nc2ccccc2s1)c1ccc(F)c(c1)S(C)(=O)=O,"InChI=1S/C21H24FN3O2S2/c1-14(2)18-13-24(15-8-9-16(22)20(12-15)29(3,26)27)10-11-25(18)21-23-17-6-4-5-7-19(17)28-21/h4-9,12,14,18H,10-11,13H2,1-3H3/t18-/m0/s1",RGPYRFIDCPYCJL-SFHVURJKSA-N,304380,"(R)-2-(4-(4-fluoro-3-(methylsulfonyl)phenyl)-2-isopropylpiperazin-1-yl)benzo[d]thiazole::US10144715, Compound 7-56",Oxysterols receptor LXR-alpha,,
50045512,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC(=O)Nc3ccc(F)cc3)ncnc12,"InChI=1S/C19H20FN7O5/c1-2-21-17(30)14-12(28)13(29)18(32-14)27-8-24-11-15(22-7-23-16(11)27)26-19(31)25-10-5-3-9(20)4-6-10/h3-8,12-14,18,28-29H,2H2,1H3,(H,21,30)(H2,22,23,25,26,31)/t12-,13+,14-,18+/m0/s1",CSPMYAVHHPHGTB-MOROJQBDSA-N,50454471,CHEMBL2113635,Adenosine receptor A3,Rattus norvegicus,
1003708,CN(C)C(=O)N1CCCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(nccn12)C(F)(F)F,"InChI=1S/C27H26F3N7O2/c1-35(2)26(39)36-15-6-4-7-19(36)24-34-21(22-23(27(28,29)30)32-14-16-37(22)24)17-9-11-18(12-10-17)25(38)33-20-8-3-5-13-31-20/h3,5,8-14,16,19H,4,6-7,15H2,1-2H3,(H,31,33,38)/t19-/m0/s1",FVQPPVMSCHMIKP-IBGZPJMESA-N,484416,"(S)-N,N-dimethyl-2- (1-(4-(pyridin-2- ylcarbamoyl)phenyl)-8- (trifluoromethyl)imidazo [1,5-a]pyrazin-3-yl) piperidine-1-carboxamide::US10933063, Compound 215",Tyrosine-protein kinase BTK,Homo sapiens,>100000
339780,CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@@H]4CCOC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1,"InChI=1S/C43H46ClN7O7S/c1-43(2)14-11-30(37(24-43)28-3-5-31(44)6-4-28)26-49-16-18-50(19-17-49)33-7-9-36(40(22-33)58-34-21-29-12-15-45-41(29)46-25-34)42(52)48-59(55,56)35-8-10-38(39(23-35)51(53)54)47-32-13-20-57-27-32/h3-10,12,15,21-23,25,32,47H,11,13-14,16-20,24,26-27H2,1-2H3,(H,45,46)(H,48,52)/t32-/m1/s1",LTQSONOIEBRYPY-JGCGQSQUSA-N,189669,"US10213433, Compound 238::US11369599, Compound 238::US9174982, 238",Apoptosis regulator Bcl-2,,
1110286,CC(C)CN1CCC(F)(CC1)C(=O)Nc1cc2cc(ccc2cn1)-n1nccn1,"InChI=1S/C21H25FN6O/c1-15(2)14-27-9-5-21(22,6-10-27)20(29)26-19-12-17-11-18(28-24-7-8-25-28)4-3-16(17)13-23-19/h3-4,7-8,11-13,15H,5-6,9-10,14H2,1-2H3,(H,23,26,29)",YNGWPBOHKOIIKD-UHFFFAOYSA-N,385363,"US10287267, Compound 1073::US10508099, Compound 1073::US10556885, Compound 1073::US11174244, Compound 1073",Dual specificity tyrosine-phosphorylation-regulated kinase 1A,Homo sapiens,
51446165,Cc1c(Nc2nc3ccccc3s2)cc(Cl)cc1OC1CCN(CC1)C(=O)CC(C(F)(F)F)C(F)(F)F,"InChI=1S/C24H22ClF6N3O2S/c1-13-17(33-22-32-16-4-2-3-5-19(16)37-22)10-14(25)11-18(13)36-15-6-8-34(9-7-15)21(35)12-20(23(26,27)28)24(29,30)31/h2-5,10-11,15,20H,6-9,12H2,1H3,(H,32,33)",IEMKKJCNFFIONU-UHFFFAOYSA-N,50584280,CHEMBL5082345,"Dihydroorotate dehydrogenase (quinone), mitochondrial",Homo sapiens, 794
51106292,CCS(=O)(=O)N1CCN(CC1)c1nc(nc(n1)-n1c(nc2c(OC)cccc12)C(F)F)N1CCOCC1,"InChI=1S/C22H28F2N8O4S/c1-3-37(33,34)31-9-7-29(8-10-31)20-26-21(30-11-13-36-14-12-30)28-22(27-20)32-15-5-4-6-16(35-2)17(15)25-19(32)18(23)24/h4-6,18H,3,7-14H2,1-2H3",GFAPOBFNHMOSKM-UHFFFAOYSA-N,50451233,CHEMBL4217752,"Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Homo sapiens,>1000
51242229,Clc1ccc(cc1)-c1ccc(o1)C(=O)N1CCN(Cc2ccc(OC3CCNCC3)c(Cl)c2)CC1,"InChI=1S/C27H29Cl2N3O3/c28-21-4-2-20(3-5-21)24-7-8-26(35-24)27(33)32-15-13-31(14-16-32)18-19-1-6-25(23(29)17-19)34-22-9-11-30-12-10-22/h1-8,17,22,30H,9-16,18H2",ILCKGRVWMQNEQC-UHFFFAOYSA-N,50508354,CHEMBL4524693,Urotensin-2 receptor,Homo sapiens, 370
50507945,Cc1cc(-c2cncs2)c2cccc(OCc3c(Cl)cncc3Cl)c2n1,"InChI=1S/C19H13Cl2N3OS/c1-11-5-13(18-8-23-10-26-18)12-3-2-4-17(19(12)24-11)25-9-14-15(20)6-22-7-16(14)21/h2-8,10H,9H2,1H3",BTMKNAFNOUAPOO-UHFFFAOYSA-N,50293873,"5-(8-((3,5-dichloropyridin-4-yl)methoxy)-2-methylquinolin-4-yl)thiazole::CHEMBL550142",B2 bradykinin receptor,Homo sapiens, 135
50273409,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,"InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1",ZEUITGRIYCTCEM-KRWDZBQOSA-N,84745,"CAS_136434-34-9::DULOXETINE::LY-248686::LY248686::USRE49340, Rank 5",Cytochrome P450 2C19,Homo sapiens, 4100
50792590,Cc1ccc(cc1)C1CCN(Cc2ccc3OCC(=O)Nc3c2)CC1,"InChI=1S/C21H24N2O2/c1-15-2-5-17(6-3-15)18-8-10-23(11-9-18)13-16-4-7-20-19(12-16)22-21(24)14-25-20/h2-7,12,18H,8-11,13-14H2,1H3,(H,22,24)",BHPFUCZWSRDHAY-UHFFFAOYSA-N,50083350,"6-(4-p-Tolyl-piperidin-1-ylmethyl)-4H-benzo[1,4]oxazin-3-one::CHEMBL346398",D(4) dopamine receptor,Homo sapiens,
50817909,C(Oc1ccc(CN2CCCCC2)cc1)c1ccc(CN2CCCCC2)cc1,"InChI=1S/C25H34N2O/c1-3-15-26(16-4-1)19-22-7-9-24(10-8-22)21-28-25-13-11-23(12-14-25)20-27-17-5-2-6-18-27/h7-14H,1-6,15-21H2",IBFTUIVACGOPQU-UHFFFAOYSA-N,50126888,1-[4-(4-Piperidin-1-ylmethyl-benzyloxy)-benzyl]-piperazine; compound with oxalic acid::CHEMBL193978::CHEMBL416053,Histamine H3 receptor,Homo sapiens,
51425652,OC(=O)CCc1cc(-c2cc(cc(c2)C(F)(F)F)C(F)(F)F)n(n1)-c1ccc(Cl)cc1,"InChI=1S/C20H13ClF6N2O2/c21-14-1-4-16(5-2-14)29-17(10-15(28-29)3-6-18(30)31)11-7-12(19(22,23)24)9-13(8-11)20(25,26)27/h1-2,4-5,7-10H,3,6H2,(H,30,31)",BAANFZMNIGINLC-UHFFFAOYSA-N,50575880,CHEMBL4855407,Retinoic acid receptor RXR-alpha,Homo sapiens,
1170204,Cc1cc(Oc2ccccc2)cc2n(Cc3nc[nH]n3)c(CO)cc12,"InChI=1S/C19H18N4O2/c1-13-7-16(25-15-5-3-2-4-6-15)9-18-17(13)8-14(11-24)23(18)10-19-20-12-21-22-19/h2-9,12,24H,10-11H2,1H3,(H,20,21,22)",LJTYNXHTGIZXIH-UHFFFAOYSA-N,554785,"US11339144, Compound I-234",GTP-binding protein Rheb,Homo sapiens, 550000
50952525,OC(=O)c1ccn[nH]1,"InChI=1S/C4H4N2O2/c7-4(8)3-1-2-5-6-3/h1-2H,(H,5,6)(H,7,8)",KOPFEFZSAMLEHK-UHFFFAOYSA-N,50132132,1H-pyrazole-3-carboxylic acid::CHEMBL128679,Lysine-specific demethylase 4C,,>200000
1036375,COc1ccccc1Nc1ccc2c(c1)nc(CSC1CCOCC1)[nH]c2=O,"InChI=1S/C21H23N3O3S/c1-26-19-5-3-2-4-17(19)22-14-6-7-16-18(12-14)23-20(24-21(16)25)13-28-15-8-10-27-11-9-15/h2-7,12,15,22H,8-11,13H2,1H3,(H,23,24,25)",VKZPJNNPHSITQV-UHFFFAOYSA-N,434162,"US10562891, Example 84::US11008308, Example 84",Protein mono-ADP-ribosyltransferase PARP14,, 5500
1200761,Cc1n[nH]c(C#N)c1C(=O)Nc1ccc2[nH]nc(-c3ccoc3)c2c1,"InChI=1S/C17H12N6O2/c1-9-15(14(7-18)22-20-9)17(24)19-11-2-3-13-12(6-11)16(23-21-13)10-4-5-25-8-10/h2-6,8H,1H3,(H,19,24)(H,20,22)(H,21,23)",PSEMOUGZQJBMEN-UHFFFAOYSA-N,568990,"5-cyano-N-(3-(furan-3-yl)- 1H-indazol-5-yl)-3-methyl-  1H-pyrazole-4-carboxamide::US11427558, Example 137",Leucine-rich repeat serine/threonine-protein kinase 2,Homo sapiens,<100
1225728,Nc1nc(N)c(CC(=O)Nc2ccc(nc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c(=O)[nH]1,,,581289,"(2S)-2-({5-[2-(2,4-diamino-6-oxo- 1,6-dihydropyrimidin-5- yl)acetamido]pyridin-2- yl}formamido)pentanedioic acid hydrochloride::US11504368, Example 7","Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial",, 154
50192372,COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-",XZXHXSATPCNXJR-ZIADKAODSA-N,50026612,"BIBF-1120::Nintedanib::US10981896, Compound Nintedanib::US11046672, Nintedanib::US11208381, Nintedanib::Vargatef",Dual specificity protein kinase CLK1,Homo sapiens,
50608303,CC(C)n1nc(c2cc(ccc12)N1CCNCC1)S(=O)(=O)c1cccc2ccccc12,"InChI=1S/C24H26N4O2S/c1-17(2)28-22-11-10-19(27-14-12-25-13-15-27)16-21(22)24(26-28)31(29,30)23-9-5-7-18-6-3-4-8-20(18)23/h3-11,16-17,25H,12-15H2,1-2H3",YKEFFXDXDCCGLC-UHFFFAOYSA-N,50330522,1-isopropyl-3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1H-indazole::CHEMBL1277837,5-hydroxytryptamine receptor 6,Homo sapiens,
50965364,Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N,"InChI=1S/C14H6F2N4O/c15-10-1-2-12(18-7-10)13-19-14(21-20-13)9-3-8(6-17)4-11(16)5-9/h1-5,7H",RBSPCALDSNXWEP-UHFFFAOYSA-N,50395923,CHEMBL2164550,Potassium voltage-gated channel subfamily H member 2,Homo sapiens,>33000
50388901,CC(C)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)N[C@@H](C)C#N,"InChI=1S/C24H28F3N3O3S/c1-15(2)13-21(23(31)29-16(3)14-28)30-22(24(25,26)27)19-7-5-17(6-8-19)18-9-11-20(12-10-18)34(4,32)33/h5-12,15-16,21-22,30H,13H2,1-4H3,(H,29,31)/t16-,21-,22-/m0/s1",KNCKOELQLLGGIP-SSKFGXFMSA-N,50214540,"(S)-4-methyl-2-[(S)-2,2,2-trifluoro-1-(4'-methanesulfonyl-biphenyl-4-yl)-ethylamino]-pentanoic acid ((S)-cyano-methyl-methyl)-amide::CHEMBL250294",Cathepsin K,Homo sapiens, 0.9
213341,CC(=O)NCCCc1ccc(Oc2ccc(OC3CCCC3)cn2)cc1,"InChI=1S/C21H26N2O3/c1-16(24)22-14-4-5-17-8-10-19(11-9-17)26-21-13-12-20(15-23-21)25-18-6-2-3-7-18/h8-13,15,18H,2-7,14H2,1H3,(H,22,24)",ZLKMOUBQZRCJNB-UHFFFAOYSA-N,50332553,"CHEMBL1630707::N-(3-(4-(5-(cyclopentyloxy)pyridin-2-yloxy)phenyl)propyl)acetamide::US8470841, 7",Acetyl-CoA carboxylase 2 [151-2458],, 1.28e+3
59868,Cc1onc(c1C(=O)n1nnc2ccccc12)-c1ccccc1,"InChI=1S/C17H12N4O2/c1-11-15(16(19-23-11)12-7-3-2-4-8-12)17(22)21-14-10-6-5-9-13(14)18-20-21/h2-10H,1H3",XWEWIQCAIBLPHV-UHFFFAOYSA-N,33433,"1-[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]-1H-1,2,3-benzotriazole::1-benzotriazolyl-(5-methyl-3-phenyl-4-isoxazolyl)methanone::MLS000099557::SMR000071313::benzotriazol-1-yl-(5-methyl-3-phenyl-1,2-oxazol-4-yl)methanone::benzotriazol-1-yl-(5-methyl-3-phenyl-isoxazol-4-yl)methanone::cid_1121978",Coagulation factor XII,, 3973.366667
50718632,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]1CCCCN(Cc2ccccc2)C1,"InChI=1S/C25H40N4O2/c1-19(26-2)24(30)28-23(21-13-7-4-8-14-21)25(31)27-22-15-9-10-16-29(18-22)17-20-11-5-3-6-12-20/h3,5-6,11-12,19,21-23,26H,4,7-10,13-18H2,1-2H3,(H,27,31)(H,28,30)/t19-,22-,23-/m0/s1",OHZBEXNQDNVNLI-VJBMBRPKSA-N,50364510,CHEMBL1950732,Baculoviral IAP repeat-containing protein 2,, 270
640436,Cn1cc(cn1)-c1cc(nc2c(F)c(Cc3cnc(nc3)C3CC3)ccc12)C(N)=O,"InChI=1S/C22H19FN6O/c1-29-11-15(10-27-29)17-7-18(21(24)30)28-20-16(17)5-4-14(19(20)23)6-12-8-25-22(26-9-12)13-2-3-13/h4-5,7-11,13H,2-3,6H2,1H3,(H2,24,30)",HPXSKODGNCBYRZ-UHFFFAOYSA-N,213095,"US9278960, 7-33::US9636337, 7-33",Metabotropic glutamate receptor 2,, 36.0
178718,COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34,"InChI=1S/C37H38N2O6/c1-38-13-11-24-18-31(41-4)33-20-27(24)28(38)16-23-7-10-30(40-3)32(17-23)44-26-8-5-22(6-9-26)15-29-35-25(12-14-39(29)2)19-34-36(37(35)45-33)43-21-42-34/h5-10,17-20,28-29H,11-16,21H2,1-4H3/t28-,29-/m0/s1",YVPXVXANRNDGTA-VMPREFPWSA-N,50242977,CHEMBL500862::Cepharanthine::cepharantine,Trypanothione reductase,Crithidia fasciculata, 1.5e+4
1168137,CC(C)Oc1cc(C)c(cn1)-n1c2ccnc3sc(C(=O)N[C@@H]4CCC[C@@H]4N)c([nH]c1=O)c23,,,485591,"N-((1R,2S)-2-Aminocyclopentyl)-5-(*S)-(6-isopropoxy-4- methylpyridin-3-yl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,8- triazaacenaphthylene-2-carboxamide::US10934310, Ex # 428::US11319329, Ex # 428",Tyrosine-protein kinase BTK,Homo sapiens, 214
51048615,CN(C)CCCn1c2-c3ccccc3C(=O)c2c2ccccc2c1=O,"InChI=1S/C21H20N2O2/c1-22(2)12-7-13-23-19-15-9-4-5-10-16(15)20(24)18(19)14-8-3-6-11-17(14)21(23)25/h3-6,8-11H,7,12-13H2,1-2H3",FYGFCQLVSPTQEJ-UHFFFAOYSA-N,50427894,CHEMBL425544,Retinoic acid receptor RXR-alpha,Homo sapiens,
50165828,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1,"InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1",BMGQWWVMWDBQGC-IIFHNQTCSA-N,50326053,CHEMBL608533::PKC-412,Interleukin-1 receptor-associated kinase 1,,
50679611,CN(C)C[C@@H]1CCn2cc(C3=C(C(=O)NC3=O)c3cn(CCO1)c1ccccc31)c1ccccc21,"InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1",ZCBUQCWBWNUWSU-SFHVURJKSA-N,17055,"(18S)-18-[(dimethylamino)methyl]-17-oxa-4,14,21-triazahexacyclo[19.6.1.1^{7,14}.0^{2,6}.0^{8,13}.0^{22,27}]nonacosa-1(28),2(6),7(29),8(13),9,11,22(27),23,25-nonaene-3,5-dione::(9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione::K00587a::LY 333531::LY-333531::LY333531::Ruboxistaurin::cid_153999",Mitogen-activated protein kinase 15,Homo sapiens,
51308350,Nc1ncnc2n([C@@H]3O[C@H](CCCOC(=O)C=C)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)cc3)nc12,"InChI=1S/C22H25ClN6O5/c1-2-15(30)33-9-3-4-14-17(31)18(32)21(34-14)29-20-16(19(24)26-11-27-20)28-22(29)25-10-12-5-7-13(23)8-6-12/h2,5-8,11,14,17-18,21,31-32H,1,3-4,9-10H2,(H,25,28)(H2,24,26,27)/t14-,17-,18-,21-/m1/s1",XOSUZIPWVSJZRF-HAXDFEGKSA-N,50531167,CHEMBL4583945,Heat shock-related 70 kDa protein 2,,
125258,Fc1ccc(NC(=O)CCC(=O)Nc2ccc(F)cc2)cc1,"InChI=1S/C16H14F2N2O2/c17-11-1-5-13(6-2-11)19-15(21)9-10-16(22)20-14-7-3-12(18)4-8-14/h1-8H,9-10H2,(H,19,21)(H,20,22)",NXRDDEZZRFPHAD-UHFFFAOYSA-N,67463,"N,N'-bis(4-fluorophenyl)butanediamide::N,N'-bis(4-fluorophenyl)succinamide::SR-01000483496-2::cid_479979",NADPH oxidase 1,Homo sapiens,>17000
51170827,COc1c(O)c(C(=O)\C=C\Nc2ccncc2)c(OC)c2ccoc12,"InChI=1S/C18H16N2O5/c1-23-16-12-6-10-25-17(12)18(24-2)15(22)14(16)13(21)5-9-20-11-3-7-19-8-4-11/h3-10,22H,1-2H3,(H,19,20)/b9-5+",UZYULOCSCOSJFD-WEVVVXLNSA-N,50480363,CHEMBL449897,Reverse transcriptase,Human immunodeficiency virus 1, 4800
50423660,CC(C)C(=O)Nc1ncc(s1)-c1ccncc1-c1ccccc1Cl,"InChI=1S/C18H16ClN3OS/c1-11(2)17(23)22-18-21-10-16(24-18)13-7-8-20-9-14(13)12-5-3-4-6-15(12)19/h3-11H,1-2H3,(H,21,22,23)",ROPKDJGJHNEEFN-UHFFFAOYSA-N,50124352,CHEMBL3623441,LIM domain kinase 1,Homo sapiens, 800
50690124,Cc1cc(C)nc(NC(=S)N2CCN(CC2)c2ccncc2)c1,"InChI=1S/C17H21N5S/c1-13-11-14(2)19-16(12-13)20-17(23)22-9-7-21(8-10-22)15-3-5-18-6-4-15/h3-6,11-12H,7-10H2,1-2H3,(H,19,20,23)",ITLPIAAGIQAGRA-UHFFFAOYSA-N,195607,"PHGDH-inactive::US11225469, Compound 71",D-3-phosphoglycerate dehydrogenase,,>57000
50099377,[Br-].[Br-].C(CCC[n+]1cc2ccccc2c2ccccc12)CC[n+]1cc2ccccc2c2ccccc12,"InChI=1S/C32H30N2.2BrH/c1(11-21-33-23-25-13-3-5-15-27(25)29-17-7-9-19-31(29)33)2-12-22-34-24-26-14-4-6-16-28(26)30-18-8-10-20-32(30)34;;/h3-10,13-20,23-24H,1-2,11-12,21-22H2;2*1H/q+2;;/p-2",GENORUDGXFJMHT-UHFFFAOYSA-L,50016849,CHEMBL3276410,Carboxylic ester hydrolase,,
51451400,COc1ccc(cc1)N1CCN(CCn2c3nc(N)nc(-c4ccc(C)o4)c3ncc2=O)[C@H](C)C1,"InChI=1S/C25H29N7O3/c1-16-15-31(18-5-7-19(34-3)8-6-18)11-10-30(16)12-13-32-21(33)14-27-23-22(20-9-4-17(2)35-20)28-25(26)29-24(23)32/h4-9,14,16H,10-13,15H2,1-3H3,(H2,26,28,29)/t16-/m1/s1",LKIIXSUVDSDCMG-MRXNPFEDSA-N,50585998,CHEMBL5091663,Adenosine receptor A2a,Homo sapiens, 296
51267339,CC(C)CN1CCc2c(ccc3[nH]ccc23)C1c1ccc(\C=C\C(O)=O)cc1,"InChI=1S/C24H26N2O2/c1-16(2)15-26-14-12-19-20-11-13-25-22(20)9-8-21(19)24(26)18-6-3-17(4-7-18)5-10-23(27)28/h3-11,13,16,24-25H,12,14-15H2,1-2H3,(H,27,28)/b10-5+",HRLHOAPGBLHTAI-BJMVGYQFSA-N,50517553,CHEMBL4451617,Estrogen receptor,, 316
51057031,CC(=O)NCCN1CCN(CC1)c1ncnc2cc(sc12)C(N)=O,"InChI=1S/C15H20N6O2S/c1-10(22)17-2-3-20-4-6-21(7-5-20)15-13-11(18-9-19-15)8-12(24-13)14(16)23/h8-9H,2-7H2,1H3,(H2,16,23)(H,17,22)",CYKFBJNULRRZFT-UHFFFAOYSA-N,50431108,CHEMBL2332051,"NAD-dependent protein deacetylase sirtuin-3, mitochondrial",, 770
51383362,Oc1cccc2ccc(nc12)C1SCC(=O)N1c1cccc(F)c1,"InChI=1S/C18H13FN2O2S/c19-12-4-2-5-13(9-12)21-16(23)10-24-18(21)14-8-7-11-3-1-6-15(22)17(11)20-14/h1-9,18,22H,10H2",MKNALTUFJWJGRJ-UHFFFAOYSA-N,50558959,CHEMBL4740594,Methionine aminopeptidase 1,Homo sapiens, 8900
196079,Cc1cccc(C)c1NC(=O)c1sccc1SCc1cccc(c1)C(F)(F)F,"InChI=1S/C21H18F3NOS2/c1-13-5-3-6-14(2)18(13)25-20(26)19-17(9-10-27-19)28-12-15-7-4-8-16(11-15)21(22,23)24/h3-11H,12H2,1-2H3,(H,25,26)",UMCWPYGKZKECIB-UHFFFAOYSA-N,89999,"MLS000325609::N-(2,6-dimethylphenyl)-3-[[3-(trifluoromethyl)benzyl]thio]thiophene-2-carboxamide::N-(2,6-dimethylphenyl)-3-[[3-(trifluoromethyl)phenyl]methylsulfanyl]thiophene-2-carboxamide::N-(2,6-dimethylphenyl)-3-[[3-(trifluoromethyl)phenyl]methylthio]-2-thiophenecarboxamide::N-(2,6-dimethylphenyl)-3-{[3-(trifluoromethyl)benzyl]sulfanyl}-2-thiophenecarboxamide::SMR000169988::cid_2765041",Corticotropin-releasing factor-binding protein,Homo sapiens,
625416,CC(NC(=O)c1cc(OC[C@H]2CCOC2)cc(c1)-c1ncc(C)s1)c1ncc(Cl)cc1F,"InChI=1S/C23H23ClFN3O3S/c1-13-9-27-23(32-13)17-5-16(6-19(7-17)31-12-15-3-4-30-11-15)22(29)28-14(2)21-20(25)8-18(24)10-26-21/h5-10,14-15H,3-4,11-12H2,1-2H3,(H,28,29)/t14?,15-/m0/s1",NHGFOVVSFOISFI-LOACHALJSA-N,319898,"N-[1-(5- Chloro-3- fluoropyridin- 2-yl)ethyl]-3- (5-methyL- 1,3-thiazol-2- yl)-5-[(3S)- tetrahydrofuran- 3-ylmethoxy] benzamide::US10174016, Example 65::US10202369, Example 65::US10472354, Example 65",P2X purinoceptor 3,Homo sapiens, 3.00
50471114,COc1ccccc1CN[C@H]1C2CCN(CC2)[C@H]1c1ccccc1,"InChI=1S/C21H26N2O/c1-24-19-10-6-5-9-18(19)15-22-20-16-11-13-23(14-12-16)21(20)17-7-3-2-4-8-17/h2-10,16,20-22H,11-15H2,1H3/t20-,21-/m0/s1",JUQHUETWINQXRD-SFTDATJTSA-N,50284131,"(2-Methoxy-benzyl)-((2S,3S)-2-phenyl-1-aza-bicyclo[2.2.2]oct-3-yl)-amine::CHEMBL166816",Substance-P receptor,Homo sapiens, 140
868677,CCC(C)c1ccc(cc1)N(C(C(=O)NC1CCCC1)c1cccnc1)C(=O)c1ccco1,"InChI=1S/C27H31N3O3/c1-3-19(2)20-12-14-23(15-13-20)30(27(32)24-11-7-17-33-24)25(21-8-6-16-28-18-21)26(31)29-22-9-4-5-10-22/h6-8,11-19,22,25H,3-5,9-10H2,1-2H3,(H,29,31)",KMPOAXYUGWTIIV-UHFFFAOYSA-N,47919,"Furan-2-carboxylic acid (4-sec-butyl-phenyl)-(cyclopentylcarbamoyl-pyridin-3-yl-methyl)-amide::MLS001222477::N-(4-butan-2-ylphenyl)-N-[2-(cyclopentylamino)-2-oxidanylidene-1-pyridin-3-yl-ethyl]furan-2-carboxamide::N-(4-butan-2-ylphenyl)-N-[2-(cyclopentylamino)-2-oxo-1-(3-pyridinyl)ethyl]-2-furancarboxamide::N-(4-butan-2-ylphenyl)-N-[2-(cyclopentylamino)-2-oxo-1-pyridin-3-ylethyl]furan-2-carboxamide::N-[2-(cyclopentylamino)-2-keto-1-(3-pyridyl)ethyl]-N-(4-sec-butylphenyl)-2-furamide::SMR000600355::acs.jmedchem.1c00409_ST.300::cid_3196508::med.21724, Compound 122",Replicase polyprotein 1a,, 34000
50983656,C[C@H](NC(=O)[C@@H](S)Cc1ccccc1)C(=O)N1CCC[C@H]1C(O)=O,"InChI=1S/C17H22N2O4S/c1-11(16(21)19-9-5-8-13(19)17(22)23)18-15(20)14(24)10-12-6-3-2-4-7-12/h2-4,6-7,11,13-14,24H,5,8-10H2,1H3,(H,18,20)(H,22,23)/t11-,13-,14-/m0/s1",YSFYVNRABGRTNY-UBHSHLNASA-N,50048514,(S)-1-[(S)-2-((S)-2-Mercapto-3-phenyl-propionylamino)-propionyl]-pyrrolidine-2-carboxylic acid::CHEMBL287896,Neprilysin,, 400
51057231,CCCCCCCC(=O)O[C@@H]1[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]3O[C@H]4N=C(C)O[C@@]4(C)[C@@]3(O)[C@H](C[C@](C)(OC(C)=O)[C@@H]12)OC(=O)CCC,"InChI=1S/C36H53NO11/c1-10-13-14-15-16-18-26(40)44-30-28-27(21(5)29(30)45-32(41)20(4)12-3)31-36(42,35(9)33(46-31)37-22(6)47-35)24(43-25(39)17-11-2)19-34(28,8)48-23(7)38/h12,24,28-31,33,42H,10-11,13-19H2,1-9H3/b20-12-/t24-,28+,29-,30-,31-,33+,34-,35+,36+/m0/s1",SQMJSIKUOUSKGN-HQNXNICLSA-N,50431169,CHEMBL2332551,Sarcoplasmic/endoplasmic reticulum calcium ATPase 1,Oryctolagus cuniculus,
50977781,CN(CC1=CC[C@H]2C[C@@H]1C2(C)C)Cc1ccc(cc1)-c1cccc(c1)C(F)(F)F,"InChI=1S/C25H28F3N/c1-24(2)21-12-11-20(23(24)14-21)16-29(3)15-17-7-9-18(10-8-17)19-5-4-6-22(13-19)25(26,27)28/h4-11,13,21,23H,12,14-16H2,1-3H3/t21-,23-/m0/s1",JQSSOYRLBSUNKQ-GMAHTHKFSA-N,50400945,CHEMBL2205084,C-X-C chemokine receptor type 3,,
958910,CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1,"InChI=1S/C31H28ClN7O2/c1-39(2)16-6-11-28(40)35-21-14-12-20(13-15-21)30(41)36-22-7-5-8-23(17-22)37-31-34-19-26(32)29(38-31)25-18-33-27-10-4-3-9-24(25)27/h3-15,17-19,33H,16H2,1-2H3,(H,35,40)(H,36,41)(H,34,37,38)/b11-6+",OBJNFLYHUXWUPF-IZZDOVSWSA-N,50110178,"CHEMBL3603847::US10787436, Compound I-23",Cyclin-dependent kinase 5 activator 1 [99-307],, 550
889140,Cn1c2ncc(cc2n(Cc2cncc(Cl)c2)c1=O)-c1cccc(F)c1F,"InChI=1S/C19H13ClF2N4O/c1-25-18-16(26(19(25)27)10-11-5-13(20)9-23-7-11)6-12(8-24-18)14-3-2-4-15(21)17(14)22/h2-9H,10H2,1H3",IFFCQSBYKDRCPL-UHFFFAOYSA-N,437039,"1-[(5-Chloro-3-pyridyl)methyl]-6-(2,3-difluorophenyl)-3-methyl-imidazo[4,5- b]pyridin-2-one::US10617676, Example 375::US11207298, Example 375","Glutamate receptor ionotropic, NMDA 2B",Homo sapiens, 1510
51028244,CC(C)(C)c1nnc2ccc(Sc3ccc(F)cc3F)cn12,"InChI=1S/C16H15F2N3S/c1-16(2,3)15-20-19-14-7-5-11(9-21(14)15)22-13-6-4-10(17)8-12(13)18/h4-9H,1-3H3",QBRGSYLNUUOUBB-UHFFFAOYSA-N,50305692,"3-tert-butyl-6-(2,4-difluorophenylthio)-[1,2,4]triazolo[4,3-a]pyridine hydrochloride::CHEMBL1198626::CHEMBL609275",Mitogen-activated protein kinase 13,Homo sapiens, 62
51230878,NS(=O)(=O)c1cc(C(=O)N2CCOCC2)c(Sc2ccccc2)cc1Cl,"InChI=1S/C17H17ClN2O4S2/c18-14-11-15(25-12-4-2-1-3-5-12)13(10-16(14)26(19,22)23)17(21)20-6-8-24-9-7-20/h1-5,10-11H,6-9H2,(H2,19,22,23)",KCHKZYKQHJUTFV-UHFFFAOYSA-N,50504945,CHEMBL4579206,Carbonic anhydrase 6,,
50577301,OC(COc1ccccc1)CN1CCC(CC1)c1ccc(Cc2ccc(F)cc2)cc1,"InChI=1S/C27H30FNO2/c28-25-12-8-22(9-13-25)18-21-6-10-23(11-7-21)24-14-16-29(17-15-24)19-26(30)20-31-27-4-2-1-3-5-27/h1-13,24,26,30H,14-20H2",VWQGDNWLMBJUHU-UHFFFAOYSA-N,50082322,1-{4-[4-(4-Fluoro-benzyl)-phenyl]-piperidin-1-yl}-3-phenoxy-propan-2-ol; hydrochloride::CHEMBL543622,Sodium channel protein type 1/2/3 subunit alpha,Rattus norvegicus, 360
50694593,CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12,"InChI=1S/C27H29FN8O3/c1-29-26(38)23-17(28)6-5-7-18(23)31-25-16-8-10-30-24(16)33-27(34-25)32-19-13-20-15(12-21(19)39-4)9-11-36(20)22(37)14-35(2)3/h5-8,10,12-13H,9,11,14H2,1-4H3,(H,29,38)(H3,30,31,32,33,34)",HZTYDQRUAWIZRE-UHFFFAOYSA-N,27817,"2-{[2-({1-[2-(dimethylamino)acetyl]-5-methoxy-2,3-dihydro-1H-indol-6-yl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-6-fluoro-N-methylbenzamide::pyrrolo[2,3-d]pyrimidine deriv., 40",Mitogen-activated protein kinase 10,Homo sapiens,
373009,CN1C(C(C(C)=O)=C(C)N(C1=O)c1cccc(c1)C(F)(F)F)c1ccc(cc1C(=O)N1CCC1)C#N,"InChI=1S/C26H23F3N4O3/c1-15-22(16(2)34)23(20-9-8-17(14-30)12-21(20)24(35)32-10-5-11-32)31(3)25(36)33(15)19-7-4-6-18(13-19)26(27,28)29/h4,6-9,12-13,23H,5,10-11H2,1-3H3",WMPDWROYDWUHHT-UHFFFAOYSA-N,211465,"US9290457, Example 1.7",Neutrophil elastase,Homo sapiens,<1
50193719,CCN(C1CCN(CCC(Cn2c(O)c(Cc3c[nH]c4ccccc34)[nH]c2=O)c2cccc(Cl)c2)CC1)C(=O)OCc1ccccc1,"InChI=1S/C37H42ClN5O4/c1-2-42(37(46)47-25-26-9-4-3-5-10-26)31-16-19-41(20-17-31)18-15-28(27-11-8-12-30(38)21-27)24-43-35(44)34(40-36(43)45)22-29-23-39-33-14-7-6-13-32(29)33/h3-14,21,23,28,31,39,44H,2,15-20,22,24-25H2,1H3,(H,40,45)",GPWGUUTTZSMWMP-UHFFFAOYSA-N,50106932,"(1-{3-(3-Chloro-phenyl)-4-[(R)-4-(1H-indol-3-ylmethyl)-2,5-dioxo-imidazolidin-1-yl]-butyl}-piperidin-4-yl)-ethyl-carbamic acid benzyl ester::CHEMBL105975",C-C chemokine receptor type 1,Homo sapiens,>1000
50738436,CN(C(=O)Cc1ccc(cc1)-c1ccccc1)c1nc(C)c(s1)S(N)(=O)=O,"InChI=1S/C19H19N3O3S2/c1-13-18(27(20,24)25)26-19(21-13)22(2)17(23)12-14-8-10-16(11-9-14)15-6-4-3-5-7-15/h3-11H,12H2,1-2H3,(H2,20,24,25)",WPXGIUPWYVACRH-UHFFFAOYSA-N,50237365,CHEMBL4090611,Carbonic anhydrase 9,Homo sapiens,
584053,CC(C)c1ccc(CN2CCN(CC2c2ccccc2)c2cccc(c2)S(C)(=O)=O)cn1,"InChI=1S/C26H31N3O2S/c1-20(2)25-13-12-21(17-27-25)18-29-15-14-28(19-26(29)22-8-5-4-6-9-22)23-10-7-11-24(16-23)32(3,30)31/h4-13,16-17,20,26H,14-15,18-19H2,1-3H3",CJVVVQGRSXIWNZ-UHFFFAOYSA-N,304576,"1-((6-isopropylpyridin-3-yl)methyl)-4-(3-(methylsulfonyl)phenyl)-2-phenylpiperazine::US10144715, Compound 46-42",Oxysterols receptor LXR-beta,,
50282490,CCN(CC)c1ccc(NC(=O)c2c(CCN3CCCCC3=O)onc2-c2c(Cl)cccc2Cl)cc1,"InChI=1S/C27H30Cl2N4O3/c1-3-32(4-2)19-13-11-18(12-14-19)30-27(35)25-22(15-17-33-16-6-5-10-23(33)34)36-31-26(25)24-20(28)8-7-9-21(24)29/h7-9,11-14H,3-6,10,15-17H2,1-2H3,(H,30,35)",RVQAINUYUARQMA-UHFFFAOYSA-N,50153547,"3-(2,6-Dichloro-phenyl)-5-[2-(2-oxo-piperidin-1-yl)-ethyl]-isoxazole-4-carboxylic acid (4-diethylamino-phenyl)-amide::CHEMBL363995",Growth hormone secretagogue receptor type 1,Homo sapiens, 9
51036733,Cc1ccnc(NCC2CCN(CC2)c2ccc(CC(NC(=O)c3c(C)cc(C)cc3C)C(O)=O)cc2)c1,"InChI=1S/C31H38N4O3/c1-20-9-12-32-28(17-20)33-19-25-10-13-35(14-11-25)26-7-5-24(6-8-26)18-27(31(37)38)34-30(36)29-22(3)15-21(2)16-23(29)4/h5-9,12,15-17,25,27H,10-11,13-14,18-19H2,1-4H3,(H,32,33)(H,34,36)(H,37,38)",RJFWKMUAMBANKC-UHFFFAOYSA-N,50423721,CHEMBL595105,Integrin alpha-5/beta-1,Homo sapiens, 2.3
20102,CC(C)C(N(Cc1ccccc1)S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(=O)NO,"InChI=1S/C16H17F9N2O4S/c1-9(2)11(12(28)26-29)27(8-10-6-4-3-5-7-10)32(30,31)16(24,25)14(19,20)13(17,18)15(21,22)23/h3-7,9,11,29H,8H2,1-2H3,(H,26,28)",VLTOUUSTKONGKC-UHFFFAOYSA-N,11342,"2-[benzyl(1,1,2,2,3,3,4,4,4-nonafluorobutane)sulfonamido]-N-hydroxy-3-methylbutanamide::Hydroxamate 22",Matrix metalloproteinase-9,Homo sapiens,
50794477,CC(C)c1noc(n1)-c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(ccc-21)C#C,"InChI=1S/C21H19N5O2/c1-4-13-7-8-15-14(10-13)21(27)25-9-5-6-16(25)18-17(22-11-26(15)18)20-23-19(12(2)3)24-28-20/h1,7-8,10-12,16H,5-6,9H2,2-3H3/t16-/m0/s1",KDGMRQJYYKGVCJ-INIZCTEOSA-N,50067436,"(S)-9-Ethynyl-3-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-3b,4,5,6-tetrahydro-2,6a,11b-triaza-benzo[g]cyclopenta[e]azulen-7-one::9-Ethynyl-3-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-3b,4,5,6-tetrahydro-2,6a,11b-triaza-benzo[g]cyclopenta[e]azulen-7-one::CHEMBL335888",Gamma-aminobutyric acid receptor subunit alpha-5/beta-3/gamma-2,Homo sapiens,
50882171,Clc1c(Cl)c(NS(=O)(=O)c2ccccc2)c(Cl)c(Cl)c1NS(=O)(=O)c1ccccc1,"InChI=1S/C18H12Cl4N2O4S2/c19-13-15(21)18(24-30(27,28)12-9-5-2-6-10-12)16(22)14(20)17(13)23-29(25,26)11-7-3-1-4-8-11/h1-10,23-24H",MGWQBOXYCUJGJI-UHFFFAOYSA-N,50268125,"CHEMBL483470::N,N'-(perchloro-1,4-phenylene)dibenzene sulfonamide",Liver carboxylesterase 1,,
536530,CN(c1ccccc1CNc1nc(cc2[nH]nc(C(N)=O)c12)-c1cc(F)c(O)cc1C1CC1)S(C)(=O)=O,"InChI=1S/C25H25FN6O4S/c1-32(37(2,35)36)20-6-4-3-5-14(20)12-28-25-22-19(30-31-23(22)24(27)34)11-18(29-25)16-9-17(26)21(33)10-15(16)13-7-8-13/h3-6,9-11,13,33H,7-8,12H2,1-2H3,(H2,27,34)(H,28,29)(H,30,31)",VFQLTBRWKTYVKQ-UHFFFAOYSA-N,281453,"6-(2-cyclopropyl-5-fluoro-4-hydroxyphenyl)-4-({2-[methyl(methylsul-fonyl)amino]benzyl}ami-no)-1H-pyrazolo[4,3-c]pyridine-3-carboxamide::US10022376, Example 47",Tyrosine-protein kinase JAK2,Homo sapiens, 28.4
50894621,Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,13216,"BMS-354825::CHEMBL1421::DASATINIB::N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide::N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide::US10294227, Code Dasatinib::cid_3062316::med.21724, Compound Dasatinib",Hepatocyte growth factor receptor,Homo sapiens,
1212739,Cc1ncc(nc1CN1CC2(CC2)OC1=O)-c1cccc(c1)C(C)(F)F,"InChI=1S/C19H19F2N3O2/c1-12-16(10-24-11-19(6-7-19)26-17(24)25)23-15(9-22-12)13-4-3-5-14(8-13)18(2,20)21/h3-5,8-9H,6-7,10-11H2,1-2H3",VYWIDDWHSQWJIW-UHFFFAOYSA-N,575408,"5-[[6-[3-(1,1-Difluoroethyl)phenyl]-3-methyl-pyrazin-2- yl]methyl]-7-oxa-5-azaspiro[2.4]heptan-6-one::US11459336, Example 43","lutamate receptor ionotropic, NMDA 1/2B",Homo sapiens, 203
50131525,OC(=O)C(=O)CC(=O)c1cccc(NS(=O)(=O)c2cc(Cl)cc(Cl)c2)c1,"InChI=1S/C16H11Cl2NO6S/c17-10-5-11(18)7-13(6-10)26(24,25)19-12-3-1-2-9(4-12)14(20)8-15(21)16(22)23/h1-7,19H,8H2,(H,22,23)",WFKJNUAGCYJPSW-UHFFFAOYSA-N,50174476,"(Z)-4-[3-(3,5-Dichloro-benzenesulfonylamino)-phenyl]-2-hydroxy-4-oxo-but-2-enoic acid::CHEMBL198813",RNA-directed RNA polymerase,Hepatitis C virus, 140
50301946,C\C(CN1CCN(C[C@@H]2ON=C3[C@H]2COc2cc(OC(=O)C4CC4)ccc32)CC1)=C/c1ccccc1,"InChI=1S/C29H33N3O4/c1-20(15-21-5-3-2-4-6-21)17-31-11-13-32(14-12-31)18-27-25-19-34-26-16-23(35-29(33)22-7-8-22)9-10-24(26)28(25)30-36-27/h2-6,9-10,15-16,22,25,27H,7-8,11-14,17-19H2,1H3/b20-15+/t25-,27-/m0/s1",COPXFRMTXFPQKE-JZACSLLISA-N,50163483,"CHEMBL175911::Cyclopropanecarboxylic acid (3R,3aS)-3-[4-((E)-2-methyl-3-phenyl-allyl)-piperazin-1-ylmethyl]-3a,4-dihydro-3H-chromeno[4,3-c]isoxazol-7-yl ester",Alpha-2A adrenergic receptor,,
50636730,Cc1cc(N2CCc3cc(Br)ccc3C2)c2ccccc2n1,"InChI=1S/C19H17BrN2/c1-13-10-19(17-4-2-3-5-18(17)21-13)22-9-8-14-11-16(20)7-6-15(14)12-22/h2-7,10-11H,8-9,12H2,1H3",ZNVWUCYUAVERRR-UHFFFAOYSA-N,50342663,"4-(6-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2-methylquinoline::CHEMBL1770742",Acid-sensing ion channel 3,Homo sapiens, 27600
50541618,CCn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=O)CC(=O)Nc4ccccc4OC)cc3F)c2s1,"InChI=1S/C28H24FN5O4S/c1-3-34-15-21(31-16-34)25-13-20-28(39-25)24(10-11-30-20)38-22-9-8-17(12-18(22)29)32-26(35)14-27(36)33-19-6-4-5-7-23(19)37-2/h4-13,15-16H,3,14H2,1-2H3,(H,32,35)(H,33,36)",WCHXVWBCCCSTPJ-UHFFFAOYSA-N,50303273,"CHEMBL566844::N1-(4-(2-(1-ethyl-1H-imidazole-4-carbonyl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)-N3-(2-methoxyphenyl)malonamide",Hepatocyte growth factor receptor,Homo sapiens, 25
51166174,Cc1ccccc1CNC(=O)[C@H]1N(CSC1(C)C)C(=O)[C@@H](O)[C@H](Cc1ccccc1)NC(=O)c1cccc(N)c1Cl,"InChI=1S/C31H35ClN4O4S/c1-19-10-7-8-13-21(19)17-34-29(39)27-31(2,3)41-18-36(27)30(40)26(37)24(16-20-11-5-4-6-12-20)35-28(38)22-14-9-15-23(33)25(22)32/h4-15,24,26-27,37H,16-18,33H2,1-3H3,(H,34,39)(H,35,38)/t24-,26-,27+/m0/s1",XCMSKSMSGDIXRD-DOEKTCAHSA-N,50478140,CHEMBL404154,Protease,,
50219543,COc1ccc2oc3ncc(OCc4ccccc4)c(-c4ccccc4)c3c2c1,"InChI=1S/C25H19NO3/c1-27-19-12-13-21-20(14-19)24-23(18-10-6-3-7-11-18)22(15-26-25(24)29-21)28-16-17-8-4-2-5-9-17/h2-15H,16H2,1H3",DXUVNKBICOWQOQ-UHFFFAOYSA-N,50395890,CHEMBL2163774,Cyclin-dependent kinase 5 activator 1,Homo sapiens,
836577,CC(C)c1ccccc1-c1ncc2[nH]c(=O)n(Cc3ccc(cc3)C(=O)N3CCOC[C@H]3C)c2n1,,,325198,"(R)-2-(2-isopropylphenyl)-9-(4-(3-methylmorpholine-::US10189841, Compound I-404::US10399980, Compound I-404",Ubiquitin carboxyl-terminal hydrolase 1,, 1100
50617288,FC(F)(F)Oc1ccc(cc1)-n1cc(Cc2ccc(cc2)C(=O)Nc2nnn[nH]2)c(n1)C1CCCCC1,"InChI=1S/C25H24F3N7O2/c26-25(27,28)37-21-12-10-20(11-13-21)35-15-19(22(32-35)17-4-2-1-3-5-17)14-16-6-8-18(9-7-16)23(36)29-24-30-33-34-31-24/h6-13,15,17H,1-5,14H2,(H2,29,30,31,33,34,36)",GDZNQMSLCBZUND-UHFFFAOYSA-N,50334492,4-((3-cyclohexyl-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-4-yl)methyl)-N-(2H-tetrazol-5-yl)benzamide::CHEMBL1644174,Gastric inhibitory polypeptide receptor,Homo sapiens,>10000
51270345,Cn1nc(-c2ccccc2Cl)c2c1nnc1c(F)cc(F)cc21,"InChI=1S/C16H9ClF2N4/c1-23-16-13(15(22-23)9-4-2-3-5-11(9)17)10-6-8(18)7-12(19)14(10)20-21-16/h2-7H,1H3",JMVKQPJFAFIGHI-UHFFFAOYSA-N,50518779,CHEMBL4453495,"cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens, 1790
606195,Cc1cccc(Cl)c1C(=O)NCC(N1CCc2ccccc2C1)c1cncs1,"InChI=1S/C22H22ClN3OS/c1-15-5-4-8-18(23)21(15)22(27)25-11-19(20-12-24-14-28-20)26-10-9-16-6-2-3-7-17(16)13-26/h2-8,12,14,19H,9-11,13H2,1H3,(H,25,27)",OVCYWUVICQPSNM-UHFFFAOYSA-N,267131,"2-chloro-6-methyl-N-[2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide::US10167281, Compound 19::US9718812, 19",P2X purinoceptor 7,, 104
1090561,Clc1ccc(Cn2nc(-c3ccccc3Cl)c3ccc(cc23)C(=O)NC2CCS(=O)(=O)C2)cc1,"InChI=1S/C25H21Cl2N3O3S/c26-18-8-5-16(6-9-18)14-30-23-13-17(25(31)28-19-11-12-34(32,33)15-19)7-10-21(23)24(29-30)20-3-1-2-4-22(20)27/h1-10,13,19H,11-12,14-15H2,(H,28,31)",AQVKVSUVKRZSTB-UHFFFAOYSA-N,517371,"1-(4-chlorobenzyl)-3-(2- chlorophenyl)-N-(1,1- dioxidotetrahydrothiophen-3-yl)- 1H-indazole-6-carboxamide::US11104690, Example 168",Diacylglycerol O-acyltransferase 2,Homo sapiens, 455
51282751,CNC(=O)c1c(oc2cc(N(c3ccc(B(O)O)c(Cl)c3)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1,"InChI=1S/C26H23BClFN2O6S/c1-30-26(32)24-19-12-18(14-3-4-14)22(13-23(19)37-25(24)15-5-7-16(29)8-6-15)31(38(2,35)36)17-9-10-20(27(33)34)21(28)11-17/h5-14,33-34H,3-4H2,1-2H3,(H,30,32)",HRDHNBASQAPPRC-UHFFFAOYSA-N,50523184,CHEMBL4528447,Cytochrome P450 3A4,Homo sapiens,>33000
51073503,Clc1ccc2n(-c3ccccc3)c3nc(=O)[nH]c(=O)c3cc2c1,"InChI=1S/C17H10ClN3O2/c18-11-6-7-14-10(8-11)9-13-15(19-17(23)20-16(13)22)21(14)12-4-2-1-3-5-12/h1-9H,(H,20,22,23)",FXRJGHFGRXIXMM-UHFFFAOYSA-N,50438876,CHEMBL2420496,Tyrosyl-DNA phosphodiesterase 2,Homo sapiens,
67780,Cc1cc(no1)C(=O)Nc1cc(C)n(Cc2ccc(Cl)cc2)n1,"InChI=1S/C16H15ClN4O2/c1-10-7-15(18-16(22)14-8-11(2)23-20-14)19-21(10)9-12-3-5-13(17)6-4-12/h3-8H,9H2,1-2H3,(H,18,19,22)",YTQNANNNIWCWCA-UHFFFAOYSA-N,37292,"MLS000087314::N-[1-(4-chlorobenzyl)-5-methyl-1H-pyrazol-3-yl]-5-methylisoxazole-3-carboxamide::N-[1-(4-chlorobenzyl)-5-methyl-pyrazol-3-yl]-5-methyl-isoxazole-3-carboxamide::N-[1-[(4-chlorophenyl)methyl]-5-methyl-3-pyrazolyl]-5-methyl-3-isoxazolecarboxamide::N-[1-[(4-chlorophenyl)methyl]-5-methyl-pyrazol-3-yl]-5-methyl-1,2-oxazole-3-carboxamide::N-[1-[(4-chlorophenyl)methyl]-5-methylpyrazol-3-yl]-5-methyl-1,2-oxazole-3-carboxamide::SMR000023537::cid_3237514",Pantothenate synthetase,,>100000
219540,O=C1N(Cc2cccc(c2)-c2ccccc2)CCCC11CCN(CC1)c1cnc2ccccc2n1,"InChI=1S/C30H30N4O/c35-29-30(15-18-33(19-16-30)28-21-31-26-12-4-5-13-27(26)32-28)14-7-17-34(29)22-23-8-6-11-25(20-23)24-9-2-1-3-10-24/h1-6,8-13,20-21H,7,14-19,22H2",DHBHYLLJTLRILL-UHFFFAOYSA-N,102152,"US8530648, 49",Orexin receptor type 2,Homo sapiens,
238115,Cc1ccc(cc1)-c1nc2cc(C)ccc2o1,"InChI=1S/C15H13NO/c1-10-3-6-12(7-4-10)15-16-13-9-11(2)5-8-14(13)17-15/h3-9H,1-2H3",RETREZSKHMFVCD-UHFFFAOYSA-N,48186,"5-methyl-2-(4-methylphenyl)-1,3-benzoxazole::5-methyl-2-(p-tolyl)-1,3-benzoxazole::MLS000113249::SMR000109153::cid_85307",Nuclear hormone receptor family member daf-12,Caenorhabditis elegans,
50579931,CN(C)c1ccc(Nc2nccc(n2)-c2sc(C)nc2C)cc1,"InChI=1S/C17H19N5S/c1-11-16(23-12(2)19-11)15-9-10-18-17(21-15)20-13-5-7-14(8-6-13)22(3)4/h5-10H,1-4H3,(H,18,20,21)",FGGSNQOBRJVAKL-UHFFFAOYSA-N,8066,"2-Anilino-4-(thiazol-5-yl)pyrimidine deriv. 37::4-(dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]-1-N,1-N-dimethylbenzene-1,4-diamine, 3::4-N-[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]-1-N,1-N-dimethylbenzene-1,4-diamine::N-[4-(2,4-Dimethylthiazol-5-yl)pyrimidin-2-yl]N,N-dimethylbenzene-1,4-diamine",Cyclin-dependent kinase 9,Homo sapiens,
50884893,CSc1ccc(\C=C2/NC(=O)NC2=O)cc1,"InChI=1S/C11H10N2O2S/c1-16-8-4-2-7(3-5-8)6-9-10(14)13-11(15)12-9/h2-6H,1H3,(H2,12,13,14,15)/b9-6-",XTMVUGQFVUETDJ-TWGQIWQCSA-N,50297154,"(Z)-5-(4-(methylthio)benzylidene)imidazolidine-2,4-dione::CHEMBL569595",Glycogen synthase kinase-3 beta,Homo sapiens, 6900
50949472,C[C@H](N)C(=O)N1C[C@@H](Cl)C[C@H]1B(O)O,"InChI=1S/C7H14BClN2O3/c1-4(10)7(12)11-3-5(9)2-6(11)8(13)14/h4-6,13-14H,2-3,10H2,1H3/t4-,5-,6-/m0/s1",HPESIFUOBXUHNB-ZLUOBGJFSA-N,50389468,CHEMBL2063028,Dipeptidyl peptidase 8,Homo sapiens, 27000
53229,Cc1ncsc1C(=O)N(Cc1cc(=O)[nH]c2c(F)cccc12)c1ccccc1Cl,"InChI=1S/C21H15ClFN3O2S/c1-12-20(29-11-24-12)21(28)26(17-8-3-2-6-15(17)22)10-13-9-18(27)25-19-14(13)5-4-7-16(19)23/h2-9,11H,10H2,1H3,(H,25,27)",PBACZNNCRUWDOK-UHFFFAOYSA-N,29240,"quinolinone, 11","Nitric oxide synthase, inducible",Homo sapiens,
370739,Cc1ncc(c(OC[C@H]2C[C@@H]2c2ccc(OC(F)F)cn2)n1)-c1ccn(C)c(=O)c1,"InChI=1S/C21H20F2N4O3/c1-12-24-10-17(13-5-6-27(2)19(28)8-13)20(26-12)29-11-14-7-16(14)18-4-3-15(9-25-18)30-21(22)23/h3-6,8-10,14,16,21H,7,11H2,1-2H3/t14-,16+/m1/s1",DDTRNWDSNZFBCL-ZBFHGGJFSA-N,209790,"US9273033, 90","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens,
233667,Cn1ccc2ncc(nc12)-c1cccnc1N[C@H]1CCCN(C1)S(C)(=O)=O,"InChI=1S/C18H22N6O2S/c1-23-10-7-15-18(23)22-16(11-20-15)14-6-3-8-19-17(14)21-13-5-4-9-24(12-13)27(2,25)26/h3,6-8,10-11,13H,4-5,9,12H2,1-2H3,(H,19,21)/t13-/m0/s1",RLYDDKYLBSDJBO-ZDUSSCGKSA-N,112547,"US8618103, I-43",Tyrosine-protein kinase JAK3,Homo sapiens, 3.254865
1217408,C[C@@](C(=O)NCC1(O)COC1)(c1ccccc1)n1ncc2c1nc(N)n1nc(nc21)-c1ccco1,"InChI=1S/C23H22N8O4/c1-22(14-6-3-2-4-7-14,20(32)25-11-23(33)12-34-13-23)31-19-15(10-26-31)18-27-17(16-8-5-9-35-16)29-30(18)21(24)28-19/h2-10,33H,11-13H2,1H3,(H2,24,28)(H,25,32)/t22-/m0/s1",AUQLMDIRDBZGIX-QFIPXVFZSA-N,577234,"(S)-2-(5-amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl)-N-((3-hydroxyoxetan-3-yl))methyl)-2-phenylpropanamide::US11472811, Example 31A",Adenosine deaminase,Homo sapiens, 28.0
681097,CC(C)CC(O)CN1CCCN(C1=O)c1cccc2n(ncc12)-c1ccccc1F,"InChI=1S/C23H27FN4O2/c1-16(2)13-17(29)15-26-11-6-12-27(23(26)30)20-9-5-10-21-18(20)14-25-28(21)22-8-4-3-7-19(22)24/h3-5,7-10,14,16-17,29H,6,11-13,15H2,1-2H3",CGMAREJKVSONFM-UHFFFAOYSA-N,344884,"1-[1-(2-fluorophenyl)-1H-::1-[1-(2-fluorophenyl)-1H-indazol-4-yl]-3-(2-hydroxy-4-methylpentyl)tetrahydropyrimidin-2(1H)-one::US9783527, Example 186",Sodium channel protein type 9 subunit alpha,, 1410
50123663,Clc1ccc(C[C@@H](NC(=O)C2Cc3ccccc3CN2)C(=O)N2CCN(CC2)C2CCCCC2)cc1,"InChI=1S/C29H37ClN4O2/c30-24-12-10-21(11-13-24)18-27(32-28(35)26-19-22-6-4-5-7-23(22)20-31-26)29(36)34-16-14-33(15-17-34)25-8-2-1-3-9-25/h4-7,10-13,25-27,31H,1-3,8-9,14-20H2,(H,32,35)/t26?,27-/m1/s1",YGHRPBJBMRFBDH-SSYAZFEXSA-N,50151504,"1,2,3,4-Tetrahydro-isoquinoline-3-carboxylic acid [(R)-1-(4-chloro-benzyl)-2-(4-cyclohexyl-piperazin-1-yl)-2-oxo-ethyl]-amide::CHEMBL361052",Melanocortin receptor 3,,
50298832,C1CC2CCC1c1c(Oc3cccnc3)nn3c(nnc3c21)-c1ccccc1,"InChI=1S/C22H19N5O/c1-2-5-16(6-3-1)20-24-25-21-18-14-8-10-15(11-9-14)19(18)22(26-27(20)21)28-17-7-4-12-23-13-17/h1-7,12-15H,8-11H2",ZTIASORFYBCQED-UHFFFAOYSA-N,50162224,"6-phenyl-4,5,7,8-tetraazatetracyclo[9.2.2.02,10.03,7]pentadeca-2(10),3,5,8-tetraen-9-yl 3-pyridyl ether::CHEMBL359638",Gamma-aminobutyric acid receptor subunit alpha-1/beta-3/gamma-2,Homo sapiens,
1178713,OC(=O)CCCCOc1ccc(nc1)-c1ccn[nH]1,"InChI=1S/C13H15N3O3/c17-13(18)3-1-2-8-19-10-4-5-11(14-9-10)12-6-7-15-16-12/h4-7,9H,1-3,8H2,(H,15,16)(H,17,18)",MZJLUDLXJNEHIX-UHFFFAOYSA-N,558212,"5-[[6-(1H-Pyrazol-5-yl)-3-pyridinyl]oxy]pentanoic Acid::US11365192, Example 10-1",Cytochrome P450 4F2,, 19000
871137,COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(cc3NC(=O)C=C)N3CCN(CC3)C(C)=O)ncn2)c1Cl,"InChI=1S/C29H32Cl2N8O5/c1-6-25(41)35-20-13-18(39-11-9-38(10-12-39)17(2)40)7-8-19(20)34-23-15-24(33-16-32-23)37(3)29(42)36-28-26(30)21(43-4)14-22(44-5)27(28)31/h6-8,13-16H,1,9-12H2,2-5H3,(H,35,41)(H,36,42)(H,32,33,34)",ZHZFVFGZCQNOAH-UHFFFAOYSA-N,249433,"US10537571, Compound 154::US10912774, Compound 154::US9434697, 154::US9730931, Compound 154",Fibroblast growth factor receptor 1,Homo sapiens, 777
155566,CCCCS(=O)(=O)N(C)[C@H]1CCN2CCc3ccccc3[C@H]2C1,"InChI=1S/C18H28N2O2S/c1-3-4-13-23(21,22)19(2)16-10-12-20-11-9-15-7-5-6-8-17(15)18(20)14-16/h5-8,16,18H,3-4,9-14H2,1-2H3/t16-,18+/m0/s1",LVHNKZNYJNTKDF-FUHWJXTLSA-N,81816,"AC1L33GU::AR-1K2981::CAS_82059-49-2::N-[(2S,11bR)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]-N-methylbutane-1-sulfonamide hydrochloride::WY26703",Alpha-2A adrenergic receptor,,
51177261,Cc1cc(C)cc(c1)S(=O)(=O)c1c([nH]c2ccc(Cl)cc12)C(=O)NCCOc1ccccc1,"InChI=1S/C25H23ClN2O4S/c1-16-12-17(2)14-20(13-16)33(30,31)24-21-15-18(26)8-9-22(21)28-23(24)25(29)27-10-11-32-19-6-4-3-5-7-19/h3-9,12-15,28H,10-11H2,1-2H3,(H,27,29)",POFQMVBGPLUTLT-UHFFFAOYSA-N,50483703,CHEMBL1766241,Reverse transcriptase,Human immunodeficiency virus 1,>40000
307629,CCOc1ccc(C)nc1C(=O)N1C2CCC1C(COc1ccc(cn1)C(F)(F)F)C2,"InChI=1S/C22H24F3N3O3/c1-3-30-18-8-4-13(2)27-20(18)21(29)28-16-6-7-17(28)14(10-16)12-31-19-9-5-15(11-26-19)22(23,24)25/h4-5,8-9,11,14,16-17H,3,6-7,10,12H2,1-2H3",PDIIAZWKWPJDTA-UHFFFAOYSA-N,163917,"US9062078, 48::US9475819, 48::US9637496, 48::US9695183, 48",Orexin/Hypocretin receptor type 1,Rattus norvegicus,
50809394,COc1cccc(c1)C(=O)NCCCN1CCN(CC1)c1ccccc1OC,"InChI=1S/C22H29N3O3/c1-27-19-8-5-7-18(17-19)22(26)23-11-6-12-24-13-15-25(16-14-24)20-9-3-4-10-21(20)28-2/h3-5,7-10,17H,6,11-16H2,1-2H3,(H,23,26)",KTPQCLNOFMRFDQ-UHFFFAOYSA-N,50068374,3-Methoxy-N-{3-[4-(2-methoxy-phenyl)-piperazin-1-yl]-propyl}-benzamide::CHEMBL357448,5-hydroxytryptamine receptor 1A,Rattus norvegicus,
50119346,CC1(C)[C@H]2C[C@@H]1[C@]1(C)OB(O[C@@H]1C2)[C@H](CCCCN)NC(=O)Cn1nc(CC#N)nc1Cc1ccccc1[N+]([O-])=O,"InChI=1S/C28H38BN7O5/c1-27(2)19-15-21(27)28(3)22(16-19)40-29(41-28)23(10-6-7-12-30)32-26(37)17-35-25(33-24(34-35)11-13-31)14-18-8-4-5-9-20(18)36(38)39/h4-5,8-9,19,21-23H,6-7,10-12,14-17,30H2,1-3H3,(H,32,37)/t19-,21-,22+,23-,28-/m0/s1",YELLYQPFWRBWSX-NYQCOFSNSA-N,50069146,"CHEMBL2373405::N-[(R)-5-Amino-1-((1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-bora-tricyclo[6.1.1.0*2,6*]dec-4-yl)-pentyl]-2-[3-cyanomethyl-5-(2-nitro-benzyl)-[1,2,4]triazol-1-yl]-acetamide",Coagulation factor VII,Homo sapiens,
51183289,CCCCc1nn(CC(OCCC)c2ccccc2)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,"InChI=1S/C31H35N7O2/c1-3-5-15-29-34-38(22-28(40-20-4-2)25-11-7-6-8-12-25)31(39)37(29)21-23-16-18-24(19-17-23)26-13-9-10-14-27(26)30-32-35-36-33-30/h6-14,16-19,28H,3-5,15,20-22H2,1-2H3,(H,32,33,35,36)",BDNZRTTUCHGDRE-UHFFFAOYSA-N,50044363,"5-Butyl-2-(2-phenyl-2-propoxy-ethyl)-4-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-2,4-dihydro-[1,2,4]triazol-3-one::CHEMBL308239",Type-1 angiotensin II receptor A/B,Rattus, 45
51012884,NC(N)=NN=Cc1ccc(Cl)c(c1)C(F)(F)F,"InChI=1S/C9H8ClF3N4/c10-7-2-1-5(4-16-17-8(14)15)3-6(7)9(11,12)13/h1-4H,(H4,14,15,17)",SYKKEBRXRXCNEC-UHFFFAOYSA-N,50394977,CHEMBL583068,Neuropeptide FF receptor 1,Homo sapiens,
50625220,CC(C)NC(=O)c1cccc(c1)-c1cc(n[nH]1)-c1ccc(CNC2CC2)cc1,"InChI=1S/C23H26N4O/c1-15(2)25-23(28)19-5-3-4-18(12-19)22-13-21(26-27-22)17-8-6-16(7-9-17)14-24-20-10-11-20/h3-9,12-13,15,20,24H,10-11,14H2,1-2H3,(H,25,28)(H,26,27)",XCCKQXYDJJDHMQ-UHFFFAOYSA-N,50337715,3-(5-(4-((cyclopropylamino)methyl)phenyl)-1H-pyrazol-3-yl)-N-isopropylbenzamide::CHEMBL1683312,Serine/threonine-protein kinase D1,Homo sapiens, 390
50505863,Fc1ccc(Cn2cccc(C(=O)NCC(=O)Nc3ccc4NC(=O)Cc4c3)c2=O)cc1F,"InChI=1S/C23H18F2N4O4/c24-17-5-3-13(8-18(17)25)12-29-7-1-2-16(23(29)33)22(32)26-11-21(31)27-15-4-6-19-14(9-15)10-20(30)28-19/h1-9H,10-12H2,(H,26,32)(H,27,31)(H,28,30)",JDUGSOODUPHJFA-UHFFFAOYSA-N,50185002,"CHEMBL3822974::US10351548, Compound IB32",3-phosphoinositide-dependent protein kinase 1,Homo sapiens, 6680
50790314,O=C1CCc2ccc(OCCCCCCN3CCCCC3)cc2N1,"InChI=1S/C20H30N2O2/c23-20-11-9-17-8-10-18(16-19(17)21-20)24-15-7-2-1-4-12-22-13-5-3-6-14-22/h8,10,16H,1-7,9,11-15H2,(H,21,23)",OPRPOGCTZWDVTJ-UHFFFAOYSA-N,50252563,CHEMBL4102298,Amine oxidase [flavin-containing] A,, 9400
51192846,CCN(CC)CCSC(=O)C(O)(c1ccccc1)c1ccccc1,"InChI=1S/C20H25NO2S/c1-3-21(4-2)15-16-24-19(22)20(23,17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,23H,3-4,15-16H2,1-2H3",BEJYISOPDBBZRK-UHFFFAOYSA-N,50491119,CHEMBL2377387,Muscarinic acetylcholine receptor M3,Homo sapiens,
456485,CC(N1CCN(Cc2cc(F)c(cc2C2CC2)C(N)=O)CC1)c1cc(Cl)cc(Cl)c1,"InChI=1S/C23H26Cl2FN3O/c1-14(16-8-18(24)11-19(25)9-16)29-6-4-28(5-7-29)13-17-10-22(26)21(23(27)30)12-20(17)15-2-3-15/h8-12,14-15H,2-7,13H2,1H3,(H2,27,30)",UHSPKNDHOJXKCW-UHFFFAOYSA-N,71525,"US9546164, 541::US9694002, 540::US9694002, 541",Sodium channel protein type 1/10/11/2/3/4/5/8/9 subunit alpha,Homo sapiens, 5.9
50910088,Cn1cc(C2=C(Sc3ccccc3)C(=O)NC2=O)c2ccccc12,"InChI=1S/C19H14N2O2S/c1-21-11-14(13-9-5-6-10-15(13)21)16-17(19(23)20-18(16)22)24-12-7-3-2-4-8-12/h2-11H,1H3,(H,20,22,23)",BLXHUSFCTBUDQK-UHFFFAOYSA-N,50312995,"3-(1-methyl-1H-indol-3-yl)-4-(phenylthio)-1H-pyrrole-2,5-dione::CHEMBL1086733",Glycogen synthase kinase-3 beta,Homo sapiens, 2000
51015226,COc1ccccc1CCCNCC1COC(O1)(c1ccccc1)c1ccccc1,"InChI=1S/C26H29NO3/c1-28-25-17-9-8-11-21(25)12-10-18-27-19-24-20-29-26(30-24,22-13-4-2-5-14-22)23-15-6-3-7-16-23/h2-9,11,13-17,24,27H,10,12,18-20H2,1H3",YKCXYNCLHSMBJV-UHFFFAOYSA-N,50415781,CHEMBL1088072,Alpha-1B adrenergic receptor,,
110063,CCCCCCCCCCCCN1[C@@H](CC(O)=O)c2cc(ccc2S1(=O)=O)C(F)(F)F,"InChI=1S/C22H32F3NO4S/c1-2-3-4-5-6-7-8-9-10-11-14-26-19(16-21(27)28)18-15-17(22(23,24)25)12-13-20(18)31(26,29)30/h12-13,15,19H,2-11,14,16H2,1H3,(H,27,28)/t19-/m0/s1",VIDDYFSFWDYDCF-IBGZPJMESA-N,58352,"2-[(3S)-1,1-diketo-2-lauryl-5-(trifluoromethyl)-3H-1,2-benzothiazol-3-yl]acetic acid::2-[(3S)-2-dodecyl-1,1-bis(oxidanylidene)-5-(trifluoromethyl)-3H-1,2-benzothiazol-3-yl]ethanoic acid::2-[(3S)-2-dodecyl-1,1-dioxo-5-(trifluoromethyl)-3H-1,2-benzothiazol-3-yl]acetic acid::MLS000881706::SMR000525337::cid_24747539",Streptokinase A,Streptococcus pyogenes M1 GAS,
50914673,NCCCn1nc(C(N)=O)c2CCc3cnc(Nc4ccccc4)nc3-c12,"InChI=1S/C19H21N7O/c20-9-4-10-26-17-14(16(25-26)18(21)27)8-7-12-11-22-19(24-15(12)17)23-13-5-2-1-3-6-13/h1-3,5-6,11H,4,7-10,20H2,(H2,21,27)(H,22,23,24)",OXICUMLYVMEXBW-UHFFFAOYSA-N,50321580,"1-(3-aminopropyl)-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide::CHEMBL1171950",Cyclin-dependent kinase 2,Homo sapiens, 1
51425372,OC(=O)C(F)(F)F.NCCCCCC1(CCCCCCCP1(O)=O)C(O)=O,"InChI=1S/C14H28NO4P.C2HF3O2/c15-11-7-4-6-10-14(13(16)17)9-5-2-1-3-8-12-20(14,18)19;3-2(4,5)1(6)7/h1-12,15H2,(H,16,17)(H,18,19);(H,6,7)",YKJIFLVZYLYOAK-UHFFFAOYSA-N,50575737,CHEMBL4861262,Carboxypeptidase B2,Homo sapiens, 1500
50702,COc1ccc(cc1)-c1ccc(C(=O)N[C@@H]([C@@H](C)OC(C)(C)C)C(O)=O)c(NC(=O)Nc2c(C)cc(C)cc2C)c1,"InChI=1S/C32H39N3O6/c1-18-15-19(2)27(20(3)16-18)35-31(39)33-26-17-23(22-9-12-24(40-8)13-10-22)11-14-25(26)29(36)34-28(30(37)38)21(4)41-32(5,6)7/h9-17,21,28H,1-8H3,(H,34,36)(H,37,38)(H2,33,35,39)/t21-,28+/m1/s1",ZYAQEXLNQYIHNU-PIKZIKFNSA-N,27730,"(2S,3R)-3-(tert-butoxy)-2-{[4-(4-methoxyphenyl)-2-{[(2,4,6-trimethylphenyl)carbamoyl]amino}phenyl]formamido}butanoic acid::anthranilimide based compound, 6","Glycogen phosphorylase, liver form",Homo sapiens, 3
80014,CC(C)OC(=O)CSc1nc2cc3OCOc3cc2cc1C#N,"InChI=1S/C16H14N2O4S/c1-9(2)22-15(19)7-23-16-11(6-17)3-10-4-13-14(21-8-20-13)5-12(10)18-16/h3-5,9H,7-8H2,1-2H3",JQGRFEXKKGQFJN-UHFFFAOYSA-N,42982,"(7-Cyano-[1,3]dioxolo[4,5-g]quinolin-6-ylsulfanyl)-acetic acid isopropyl ester::2-[(7-cyano-[1,3]dioxolo[4,5-g]quinolin-6-yl)thio]acetic acid isopropyl ester::2-[(7-cyano-[1,3]dioxolo[4,5-g]quinolin-6-yl)thio]acetic acid propan-2-yl ester::MLS000121901::SMR000119314::cid_1450739::propan-2-yl 2-[(7-cyano-[1,3]dioxolo[4,5-g]quinolin-6-yl)sulfanyl]acetate::propan-2-yl 2-[(7-cyano-[1,3]dioxolo[4,5-g]quinolin-6-yl)sulfanyl]ethanoate",Nuclear receptor coactivator 1,Homo sapiens,
1249255,CCn1c(c2CC(C)(C)COC(=O)[C@@H]3CCCN(N3)C(=O)[C@H](Cc3nc(cs3)-c3ccc1c2c3)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@@H]1CCN(C1)S(=O)(=O)C=C)-c1cncnc1,"InChI=1S/C43H55N9O7S2/c1-8-51-35-13-12-27-17-30(35)31(38(51)29-20-44-25-45-21-29)19-43(5,6)24-59-42(56)32-11-10-15-52(48-32)41(55)33(18-36-46-34(27)23-60-36)47-39(53)37(26(3)4)49(7)40(54)28-14-16-50(22-28)61(57,58)9-2/h9,12-13,17,20-21,23,25-26,28,32-33,37,48H,2,8,10-11,14-16,18-19,22,24H2,1,3-7H3,(H,47,53)/t28-,32+,33+,37+/m1/s1",YCYZNUUCFHQODQ-PLUYPHSKSA-N,591492,"US11566007, Example A170",GTPase KRas [G12D],,>10000
50469118,CCCc1nc(CC)c(C(=O)OCCCC(=O)Nc2ccccc2)n1Cc1ccc(cc1F)-c1ccccc1S(=O)(=O)NC(=O)OCCC(C)C,"InChI=1S/C38H45FN4O7S/c1-5-13-34-41-32(6-2)36(37(45)49-22-12-18-35(44)40-29-14-8-7-9-15-29)43(34)25-28-20-19-27(24-31(28)39)30-16-10-11-17-33(30)51(47,48)42-38(46)50-23-21-26(3)4/h7-11,14-17,19-20,24,26H,5-6,12-13,18,21-23,25H2,1-4H3,(H,40,44)(H,42,46)",PBNKWFOVOSXATB-UHFFFAOYSA-N,50283228,Biphenylsulfonylcarbamate compound::CHEMBL430792,Type-1 angiotensin II receptor,Homo sapiens, 0.200000
976139,Cc1cc(Oc2ccccc2)ccc1-n1c2ccnc3sc(C(=O)N[C@@H]4CCCN(C4)C(=O)[C@H]4CCN4)c([nH]c1=O)c23,,,468174,"N-((R)-1-((R)-Azetidine-2-carbonyl)piperidin-3-yl)-5-(2-methyl-4- phenoxyphenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,8- triazaacenaphthylene-2-carboxamide;::US10800792, Example 849::US10822348, Example 849",Tyrosine-protein kinase BTK [386-659],, 25.1
50815356,CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12,"InChI=1S/C12H16N6O4/c1-2-14-11(21)8-6(19)7(20)12(22-8)18-4-17-5-9(13)15-3-16-10(5)18/h3-4,6-8,12,19-20H,2H2,1H3,(H,14,21)(H2,13,15,16)/t6-,7+,8-,12+/m0/s1",JADDQZYHOWSFJD-FLNNQWSLSA-N,21220,"(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide::Adenosine analog, 3::Adenosine, N6-Ethyl-carboxamido::Adenosine-5-(N-ethylcarboxamide)::CHEMBL464859::N-Ethylcarboxamidoadenosine::NECA",Adenosine receptor A2a,Homo sapiens,
51216520,Oc1cc(cc(O)c1O)-c1coc2cc(O)c(O)c(O)c2c1=O,"InChI=1S/C15H10O8/c16-7-1-5(2-8(17)13(7)20)6-4-23-10-3-9(18)14(21)15(22)11(10)12(6)19/h1-4,16-18,20-22H",DFURNQJNFBMYHM-UHFFFAOYSA-N,50456401,IRIGENOL,Receptor-type tyrosine-protein phosphatase S,, 500
50610235,Cn1ccnc1C(=O)NCC(C)(C)CN(C1=NS(=O)(=O)c2cc(F)ccc12)c1ccccc1,"InChI=1S/C23H24FN5O3S/c1-23(2,14-26-22(30)21-25-11-12-28(21)3)15-29(17-7-5-4-6-8-17)20-18-10-9-16(24)13-19(18)33(31,32)27-20/h4-13H,14-15H2,1-3H3,(H,26,30)",MRFUMRJHDPXIAR-UHFFFAOYSA-N,50331486,"1-Methyl-1H-imidazole-2-carboxylic acid{3-[(6-fluoro-1,1-dioxo-1H-1lambda*6*-benzo[d]isothiazol-3-yl)-phenyl-amino]-2,2-dimethyl-propyl}-amide::CHEMBL1289070",Potassium voltage-gated channel subfamily A member 3,Homo sapiens, 550
922653,C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#CC3CCN(CC3)S(C)(=O)=O)c2c(=O)n1-c1ccccc1,"InChI=1S/C32H29N7O4S/c1-21(35-31(40)28-29(33)36-38-17-7-16-34-30(28)38)26-20-24-9-6-8-23(13-12-22-14-18-37(19-15-22)44(2,42)43)27(24)32(41)39(26)25-10-4-3-5-11-25/h3-11,16-17,20-22H,14-15,18-19H2,1-2H3,(H,35,40)/t21-/m0/s1",CHXRHBPWUKCOBK-NRFANRHFSA-N,342532,"US10329299, Compound 83::US10675286, Compound 83::US9775844, Compound 83","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",Homo sapiens, 2000
51019827,COc1ccc(CCNc2cc(nc(OC)n2)-c2ccc(cc2)N(C)C)cc1,"InChI=1S/C22H26N4O2/c1-26(2)18-9-7-17(8-10-18)20-15-21(25-22(24-20)28-4)23-14-13-16-5-11-19(27-3)12-6-16/h5-12,15H,13-14H2,1-4H3,(H,23,24,25)",ICYPTMNUYMAVJH-UHFFFAOYSA-N,50417750,CHEMBL1644249,Prostaglandin D2 receptor,, 41.69
173243,Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12,"InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31)",GZKLJWGUPQBVJQ-UHFFFAOYSA-N,50001786,1-(2-{4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]piperidin-1-yl}ethyl)imidazolidin-2-one::1-[2-[4-[5-chloro-1-(4-fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one::CHEMBL12713::Sertindole,Beta-arrestin-1,Oryctolagus cuniculus,
504090,Oc1ccc(CCC(=O)NCc2ccc(cc2)C(F)(F)F)cc1O,"InChI=1S/C17H16F3NO3/c18-17(19,20)13-5-1-12(2-6-13)10-21-16(24)8-4-11-3-7-14(22)15(23)9-11/h1-3,5-7,9,22-23H,4,8,10H2,(H,21,24)",XORVBPRQFULSIV-UHFFFAOYSA-N,264584,"US9718760, C345",Plasminogen activator inhibitor 1/Urokinase-type plasminogen activator,Homo sapiens, 539000
859389,CCc1nc2ccc(cn2c1N(C)c1nc(cs1)-c1ccc(F)cc1)C1CCN(CC(=O)N2CCC(CO)C2)CC1,"InChI=1S/C31H37FN6O2S/c1-3-26-30(35(2)31-34-27(20-41-31)23-4-7-25(32)8-5-23)38-17-24(6-9-28(38)33-26)22-11-13-36(14-12-22)18-29(40)37-15-10-21(16-37)19-39/h4-9,17,20-22,39H,3,10-16,18-19H2,1-2H3",FBHBZQSDEWXGTJ-UHFFFAOYSA-N,426481,"US10526329, Compound 117::US11072611, Compound 117",Ectonucleotide pyrophosphatase/phosphodiesterase family member 2,, 300
908850,CC(C)c1c([nH]c2ccc(cc12)C1CCN(CC1)C(=O)CN1CCC[C@@H]1CO)-c1cc(C)nc(C)c1,,,443824,"US10660877, Example 412",Toll-like receptor 8,, 34.0
50702144,Clc1ccc(cc1)C1CCN(CCCC(=O)c2ccc3CCN(CCc3c2)C(=O)c2ccccc2)CC1,"InChI=1S/C32H35ClN2O2/c33-30-12-10-24(11-13-30)26-14-19-34(20-15-26)18-4-7-31(36)29-9-8-25-16-21-35(22-17-28(25)23-29)32(37)27-5-2-1-3-6-27/h1-3,5-6,8-13,23,26H,4,7,14-22H2",ZIYJTXYUZSCVHR-UHFFFAOYSA-N,50357506,CHEMBL1914635,Melanin-concentrating hormone receptor 1,Rattus, 79
50506997,CCCCc1ccc(CN(CCCCOCC(O)=O)S(C)(=O)=O)cc1,"InChI=1S/C18H29NO5S/c1-3-4-7-16-8-10-17(11-9-16)14-19(25(2,22)23)12-5-6-13-24-15-18(20)21/h8-11H,3-7,12-15H2,1-2H3,(H,20,21)",LEMTUKURILRYMX-UHFFFAOYSA-N,50293505,2-(4-(N-(4-butylbenzyl)methylsulfonamido)butoxy)acetic acid::CHEMBL559561,Prostaglandin E2 receptor EP2 subtype,Rattus norvegicus, 701
50442614,Cc1cc(C)cc(C[C@H]2CCCCN2C(=O)CN2c3ccccc3-n3c(nnc3-c3ccccc3)[C@H](Cc3n[nH]c4ccccc34)C2=O)c1,"InChI=1S/C40H39N7O2/c1-26-20-27(2)22-28(21-26)23-30-14-10-11-19-45(30)37(48)25-46-35-17-8-9-18-36(35)47-38(29-12-4-3-5-13-29)43-44-39(47)32(40(46)49)24-34-31-15-6-7-16-33(31)41-42-34/h3-9,12-13,15-18,20-22,30,32H,10-11,14,19,23-25H2,1-2H3,(H,41,42)/t30-,32+/m1/s1",ZJGPYSQTJSMQNL-BHYZAODMSA-N,50380728,CHEMBL2017835,Gastrin/cholecystokinin type B receptor,Homo sapiens, 10.0
94317,OC(=O)c1ccc(cc1)-n1cccc1C=NNC(=O)c1cc2cc(Br)ccc2o1,"InChI=1S/C21H14BrN3O4/c22-15-5-8-18-14(10-15)11-19(29-18)20(26)24-23-12-17-2-1-9-25(17)16-6-3-13(4-7-16)21(27)28/h1-12H,(H,24,26)(H,27,28)",SIFPICQLVICEFD-UHFFFAOYSA-N,50726,4-[2-[[(5-bromanyl-1-benzofuran-2-yl)carbonylhydrazinylidene]methyl]pyrrol-1-yl]benzoic acid::4-[2-[[(5-bromo-1-benzofuran-2-carbonyl)hydrazinylidene]methyl]pyrrol-1-yl]benzoic acid::4-[2-[[(5-bromobenzofuran-2-carbonyl)hydrazono]methyl]pyrrol-1-yl]benzoic acid::4-[2-[[[(5-bromo-2-benzofuranyl)-oxomethyl]hydrazinylidene]methyl]-1-pyrrolyl]benzoic acid::4-{2-[(5-Bromo-benzofuran-2-carbonyl)-hydrazonomethyl]-pyrrol-1-yl}-benzoic acid::MLS001043301::SMR000414988::cid_1003204,Induced myeloid leukemia cell differentiation protein Mcl-1,Homo sapiens,1721.431107
1257951,Cc1nn(cc1Nc1ncc(Cl)c(OCC2COC2)n1)C(C)(C)C#N,"InChI=1S/C16H19ClN6O2/c1-10-13(5-23(22-10)16(2,3)9-18)20-15-19-4-12(17)14(21-15)25-8-11-6-24-7-11/h4-5,11H,6-8H2,1-3H3,(H,19,20,21)",XPGBSNMUIPRALK-UHFFFAOYSA-N,593180,"2-(4-((5-chloro-4-(oxetan-3- ylmethoxy)pyrimidin-2-yl)amino)- 3-methyl-1H-pyrazol-1-yl)-2- methylpropanenitrile::US11578061, Example 158",Leucine-rich repeat serine/threonine-protein kinase 2 [970-2527],, 125
50376960,Clc1cccc(c1)N1CCN(CCCCN2C(=O)C[C@H](NC(=O)C34CC5CC(CC(C5)C3)C4)C2=O)CC1,"InChI=1S/C29H39ClN4O3/c30-23-4-3-5-24(15-23)33-10-8-32(9-11-33)6-1-2-7-34-26(35)16-25(27(34)36)31-28(37)29-17-20-12-21(18-29)14-22(13-20)19-29/h3-5,15,20-22,25H,1-2,6-14,16-19H2,(H,31,37)/t20?,21?,22?,25-,29?/m0/s1",PWFKOTHBUIUXGW-FADFPCINSA-N,50206354,"CHEMBL231825::N-((S)-1-{4-[4-(3-chlorophenyl)piperazin-1-yl]butyl}pyrrolidin-2,5-dion-yl)-1-adamantanecarboxamide",5-hydroxytryptamine receptor 2A,Rattus norvegicus,
1165678,Oc1c2C(=O)N3CN([C@H]4c5ccccc5SCc5c(F)c(F)cc(OC\C=C/C33CC3)c45)n2ccc1=O,"InChI=1S/C27H21F2N3O4S/c28-17-12-19-21-16(22(17)29)13-37-20-5-2-1-4-15(20)23(21)32-14-30(27(8-9-27)7-3-11-36-19)26(35)24-25(34)18(33)6-10-31(24)32/h1-7,10,12,23,34H,8-9,11,13-14H2/b7-3-/t23-/m0/s1",QYYFWNWGMIOOMO-DFTTYVQVSA-N,552335,"US11312727, Compound 108C",Polymerase basic protein 2,, 2388
172594,C(Oc1cccnc1)[C@@H]1CCN1,"InChI=1S/C9H12N2O/c1-2-9(6-10-4-1)12-7-8-3-5-11-8/h1-2,4,6,8,11H,3,5,7H2/t8-/m0/s1",XKFMBGWHHBCWCD-QMMMGPOBSA-N,50049750,(S)-3-(azetidin-2-ylmethoxy)pyridine::3-((S)-1-Azetidin-2-ylmethoxy)-pyridine::A-159470::A-85380::CHEMBL59986,Acetylcholine receptor subunit alpha,Rattus,
51192413,CC(C)c1nc(SCc2ccc(cc2)-c2ccccc2C#N)c2ccccc2n1,"InChI=1S/C25H21N3S/c1-17(2)24-27-23-10-6-5-9-22(23)25(28-24)29-16-18-11-13-19(14-12-18)21-8-4-3-7-20(21)15-26/h3-14,17H,16H2,1-2H3",PMFZGFZEBDYMHD-UHFFFAOYSA-N,50490850,CHEMBL2349281,"High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A/cAMP-specific 3',5'-cyclic phosphodiesterase 7B",Homo sapiens,>100000
50511965,CCCCCCCCCCCCNC(=O)Oc1ccc(cc1)C1=NCCS1,"InChI=1S/C22H34N2O2S/c1-2-3-4-5-6-7-8-9-10-11-16-24-22(25)26-20-14-12-19(13-15-20)21-23-17-18-27-21/h12-15H,2-11,16-18H2,1H3,(H,24,25)",BNGJKAJIYBXVJX-UHFFFAOYSA-N,50295660,"CHEMBL557234::Dodecylcarbamic acid 4-(4,5-dihydrothiazol-2-yl)phenylester",Fatty-acid amide hydrolase 1 [30-579],, 6.3
786204,COc1ccc(CNC(=O)c2cnc(CNS(=O)(=O)c3ccc(F)c(Cl)c3)cn2)cn1,"InChI=1S/C19H17ClFN5O4S/c1-30-18-5-2-12(7-24-18)8-25-19(27)17-11-22-13(9-23-17)10-26-31(28,29)14-3-4-16(21)15(20)6-14/h2-7,9,11,26H,8,10H2,1H3,(H,25,27)",GIPLPUQPFVMLLX-UHFFFAOYSA-N,393190,"5-(3-chloro-4- fluorobenzenesulfon- amidomethyl)-N-[(6- methoxypyridin-3- yl)methyl]pyrazine-2- carboxamide::US9963434, Table 12.133","Glutamate receptor ionotropic, NMDA 2A",, 10000
50670651,CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1,"InChI=1S/C26H30FN7O3/c1-2-34(10-11-35)9-4-12-37-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(36)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17,35H,2,4,9-12,15H2,1H3,(H,30,36)(H2,28,29,31,32,33)",QYZOGCMHVIGURT-UHFFFAOYSA-N,26300,"2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1H-pyrazol-5-yl}-N-(3-fluorophenyl)acetamide::CHEMBL215152::cid_16007391::pyrazoloquinazoline deriv., 34",Serine/threonine-protein kinase 25,Homo sapiens,
51015754,Cc1ccc2cc(sc2c1)C(=O)NC1(CCCC1)C(=O)N[C@@H](CCCN1CCN(CC1)C(=O)c1cccn1C)Cc1ccccc1,"InChI=1S/C37H45N5O3S/c1-27-14-15-29-26-33(46-32(29)24-27)34(43)39-37(16-6-7-17-37)36(45)38-30(25-28-10-4-3-5-11-28)12-8-19-41-20-22-42(23-21-41)35(44)31-13-9-18-40(31)2/h3-5,9-11,13-15,18,24,26,30H,6-8,12,16-17,19-23,25H2,1-2H3,(H,38,45)(H,39,43)/t30-/m0/s1",GEIAIWAMZLASTE-PMERELPUSA-N,50415929,CHEMBL1083880,Substance-K receptor,Homo sapiens,
561207,Cc1cc(C)nc(n1)N1CC2CN(CC2C1)C(=O)c1ccccc1-c1nccn1C,"InChI=1S/C23H26N6O/c1-15-10-16(2)26-23(25-15)29-13-17-11-28(12-18(17)14-29)22(30)20-7-5-4-6-19(20)21-24-8-9-27(21)3/h4-10,17-18H,11-14H2,1-3H3",FSJYWJFWTBGKNF-UHFFFAOYSA-N,118386,"US11059828, Example 39::US8653263, 39::US9586962, Example 39::USRE48841, Example 39",Orexin receptor type 2,Homo sapiens,
802581,NC1CNc2c(C(N)=O)c(nn2C1)-c1ccc(Oc2ccccc2)cc1,"InChI=1S/C19H19N5O2/c20-13-10-22-19-16(18(21)25)17(23-24(19)11-13)12-6-8-15(9-7-12)26-14-4-2-1-3-5-14/h1-9,13,22H,10-11,20H2,(H2,21,25)",IOIPGNPFRJOTEC-UHFFFAOYSA-N,249955,"US10005782, Compound 84::US9447106, 84::US9556188, Compound 84",Tyrosine-protein kinase BTK,Homo sapiens, 2900
888057,CCNc1ncc2c(n1)N(C)CCN(c1cccc(OC(CCNC)c3ccccn3)c1)C2=O,"InChI=1S/C25H31N7O2/c1-4-27-25-29-17-20-23(30-25)31(3)14-15-32(24(20)33)18-8-7-9-19(16-18)34-22(11-13-26-2)21-10-5-6-12-28-21/h5-10,12,16-17,22,26H,4,11,13-15H2,1-3H3,(H,27,29,30)",AWBSENWJRYCHOK-UHFFFAOYSA-N,436418,"2-(ethylamino)-9- methyl-6-(3-(3- (methylamino)-1- (pyridin-2- yl)propoxy)phenyl)- 6,7,8,9-tetrahydro-5H- pyrimido[4,5- e][1,4]diazepin-5-one::US10590140, Example 193",Voltage-dependent calcium channel subunit alpha-2/delta-1 [25-1103],,
1124406,COC(=O)c1cc2NC(=O)\C(=C(/Nc3ccc(cc3)C(=O)N3CCN(CCO)CC3)c3ccccc3)c2cc1C,"InChI=1S/C31H32N4O5/c1-20-18-25-26(19-24(20)31(39)40-2)33-29(37)27(25)28(21-6-4-3-5-7-21)32-23-10-8-22(9-11-23)30(38)35-14-12-34(13-15-35)16-17-36/h3-11,18-19,32,36H,12-17H2,1-2H3,(H,33,37)/b28-27-",BLYDOULCQABGHT-DQSJHHFOSA-N,445228,"US10669235, Example 19::US11208381, Example 19",Platelet-derived growth factor receptor alpha,Homo sapiens,
1013308,CC(C)CNC(=O)N1C2CC1CN(C2)c1ccc(cn1)-c1cc(OCC(C)(C)O)cn2ncc(C#N)c12,"InChI=1S/C27H33N7O3/c1-17(2)10-30-26(35)34-20-7-21(34)14-32(13-20)24-6-5-18(11-29-24)23-8-22(37-16-27(3,4)36)15-33-25(23)19(9-28)12-31-33/h5-6,8,11-12,15,17,20-21,36H,7,10,13-14,16H2,1-4H3,(H,30,35)",NMVDCRRHAXXYDL-UHFFFAOYSA-N,296682,"US10112942, Example 417::US10137124, Example 417::US10172851, Example 417::US10555944, Example 417::US10953005, Example 417",Proto-oncogene tyrosine-protein kinase receptor Ret,Homo sapiens, 109
93254,Nc1ccc(cc1N1CCCCC1)N1CCCCC1,"InChI=1S/C16H25N3/c17-15-8-7-14(18-9-3-1-4-10-18)13-16(15)19-11-5-2-6-12-19/h7-8,13H,1-6,9-12,17H2",CHRDROHURUMVLJ-UHFFFAOYSA-N,34166,"(2,4-dipiperidinophenyl)amine::2,4-Di-piperidin-1-yl-phenylamine::2,4-bis(1-piperidinyl)aniline::2,4-di(piperidin-1-yl)aniline::MLS000033228::SMR000012925::cid_655480",Induced myeloid leukemia cell differentiation protein Mcl-1,Homo sapiens, 54000
51370517,CCn1nc2CCCCc2c1Nc1nc(cs1)-c1ccc(c(OC)n1)-n1cnc(C)c1,"InChI=1S/C22H25N7OS/c1-4-29-20(15-7-5-6-8-16(15)27-29)26-22-25-18(12-31-22)17-9-10-19(21(24-17)30-3)28-11-14(2)23-13-28/h9-13H,4-8H2,1-3H3,(H,25,26)",JPFIVLHIBZXRKR-UHFFFAOYSA-N,50534361,CHEMBL4445443,"1,3-beta-glucan synthase component GSC2",Saccharomyces cerevisiae, 8600
50319900,OC(=O)C1=C(CCC1)C(=O)Nc1ccc(cc1)-c1ccccc1,"InChI=1S/C19H17NO3/c21-18(16-7-4-8-17(16)19(22)23)20-15-11-9-14(10-12-15)13-5-2-1-3-6-13/h1-3,5-6,9-12H,4,7-8H2,(H,20,21)(H,22,23)",KKMNLDWJDASMGY-UHFFFAOYSA-N,16109,2-[(4-phenylphenyl)carbamoyl]cyclopent-1-ene-1-carboxylic acid::Biphenyl-4-ylcarbamoyl Cyclopentene Analog 1::CHEMBL348270,"Dihydroorotate dehydrogenase (quinone), mitochondrial",Rattus norvegicus, 1500
715417,FC(F)c1ccc(CCN2CCC(Nc3ncnc4[nH]ncc34)C(F)(F)C2)cc1,,,361999,"US10221182, Compound E1-1.6::US10221182, Compound E2-1.6","Glutamate receptor ionotropic, NMDA 2B",Homo sapiens, 21.2
281324,Oc1ccc(Nc2nc(NCCOCCOCCNC(=O)c3ccccc3)nc(Nc3ccc(cc3)C(=O)NCc3ccc(F)cc3)n2)cc1,"InChI=1S/C36H37FN8O5/c37-28-10-6-25(7-11-28)24-40-33(48)27-8-12-29(13-9-27)41-35-43-34(44-36(45-35)42-30-14-16-31(46)17-15-30)39-19-21-50-23-22-49-20-18-38-32(47)26-4-2-1-3-5-26/h1-17,46H,18-24H2,(H,38,47)(H,40,48)(H3,39,41,42,43,44,45)",KBZDTVRBFCWJHU-UHFFFAOYSA-N,144810,"US8952150, 99",Solute carrier organic anion transporter family member 2A1,, 23.7
50470691,CO[C@H]1[C@H](C[C@@H]2O[C@@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)[N+](C)(C)C,"InChI=1S/C30H30N4O3/c1-30-28(36-5)21(34(2,3)4)14-22(37-30)32-19-12-8-6-10-16(19)24-25-18(15-31-29(25)35)23-17-11-7-9-13-20(17)33(30)27(23)26(24)32/h6-13,21-22,28H,14-15H2,1-5H3/p+1/t21-,22-,28-,30+/m0/s1",MYOUXQLHWTWXON-VZYCLNPTSA-O,50283895,"3-methoxy-2-methyl-16-oxo-(2R,3S,4S,6S)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8(13),9,11,14,19,21(26),22,24,27-nonaen-4-yl(trimethyl)ammonium::CHEMBL335648",Epidermal growth factor receptor,Homo sapiens, 19
436249,Cc1ccc(cc1C)C(=O)Nc1ccc(cc1)[C@H]1CCCNC1,"InChI=1S/C20H24N2O/c1-14-5-6-17(12-15(14)2)20(23)22-19-9-7-16(8-10-19)18-4-3-11-21-13-18/h5-10,12,18,21H,3-4,11,13H2,1-2H3,(H,22,23)/t18-/m0/s1",GEPKFYJSXOSMME-SFHVURJKSA-N,250350,"US10501411, Example 260::US9452980, 260",Trace amine-associated receptor 1,Mus musculus,
69288,CCc1ccccc1NC(=O)C(Cc1cccnc1)C#N,"InChI=1S/C17H17N3O/c1-2-14-7-3-4-8-16(14)20-17(21)15(11-18)10-13-6-5-9-19-12-13/h3-9,12,15H,2,10H2,1H3,(H,20,21)",YICFJGNYIQOYJB-UHFFFAOYSA-N,37605,2-Cyano-N-(2-ethyl-phenyl)-2-pyridin-3-ylmethyl-acetamide::2-cyano-N-(2-ethylphenyl)-3-(3-pyridinyl)propanamide::2-cyano-N-(2-ethylphenyl)-3-(3-pyridyl)propionamide::2-cyano-N-(2-ethylphenyl)-3-pyridin-3-yl-propanamide::2-cyano-N-(2-ethylphenyl)-3-pyridin-3-ylpropanamide::MLS000035720::SMR000002073::cid_646700,fMet-Leu-Phe receptor,Homo sapiens,
50797899,NS(=O)(=O)c1ccc(Nc2ccnc(NC(=O)c3c(F)c(F)c(F)c(F)c3F)n2)cc1,"InChI=1S/C17H10F5N5O3S/c18-11-10(12(19)14(21)15(22)13(11)20)16(28)27-17-24-6-5-9(26-17)25-7-1-3-8(4-2-7)31(23,29)30/h1-6H,(H2,23,29,30)(H2,24,25,26,27,28)",BYXYWDVAUCLHPP-UHFFFAOYSA-N,50094368,"2,3,4,5,6-Pentafluoro-N-[4-(4-sulfamoyl-phenylamino)-pyrimidin-2-yl]-benzamide::CHEMBL140696",Carbonic anhydrase 1,Homo sapiens,
50717208,O[C@]1(CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1cccnn1,"InChI=1S/C24H28F3N5O3/c25-24(26,27)17-4-1-3-16(13-17)22(34)28-14-21(33)30-18-8-12-32(15-18)19-6-9-23(35,10-7-19)20-5-2-11-29-31-20/h1-5,11,13,18-19,35H,6-10,12,14-15H2,(H,28,34)(H,30,33)/t18-,19-,23-/m1/s1",CZBSLXMXLJXEBP-DNVFCKCGSA-N,50363949,CHEMBL1951774,C-C chemokine receptor type 2,, 7.3
51053615,Fc1cccc(NC(=O)\C=C\c2ccccc2)c1,"InChI=1S/C15H12FNO/c16-13-7-4-8-14(11-13)17-15(18)10-9-12-5-2-1-3-6-12/h1-11H,(H,17,18)/b10-9+",SQJXVMSLVGLGQR-MDZDMXLPSA-N,50429756,CHEMBL2336360::N-(3-Fluorophenyl)Cinnamamide,72 kDa type IV collagenase,, 1859
866084,COc1cc(cn2ncnc12)-c1[nH]c2ccc(nc2c1C(C)C)C1CCN(CC#N)CC1,"InChI=1S/C24H27N7O/c1-15(2)21-22(17-12-20(32-3)24-26-14-27-31(24)13-17)29-19-5-4-18(28-23(19)21)16-6-9-30(10-7-16)11-8-25/h4-5,12-16,29H,6-7,9-11H2,1-3H3",HGBATMHFIUZDDU-UHFFFAOYSA-N,428120,"US10544143, Example 555::US10730877, Example 555::US11053244, Example 555",Toll-like receptor 8,, 3.00
50300651,CCOC(=O)c1c(NC(=O)c2sc(Nc3ccc(C)cc3)nc2N(C)C)sc2CCCCc12,"InChI=1S/C24H28N4O3S2/c1-5-31-23(30)18-16-8-6-7-9-17(16)32-22(18)27-21(29)19-20(28(3)4)26-24(33-19)25-15-12-10-14(2)11-13-15/h10-13H,5-9H2,1-4H3,(H,25,26)(H,27,29)",UPSIRQTVGYTHEF-UHFFFAOYSA-N,50064621,CHEMBL3403729,Adenosine receptor A3,Homo sapiens,
51254727,CN1CCC(CC1)C(=O)N1N=CCC1c1ccccc1,"InChI=1S/C16H21N3O/c1-18-11-8-14(9-12-18)16(20)19-15(7-10-17-19)13-5-3-2-4-6-13/h2-6,10,14-15H,7-9,11-12H2,1H3",OKWCYSLFQVMVIB-UHFFFAOYSA-N,50513052,CHEMBL4527680,Receptor-interacting serine/threonine-protein kinase 1,,>10000
670697,Cc1ccc(cc1)-c1c(cc(OC[C@@H]2CCNC2)c2nn(CCOc3ccccc3)c(=O)n12)-c1ccc(cc1)C#N,"InChI=1S/C33H31N5O3/c1-23-7-11-27(12-8-23)31-29(26-13-9-24(20-34)10-14-26)19-30(41-22-25-15-16-35-21-25)32-36-37(33(39)38(31)32)17-18-40-28-5-3-2-4-6-28/h2-14,19,25,35H,15-18,21-22H2,1H3/t25-/m1/s1",AGVSWFFMFSYIIC-RUZDIDTESA-N,304057,"4-{5-(4-methylphenyl)-3-oxo-2-(2-phenoxyethyl)-8-[(3R)-pyrrolidin-3-ylmethoxy]-2,3-dihydro[1,2,4]triazolo[4,3-a]pyridin-6-yl}benzonitrile::US10138249, Example 14::US9758523, Example 14",Lysine-specific histone demethylase 1A,Homo sapiens,<50
50860661,CC(C)(C)Cn1cnc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)-c1c(F)cccc1F,"InChI=1S/C26H22F3N5/c1-26(2,3)13-34-14-30-20-12-11-19(31-25(20)34)23-22(15-7-9-16(27)10-8-15)32-24(33-23)21-17(28)5-4-6-18(21)29/h4-12,14H,13H2,1-3H3,(H,32,33)",MRTSPTRJKFTETB-UHFFFAOYSA-N,50373948,CHEMBL404118,Mitogen-activated protein kinase 14,Homo sapiens, 7.2
754746,COc1ccc(F)c(-c2nc(C(=O)Nc3cnc4[C@H](O)CCc4c3N3CCC[C@H](N)C3)c(N)s2)c1F,"InChI=1S/C24H26F2N6O3S/c1-35-16-7-5-13(25)17(18(16)26)24-31-20(22(28)36-24)23(34)30-14-9-29-19-12(4-6-15(19)33)21(14)32-8-2-3-11(27)10-32/h5,7,9,11,15,33H,2-4,6,8,10,27-28H2,1H3,(H,30,34)/t11-,15+/m0/s1",FWNRHQYQQFAYQE-XHDPSFHLSA-N,377212,"US10265307, Example 53-2::US10517858, Example 53 (Diastereoisomer 2)::US10828290, Example 53 (Diastereoisomer 2)",Serine/threonine-protein kinase pim-3,Homo sapiens,<100
627677,CO[C@H](C(=O)N1CCN(CC1)c1ccc(cn1)-c1cc(cn2ncc(C#N)c12)-c1cnc(C)o1)c1ccccc1,"InChI=1S/C30H27N7O3/c1-20-32-18-26(40-20)23-14-25(28-24(15-31)17-34-37(28)19-23)22-8-9-27(33-16-22)35-10-12-36(13-11-35)30(38)29(39-2)21-6-4-3-5-7-21/h3-9,14,16-19,29H,10-13H2,1-2H3/t29-/m0/s1",HZAPGFUEDAAMHV-LJAQVGFWSA-N,284684,"US10023570, Example 719::US10174027, Example 719",Proto-oncogene tyrosine-protein kinase receptor Ret,Homo sapiens, 87.6
851342,Cn1cc(cn1)-c1ccc2cnc(NC(=O)C3CCN(CC(C)(F)F)CC3)cc2c1,"InChI=1S/C22H25F2N5O/c1-22(23,24)14-29-7-5-15(6-8-29)21(30)27-20-10-18-9-16(3-4-17(18)11-25-20)19-12-26-28(2)13-19/h3-4,9-13,15H,5-8,14H2,1-2H3,(H,25,27,30)",OBYONDURSTUMQK-UHFFFAOYSA-N,385083,"US10287267, Compound 83::US10508099, Compound 83::US10556885, Compound 83::US11174244, Compound 83",Glycogen synthase kinase-3 beta,Homo sapiens,
50031050,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12,"InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3",GDLIGKIOYRNHDA-UHFFFAOYSA-N,77970,"3-(2-chloranyl-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethyl-propan-1-amine;hydrochloride::3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethyl-1-propanamine;hydrochloride::3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine;hydrochloride::3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl-dimethyl-amine;hydrochloride::CHLORIMIPRAMINE::CLOMIPRAMINE::CLOMIPRAMINE HYDROCHLORIDE::CLOMIPRIMINE::MLS000028511::SMR000058295::cid_68539::med.21724, Compound Clomipramine",Alpha-1A/Alpha-1B/Alpha-1D adrenergic receptor,,
1133934,Fc1ccc(cc1)S(=O)(NC(=O)Nc1c2CCCc2cc2CCCc12)=NC#N,"InChI=1S/C20H19FN4O2S/c21-15-7-9-16(10-8-15)28(27,23-12-22)25-20(26)24-19-17-5-1-3-13(17)11-14-4-2-6-18(14)19/h7-11H,1-6H2,(H2,23,24,25,26,27)",HUXGQLXQWZDOQV-UHFFFAOYSA-N,534822,"US11236045, Example 21",Uromodulin,, 62.0
50114222,Cc1noc(NS(=O)(=O)c2sccc2C(=O)Cc2cc3OCOc3cc2C)c1Cl,"InChI=1S/C18H15ClN2O6S2/c1-9-5-14-15(26-8-25-14)7-11(9)6-13(22)12-3-4-28-18(12)29(23,24)21-17-16(19)10(2)20-27-17/h3-5,7,21H,6,8H2,1-2H3",SWOBCLGSVXXLQF-UHFFFAOYSA-N,50066398,"3-[2-(6-Methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-2-sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide::CHEMBL326059",Endothelin receptor type B,Homo sapiens,
388179,CN1C2COCC1CC(C2)NC(=O)c1cn(-c2nccs2)c2ncc(F)cc12,"InChI=1S/C19H20FN5O2S/c1-24-13-5-12(6-14(24)10-27-9-13)23-18(26)16-8-25(19-21-2-3-28-19)17-15(16)4-11(20)7-22-17/h2-4,7-8,12-14H,5-6,9-10H2,1H3,(H,23,26)",VRBYIQKJZRNKLG-UHFFFAOYSA-N,221657,"US9303045, 162::US9695195, 162",5-hydroxytryptamine receptor 3A,Homo sapiens, 1.81
746524,C[C@H](Nc1nccc(NCCO)c1F)c1cc2cc(Cl)ccc2[nH]c1=O,,,375176,"6-chloro-3-[(1S)-1-({3-::US10253015, Compound I-36",Isocitrate dehydrogenase [NADP] cytoplasmic [R132C],,>1000
853229,Clc1ccc(NC(=O)Nc2ccc(CCC3CCNC3)cc2)cc1,"InChI=1S/C19H22ClN3O/c20-16-5-9-18(10-6-16)23-19(24)22-17-7-3-14(4-8-17)1-2-15-11-12-21-13-15/h3-10,15,21H,1-2,11-13H2,(H2,22,23,24)",FCHJTQQSYFFFBE-UHFFFAOYSA-N,250206,"US10501411, Example 116::US9452980, 116",Trace amine-associated receptor 1,Mus musculus,
131832,Oc1cc2ccccc2cc1C(=O)NN=Cc1ccncc1,"InChI=1S/C17H13N3O2/c21-16-10-14-4-2-1-3-13(14)9-15(16)17(22)20-19-11-12-5-7-18-8-6-12/h1-11,21H,(H,20,22)",LVOVRLMOYZZYDY-UHFFFAOYSA-N,65668,3-hydroxy-N-(4-pyridylmethyleneamino)-2-naphthamide::3-hydroxy-N-(pyridin-4-ylmethylideneamino)-2-naphthalenecarboxamide::3-hydroxy-N-(pyridin-4-ylmethylideneamino)naphthalene-2-carboxamide::3-oxidanyl-N-(pyridin-4-ylmethylideneamino)naphthalene-2-carboxamide::MLS001123699::SMR000658768::cid_795958,Heat shock factor protein 1,Mus musculus,
51379537,Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F,"InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)",RZEKVGVHFLEQIL-UHFFFAOYSA-N,11639,"4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide::CHEMBL118::CLX::Celebrex::Celecoxib::US10322118, Urea-Based Scaffold Entry 9::US11478464, Compound Celecoxib::US8741944, Comparative Compound::US9388139, Celecoxib::cid_2662",Prostaglandin G/H synthase 2,Homo sapiens, 90
50097646,CSCC[C@H](NC(=O)c1cccc2cc(NC[C@@H](N)CS)ccc12)C(O)=O,"InChI=1S/C19H25N3O3S2/c1-27-8-7-17(19(24)25)22-18(23)16-4-2-3-12-9-14(5-6-15(12)16)21-10-13(20)11-26/h2-6,9,13,17,21,26H,7-8,10-11,20H2,1H3,(H,22,23)(H,24,25)/t13-,17+/m1/s1",YUXOGMIOPNYIQR-DYVFJYSZSA-N,50058204,(S)-2-{[6-((R)-2-Amino-3-mercapto-propylamino)-naphthalene-1-carbonyl]-amino}-4-methylsulfanyl-butyric acid::CHEMBL48866::RPR-113829,Dimer of Protein farnesyltransferase subunit beta,Homo sapiens, 1.8
981991,Nc1ncnc2n(nc(-c3cc4ccccc4[nH]3)c12)C1CC[C@@H](CC1)NC(=O)C1CC1,,,473662,"N-(trans-4-(4-Amino-3-(1H-indol-2-yl)-1H- pyrazolo[3,4-d]pyrimidin-1- yl)cyclohexyl)cyclopropanecarboxamide::US10844067, Example 5",Proto-oncogene tyrosine-protein kinase receptor Ret,Homo sapiens, 28.5
51451743,Cl.Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)[C@H](CC[C@@]35O)NC(=O)c1ccoc1,"InChI=1S/C25H28N2O5.ClH/c28-18-4-3-15-11-19-25(30)7-5-17(26-23(29)16-6-10-31-13-16)22-24(25,20(15)21(18)32-22)8-9-27(19)12-14-1-2-14;/h3-4,6,10,13-14,17,19,22,28,30H,1-2,5,7-9,11-12H2,(H,26,29);1H/t17-,19+,22-,24-,25+;/m0./s1",WBSVANNKUKFNOK-UQCSYHANSA-N,50586123,CHEMBL5073592,Delta-type opioid receptor,Homo sapiens,
50732830,NS(=O)(=O)c1ccc(cc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)NCC(O)=O,"InChI=1S/C15H17N5O6S/c16-27(25,26)11-3-1-9(2-4-11)14(23)20-12(5-10-6-17-8-19-10)15(24)18-7-13(21)22/h1-4,6,8,12H,5,7H2,(H,17,19)(H,18,24)(H,20,23)(H,21,22)(H2,16,25,26)/t12-/m0/s1",CWCWATFNQGYAKJ-LBPRGKRZSA-N,50101378,CHEMBL52227::[(S)-3-(3H-Imidazol-4-yl)-2-(4-sulfamoyl-benzoylamino)-propionylamino]-acetic acid,Carbonic anhydrase 1,Homo sapiens,
44298,OC(=O)CN1C(=O)C(Cc2ccccc12)NC(=O)c1cc2cc(Cl)ccc2[nH]1,"InChI=1S/C20H16ClN3O4/c21-13-5-6-14-12(7-13)9-15(22-14)19(27)23-16-8-11-3-1-2-4-17(11)24(20(16)28)10-18(25)26/h1-7,9,16,22H,8,10H2,(H,23,27)(H,25,26)",CCGBIWYBXDWOOH-UHFFFAOYSA-N,24371,"2-{3-[(5-chloro-1H-indole-2-)amido]-2-oxo-1,2,3,4-tetrahydroquinolin-1-yl}acetic acid::3,4-dihydro-2-quinolone (DHQ) derivative, 10","Glycogen phosphorylase, liver form",Homo sapiens, 237
51216538,Cc1ccc(C(O)=O)c(C)c1NC(=O)c1cc(cc2ccccc12)-c1cccc(Cl)c1,"InChI=1S/C26H20ClNO3/c1-15-10-11-21(26(30)31)16(2)24(15)28-25(29)23-14-19(17-7-5-8-20(27)13-17)12-18-6-3-4-9-22(18)23/h3-14H,1-2H3,(H,28,29)(H,30,31)",SIIGKILIYGRIJN-UHFFFAOYSA-N,50140258,CHEMBL3740325,Prostaglandin E2 receptor EP1 subtype,,
50664117,NC(=O)c1ccc(Nc2nnc(-c3ccc(O)cc3)c3ccccc23)cc1,"InChI=1S/C21H16N4O2/c22-20(27)14-5-9-15(10-6-14)23-21-18-4-2-1-3-17(18)19(24-25-21)13-7-11-16(26)12-8-13/h1-12,26H,(H2,22,27)(H,23,25)",LGCIFOOQZRHNIN-UHFFFAOYSA-N,50354686,CHEMBL1524400,Serine/threonine-protein kinase B-raf,Homo sapiens,
1100902,Oc1ccc2C(=C(CCc2c1)c1ccc(Cl)cc1Cl)c1ccc(O[C@H]2CCN(CCCF)C2)cc1,"InChI=1S/C29H28Cl2FNO2/c30-21-5-10-26(28(31)17-21)27-9-4-20-16-22(34)6-11-25(20)29(27)19-2-7-23(8-3-19)35-24-12-15-33(18-24)14-1-13-32/h2-3,5-8,10-11,16-17,24,34H,1,4,9,12-15,18H2/t24-/m0/s1",LINFCFKJWGTADI-DEOSSOPVSA-N,521190,"6-(2,4- dichlorophenyl)- 5-[4-[(3S)-1-(3- fluoropropyl)pyr- rolidin-3- yl]oxyphenyl]- 7,8- dihydronaphtha- len-2-ol::US11149031, Example 14","Estrogen receptor [298-554,D538G]",, 3310
51102404,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@H](NC1=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)[C@@H](C)O,"InChI=1S/C63H96N20O18S2/c1-4-32(2)48-58(98)78-40-30-102-103-31-41(77-52(92)35(15-8-20-68-62(64)65)72-45(86)27-70-50(90)37(26-47(88)89)74-56(96)42-17-10-23-82(42)60(100)38(75-54(40)94)25-34-13-6-5-7-14-34)55(95)80-49(33(3)85)59(99)73-36(16-9-21-69-63(66)67)53(93)76-39(29-84)51(91)71-28-46(87)81-22-12-19-44(81)61(101)83-24-11-18-43(83)57(97)79-48/h5-7,13-14,32-33,35-44,48-49,84-85H,4,8-12,15-31H2,1-3H3,(H,70,90)(H,71,91)(H,72,86)(H,73,99)(H,74,96)(H,75,94)(H,76,93)(H,77,92)(H,78,98)(H,79,97)(H,80,95)(H,88,89)(H4,64,65,68)(H4,66,67,69)/t32-,33+,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,48-,49-/m0/s1",WPGYEGGDARHIAP-NEPSLTQLSA-N,50449675,CHEMBL4175285,Serine protease 1,Homo sapiens,
50704371,Cn1nc(nc1C1(CC1)c1ccccc1)-c1cnc(N)c(n1)-n1cnc2ccccc12,"InChI=1S/C23H20N8/c1-30-22(23(11-12-23)15-7-3-2-4-8-15)28-20(29-30)17-13-25-19(24)21(27-17)31-14-26-16-9-5-6-10-18(16)31/h2-10,13-14H,11-12H2,1H3,(H2,24,25)",YWIDMRZQZDODER-UHFFFAOYSA-N,50234172,CHEMBL4088819,"Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Homo sapiens,>31623
50339121,OC(=O)c1cccc(c1)-c1ncccc1-c1cc(Cl)ccc1OCc1ccccc1,"InChI=1S/C25H18ClNO3/c26-20-11-12-23(30-16-17-6-2-1-3-7-17)22(15-20)21-10-5-13-27-24(21)18-8-4-9-19(14-18)25(28)29/h1-15H,16H2,(H,28,29)",KDRGQJRCUVUELE-UHFFFAOYSA-N,50183183,3-(3-(2-(benzyloxy)-5-chlorophenyl)pyridin-2-yl)benzoic acid::CHEMBL206096,Cytochrome P450 1A2,Homo sapiens,>50000
51197814,OCCC(N1CCC(CC1)=C(c1ccccc1)c1ccccc1)C(=O)NCc1ccc(F)cc1,"InChI=1S/C29H31FN2O2/c30-26-13-11-22(12-14-26)21-31-29(34)27(17-20-33)32-18-15-25(16-19-32)28(23-7-3-1-4-8-23)24-9-5-2-6-10-24/h1-14,27,33H,15-21H2,(H,31,34)",GKPAFQFQYVEMJQ-UHFFFAOYSA-N,50492912,CHEMBL2414193,Sodium- and chloride-dependent GABA transporter 1,Rattus norvegicus, 9772
50850705,CCCCCCCCCCC#CC(O)c1ccccc1-c1ccc(Sc2ccc(OCCCCCC)cc2)c(c1)S([O-])(=O)=O,"InChI=1S/C37H48O5S2/c1-3-5-7-9-10-11-12-13-14-15-21-35(38)34-20-17-16-19-33(34)30-22-27-36(37(29-30)44(39,40)41)43-32-25-23-31(24-26-32)42-28-18-8-6-4-2/h16-17,19-20,22-27,29,35,38H,3-14,18,28H2,1-2H3,(H,39,40,41)/p-1",JEPABZVKYKGQIC-UHFFFAOYSA-M,50208894,CHEMBL277377::sodium 4-[(4-hexyloxyphenyl)thio]-20-(1-hydroxytridec-2-yl)biphenyl-3-sulfonate,Sphingosine 1-phosphate receptor 1,Homo sapiens, 520
50455328,Nc1nc(C(=O)NCc2cccc3cccnc23)c2cc(F)c(F)cc2n1,"InChI=1S/C19H13F2N5O/c20-13-7-12-15(8-14(13)21)25-19(22)26-17(12)18(27)24-9-11-4-1-3-10-5-2-6-23-16(10)11/h1-8H,9H2,(H,24,27)(H2,22,25,26)",RFBOIDHBCYJRIH-UHFFFAOYSA-N,50139777,CHEMBL3764260,Adenosine receptor A1,Homo sapiens,
322,COc1cccc2nc(oc12)C(=O)[C@H](CC(O)=O)NC(=O)c1ccc(CNS(=O)(=O)c2ccc(O)c(c2)C(O)=O)nc1,"InChI=1S/C26H22N4O11S/c1-40-20-4-2-3-17-23(20)41-25(30-17)22(34)18(10-21(32)33)29-24(35)13-5-6-14(27-11-13)12-28-42(38,39)15-7-8-19(31)16(9-15)26(36)37/h2-9,11,18,28,31H,10,12H2,1H3,(H,29,35)(H,32,33)(H,36,37)/t18-/m0/s1",SIRDBTDSADKLJV-SFHVURJKSA-N,279,"5-{[(5-{[(2S)-3-carboxy-1-(7-methoxy-1,3-benzoxazol-2-yl)-1-oxopropan-2-yl]carbamoyl}pyridin-2-yl)methyl]sulfamoyl}-2-hydroxybenzoic acid::6-[(4-Hydroxy-3-methyl-benzenesulfonylamino)methyl]-N-[1-(7-methoxy-benzooxazole-2-carbonyl)propyl]nicotinamide::Inhibitor 61::Pyridine Scaffold 61",Caspase-3,Homo sapiens,
50075335,Cc1cc2CSc3c(nn(c3-c2cc1F)-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F,"InChI=1S/C18H13F4N3O2S2/c1-9-6-10-8-28-16-15(13(10)7-14(9)19)25(24-17(16)18(20,21)22)11-2-4-12(5-3-11)29(23,26)27/h2-7H,8H2,1H3,(H2,23,26,27)",DADHJCHABCTJSK-UHFFFAOYSA-N,50288333,"4-(8-Fluoro-7-methyl-3-trifluoromethyl-5H-isothiochromeno[4,3-c]pyrazol-1-yl)-benzenesulfonamide::CHEMBL94494",Prostaglandin G/H synthase 1,, 11099
50451050,CC[C@@]12C[C@H](O)[C@@](O)(C[C@H]1CCc1cc(O)ccc21)C#CC,"InChI=1S/C19H24O3/c1-3-9-19(22)11-14-6-5-13-10-15(20)7-8-16(13)18(14,4-2)12-17(19)21/h7-8,10,14,17,20-22H,4-6,11-12H2,1-2H3/t14-,17+,18-,19+/m1/s1",LENKTUVVULSELH-FDPIWHGQSA-N,50276471,"(2R,3S,4aR,10aR)-4a-Ethyl-2-prop-1-ynyl-1,2,3,4,4a,9,10,10aoctahydrophenanthrene-2,3,7-triol::CHEMBL457241",Glucocorticoid receptor,, 63
760052,O=C(Nc1ccc(cc1)-c1n[nH]c(=O)c2ccccc12)c1cnn2cc(OCCN3CCOCC3)ccc12,"InChI=1S/C28H26N6O4/c35-27(24-17-29-34-18-21(9-10-25(24)34)38-16-13-33-11-14-37-15-12-33)30-20-7-5-19(6-8-20)26-22-3-1-2-4-23(22)28(36)32-31-26/h1-10,17-18H,11-16H2,(H,30,35)(H,32,36)",NNZDJMDSGQADMM-UHFFFAOYSA-N,380193,"6-[2-(morpholin-4- yl)ethoxy]-N-[4-(4-oxo- 3,4-dihydrophthalazin-1- yl)phenyl]pyrazolo[1,5- a]pyridine-3- carboxamide::US9926282, Example 188",Rho-associated protein kinase 1,Homo sapiens,<100
1213469,CC1CN(CCN2CCC(CC2)c2noc3ccccc23)C(=O)c2ccn(C)c12,"InChI=1S/C23H28N4O2/c1-16-15-27(23(28)19-9-10-25(2)22(16)19)14-13-26-11-7-17(8-12-26)21-18-5-3-4-6-20(18)29-24-21/h3-6,9-10,16-17H,7-8,11-15H2,1-2H3",JLSHFCOIGLDZJK-UHFFFAOYSA-N,458608,"US10745401, Example 82::US11466007, Example 82",D(2) dopamine receptor,Homo sapiens,
50145888,COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,"InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)",NOYPYLRCIDNJJB-UHFFFAOYSA-N,18268,"5-methyl-6-{[(3,4,5-trimethoxyphenyl)amino]methyl}quinazoline-2,4-diamine::CHEMBL119::TMQ::Trimetrexate::US11111252, Compound TMQ::US11530198, Example Trimetrexate",Dihydrofolate reductase,Rattus norvegicus, 3
685700,OC(CC1c2cc(F)ccc2-c2cncn12)C12CC3CC(CC(C3)C1)C2,"InChI=1S/C22H25FN2O/c23-16-1-2-17-18(6-16)19(25-12-24-11-20(17)25)7-21(26)22-8-13-3-14(9-22)5-15(4-13)10-22/h1-2,6,11-15,19,21,26H,3-5,7-10H2",TVYSAKSWTQIQBL-UHFFFAOYSA-N,347004,"US10202388, Compound 7","Indoleamine 2,3-dioxygenase 1",Homo sapiens, 300
160484,CN1CCc2cc(Br)c(O)cc2C(C1)c1ccccc1,"InChI=1S/C17H18BrNO/c1-19-8-7-13-9-16(18)17(20)10-14(13)15(11-19)12-5-3-2-4-6-12/h2-6,9-10,15,20H,7-8,11H2,1H3",XFTVOHWWEQGXLS-UHFFFAOYSA-N,50010301,"8-Bromo-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol(SKF 83566)::CHEMBL324017::SKF 83566",5-hydroxytryptamine receptor 5B,Rattus,
1027976,Cc1cc(cc(C)n1)-c1nnc(N)nc1-c1ccccc1,"InChI=1S/C16H15N5/c1-10-8-13(9-11(2)18-10)15-14(19-16(17)21-20-15)12-6-4-3-5-7-12/h3-9H,1-2H3,(H2,17,19,21)",SORFNYWLKDSNNF-UHFFFAOYSA-N,50382492,"CHEMBL2024115::US10988455, Example 5(viii)",Adenosine receptor A1,Homo sapiens,
522025,FCCNC[C@H]1CC[C@@H](CC1)c1nnn2cnc3[nH]ccc3c12,,,198300,"US9216999, 107::US9556187, Example 107",Tyrosine-protein kinase JAK1,Homo sapiens, 310
192742,CCOC(=O)Cc1csc(NC(=O)c2sc3nc4cc(C)ccc4cc3c2N)n1,"InChI=1S/C20H18N4O3S2/c1-3-27-15(25)8-12-9-28-20(22-12)24-18(26)17-16(21)13-7-11-5-4-10(2)6-14(11)23-19(13)29-17/h4-7,9H,3,8,21H2,1-2H3,(H,22,24,26)",DGVJQCOKXOACNG-UHFFFAOYSA-N,52442,"2-[2-[(3-amino-7-methyl-thieno[2,3-b]quinoline-2-carbonyl)amino]thiazol-4-yl]acetic acid ethyl ester::2-[2-[[(3-amino-7-methyl-2-thieno[2,3-b]quinolinyl)-oxomethyl]amino]-4-thiazolyl]acetic acid ethyl ester::MLS000564527::SMR000172488::cid_3167478::ethyl 2-[2-[(3-amino-7-methylthieno[2,3-b]quinoline-2-carbonyl)amino]-1,3-thiazol-4-yl]acetate::ethyl 2-[2-[(3-azanyl-7-methyl-thieno[2,3-b]quinolin-2-yl)carbonylamino]-1,3-thiazol-4-yl]ethanoate::{2-[(3-Amino-7-methyl-thieno[2,3-b]quinoline-2-carbonyl)-amino]-thiazol-4-yl}-acetic acid ethyl ester",Delta-type opioid receptor,Homo sapiens,
51388483,COc1cccc(Nc2ccc([N+]([O-])=O)c3[nH]c(cc23)C(=O)NS(=O)(=O)c2cccc(OC)c2)c1,"InChI=1S/C23H20N4O7S/c1-33-15-6-3-5-14(11-15)24-19-9-10-21(27(29)30)22-18(19)13-20(25-22)23(28)26-35(31,32)17-8-4-7-16(12-17)34-2/h3-13,24-25H,1-2H3,(H,26,28)",PGYMTMDKJWTZNQ-UHFFFAOYSA-N,50560937,CHEMBL4740367,"Fructose-1,6-bisphosphatase 1",, 150
50134103,CCCCN(CC)c1nc(C)nc2n(-c3ccc(cc3Br)C(C)C)c(=S)sc12,"InChI=1S/C21H27BrN4S2/c1-6-8-11-25(7-2)19-18-20(24-14(5)23-19)26(21(27)28-18)17-10-9-15(13(3)4)12-16(17)22/h9-10,12-13H,6-8,11H2,1-5H3",LJRUUGDTTFDUCX-UHFFFAOYSA-N,50076896,"3-(2-Bromo-4-isopropyl-phenyl)-7-(butyl-ethyl-amino)-5-methyl-3H-thiazolo[4,5-d]pyrimidine-2-thione::CHEMBL18230",Corticotropin-releasing factor receptor 1,Homo sapiens,
50849589,O=C(Nc1nc2ccccc2n2n1nc(-c1ccccc1)c2=O)c1ccccc1,"InChI=1S/C22H15N5O2/c28-20(16-11-5-2-6-12-16)24-22-23-17-13-7-8-14-18(17)26-21(29)19(25-27(22)26)15-9-3-1-4-10-15/h1-14H,(H,23,24,28)",OFDQIHUVLITVFQ-UHFFFAOYSA-N,50224353,"CHEMBL235294::N-(1-oxo-2-phenyl-1H-3,3a,5,9b-tetraaza-cyclopenta[a]naphthalen-4-yl)-benzamide",Adenosine receptor A1,Homo sapiens,
51031745,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1,"InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2",QWCRAEMEVRGPNT-UHFFFAOYSA-N,50001859,"(buspirone) 8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione::8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione : (Hydrochloride)::8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione; Hydrochloride(Buspirone)::8-[4-(4-pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione::BUSPAR::BUSPIRONE::CHEMBL49::US10562853, Compound Buspirone",5-hydroxytryptamine receptor 1A,,
51263694,CS(=O)(=O)c1cccc(c1)-c1ccc(s1)C(=O)c1cc(F)c(F)c(O)c1F,"InChI=1S/C18H11F3O4S2/c1-27(24,25)10-4-2-3-9(7-10)13-5-6-14(26-13)17(22)11-8-12(19)16(21)18(23)15(11)20/h2-8,23H,1H3",ASDUNIRPFAQIPX-UHFFFAOYSA-N,50516201,CHEMBL4528459,17-beta-hydroxysteroid dehydrogenase type 2,Homo sapiens, 18
51263880,FC(F)Oc1ccc(NC(=O)NC2CCN(CC2)c2ncnc3n(c(nc23)-c2ccccc2Cl)-c2ccc(Cl)cc2)cn1,"InChI=1S/C29H24Cl2F2N8O2/c30-17-5-8-20(9-6-17)41-25(21-3-1-2-4-22(21)31)39-24-26(35-16-36-27(24)41)40-13-11-18(12-14-40)37-29(42)38-19-7-10-23(34-15-19)43-28(32)33/h1-10,15-16,18,28H,11-14H2,(H2,37,38,42)",LTNOPYMLPTUXSM-UHFFFAOYSA-N,50516235,CHEMBL4563408,Muscarinic acetylcholine receptor M2,,
528563,O=S1(=O)CCC(CC1)Oc1ccc(cc1C#N)-c1ncnc(Nc2ccc(cc2)N2CCN(CC2)C2COC2)n1,"InChI=1S/C28H31N7O4S/c29-16-21-15-20(1-6-26(21)39-25-7-13-40(36,37)14-8-25)27-30-19-31-28(33-27)32-22-2-4-23(5-3-22)34-9-11-35(12-10-34)24-17-38-18-24/h1-6,15,19,24-25H,7-14,17-18H2,(H,30,31,32,33)",LAHRVRATNQJNBP-UHFFFAOYSA-N,277795,"2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)oxy)-5-(4-((4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)amino)-1,3,5-triazin-2-yl)benzonitrile::US10040781, Example 17::US10040781, Example 270::US10253019, Example 17",Tyrosine-protein kinase JAK2,Homo sapiens, 804000
50325650,COc1cc2CC[C@H](NC(=O)c3ccc(cc3)C(=O)Nc3cc(ccc3N)-c3cccs3)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC,"InChI=1S/C38H35N3O7S/c1-45-31-16-13-25-26(20-30(31)42)28(15-12-24-19-32(46-2)35(47-3)36(48-4)34(24)25)40-37(43)21-7-9-22(10-8-21)38(44)41-29-18-23(11-14-27(29)39)33-6-5-17-49-33/h5-11,13-14,16-20,28H,12,15,39H2,1-4H3,(H,40,43)(H,41,44)/t28-/m0/s1",ZJQWHJDXKHHLEP-NDEPHWFRSA-N,50079497,CHEMBL3417210,Histone deacetylase 1,Homo sapiens, 2240
51357265,CC1Cc2ccccc2N1CC(=O)N1CCCCC1,"InChI=1S/C16H22N2O/c1-13-11-14-7-3-4-8-15(14)18(13)12-16(19)17-9-5-2-6-10-17/h3-4,7-8,13H,2,5-6,9-12H2,1H3",GZJGEXMJBMQREH-UHFFFAOYSA-N,50548798,CHEMBL4793864,Muscarinic acetylcholine receptor M1,,
50752153,OCC(O)CO\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12,"InChI=1S/C19H17N3O4/c23-9-11(24)10-26-22-17-13-6-2-4-8-15(13)20-18(17)16-12-5-1-3-7-14(12)21-19(16)25/h1-8,11,20,23-24H,9-10H2,(H,21,25)/b18-16-,22-17+",ZWXBEUSAAVHLFW-DLOIKSOESA-N,50005337,CHEMBL1276317,Cyclin-dependent kinase 6/G1/S-specific cyclin-D3,Homo sapiens, 75
50150725,COc1ccc(cc1)S(=O)(=O)N1CCN(CC1C(=O)NO)C(=O)NCCc1ccccc1,"InChI=1S/C21H26N4O6S/c1-31-17-7-9-18(10-8-17)32(29,30)25-14-13-24(15-19(25)20(26)23-28)21(27)22-12-11-16-5-3-2-4-6-16/h2-10,19,28H,11-15H2,1H3,(H,22,27)(H,23,26)",DYVJPNSKJGHBKT-UHFFFAOYSA-N,50084752,"4-(4-Methoxy-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-hydroxyamide 1-(phenethyl-amide)::CHEMBL125755",Stromelysin-1,, 27
51116288,C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12,"InChI=1S/C20H14NO4/c1-21-8-15-12(4-5-16-20(15)25-10-22-16)13-3-2-11-6-17-18(24-9-23-17)7-14(11)19(13)21/h2-8H,9-10H2,1H3/q+1",INVGWHRKADIJHF-UHFFFAOYSA-N,25525,"24-methyl-5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.0^{2,10}.0^{4,8}.0^{14,22}.0^{17,21}]tetracosa-1(13),2,4(8),9,11,14(22),15,17(21),23-nonaen-24-ium::CHEMBL490129::Pseudochelerythrine::Veadent::cid_5154::sanguinarine::sangvinarin",Regulator of G-protein signaling 17,, 12000
1215917,COc1cccc2[nH]c(cc12)C(=O)N[C@@H](CC1CC1)C(=O)N[C@@H](C[C@@H]1CCCNC1=O)C#N,,,509908,"US11124497, Compound 491::US11124497, Compound 491A (Isomer 1)::US11312704, Compound 491::US11472793, Compound 491::US11524940, Compound 491A (Isomer 1)",Replicase polyprotein 1ab,,>30000
50837878,CCCCCCCCCCCCCCCC(=O)c1c(O)oc(CO)c1O,"InChI=1S/C21H36O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-17(23)19-20(24)18(16-22)26-21(19)25/h22,24-25H,2-16H2,1H3",BKBKOAWPAIKUCJ-UHFFFAOYSA-N,50104694,(R)-4-hydroxy-5-(hydroxymethyl)-3-palmitoylfuran-2(5H)-one::(R)-5-Ethyl-3-hexadecanoyl-4-methyl-5H-furan-2-oneo::3-Hexadecanoyl-4-hydroxy-5-hydroxymethyl-5H-furan-2-one::CHEMBL108441::RK-682,Tyrosine-protein phosphatase non-receptor type 1,Homo sapiens, 4500
1102121,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@](O)(CC[C@]4(C)[C@H]3CC[C@]12C)C(F)(F)F,"InChI=1S/C28H47F3O2/c1-18(7-6-13-24(2,3)32)21-10-11-22-20-9-8-19-17-27(33,28(29,30)31)16-15-25(19,4)23(20)12-14-26(21,22)5/h18-23,32-33H,6-17H2,1-5H3/t18-,19+,20+,21-,22+,23+,25+,26-,27+/m1/s1",PRAIWHBPXMVDTR-RYNHHEBDSA-N,521705,"US11149054, Compound 5116","Glutamate receptor ionotropic, NMDA 2A",,
99262,CN1C(=S)NC(=O)\C(=C/c2ccc(o2)N2CCCCCC2)C1=O,"InChI=1S/C16H19N3O3S/c1-18-15(21)12(14(20)17-16(18)23)10-11-6-7-13(22-11)19-8-4-2-3-5-9-19/h6-7,10H,2-5,8-9H2,1H3,(H,17,20,23)/b12-10+",HURVNUBCCDEKRW-ZRDIBKRKSA-N,52242,"(5E)-5-[[5-(1-azepanyl)-2-furanyl]methylidene]-1-methyl-2-sulfanylidene-1,3-diazinane-4,6-dione::(5E)-5-[[5-(azepan-1-yl)-2-furyl]methylene]-1-methyl-2-thioxo-hexahydropyrimidine-4,6-quinone::(5E)-5-[[5-(azepan-1-yl)furan-2-yl]methylidene]-1-methyl-2-sulfanylidene-1,3-diazinane-4,6-dione::5-{[5-(1-azepanyl)-2-furyl]methylene}-1-methyl-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione::MLS000594435::SMR000114505::cid_1740011",POsterior Segregation,Caenorhabditis elegans,
446333,CN1c2ccc(cc2N(C)S1(=O)=O)-n1cc(C(O)=O)c(=O)n(Cc2cccc(Cl)c2C(F)(F)F)c1=O,"InChI=1S/C21H16ClF3N4O6S/c1-26-15-7-6-12(8-16(15)27(2)36(26,34)35)28-10-13(19(31)32)18(30)29(20(28)33)9-11-4-3-5-14(22)17(11)21(23,24)25/h3-8,10H,9H2,1-2H3,(H,31,32)",SEJKURQMYZQGQO-UHFFFAOYSA-N,256000,"US9481672, 178",chymase,, 16
972794,Clc1cc(ccc1NC1CCN(Cc2ccccc2)C1)S(=O)(=O)Nc1ncns1,"InChI=1S/C19H20ClN5O2S2/c20-17-10-16(29(26,27)24-19-21-13-22-28-19)6-7-18(17)23-15-8-9-25(12-15)11-14-4-2-1-3-5-14/h1-7,10,13,15,23H,8-9,11-12H2,(H,21,22,24)",RGZJDZOTNRSBIE-UHFFFAOYSA-N,373759,"4-((1-benzylpyrrolidin-3-yl)amino)-3-chloro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide trifluoroacetate::US10246453, Example 26::US10662184, Example 26::US10815229, Example 26::US11299490, Example 26",Sodium channel protein type 1 subunit alpha,, 15014
51234655,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)NCCOCCOCCOCCNC(=O)CCC1=[N+]2C(C=C1)=Cc1c(C)cc(C)n1[B-]2(F)F,"InChI=1S/C49H54BF2N7O7/c1-29-25-30(2)58-39(29)26-32-14-13-31(59(32)50(58,51)52)15-16-40(60)54-18-20-64-22-24-65-23-21-63-19-17-53-36-27-41-56-37-11-7-5-9-33(37)43-44-35(28-55-48(44)61)42-34-10-6-8-12-38(34)57(46(42)45(43)56)49(3,66-41)47(36)62-4/h5-14,25-26,36,41,47,53H,15-24,27-28H2,1-4H3,(H,54,60)(H,55,61)/t36-,41-,47-,49+/m1/s1",NXSJMRCTGYTSTK-SQHKIPTKSA-N,50505541,CHEMBL4465866,Tyrosine-protein kinase Mer,Homo sapiens,
867768,CCn1c(nc2c(ncnc12)-c1ccc2NC(=O)C(C)(NCC3(F)COC3)c2c1)-c1cnc(C)nc1,"InChI=1S/C25H25FN8O2/c1-4-34-21(16-8-27-14(2)28-9-16)33-20-19(29-13-30-22(20)34)15-5-6-18-17(7-15)24(3,23(35)32-18)31-10-25(26)11-36-12-25/h5-9,13,31H,4,10-12H2,1-3H3,(H,32,35)",VQGRMRNBGZTLBM-UHFFFAOYSA-N,428755,"(R or S)-5-(9-ethyl-8-(2- methylpyrimidin-5-yl)-9H- purin-6-yl)-3-(((3- fluorooxetan-3- yl)methyl)amino)-3- methylindolin-2-one::US10544147, Compound 2-71::US10544147, Compound 2-72","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens, 3.00
50693929,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1,"InChI=1S/C18H14N6O2/c19-16-15-17(24-18(20)23-16)22-14(10-4-2-6-12(26)8-10)13(21-15)9-3-1-5-11(25)7-9/h1-8,25-26H,(H4,19,20,22,23,24)",UJIAQDJKSXQLIT-UHFFFAOYSA-N,25084,"3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol::JMC504279 Compound 6::TG100-115",Serine/threonine-protein kinase ULK2,Homo sapiens,
944434,C=CC(=O)N1CC[C@@]2(C[C@@H](C2)n2c(NC(=O)c3ccc(s3)-c3cnco3)nc3ccccc23)C1,"InChI=1S/C25H23N5O3S/c1-2-22(31)29-10-9-25(14-29)11-16(12-25)30-18-6-4-3-5-17(18)27-24(30)28-23(32)21-8-7-20(34-21)19-13-26-15-33-19/h2-8,13,15-16H,1,9-12,14H2,(H,27,28,32)/t16-,25-",FINZRTUQZUBKBD-ODAJSGAPSA-N,50458592,"CHEMBL4211372::US10752615, Compound 16",Tyrosine-protein kinase ITK/TSK,Homo sapiens, 0.810
50782688,CCCCCCCCCCCCCCCC(=O)N[C@@H](COC1OC(COS([O-])(=O)=O)C(OS([O-])(=O)=O)C(OCc2ccccc2)C1OCc1ccccc1)[C@H](OCc1ccccc1)\C=C\CCCCCCCCCCCCC,"InChI=1S/C61H95NO14S2/c1-3-5-7-9-11-13-15-17-19-21-23-25-36-44-55(70-46-51-38-30-27-31-39-51)54(62-57(63)45-37-26-24-22-20-18-16-14-12-10-8-6-4-2)49-73-61-60(72-48-53-42-34-29-35-43-53)59(71-47-52-40-32-28-33-41-52)58(76-78(67,68)69)56(75-61)50-74-77(64,65)66/h27-36,38-44,54-56,58-61H,3-26,37,45-50H2,1-2H3,(H,62,63)(H,64,65,66)(H,67,68,69)/p-2/b44-36+/t54-,55+,56?,58?,59?,60?,61?/m0/s1",IABOBGKQJAGWNX-YYJCAEBZSA-L,50061136,"(2S,3R,4E)-3-(Benzoyloxy)-2-(hexadecanoylamino)-1-[[2,3-di-O-benzoyl-4,6-bis-O-(sodium oxysulfonyl)-beta-D-galactopyranosyl]oxy]-4-octadecene::CHEMBL215557",P-selectin,Homo sapiens, 100
249445,CC(C)CN(Cc1cc(Cl)c2OCC(F)(F)COc2c1)C(=O)C1CCN(Cc2cccc3cc[nH]c23)C1,"InChI=1S/C28H32ClF2N3O3/c1-18(2)12-34(13-19-10-23(29)26-24(11-19)36-16-28(30,31)17-37-26)27(35)22-7-9-33(15-22)14-21-5-3-4-20-6-8-32-25(20)21/h3-6,8,10-11,18,22,32H,7,9,12-17H2,1-2H3",NYZQNXXCSARADX-UHFFFAOYSA-N,121321,"US8722896, (-)-(3R)-1-(Indol-7-ylmethyl)- N-(9-chloro-3,3-difluoro- 3,4-dihydro-2H-1,5- benzodioxepin-7-ylmethyl)- N-isobutylpyrrolidine-3- carboxamide",Prokineticin receptor 2,,
250742,CO\N=C1\CCN(C1)c1nc(cc2ncn(C)c(=O)c12)-c1ccc(cc1)N1CCOCC1,"InChI=1S/C23H26N6O3/c1-27-15-24-20-13-19(16-3-5-18(6-4-16)28-9-11-32-12-10-28)25-22(21(20)23(27)30)29-8-7-17(14-29)26-31-2/h3-6,13,15H,7-12,14H2,1-2H3/b26-17-",BNNXOFKDIGLFSC-ONUIUJJFSA-N,122157,"US8722692, 597",Tyrosine-protein kinase SYK,Homo sapiens, 475
50428077,C[C@H](NC(=O)\C=C\c1ccccc1)C(=O)NCCc1c[nH]c2ccccc12,"InChI=1S/C22H23N3O2/c1-16(25-21(26)12-11-17-7-3-2-4-8-17)22(27)23-14-13-18-15-24-20-10-6-5-9-19(18)20/h2-12,15-16,24H,13-14H2,1H3,(H,23,27)(H,25,26)/b12-11+/t16-/m0/s1",IQLJMUHXUMZOMQ-PCUGXKRQSA-N,50244924,(S)-N-(1-(2-(1H-indol-3-yl)ethylamino)-1-oxopropan-2-yl)cinnamamide::CHEMBL472516,NAD-dependent protein deacetylase sirtuin-2,Homo sapiens, 109000
50450418,OC(=O)c1ccc(CN2\C(S\C(=C/c3ccc4ccccc4c3)C2=O)=N\c2ccccc2)cc1,"InChI=1S/C28H20N2O3S/c31-26-25(17-20-12-13-21-6-4-5-7-23(21)16-20)34-28(29-24-8-2-1-3-9-24)30(26)18-19-10-14-22(15-11-19)27(32)33/h1-17H,18H2,(H,32,33)/b25-17-,29-28-",YMCAFJIHSRLDLR-HZPABMAHSA-N,50267100,4-[(5-Naphthalen-2-ylmethylene-4-oxo-2-phenyliminothiazolidin-3-yl)methyl] benzoic acid::CHEMBL476666,Low molecular weight phosphotyrosine protein phosphatase,Saccharomyces cerevisiae, 27600
1029845,OCCNC(=O)CSc1nonc1\C(NC1Cc2cc(F)c(Cl)cc12)=N\O,"InChI=1S/C15H15ClFN5O4S/c16-9-5-8-7(3-10(9)17)4-11(8)19-14(20-25)13-15(22-26-21-13)27-6-12(24)18-1-2-23/h3,5,11,23,25H,1-2,4,6H2,(H,18,24)(H,19,20)",JCAJMOLQZWXAJA-UHFFFAOYSA-N,494819,"2-({4-[N-(4-chloro-3- fluorobicyclo[4.2.0]octa-1,3,5- trien-7-yl)-N'- hydroxycarbamimidoyl]-1,2,5- oxadiazo1-3-yl}sulfanyl)-N-(2- hydroxyethyl)acetamide::US10988487, Example 215","Indoleamine 2,3-dioxygenase 1",Homo sapiens, 261
1260137,CC[C@@H]1CN([C@@H](C)CN1C(C)c1ccc(CNC(=O)OC)cc1)c1nc(=O)n(C)c2ccc(nc12)C#N,"InChI=1S/C27H33N7O3/c1-6-22-16-33(25-24-23(32(4)26(35)31-25)12-11-21(13-28)30-24)17(2)15-34(22)18(3)20-9-7-19(8-10-20)14-29-27(36)37-5/h7-12,17-18,22H,6,14-16H2,1-5H3,(H,29,36)/t17-,18?,22+/m0/s1",ZEGCCFYQRNQFTI-UMJFLEMOSA-N,594548,"US11584747, Example 359::US11584747, Example 360",Diacylglycerol kinase alpha [9-727],, 150
51163837,CN1c2ccccc2C(=N[C@H](NC(=O)C2(CCC2)C(=O)N[C@H](O)C2CCCCC2)C1=O)c1ccc(cc1)C(F)(F)F,"InChI=1S/C30H33F3N4O4/c1-37-22-11-6-5-10-21(22)23(18-12-14-20(15-13-18)30(31,32)33)34-24(26(37)39)35-27(40)29(16-7-17-29)28(41)36-25(38)19-8-3-2-4-9-19/h5-6,10-15,19,24-25,38H,2-4,7-9,16-17H2,1H3,(H,35,40)(H,36,41)/t24-,25-/m1/s1",YXAAEFGOUNJTQF-JWQCQUIFSA-N,50476863,CHEMBL273493,Presenilin-1,, 280
51174976,Oc1c(nc2sc(cn2c1=O)N1CCOCC1)C(=O)NCc1ccc(F)cc1,"InChI=1S/C18H17FN4O4S/c19-12-3-1-11(2-4-12)9-20-16(25)14-15(24)17(26)23-10-13(28-18(23)21-14)22-5-7-27-8-6-22/h1-4,10,24H,5-9H2,(H,20,25)",OECRFKJOFOFEPR-UHFFFAOYSA-N,50482786,CHEMBL1257223,Integrase,, 1130
50672201,CCn1cc(C(O)=O)c(=O)c2cc(F)c(-c3cc(C)nc(C)c3)c(F)c12,"InChI=1S/C19H16F2N2O3/c1-4-23-8-13(19(25)26)18(24)12-7-14(20)15(16(21)17(12)23)11-5-9(2)22-10(3)6-11/h5-8H,4H2,1-3H3,(H,25,26)",ZQZJGSJCJYPTBV-UHFFFAOYSA-N,50231261,CHEMBL94671,DNA topoisomerase 2-alpha/2-beta,Homo sapiens,
1209861,CCNc1c(F)cccc1-c1ncc2c(nc(OCC34CCCN3CCC4)nc2c1F)N1CC2CCC(C1)N2,"InChI=1S/C29H35F2N7O/c1-2-32-24-20(6-3-7-22(24)30)25-23(31)26-21(14-33-25)27(37-15-18-8-9-19(16-37)34-18)36-28(35-26)39-17-29-10-4-12-38(29)13-5-11-29/h3,6-7,14,18-19,32,34H,2,4-5,8-13,15-17H2,1H3",OONFMMSTVBWDOG-UHFFFAOYSA-N,573411,"US11453683, Example 269",GTPase KRas [G12D],, 4038
50221878,Cc1ccc2c(OCCN3CCC(Cc4cccc(c4)N4CCCS4(=O)=O)CC3)cccc2n1,"InChI=1S/C27H33N3O3S/c1-21-9-10-25-26(28-21)7-3-8-27(25)33-17-16-29-14-11-22(12-15-29)19-23-5-2-6-24(20-23)30-13-4-18-34(30,31)32/h2-3,5-10,20,22H,4,11-19H2,1H3",WQRVLZPCOXHNAI-UHFFFAOYSA-N,50412131,CHEMBL522708,Beta-2 adrenergic receptor,Homo sapiens,
1210742,Nc1nc2n(cnc2c(=O)[nH]1)[C@@H]1S[C@@H]2COP(O)(=O)OC3[C@@H](COP(O)(=O)O[C@H]1C2O)O[C@H]([C@H]3O)n1cnc2c(N)ncnc12,,,573847,"(5R,7R,8R,12aR,14R,15R,15aS,16S)-7-(2-amino- 6-oxo-1,6-dihydro-9H-purin-9-yl)-14-(6-amino- 9H-purin-9-yl)-15,16-dihydroxyoctahydro-12H- 5,8-methanofuro[3,2-l][1,3,9,11,6,2,10] tetraoxathiadiphosphacyclotetradecine-2,10- diolate 2,10-dioxide::US11453697, Example 11","Stimulator of interferon genes protein [1-379,R71H,G230A,H232R,R293Q]",,
132563,CCOC(=O)NC1(N=C(NC1=O)c1ccccc1)C(F)(F)F,"InChI=1S/C13H12F3N3O3/c1-2-22-11(21)19-12(13(14,15)16)10(20)17-9(18-12)8-6-4-3-5-7-8/h3-7H,2H2,1H3,(H,19,21)(H,17,18,20)",UTBXQXDHJQPHJP-UHFFFAOYSA-N,73332,"MLS000052544::N-[5-keto-2-phenyl-4-(trifluoromethyl)-2-imidazolin-4-yl]carbamic acid ethyl ester::N-[5-oxo-2-phenyl-4-(trifluoromethyl)-1H-imidazol-4-yl]carbamic acid ethyl ester::SMR000082028::cid_2978721::ethyl N-[5-oxidanylidene-2-phenyl-4-(trifluoromethyl)-1H-imidazol-4-yl]carbamate::ethyl N-[5-oxo-2-phenyl-4-(trifluoromethyl)-1H-imidazol-4-yl]carbamate::ethyl [5-oxo-2-phenyl-4-(trifluoromethyl)-4,5-dihydro-1H-imidazol-4-yl]carbamate",Protein LANA1,Human herpesvirus 8,
51021800,COc1cc(C)c(c(C)c1C)S(=O)(=O)N[C@@H](Cc1ccc(Cl)cc1)C(=O)NCCCN1CCN(C)CC1,"InChI=1S/C27H39ClN4O4S/c1-19-17-25(36-5)20(2)21(3)26(19)37(34,35)30-24(18-22-7-9-23(28)10-8-22)27(33)29-11-6-12-32-15-13-31(4)14-16-32/h7-10,17,24,30H,6,11-16,18H2,1-5H3,(H,29,33)/t24-/m0/s1",UJNSLNJBUGNTIQ-DEOSSOPVSA-N,50418388,CHEMBL1773995,Vasopressin V1a receptor,,
666640,CN(C)S(=O)(=O)c1cc(cnc1N)-c1ccnc(NC(C)=O)c1,"InChI=1S/C14H17N5O3S/c1-9(20)18-13-7-10(4-5-16-13)11-6-12(14(15)17-8-11)23(21,22)19(2)3/h4-8H,1-3H3,(H2,15,17)(H,16,18,20)",CUSNPYAULLUKDQ-UHFFFAOYSA-N,337943,"US9751854, Compound I-119::US9802960, Compound I-119",Phosphatidylinositol 3-kinase catalytic subunit type 3,Homo sapiens,<10
196941,CC(C)Cc1ccc(cc1)C(C)C(=O)Nc1ccccc1O,"InChI=1S/C19H23NO2/c1-13(2)12-15-8-10-16(11-9-15)14(3)19(22)20-17-6-4-5-7-18(17)21/h4-11,13-14,21H,12H2,1-3H3,(H,20,22)",UMZHDHGUJFZBPU-UHFFFAOYSA-N,90667,MLS000778270::N-(2-Hydroxy-phenyl)-2-(4-isobutyl-phenyl)-propionamide::N-(2-hydroxyphenyl)-2-(4-isobutylphenyl)propionamide::N-(2-hydroxyphenyl)-2-[4-(2-methylpropyl)phenyl]propanamide::SMR000414944::cid_2849603,Corticotropin-releasing factor-binding protein,Homo sapiens,
359344,CCOCCCCNC(CC(C)C)C1(CCC1)c1ccc(SC)cc1,"InChI=1S/C22H37NOS/c1-5-24-16-7-6-15-23-21(17-18(2)3)22(13-8-14-22)19-9-11-20(25-4)12-10-19/h9-12,18,21,23H,5-8,13-17H2,1-4H3",OZMCXSBQOWTTBK-UHFFFAOYSA-N,202581,"US10035761, Compound 7g::US9238625, 7g",Sodium-dependent serotonin transporter,Homo sapiens,
51301509,CCOC(=O)N1CC2(C1)CC(C2)=CC#Cc1cccc(C)n1,"InChI=1S/C18H20N2O2/c1-3-22-17(21)20-12-18(13-20)10-15(11-18)7-5-9-16-8-4-6-14(2)19-16/h4,6-8H,3,10-13H2,1-2H3",YNPRRNZDLRQOKC-UHFFFAOYSA-N,50529956,CHEMBL4551238,Metabotropic glutamate receptor 5,Homo sapiens,
50653471,Cc1cccc2C(=O)N(C(=O)c12)c1ccnc(Cl)c1,"InChI=1S/C14H9ClN2O2/c1-8-3-2-4-10-12(8)14(19)17(13(10)18)9-5-6-16-11(15)7-9/h2-7H,1H3",YDJMWNHJNJVVMM-UHFFFAOYSA-N,50350123,CHEMBL1229651,Thymidylate synthase,Lactobacillus casei,
50880521,COc1ccc(C2=NC(C(N2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1,"InChI=1S/C25H24Cl2N2O2/c1-15(2)31-22-14-20(30-3)12-13-21(22)25-28-23(16-4-8-18(26)9-5-16)24(29-25)17-6-10-19(27)11-7-17/h4-15,23-24H,1-3H3,(H,28,29)",YRGSRFXZNYCJNK-UHFFFAOYSA-N,50266942,"4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole::CHEMBL515487",E3 ubiquitin-protein ligase Mdm2,Homo sapiens, 90
50169132,NC(=O)c1cnc(NC[C@@H]2CCCN2)c2cc(sc12)-c1ccc(Cl)cc1,"InChI=1S/C19H19ClN4OS/c20-12-5-3-11(4-6-12)16-8-14-17(26-16)15(18(21)25)10-24-19(14)23-9-13-2-1-7-22-13/h3-6,8,10,13,22H,1-2,7,9H2,(H2,21,25)(H,23,24)/t13-/m0/s1",DCMSFYRENMMFPF-ZDUSSCGKSA-N,50332123,"(S)-2-(4-chlorophenyl)-4-(pyrrolidin-2-ylmethylamino)thieno[3,2-c]pyridine-7-carboxamide::CHEMBL1288219",Serine/threonine-protein kinase Chk1,Homo sapiens, 197
50817294,CC(N)=NCCCC[C@H](N)C(O)=O,"InChI=1S/C8H17N3O2/c1-6(9)11-5-3-2-4-7(10)8(12)13/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13)/t7-/m0/s1",ONYFNWIHJBLQKE-ZETCQYMHSA-N,50063300,(L-N6-1-iminoethyl)lysine::(S)-6-Acetimidoylamino-2-amino-hexanoic acid::6-Acetimidoylamino-2-amino-hexanoic acid::CHEMBL1744034::CHEMBL7889::L-N6-(1-iminoethyl)lysine::N~6~-[(1Z)-ethanimidoyl]-L-lysine::l-NIL,"Nitric oxide synthase, endothelial",, 2600
50091434,COc1cc(cc(OC)c1OC)[C@@H]1[C@@H](C2CC2)[C@H]2[C@@H]1c1c(OC2(C)C)c2ccccc2[nH]c1=O,"InChI=1S/C28H31NO5/c1-28(2)24-21(14-10-11-14)20(15-12-18(31-3)26(33-5)19(13-15)32-4)22(24)23-25(34-28)16-8-6-7-9-17(16)29-27(23)30/h6-9,12-14,20-22,24H,10-11H2,1-5H3,(H,29,30)/t20-,21-,22+,24+/m1/s1",HWHNPTUQTILZGI-SVPADUAOSA-N,50011380,CHEMBL3261032,Toll-like receptor 4,Homo sapiens,
50876290,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)[C@H](C)O)[C@@H](C)CC,"InChI=1S/C76H111N23O16S2/c1-7-39(3)58-71(112)94-54-36-116-117-37-55(69(110)97-60(42(6)101)72(113)86-41(5)61(102)92-53(35-100)67(108)96-59(40(4)8-2)74(115)99-29-17-25-57(99)73(114)98-28-16-24-56(98)70(111)95-58)93-63(104)49(23-15-27-83-76(79)80)88-65(106)51(31-44-33-84-47-21-13-12-20-46(44)47)90-62(103)48(22-14-26-82-75(77)78)87-64(105)50(30-43-18-10-9-11-19-43)89-66(107)52(91-68(54)109)32-45-34-81-38-85-45/h9-13,18-21,33-34,38-42,48-60,84,100-101H,7-8,14-17,22-32,35-37H2,1-6H3,(H,81,85)(H,86,113)(H,87,105)(H,88,106)(H,89,107)(H,90,103)(H,91,109)(H,92,102)(H,93,104)(H,94,112)(H,95,111)(H,96,108)(H,97,110)(H4,77,78,82)(H4,79,80,83)/t39-,40-,41-,42-,48-,49-,50+,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-/m0/s1",DBJGVYJTQHCOAH-KTIGORNTSA-N,50263804,CHEMBL4074074,Melanocyte-stimulating hormone receptor,,
50333246,OCc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O,"InChI=1S/C17H15N3O4/c21-11-13-4-1-2-7-16(13)19-9-8-15(18-17(19)22)12-5-3-6-14(10-12)20(23)24/h1-8,10,21H,9,11H2,(H,18,22)",BVJGNDZMKADVPL-UHFFFAOYSA-N,50083006,CHEMBL3422800,Transient receptor potential cation channel subfamily M member 8,,
50466813,OC(=O)CCc1ccccc1C[C@@H]1CCC[C@@H]1c1nc(co1)C(=O)NCCCCC1CCCCC1,"InChI=1S/C29H40N2O4/c32-27(33)17-16-22-12-4-5-13-23(22)19-24-14-8-15-25(24)29-31-26(20-35-29)28(34)30-18-7-6-11-21-9-2-1-3-10-21/h4-5,12-13,20-21,24-25H,1-3,6-11,14-19H2,(H,30,34)(H,32,33)/t24-,25-/m0/s1",REOJLAXLWPJOTB-DQEYMECFSA-N,50281918,3-(2-{2-[4-(4-Cyclohexyl-butylcarbamoyl)-oxazol-2-yl]-cyclopentylmethyl}-phenyl)-propionic acid::CHEMBL22244,Thromboxane A2 receptor,,
596328,ONC(=O)CCCCCCN(c1nccs1)c1ccccn1,"InChI=1S/C15H20N4O2S/c20-14(18-21)8-3-1-2-6-11-19(15-17-10-12-22-15)13-7-4-5-9-16-13/h4-5,7,9-10,12,21H,1-3,6,8,11H2,(H,18,20)",NSWXYHYGBYWCCU-UHFFFAOYSA-N,310737,"N-Hydroxy-7-(pyridin-2-yl(thiazol-2-yl)amino)heptanamide::US10150763, Example KK",Histone deacetylase 1,Homo sapiens, 5500
50103942,Clc1cccc(N2CCN(CCCCOc3cccc4c(C=O)cnn34)CC2)c1Cl,"InChI=1S/C22H24Cl2N4O2/c23-18-5-3-7-20(22(18)24)27-12-10-26(11-13-27)9-1-2-14-30-21-8-4-6-19-17(16-29)15-25-28(19)21/h3-8,15-16H,1-2,9-14H2",ZHLBCCKGUNFWNS-UHFFFAOYSA-N,50018951,CHEMBL3287400,D(3) dopamine receptor,,
354222,Oc1cc2CCN3CCc4c(CC3c2cc1O)ccc(O)c4O,"InChI=1S/C18H19NO4/c20-15-2-1-10-7-14-13-9-17(22)16(21)8-11(13)3-5-19(14)6-4-12(10)18(15)23/h1-2,8-9,14,20-23H,3-7H2",CTNWBZPXZUTRQV-UHFFFAOYSA-N,199161,"5,6,8,9,14,14a-hexahydrobenzo[4,5]azepino[2,1-a]isoquinoline-2,3,10,11-tetraol (18)",D(1A) dopamine receptor,, 1.1450e+5
789010,O[C@@H](CNC(=O)c1ncnc(NC2COC2)c1F)CN1CCc2ccccc2C1,"InChI=1S/C20H24FN5O3/c21-17-18(23-12-24-19(17)25-15-10-29-11-15)20(28)22-7-16(27)9-26-6-5-13-3-1-2-4-14(13)8-26/h1-4,12,15-16,27H,5-11H2,(H,22,28)(H,23,24,25)/t16-/m0/s1",NGRJZDNVHHKBIM-INIZCTEOSA-N,394777,"US10307413, Compound 422",Protein arginine N-methyltransferase 5,,<100
50424167,Fc1ccc(-c2noc(n2)C2CCN(CC2)c2cnc3ccc(Cl)cc3c2)c(Cl)c1,"InChI=1S/C22H17Cl2FN4O/c23-15-1-4-20-14(9-15)10-17(12-26-20)29-7-5-13(6-8-29)22-27-21(28-30-22)18-3-2-16(25)11-19(18)24/h1-4,9-13H,5-8H2",KZPYBMNBUZPMKP-UHFFFAOYSA-N,50261729,"6-chloro-3-(4-(3-(2-chloro-4-fluorophenyl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)quinoline::CHEMBL468176",Muscarinic acetylcholine receptor M1,,
285203,CC1CN(C1)[C@@H]1CC[C@@H]([C@H](C1)C#N)n1cc(C(N)=O)c(Nc2ccc(cc2)S(=O)(=O)C(F)(F)F)n1,"InChI=1S/C22H25F3N6O3S/c1-13-10-30(11-13)16-4-7-19(14(8-16)9-26)31-12-18(20(27)32)21(29-31)28-15-2-5-17(6-3-15)35(33,34)22(23,24)25/h2-3,5-6,12-14,16,19H,4,7-8,10-11H2,1H3,(H2,27,32)(H,28,29)/t14-,16-,19+/m1/s1",CWIWGDKSABCMGA-OGWOLHLISA-N,147863,"US8962608, 28-187",Tyrosine-protein kinase JAK1,Homo sapiens, 0.2
50732138,NS(=O)(=O)c1cccc(NS(=O)(=O)c2ccc(NCc3cc(=O)oc4cc(Cl)ccc34)cc2)c1,"InChI=1S/C22H18ClN3O6S2/c23-15-4-9-20-14(10-22(27)32-21(20)11-15)13-25-16-5-7-18(8-6-16)34(30,31)26-17-2-1-3-19(12-17)33(24,28)29/h1-12,25-26H,13H2,(H2,24,28,29)",CWWNTMKCOPSSCO-UHFFFAOYSA-N,50087256,3-[4-(7-chloro-2-oxo-2H-4-chromenylmethylamino)phenylsulfonamido]-1-benzenesulfonamide::CHEMBL161658,Carbonic anhydrase 2,Homo sapiens,
50735057,CCCN(CCCCOc1ccn2nccc2c1)[C@@H]1CCc2c(O)cccc2C1,"InChI=1S/C24H31N3O2/c1-2-13-26(20-8-9-23-19(17-20)6-5-7-24(23)28)14-3-4-16-29-22-11-15-27-21(18-22)10-12-25-27/h5-7,10-12,15,18,20,28H,2-4,8-9,13-14,16-17H2,1H3/t20-/m1/s1",IWAHIMCMPBOXKG-HXUWFJFHSA-N,50236964,CHEMBL4094869,D(2) dopamine receptor,Homo sapiens,
261572,COc1ncc(-c2nc3C(=O)N(C(c3n2C(C)C)c2ccc(Cl)cc2)c2cc(Cl)cnc2O)c(OC)n1,"InChI=1S/C25H22Cl2N6O4/c1-12(2)32-20-18(30-21(32)16-11-29-25(37-4)31-23(16)36-3)24(35)33(17-9-15(27)10-28-22(17)34)19(20)13-5-7-14(26)8-6-13/h5-12,19H,1-4H3,(H,28,34)",CHOHEJZMEHHXSJ-UHFFFAOYSA-N,129843,"US8815926, 122",E3 ubiquitin-protein ligase Mdm2,Homo sapiens, 0.25
50342470,C(N1CCC(=CC1)c1ccccc1)c1cnn(c1)-c1ccccc1,"InChI=1S/C21H21N3/c1-3-7-19(8-4-1)20-11-13-23(14-12-20)16-18-15-22-24(17-18)21-9-5-2-6-10-21/h1-11,15,17H,12-14,16H2",UOKGFRGTMUWXQL-UHFFFAOYSA-N,50184792,"4-phenyl-1-((1-phenyl-1H-pyrazol-4-yl)methyl)-1,2,3,6-tetrahydropyridine::CHEMBL378455",D(2) dopamine receptor,Homo sapiens,
146267,CCOC(=O)c1c2ccc(OCC(=O)NN=Cc3ccc(C)cc3)cc2n2ccccc12,"InChI=1S/C25H23N3O4/c1-3-31-25(30)24-20-12-11-19(14-22(20)28-13-5-4-6-21(24)28)32-16-23(29)27-26-15-18-9-7-17(2)8-10-18/h4-15H,3,16H2,1-2H3,(H,27,29)",ULGZIELJJFJICI-UHFFFAOYSA-N,34724,"3-[2-[2-[(4-methylphenyl)methylidene]hydrazinyl]-2-oxoethoxy]-10-pyrido[1,2-a]indolecarboxylic acid ethyl ester::3-[2-keto-2-[N'-(4-methylbenzylidene)hydrazino]ethoxy]pyrid[1,2-a]indole-10-carboxylic acid ethyl ester::MLS000326532::SMR000179109::cid_1484858::ethyl 3-(2-{2-[(E)-(4-methylphenyl)methylidene]hydrazino}-2-oxoethoxy)pyrido[1,2-a]indole-10-carboxylate::ethyl 3-[2-[2-[(4-methylphenyl)methylidene]hydrazinyl]-2-oxidanylidene-ethoxy]pyrido[1,2-a]indole-10-carboxylate::ethyl 3-[2-[2-[(4-methylphenyl)methylidene]hydrazinyl]-2-oxoethoxy]pyrido[1,2-a]indole-10-carboxylate",X-box-binding protein 1,Homo sapiens, 9960
840520,CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)COC(=O)NS(=O)(=O)c4ccc(cc4)-c4ncccn4)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12,"InChI=1S/C35H49N3O6S/c1-5-25-29-19-23(39)13-15-35(29,4)28-14-16-34(3)26(11-12-27(34)30(28)31(25)40)21(2)20-44-33(41)38-45(42,43)24-9-7-22(8-10-24)32-36-17-6-18-37-32/h6-10,17-18,21,23,25-31,39-40H,5,11-16,19-20H2,1-4H3,(H,38,41)/t21-,23-,25-,26-,27+,28+,29+,30+,31-,34-,35-/m1/s1",UPGSBBQNJFCRDC-VPWDKUPFSA-N,419353,"US10457703, Example 36",Bile acid receptor,Homo sapiens,
409249,COc1ccc(nc1)[C@H]1C[C@@H]1COc1cc(NCc2csc(C)n2)c(=O)n(C)n1,"InChI=1S/C20H23N5O3S/c1-12-23-14(11-29-12)8-21-18-7-19(24-25(2)20(18)26)28-10-13-6-16(13)17-5-4-15(27-3)9-22-17/h4-5,7,9,11,13,16,21H,6,8,10H2,1-3H3/t13-,16+/m1/s1",PJFTYDNWISQOJF-CJNGLKHVSA-N,234755,"US9353104, 49","Isoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)",,
50744371,OC(=O)C1CCCN1C(=O)CC(SC(=O)c1ccccc1)C(=O)c1ccc(Br)cc1,"InChI=1S/C22H20BrNO5S/c23-16-10-8-14(9-11-16)20(26)18(30-22(29)15-5-2-1-3-6-15)13-19(25)24-12-4-7-17(24)21(27)28/h1-3,5-6,8-11,17-18H,4,7,12-13H2,(H,27,28)",JQTULICRTAABED-UHFFFAOYSA-N,50027628,1-[3-Benzoylsulfanyl-4-(4-bromo-phenyl)-4-oxo-butyryl]-pyrrolidine-2-carboxylic acid::CHEMBL130584,Angiotensin-converting enzyme,Rattus norvegicus, 115
50695456,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1,"InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)",YCOYDOIWSSHVCK-UHFFFAOYSA-N,4851,(4-chlorophenyl)-[4-(4-pyridylmethyl)phthalazin-1-yl]amine::(A) PTK787::CGP 79787::CHEMBL101253::CHEMBL75232::N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)-1-phthalazinamine::N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine::PTK-787::PTK787::ZK222584::cid_151194,NUAK family SNF1-like kinase 1,Homo sapiens,
50414201,CN(CCN1CCCCC1)CCc1ccc(OC(F)(F)F)cc1,"InChI=1S/C17H25F3N2O/c1-21(13-14-22-10-3-2-4-11-22)12-9-15-5-7-16(8-6-15)23-17(18,19)20/h5-8H,2-4,9-14H2,1H3",QTWYMQIZRRTWFB-UHFFFAOYSA-N,50261083,CHEMBL498564::N-Methyl-2-piperidin-1-yl-N-{2-[4-(trifluoromethoxy)phenyl]-ethyl}ethanamine,Sigma non-opioid intracellular receptor 1,Rattus,
1023983,CCCC[C@@H](C)Oc1ccnc(C[C@@](O)([C@@H](N)CSCC(C)C)C(O)=O)c1,"InChI=1S/C20H34N2O4S/c1-5-6-7-15(4)26-17-8-9-22-16(10-17)11-20(25,19(23)24)18(21)13-27-12-14(2)3/h8-10,14-15,18,25H,5-7,11-13,21H2,1-4H3,(H,23,24)/t15-,18+,20-/m1/s1",ULLYSVQFEAUMPV-MOXGXCLJSA-N,271289,"US10059720, Example 104::US10975091, Example 104",Leucyl-cystinyl aminopeptidase,Homo sapiens, 26.0
125989,Nc1c(sc2nc(ccc12)-c1cccs1)C(=O)Nc1nc2ccccc2s1,"InChI=1S/C19H12N4OS3/c20-15-10-7-8-12(13-6-3-9-25-13)21-18(10)27-16(15)17(24)23-19-22-11-4-1-2-5-14(11)26-19/h1-9H,20H2,(H,22,23,24)",WVHBEUUJHVJCPR-UHFFFAOYSA-N,41051,"3-Amino-6-thiophen-2-yl-thieno[2,3-b]pyridine-2-carboxylic acid benzothiazol-2-ylamide::3-amino-N-(1,3-benzothiazol-2-yl)-6-(2-thienyl)thieno[2,3-b]pyridine-2-carboxamide::3-amino-N-(1,3-benzothiazol-2-yl)-6-thiophen-2-yl-2-thieno[2,3-b]pyridinecarboxamide::3-amino-N-(1,3-benzothiazol-2-yl)-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide::3-azanyl-N-(1,3-benzothiazol-2-yl)-6-thiophen-2-yl-thieno[2,3-b]pyridine-2-carboxamide::MLS000556593::SMR000147910::cid_1928929",DNA damage-inducible transcript 3 protein,Mus musculus,>10000
51020212,O=c1[nH]ccc2cc(O[C@H]3CCNC3)ccc12,"InChI=1S/C13H14N2O2/c16-13-12-2-1-10(7-9(12)3-6-15-13)17-11-4-5-14-8-11/h1-3,6-7,11,14H,4-5,8H2,(H,15,16)/t11-/m0/s1",MJHLFDZNTKULCZ-NSHDSACASA-N,50417856,CHEMBL1667972,Rho-associated protein kinase 1,Homo sapiens, 524.81
558118,CNC(=O)[C@@H]1CCN1c1cc(cc(n1)-c1cnn2ccc(nc12)-c1cccs1)C(=O)NC[C@H](C)N,"InChI=1S/C24H26N8O2S/c1-14(25)12-27-23(33)15-10-18(29-21(11-15)31-7-6-19(31)24(34)26-2)16-13-28-32-8-5-17(30-22(16)32)20-4-3-9-35-20/h3-5,8-11,13-14,19H,6-7,12,25H2,1-2H3,(H,26,34)(H,27,33)/t14-,19-/m0/s1",DBLNFPKHQWSNDD-LIRRHRJNSA-N,292649,"N-((S)-2-aminopropyl)-2-((S)-2-(methylcarbamoyl)azetidin-1-yl)-6-(5-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl)isonicotinamide::US10100058, Example 305",Calcium/calmodulin-dependent protein kinase type II subunit delta,,
51436053,Cn1c(NC(=O)Nc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cc(=O)n(Cc2ccc(Cl)c(Cl)c2)c1=O,"InChI=1S/C25H23Cl2N5O8/c1-31-19(11-20(33)32(25(31)40)12-13-2-7-16(26)17(27)10-13)30-24(39)28-15-5-3-14(4-6-15)22(36)29-18(23(37)38)8-9-21(34)35/h2-7,10-11,18H,8-9,12H2,1H3,(H,29,36)(H,34,35)(H,37,38)(H2,28,30,39)/t18-/m0/s1",GSPWQHDZSQRWHV-SFHVURJKSA-N,50580121,CHEMBL5085594,"C-1-tetrahydrofolate synthase, cytoplasmic",,>10000
50745698,CNC1CC(c2ccccc12)c1ccc(Cl)cc1Cl,"InChI=1S/C16H15Cl2N/c1-19-16-9-14(11-4-2-3-5-13(11)16)12-7-6-10(17)8-15(12)18/h2-8,14,16,19H,9H2,1H3",FZVZQSNRXRBRNV-UHFFFAOYSA-N,50021221,"CHEMBL542117::[3-(2,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine; hydrochloride",Sodium-dependent serotonin transporter,Rattus norvegicus, 21
673038,C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)\C=C\c1ccc(Cl)cc1Cc1nnn(C)n1,"InChI=1S/C24H26ClFN6O/c1-17-15-31(16-18-3-8-22(26)9-4-18)11-12-32(17)24(33)10-6-19-5-7-21(25)13-20(19)14-23-27-29-30(2)28-23/h3-10,13,17H,11-12,14-16H2,1-2H3/b10-6+/t17-/m1/s1",OLAMNGYDXFIKIV-DKISHCGFSA-N,322055,"(R,E)-3-(4-Chloro-2-((2-methyl-2H-tetrazol-5-yl)methyl)phenyl)-1-(4-(4-fluorobenzyl)-2-methylpiperazin-1-yl)prop-2-en-1-one::US10183025, Example 143::US9763957, Example 143",Ataxin-1,, 31.0
331630,COc1ccc(cc1-c1cccc(c1)C(CC(O)=O)c1nnc(C)o1)C(C)(C)C,"InChI=1S/C23H26N2O4/c1-14-24-25-22(29-14)19(13-21(26)27)16-8-6-7-15(11-16)18-12-17(23(2,3)4)9-10-20(18)28-5/h6-12,19H,13H2,1-5H3,(H,26,27)",DIAALKGBJIRCNN-UHFFFAOYSA-N,183760,"US9150526, 9",Lysosomal protective protein [29-480],, 61
51346848,Cc1cc(NS(=O)(=O)c2ccc(Nc3ccnc(SCC(=O)c4ccc(F)cc4)n3)cc2)no1,"InChI=1S/C22H18FN5O4S2/c1-14-12-21(27-32-14)28-34(30,31)18-8-6-17(7-9-18)25-20-10-11-24-22(26-20)33-13-19(29)15-2-4-16(23)5-3-15/h2-12H,13H2,1H3,(H,27,28)(H,24,25,26)",PGDLAIFDDVHUEY-UHFFFAOYSA-N,50544892,CHEMBL4633334,Carbonic anhydrase 9,Homo sapiens,
50190038,Cc1ccc(cc1)-c1c([N-]S(=O)(=O)c2ccc(cc2)C(C)(C)C)ncnc1OCCOc1ncc(Cl)cn1,"InChI=1S/C27H27ClN5O4S/c1-18-5-7-19(8-6-18)23-24(33-38(34,35)22-11-9-20(10-12-22)27(2,3)4)31-17-32-25(23)36-13-14-37-26-29-15-21(28)16-30-26/h5-12,15-17H,13-14H2,1-4H3/q-1",HLZRFVXMFALVBN-UHFFFAOYSA-N,50105027,CHEMBL176272::sodium salt of 4-tert-Butyl-N-{6-[2-(5-chloro-pyrimidin-2-yloxy)-ethoxy]-5-p-tolyl-pyrimidin-4-yl}-benzenesulfonamide,Endothelin-1 receptor,Rattus, 0.08
50548895,CCN(CC)C(=O)c1ccc(cc1)C1(CCN(CC=C)CC1)c1cccc(O)c1,"InChI=1S/C25H32N2O2/c1-4-16-26-17-14-25(15-18-26,22-8-7-9-23(28)19-22)21-12-10-20(11-13-21)24(29)27(5-2)6-3/h4,7-13,19,28H,1,5-6,14-18H2,2-3H3",GHGXXGRQBXBJPK-UHFFFAOYSA-N,50306297,"4-(1-allyl-4-(3-hydroxyphenyl)piperidin-4-yl)-N,N-diethylbenzamide::CHEMBL605931",Kappa-type opioid receptor,Homo sapiens,
222768,Cn1c2CC3CCC(N3)c2c2cc(ccc12)S(=O)(=O)c1cccc(OC(F)F)c1,"InChI=1S/C21H20F2N2O3S/c1-25-18-8-6-15(11-16(18)20-17-7-5-12(24-17)9-19(20)25)29(26,27)14-4-2-3-13(10-14)28-21(22)23/h2-4,6,8,10-12,17,21,24H,5,7,9H2,1H3",VMNCYKLGFBECRY-UHFFFAOYSA-N,104277,"US8575186, 40",5-hydroxytryptamine receptor 6,Homo sapiens,
51300223,Cc1cn(C[C@](C)(O)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F)c2ccc(F)cc12,"InChI=1S/C21H17F4N3O2/c1-12-10-28(18-6-4-14(22)7-16(12)18)11-20(2,30)19(29)27-15-5-3-13(9-26)17(8-15)21(23,24)25/h3-8,10,30H,11H2,1-2H3,(H,27,29)/t20-/m0/s1",DAXZYVGQYZDTFR-FQEVSTJZSA-N,50529663,CHEMBL4442857,Androgen receptor,Homo sapiens, 157
1013676,COc1cc(-c2ccc(nc2)N2CC3CC(C2)N3Cc2ccc(OC)nc2)c2c(CC#N)cnn2c1,"InChI=1S/C27H27N7O2/c1-35-23-10-24(27-20(7-8-28)13-31-34(27)17-23)19-4-5-25(29-12-19)32-15-21-9-22(16-32)33(21)14-18-3-6-26(36-2)30-11-18/h3-6,10-13,17,21-22H,7,9,14-16H2,1-2H3",DZBVCAIUXMOOKD-UHFFFAOYSA-N,296823,"US10112942, Example 558::US10137124, Example 558::US10172851, Example 558::US10555944, Example 558::US10953005, Example 558",Proto-oncogene tyrosine-protein kinase receptor Ret [G810R],, 3621
50419724,CNCc1cc(ccc1Cc1ccc(Cl)c(Cl)c1)S(N)(=O)=O,"InChI=1S/C15H16Cl2N2O2S/c1-19-9-12-8-13(22(18,20)21)4-3-11(12)6-10-2-5-14(16)15(17)7-10/h2-5,7-8,19H,6,9H2,1H3,(H2,18,20,21)",FFJCCOLDJHZNND-UHFFFAOYSA-N,50252069,"4-(3,4-dichlorobenzyl)-3-((methylamino)methyl)benzenesulfonamide::CHEMBL481306",Sodium-dependent serotonin transporter,Homo sapiens, 6
51192953,NS(=O)(=O)c1ccc(CN2C(=O)CCC2=O)cc1,"InChI=1S/C11H12N2O4S/c12-18(16,17)9-3-1-8(2-4-9)7-13-10(14)5-6-11(13)15/h1-4H,5-7H2,(H2,12,16,17)",AYNHSSHRIRNWEB-UHFFFAOYSA-N,50035688,CHEMBL2377780,Prostaglandin G/H synthase 2,Ovis aries,>100000
1069145,COc1nc(O[C@H]2C[C@@]3(C[C@@H](C3)NC(=O)c3cnn(c3C)-c3ccc(cn3)C(F)(F)F)C2)c(s1)C(N)=O,"InChI=1S/C23H23F3N6O4S/c1-11-15(10-29-32(11)16-4-3-12(9-28-16)23(24,25)26)19(34)30-13-5-22(6-13)7-14(8-22)36-20-17(18(27)33)37-21(31-20)35-2/h3-4,9-10,13-14H,5-8H2,1-2H3,(H2,27,33)(H,30,34)/t13-,14-,22-/m0/s1",QXKYZQBNLYXSQC-OKHZJLECSA-N,510935,"2-methoxy-4-{[(4s)-6-{5- methyl-1-[5- (trifluoromethyl)pyridin-2- yl]-1H-pyrazole-4- amido}spiro[3.3]heptan-2- yl]oxy}-1,3-thiazole-5- carboxamide::US11078197, Example 114",Rho-associated protein kinase 2,Homo sapiens, 115000
501519,COc1ccc2CN([C@@H](Cc2c1OCC#Cc1ccccc1)C(O)=O)C(=O)C(c1ccccc1)c1ccccc1,"InChI=1S/C34H29NO5/c1-39-30-20-19-27-23-35(33(36)31(25-15-7-3-8-16-25)26-17-9-4-10-18-26)29(34(37)38)22-28(27)32(30)40-21-11-14-24-12-5-2-6-13-24/h2-10,12-13,15-20,29,31H,21-23H2,1H3,(H,37,38)/t29-/m0/s1",YKXFIJFGQNQILE-LJAQVGFWSA-N,263930,"US9714224, 50",Type-2 angiotensin II receptor,, 96.2
51085177,CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CNCCO)cn1,"InChI=1S/C22H34N6O2/c1-2-3-10-24-22-26-15-19(20-9-4-16(14-25-20)13-23-11-12-29)21(28-22)27-17-5-7-18(30)8-6-17/h4,9,14-15,17-18,23,29-30H,2-3,5-8,10-13H2,1H3,(H2,24,26,27,28)/t17-,18-",NLXWFBBYANWXPR-IYARVYRRSA-N,50444068,CHEMBL3092797,Tyrosine-protein kinase receptor UFO,, 70
51076166,CC(CNS(C)(=O)=O)[C@@H](c1ccccc1)c1ccc2n(ncc2c1)-c1ccc(F)cc1,"InChI=1S/C24H24FN3O2S/c1-17(15-27-31(2,29)30)24(18-6-4-3-5-7-18)19-8-13-23-20(14-19)16-26-28(23)22-11-9-21(25)10-12-22/h3-14,16-17,24,27H,15H2,1-2H3/t17?,24-/m0/s1",JWWHDSCWSHFYDM-UCSBTNPJSA-N,50440100,CHEMBL2426120,Glucocorticoid receptor,,
51244581,CN1CCN(CC1)c1ccc2c3CCN(Cc3c(=O)oc2c1C)C(=O)c1ccc(NS(C)(=O)=O)c(F)c1,"InChI=1S/C26H29FN4O5S/c1-16-23(30-12-10-29(2)11-13-30)7-5-19-18-8-9-31(15-20(18)26(33)36-24(16)19)25(32)17-4-6-22(21(27)14-17)28-37(3,34)35/h4-7,14,28H,8-13,15H2,1-3H3",YIENLOQGUANJTL-UHFFFAOYSA-N,50509360,CHEMBL4538356,"C-1-tetrahydrofolate synthase, cytoplasmic",Homo sapiens, 8000
874903,Fc1cc2CN(Cc2cc1OC1CCCNC1)c1cn[nH]c(=O)c1C(F)(F)F,,,431078,"5-[5-fluoro-6-(piperidin-3-yloxy)-2,3-dihydro-1H-isoindol-2-yl]-4-(trifluoromethyl)-2,3-dihydropyridazin-3-one::US10550105, Example 58::US10870641, Example 58::US11014913, Example 58",Protein mono-ADP-ribosyltransferase TIPARP,,<100
50321102,N#Cc1cnc2cnc(NCCN3CCOCC3)cc2c1Nc1ccc(Oc2ccccc2)cc1,"InChI=1S/C27H26N6O2/c28-17-20-18-30-25-19-31-26(29-10-11-33-12-14-34-15-13-33)16-24(25)27(20)32-21-6-8-23(9-7-21)35-22-4-2-1-3-5-22/h1-9,16,18-19H,10-15H2,(H,29,31)(H,30,32)",YUYWSKXPXLUJNA-UHFFFAOYSA-N,50173837,"6-(2-morpholinoethylamino)-4-(4-phenoxyphenylamino)-1,7-naphthyridine-3-carbonitrile::6-[(2-morpholin-4-ylethyl)amino]-4-[(4-phenoxyphenyl)amino]-[1,7]naphthyridine-3-carbonitrile::CHEMBL371095",Dual specificity mitogen-activated protein kinase kinase 1,Homo sapiens, 800
1249923,CCn1c(c2CC(C)(C)COC(=O)[C@@H]3CCCN(N3)C(=O)[C@H](Cc3cc(O)cc(c3)-c3ccc1c2c3)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CCN(C1)C(=O)C=C)-c1cnccc1[C@H](C)OC,"InChI=1S/C51H65N7O8/c1-10-44(60)56-20-17-34(28-56)48(62)55(8)45(30(3)4)47(61)53-42-23-32-21-35(24-36(59)22-32)33-14-15-43-38(25-33)39(46(57(43)11-2)40-27-52-18-16-37(40)31(5)65-9)26-51(6,7)29-66-50(64)41-13-12-19-58(54-41)49(42)63/h10,14-16,18,21-22,24-25,27,30-31,34,41-42,45,54,59H,1,11-13,17,19-20,23,26,28-29H2,2-9H3,(H,53,61)/t31-,34-,41-,42-,45-/m0/s1",XVALWQLJSNYOAZ-PGZWVAKSSA-N,591398,"US11566007, Example A112::US11566007, Example A76",GTPase KRas [G13C],, 55.0
960812,CC1CN(CCC1n1cccn1)c1ccnc(n1)-c1cnc2ccc(cn12)C(F)(F)F,"InChI=1S/C21H20F3N7/c1-14-12-29(10-6-16(14)31-9-2-7-27-31)19-5-8-25-20(28-19)17-11-26-18-4-3-15(13-30(17)18)21(22,23)24/h2-5,7-9,11,13-14,16H,6,10,12H2,1H3",QRQDKCUJDSBNFH-UHFFFAOYSA-N,465046,"US10793563, Compound I-379",eIF-2-alpha kinase GCN2,Homo sapiens, 55
50779675,COC(=O)[C@H]([C@@H]1CCCCN1)c1cccc(F)c1,"InChI=1S/C14H18FNO2/c1-18-14(17)13(12-7-2-3-8-16-12)10-5-4-6-11(15)9-10/h4-6,9,12-13,16H,2-3,7-8H2,1H3/t12-,13-/m0/s1",GKVAYKZYNJEOFY-STQMWFEESA-N,50050123,(S)-(3-Fluoro-phenyl)-(S)-piperidin-2-yl-acetic acid methyl ester; hydrochloride::CHEMBL537930,Sodium-dependent dopamine transporter,Rattus norvegicus, 41
613357,CN1CC(COc2cc(-c3ccc(nc3)N3CCC(C)(CC3)NC(=O)c3ccccn3)c3c(cnn3c2)C#N)C1,"InChI=1S/C30H32N8O2/c1-30(35-29(39)26-5-3-4-10-32-26)8-11-37(12-9-30)27-7-6-22(15-33-27)25-13-24(40-20-21-17-36(2)18-21)19-38-28(25)23(14-31)16-34-38/h3-7,10,13,15-16,19,21H,8-9,11-12,17-18,20H2,1-2H3,(H,35,39)",JOHAMULTITXGOP-UHFFFAOYSA-N,305443,"US10144734, Example 460::US10172845, Example 460::US10441581, Example 460::US10881652, Example 460","Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M]",, 87.4
50608943,[Cl-].C[N+](C)(CC(=O)Nc1ccccc1)CC(=O)Nc1ccccc1,"InChI=1S/C18H21N3O2/c1-21(2,13-17(22)19-15-9-5-3-6-10-15)14-18(23)20-16-11-7-4-8-12-16/h3-12H,13-14H2,1-2H3,(H-,19,20,22,23)/p+1",MPOXTHSNJVUPKR-UHFFFAOYSA-O,50225700,Carcainium Chloride,Sodium channel protein type 1/2/3 subunit alpha,, 3900
50991145,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3[nH]ncc23)CC1,"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)",LHNIIDJUOCFXAP-UHFFFAOYSA-N,25028,"4-[2-(1H-indazol-4-yl)-6-[(4-methanesulfonylpiperazin-1-yl)methyl]thieno[3,2-d]pyrimidin-4-yl]morpholine::GDC-0941::GDC0941::US10112932, pictilisib::US10851091, Compound pictilisib","Phosphatidylinositol 3-kinase regulatory subunit alpha/4,5-bisphosphate 3-kinase catalytic subunit beta isoform",Homo sapiens, 54
51115843,COCCCN1CC2C(CNC(=O)c3cccc4c(Cl)c(nn34)C(C)C)C2C1,"InChI=1S/C21H29ClN4O2/c1-13(2)20-19(22)17-6-4-7-18(26(17)24-20)21(27)23-10-14-15-11-25(12-16(14)15)8-5-9-28-3/h4,6-7,13-16H,5,8-12H2,1-3H3,(H,23,27)",KLECHXMLPPZMLD-UHFFFAOYSA-N,50456148,CHEMBL4214953,5-hydroxytryptamine receptor 4,,
699701,Cc1[nH]c2c(ccc(N3CCCC(C3)NC(=O)C=C)c2c1C)C(N)=O,,,165287,"US10604504, Example 83::US9688629, 83::US9802915, Example 83::US9920031, Example 83",Tyrosine-protein kinase BTK,Homo sapiens, 3.30
50445488,CCCCC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4C(=O)Cn4cncn4)[C@@H]3CC=C2C1,"InChI=1S/C28H39N3O3/c1-4-5-6-26(33)34-20-11-13-27(2)19(15-20)7-8-21-22-9-10-24(28(22,3)14-12-23(21)27)25(32)16-31-18-29-17-30-31/h7,10,17-18,20-23H,4-6,8-9,11-16H2,1-3H3/t20-,21-,22-,23-,27-,28-/m0/s1",UCAXUDRLNVTQLE-APJCQQALSA-N,50135090,CHEMBL3735678,3-oxo-5-alpha-steroid 4-dehydrogenase 1,Rattus norvegicus, 320000
1140838,CSc1cnc(N[C@H]2CC[C@@H](C2)Nc2nc3ccc(cc3s2)C(=O)N2CCC3(CCOC3)CC2)nc1,"InChI=1S/C26H32N6O2S2/c1-35-20-14-27-24(28-15-20)29-18-3-4-19(13-18)30-25-31-21-5-2-17(12-22(21)36-25)23(33)32-9-6-26(7-10-32)8-11-34-16-26/h2,5,12,14-15,18-19H,3-4,6-11,13,16H2,1H3,(H,30,31)(H,27,28,29)/t18-,19-/m0/s1",TTXQKOOPKSEEFT-OALUTQOASA-N,537846,"US11248001, Example 321",Proprotein convertase subtilisin/kexin type 9,,
50024595,Cc1nc2ccc(CN(CC#C)c3ccc(cc3)C(=O)NC(CCC(O)=O)C(O)=O)cc2c(=O)[nH]1,"InChI=1S/C25H24N4O6/c1-3-12-29(14-16-4-9-20-19(13-16)24(33)27-15(2)26-20)18-7-5-17(6-8-18)23(32)28-21(25(34)35)10-11-22(30)31/h1,4-9,13,21H,10-12,14H2,2H3,(H,28,32)(H,30,31)(H,34,35)(H,26,27,33)",PMTUUSDTAKQWQJ-UHFFFAOYSA-N,50012244,"2-{4-[(2-Methyl-4-oxo-3,4-dihydro-quinazolin-6-ylmethyl)-prop-2-ynyl-amino]-benzoylamino}-pentanedioic acid::2-{4-[(2-Methyl-4-oxo-3,4-dihydro-quinazolin-6-ylmethyl)-prop-2-ynyl-amino]-benzoylamino}-pentanedioic acid(DMPDDF)::CHEMBL25889",Dihydrofolate reductase,Lactobacillus casei, 35000
50965527,OC(=O)c1ccnc(c1)-c1cc(ccn1)C(=O)NCCc1ccccc1,"InChI=1S/C20H17N3O3/c24-19(23-9-6-14-4-2-1-3-5-14)15-7-10-21-17(12-15)18-13-16(20(25)26)8-11-22-18/h1-5,7-8,10-13H,6,9H2,(H,23,24)(H,25,26)",DSGOLESVOJUGOK-UHFFFAOYSA-N,50396019,"4&#39;-(phenethylcarbamoyl)-[2,2&#39;-bipyridine]-4-carboxylic acid (N3)::CHEMBL2169917",Lysine-specific demethylase 4E,Homo sapiens, 110
50822376,CCCCCCCCc1ccc2nc([nH]c2c1)[C@@H](N)CO,"InChI=1S/C17H27N3O/c1-2-3-4-5-6-7-8-13-9-10-15-16(11-13)20-17(19-15)14(18)12-21/h9-11,14,21H,2-8,12,18H2,1H3,(H,19,20)/t14-/m0/s1",XKKHMNGIHWTYAT-AWEZNQCLSA-N,50152541,(R)-2-Amino-2-(6-octyl-1H-benzoimidazol-2-yl)-ethanol; TFA::CHEMBL363076,Sphingosine 1-phosphate receptor 5,Homo sapiens,
1177491,CC(C)(C)NC(=O)c1cc(NC(=O)Cc2cc(Cl)cc(Cl)c2)ccn1,"InChI=1S/C18H19Cl2N3O2/c1-18(2,3)23-17(25)15-10-14(4-5-21-15)22-16(24)8-11-6-12(19)9-13(20)7-11/h4-7,9-10H,8H2,1-3H3,(H,23,25)(H,21,22,24)",IUBSSKSCLLEUOB-UHFFFAOYSA-N,509621,"US11364246, Example 5.19::US20200361871A1, Example 5.19",Anoctamin-1,Homo sapiens,
350135,CC(C)OC(=O)c1ccc(nc1)N1CCC(CC1)OC(=O)N1CCN(CC1)C(C)C,"InChI=1S/C22H34N4O4/c1-16(2)24-11-13-26(14-12-24)22(28)30-19-7-9-25(10-8-19)20-6-5-18(15-23-20)21(27)29-17(3)4/h5-6,15-17,19H,7-14H2,1-4H3",IIDWRCSIRLZSTB-UHFFFAOYSA-N,197067,"US9216182, 1.13",Histamine H3 receptor,Homo sapiens,
931679,OC(=O)c1ccc(CN2CC[C@@]3([C@H]2CCc2cc(ccc32)C(F)(C(F)(F)F)C(F)(F)F)S(=O)(=O)c2ccc(F)cc2)cc1Cl,"InChI=1S/C29H22ClF8NO4S/c30-23-13-16(1-8-21(23)25(40)41)15-39-12-11-26(44(42,43)20-6-4-19(31)5-7-20)22-9-3-18(14-17(22)2-10-24(26)39)27(32,28(33,34)35)29(36,37)38/h1,3-9,13-14,24H,2,10-12,15H2,(H,40,41)/t24-,26-/m1/s1",FJYXVQNSINUYKK-AOYPEHQESA-N,383058,"US10273259, Example 769::US10711020, Example 769",Nuclear receptor ROR-gamma [262-507],, 117
51238060,Nc1c(C(=O)N[C@H]2CC[C@H](CC2)c2ccccc2)n(-c2ccccc2)c(=O)[nH]c1=O,"InChI=1S/C23H24N4O3/c24-19-20(27(23(30)26-21(19)28)18-9-5-2-6-10-18)22(29)25-17-13-11-16(12-14-17)15-7-3-1-4-8-15/h1-10,16-17H,11-14,24H2,(H,25,29)(H,26,28,30)/t16-,17+",OZJCVDROTRKHCV-CALCHBBNSA-N,50506736,CHEMBL4584322,Endothelial lipase,Homo sapiens, 2350
50589181,NCCCCNCCCN,"InChI=1S/C7H19N3/c8-4-1-2-6-10-7-3-5-9/h10H,1-9H2",ATHGHQPFGPMSJY-UHFFFAOYSA-N,50009353,"1,5,10-triazadecane::4-azaoctamethylenediamine::4-azaoctane-1,8-diamine::CHEMBL19612::N-(3-aminopropyl)butane-1,4-diamine::spermidine","Carbonic anhydrase 5A, mitochondrial",Homo sapiens,
51379505,CC(=O)Oc1ccccc1C(O)=O,"InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)",BSYNRYMUTXBXSQ-UHFFFAOYSA-N,22360,2-(acetyloxy)benzoate::2-(acetyloxy)benzoic acid::Acetylsalicylic acid::Aspirin::Endosprin::Polopirin::Zorprin::acetylsalicylate::cid_2244,Prostaglandin G/H synthase 1,, 350
51406065,Fc1cccc(NS(=O)(=O)c2cc(F)c(O[C@H]3CCN(CC(F)(F)F)C[C@@H]3c3ccc(F)c(F)c3)c(F)c2)n1,"InChI=1S/C24H19F8N3O3S/c25-16-5-4-13(8-17(16)26)15-11-35(12-24(30,31)32)7-6-20(15)38-23-18(27)9-14(10-19(23)28)39(36,37)34-22-3-1-2-21(29)33-22/h1-5,8-10,15,20H,6-7,11-12H2,(H,33,34)/t15-,20+/m1/s1",ALYSSPGOUMAGSF-QRWLVFNGSA-N,50568138,CHEMBL4854735,Sodium channel protein type 5 subunit alpha,, 65
50567623,COc1ccc(cn1)N(C)C(=O)c1cnc(cn1)-c1ccc(cc1C)C#N,"InChI=1S/C20H17N5O2/c1-13-8-14(9-21)4-6-16(13)17-11-23-18(12-22-17)20(26)25(2)15-5-7-19(27-3)24-10-15/h4-8,10-12H,1-3H3",OJOXFOACQKDTBX-UHFFFAOYSA-N,50314508,5-(4-cyano-2-methylphenyl)-N-(6-methoxypyridin-3-yl)-N-methylpyrazine-2-carboxamide::CHEMBL1093367,Vasopressin V2 receptor,,
358103,CC(C)(O)[C@@H](NC(=O)Nc1cc2[nH]nc(N)c2cn1)c1ccc(F)cc1,,,202011,"US9233979, 443",Mitogen-activated protein kinase 1,Homo sapiens, 0.7
50481608,COc1cc(\C=N\NC(=O)Cn2c3ccccc3nc(C)c2=O)cc(OC)c1OC,"InChI=1S/C23H25ClFNO2/c24-18-7-5-17(6-8-18)23(28)14-20-11-12-21(15-23)26(20)13-1-2-22(27)16-3-9-19(25)10-4-16/h3-10,20-21,28H,1-2,11-15H2",CXQUOFVDYCOSEZ-UHFFFAOYSA-N,50155519,CHEMBL3775970,Aminopeptidase N,, 57550
501316,Oc1ccc2c(CCCC(c3ccncc3)=C2c2ccc(O[C@H]3CCN(CCCF)C3)cc2)c1,"InChI=1S/C29H31FN2O2/c30-14-2-17-32-18-13-26(20-32)34-25-8-5-22(6-9-25)29-27(21-11-15-31-16-12-21)4-1-3-23-19-24(33)7-10-28(23)29/h5-12,15-16,19,26,33H,1-4,13-14,17-18,20H2/t26-/m0/s1",VQJJJXIRLQIHGO-SANMLTNESA-N,263822,"5-[4-[(3S)- 1-(3- fluoropropyl)- pyrrolidin-3- yl]oxy- phenyl]-6-(4- pyridyl)- 8,9- dihydro- 7H- benzo[7]- annulen-2-ol::US9714221, Example 153",Estrogen receptor [D538G],, 74.0
50389057,CC(C)C[C@@H](N)c1cccc(c1N1CCN(CC1)C(=O)[C@@H](Cc1ccc(Cl)cc1Cl)NC(=O)CCN)C(F)(F)F,"InChI=1S/C28H36Cl2F3N5O2/c1-17(2)14-23(35)20-4-3-5-21(28(31,32)33)26(20)37-10-12-38(13-11-37)27(40)24(36-25(39)8-9-34)15-18-6-7-19(29)16-22(18)30/h3-7,16-17,23-24H,8-15,34-35H2,1-2H3,(H,36,39)/t23-,24-/m1/s1",QKOLGGSRJVIDED-DNQXCXABSA-N,50214683,"1-{4-[(1R)-2-(amino-3-methylbutyl)-6-trifluoromethylphenyl]-4-[(2R)-(3-aminopropionylamido)-3-(2,4-dichlorophenyl)propionyl]}-piperazine::CHEMBL391219",Melanocortin receptor 4,,
50154357,CCCN(CCC)C(=O)c1cc(cc(c1)S(=O)(=O)c1ccccc1)C(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNCc1cccc(OC)c1,"InChI=1S/C38H43F2N3O6S/c1-4-14-43(15-5-2)38(46)29-20-28(21-34(22-29)50(47,48)33-12-7-6-8-13-33)37(45)42-35(19-27-16-30(39)23-31(40)17-27)36(44)25-41-24-26-10-9-11-32(18-26)49-3/h6-13,16-18,20-23,35-36,41,44H,4-5,14-15,19,24-25H2,1-3H3,(H,42,45)/t35-,36+/m0/s1",SUHUZGDMCOOSBZ-MPQUPPDSSA-N,50294651,"CHEMBL555436::N1-((2S,3R)-1-(3,5-difluorophenyl)-3-hydroxy-4-(3-methoxybenzylamino)butan-2-yl)-5-(phenylsulfonyl)-N3,N3-dipropylisophthalamide",Beta-secretase 1,Homo sapiens, 11
50508971,Cc1ccc(NS(=O)(=O)c2cccs2)cc1Cl,"InChI=1S/C11H10ClNO2S2/c1-8-4-5-9(7-10(8)12)13-17(14,15)11-3-2-6-16-11/h2-7,13H,1H3",KOTPGHDHHVOARW-UHFFFAOYSA-N,50294367,CHEMBL558100::N-(3-Chloro-4-methylphenyl)thiophene-2-sulfonamide,Lethal factor,Bacillus anthracis,>100000
830001,CC(Nc1ncnc2[nH]cnc12)c1nc2cccc(C)n2c(=O)c1-c1ccc(cc1)C#N,,,394341,"US10428087, Example 61::US10829502, Example 61::US11401280, Example 61::US9975907, Example 61","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens,>500
848504,CC(C)(C)c1ccc(cc1)N(C(C(=O)NC1CCCC1)c1cccnc1)C(=O)c1c[nH]cn1,,,420993,"US9975885, Compound 47",Replicase polyprotein 1ab,Human SARS coronavirus, 1700
50029788,CC(Oc1ccccc1-c1ccccc1)C1=NCCN1,"InChI=1S/C17H18N2O/c1-13(17-18-11-12-19-17)20-16-10-6-5-9-15(16)14-7-3-2-4-8-14/h2-10,13H,11-12H2,1H3,(H,18,19)",OGOLMGZJNRNULQ-UHFFFAOYSA-N,50412250,CHEMBL128168,Alpha-2B adrenergic receptor,,
50180054,Fc1ccccc1N1CCN(Cc2c[nH]c3ncccc23)CC1,"InChI=1S/C18H19FN4/c19-16-5-1-2-6-17(16)23-10-8-22(9-11-23)13-14-12-21-18-15(14)4-3-7-20-18/h1-7,12H,8-11,13H2,(H,20,21)",OOKNJSVAHXTYKL-UHFFFAOYSA-N,50099887,"3-[4-(2-Fluoro-phenyl)-piperazin-1-ylmethyl]-1H-pyrrolo[2,3-b]pyridine::CHEMBL282424",5-hydroxytryptamine receptor 1E,Homo sapiens,
791715,Cc1nc2nonc2c(N)c1Cc1ccc(C#N)c(OCC(F)F)n1,"InChI=1S/C15H12F2N6O2/c1-7-10(12(19)13-14(20-7)23-25-22-13)4-9-3-2-8(5-18)15(21-9)24-6-11(16)17/h2-3,11H,4,6,19H2,1H3",IBUYTGADUJQKQO-UHFFFAOYSA-N,396206,"6-(7-Amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridin-6-ylmethyl)-2-(2,2-difluoro-ethoxy)-nicotinonitrile::US10308667, Example 109",Ghrelin O-acyltransferase,, 0.093
51144831,COc1ccc2c3CN(COc3ccc2c1)c1nc(cs1)-c1ccc(F)cc1,"InChI=1S/C22H17FN2O2S/c1-26-17-7-8-18-15(10-17)4-9-21-19(18)11-25(13-27-21)22-24-20(12-28-22)14-2-5-16(23)6-3-14/h2-10,12H,11,13H2,1H3",WQIGYQSUSNXXAB-UHFFFAOYSA-N,50469026,CHEMBL4283605,Reverse transcriptase,Human immunodeficiency virus 1,
50325186,O=S(=O)(Nc1ccccc1)N1CCC(CC1)(c1nccn1Cc1ccccc1)c1ccccc1,"InChI=1S/C27H28N4O2S/c32-34(33,29-25-14-8-3-9-15-25)31-19-16-27(17-20-31,24-12-6-2-7-13-24)26-28-18-21-30(26)22-23-10-4-1-5-11-23/h1-15,18,21,29H,16-17,19-20,22H2",FBLAYKAWVSYTGT-UHFFFAOYSA-N,50175717,"4-(1-benzyl-1H-imidazol-2-yl)-N,4-diphenylpiperidine-1-sulfonamide::CHEMBL199518",Mu-type opioid receptor,Homo sapiens,
51362655,Clc1ccc(cc1)-n1c(nc2ccccc2c1=O)-c1sc(NC(=O)c2ccco2)nc1-c1ccccc1,"InChI=1S/C28H17ClN4O3S/c29-18-12-14-19(15-13-18)33-25(30-21-10-5-4-9-20(21)27(33)35)24-23(17-7-2-1-3-8-17)31-28(37-24)32-26(34)22-11-6-16-36-22/h1-16H,(H,31,32,34)",OTAAAJWYDQOTRS-UHFFFAOYSA-N,50550814,CHEMBL4747947,Adenosine receptor A1,Rattus norvegicus,
612449,Cc1ccc(Cl)cc1C(=O)NC1(C)CCN(CC1)c1ccc(cn1)-c1cc(OCC(C)(C)O)cn2ncc(C#N)c12,"InChI=1S/C31H33ClN6O3/c1-20-5-7-23(32)13-25(20)29(39)36-31(4)9-11-37(12-10-31)27-8-6-21(16-34-27)26-14-24(41-19-30(2,3)40)18-38-28(26)22(15-33)17-35-38/h5-8,13-14,16-18,40H,9-12,19H2,1-4H3,(H,36,39)",IPFAVAPMBUVAOH-UHFFFAOYSA-N,305057,"5-chloro-N-(1-(5-(3- cyano-6-(2-hydroxy-2- methylpropoxy)pyrazolo [1,5-a]pyridin-4-yl) pyridin-2-yl)-4- methylpiperidin-4-yl)-2- methylbenzamide::US10144734, Example 73::US10172845, Example 73::US10441581, Example 73::US10881652, Example 73",Proto-oncogene tyrosine-protein kinase receptor Ret [658-1114],, 16.3
51346371,Oc1ccc(cc1)C(c1ccc(O)cc1)C(Cl)(Cl)Cl,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H",IUGDILGOLSSKNE-UHFFFAOYSA-N,50410509,CHEMBL196585::SJ000143975,Estrogen receptor,, 43
50600924,COC(=O)[C@@H]1C[C@H](I)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1,"InChI=1S/C21H25IO6/c1-20-6-4-12-19(25)28-15(11-5-7-27-10-11)9-21(12,2)17(20)16(23)14(22)8-13(20)18(24)26-3/h5,7,10,12-15,17H,4,6,8-9H2,1-3H3/t12-,13-,14-,15-,17-,20-,21-/m0/s1",ZMMLDLJAIWFEMI-CEFSSPBYSA-N,50327507,"(3S,4aR,4bS,6S,8R,8aR,10aR)-3-Furan-3-yl-6-iodo-4a,8a-dimethyl-1,5-dioxo-dodecahydro-2-oxa-phenanthrene-8-carboxylic acid methyl ester::CHEMBL1257731",Kappa-type opioid receptor,Homo sapiens,
50461276,CO[C@@H]1CN(CCC(=O)N2CCOCC2)CC[C@@H]1NC(=O)c1cc(Cl)c(N)cc1OC,"InChI=1S/C21H31ClN4O5/c1-29-18-12-16(23)15(22)11-14(18)21(28)24-17-3-5-25(13-19(17)30-2)6-4-20(27)26-7-9-31-10-8-26/h11-12,17,19H,3-10,13,23H2,1-2H3,(H,24,28)/t17-,19+/m0/s1",OCVUHLRJDQASOP-PKOBYXMFSA-N,50142908,CHEMBL3758410,5-hydroxytryptamine receptor 4,, 954
51375109,Oc1ccc2C(=O)c3nnn(c3C(=O)c2c1)-c1ccc(F)c(Cl)c1,"InChI=1S/C16H7ClFN3O3/c17-11-5-7(1-4-12(11)18)21-14-13(19-20-21)15(23)9-3-2-8(22)6-10(9)16(14)24/h1-6,22H",KUSQYZAWKVNEKI-UHFFFAOYSA-N,50556075,CHEMBL4747007,"Indoleamine 2,3-dioxygenase 1",Homo sapiens, 355
50199925,CC(C)C1NC(=O)[C@@H](Cc2ccccc2)NC(=O)C(CC(O)=O)NC(=O)NNC(=O)C(CCCNC(N)=N)NC1=O,"InChI=1S/C25H37N9O7/c1-13(2)19-23(40)29-15(9-6-10-28-24(26)27)22(39)33-34-25(41)31-17(12-18(35)36)20(37)30-16(21(38)32-19)11-14-7-4-3-5-8-14/h3-5,7-8,13,15-17,19H,6,9-12H2,1-2H3,(H,29,40)(H,30,37)(H,32,38)(H,33,39)(H,35,36)(H4,26,27,28)(H2,31,34,41)/t15?,16-,17?,19?/m1/s1",DPVUQQDISRAKFA-DSICWQNTSA-N,50110233,"CHEMBL267155::[8-Benzyl-14-(3-guanidino-propyl)-11-isopropyl-3,6,9,12,15-pentaoxo-1,2,4,7,10,13hexaaza-cyclopentadec-5-yl]-acetic acid",Integrin alpha-V/beta-5,Homo sapiens, 2100
82435,CC1CCCN(C1)c1nc2ccccc2nc1C(C#N)C(=O)OC1CCCCC1,"InChI=1S/C23H28N4O2/c1-16-8-7-13-27(15-16)22-21(25-19-11-5-6-12-20(19)26-22)18(14-24)23(28)29-17-9-3-2-4-10-17/h5-6,11-12,16-18H,2-4,7-10,13,15H2,1H3",QXRWTYKHXFRJOY-UHFFFAOYSA-N,44435,2-cyano-2-[3-(3-methyl-1-piperidinyl)-2-quinoxalinyl]acetic acid cyclohexyl ester::2-cyano-2-[3-(3-methylpiperidino)quinoxalin-2-yl]acetic acid cyclohexyl ester::MLS000040157::SMR000043328::cid_662746::cyclohexyl 2-cyano-2-[3-(3-methylpiperidin-1-yl)quinoxalin-2-yl]acetate::cyclohexyl 2-cyano-2-[3-(3-methylpiperidin-1-yl)quinoxalin-2-yl]ethanoate,Ephrin type-A receptor 4,Mus musculus, 9810
587633,O=C(NCCCc1ncc[nH]1)c1ccc2nc(C3=CCOCC3)c(nc2c1)-c1cccs1,"InChI=1S/C24H23N5O2S/c30-24(27-9-1-4-21-25-10-11-26-21)17-5-6-18-19(15-17)29-23(20-3-2-14-32-20)22(28-18)16-7-12-31-13-8-16/h2-3,5-7,10-11,14-15H,1,4,8-9,12-13H2,(H,25,26)(H,27,30)",WHPNGTOQYUNLJS-UHFFFAOYSA-N,306138,"US10144742, Compound I-300",Nicotinamide phosphoribosyltransferase,Homo sapiens,<100
22101,N[C@@H](CC(=O)N1CCc2ccccc2C1)C(=O)N1CCC[C@H]1C#N,"InChI=1S/C18H22N4O2/c19-11-15-6-3-8-22(15)18(24)16(20)10-17(23)21-9-7-13-4-1-2-5-14(13)12-21/h1-2,4-5,15-16H,3,6-10,12,20H2/t15-,16-/m0/s1",XCUPYUKEECXEPG-HOTGVXAUSA-N,12182,"(2S)-1-[(2S)-2-amino-4-oxo-4-(1,2,3,4-tetrahydroisoquinolin-2-yl)butanoyl]pyrrolidine-2-carbonitrile::CHEMBL179289::cyanopyrrolidine derivative 5",Dipeptidyl peptidase 2,Homo sapiens, 31259
51379910,Cc1cccc2n(Cc3cccc(c3C#N)C(F)(F)F)c(=O)n(C[C@H]3CC[C@@H](CC3)C(O)=O)c(=O)c12,"InChI=1S/C26H24F3N3O4/c1-15-4-2-7-21-22(15)23(33)32(13-16-8-10-17(11-9-16)24(34)35)25(36)31(21)14-18-5-3-6-20(19(18)12-30)26(27,28)29/h2-7,16-17H,8-11,13-14H2,1H3,(H,34,35)/t16-,17-",QDVBJHFEZRTDHU-QAQDUYKDSA-N,50557897,CHEMBL4761298,Cytochrome P450 2D6,,>100000
51132253,Cn1ccc(n1)-c1ccc(Cc2cc(nc3n(C)ccc23)C(=O)NC2CCOC(C)(C)C2)cn1,"InChI=1S/C26H30N6O2/c1-26(2)15-19(9-12-34-26)28-25(33)23-14-18(20-7-10-31(3)24(20)29-23)13-17-5-6-21(27-16-17)22-8-11-32(4)30-22/h5-8,10-11,14,16,19H,9,12-13,15H2,1-4H3,(H,28,33)",JPTMWXJBVKWMOU-UHFFFAOYSA-N,50464173,CHEMBL4238850,Muscarinic acetylcholine receptor M1,Rattus,
51414173,Cl.COc1ccc2nc3CC4CC(CC(C)=C4)c3c(N)c2c1,"InChI=1S/C18H20N2O.ClH/c1-10-5-11-7-12(6-10)17-16(8-11)20-15-4-3-13(21-2)9-14(15)18(17)19;/h3-5,9,11-12H,6-8H2,1-2H3,(H2,19,20);1H",KCMWKNABWVNMDK-UHFFFAOYSA-N,50571191,CHEMBL4850590,Cholinesterase,Homo sapiens, 3760
932712,C[C@@H]1CCCN1CCCOc1ccc(cc1)-n1c(C)nc2ccc(cc2c1=O)S(F)(F)(F)(F)F,"InChI=1S/C23H26F5N3O2S/c1-16-5-3-12-30(16)13-4-14-33-19-8-6-18(7-9-19)31-17(2)29-22-11-10-20(15-21(22)23(31)32)34(24,25,26,27)28/h6-11,15-16H,3-5,12-14H2,1-2H3/t16-/m1/s1",ZSYSMHSIJUGKDW-MRXNPFEDSA-N,438110,"US10618886, Compound IV::US10730853, Compound IV::US11420955, Compound IV",Histamine H3 receptor,Homo sapiens, 8.15
540042,CCN(C1CN(N=C1c1ccc(Cl)c(Cl)c1)C(\Nc1cc(F)cc(OC(F)F)c1)=N/C#N)C(=O)CO,"InChI=1S/C22H19Cl2F3N6O3/c1-2-32(19(35)10-34)18-9-33(31-20(18)12-3-4-16(23)17(24)5-12)22(29-11-28)30-14-6-13(25)7-15(8-14)36-21(26)27/h3-8,18,21,34H,2,9-10H2,1H3,(H,29,30)",GOXPTBFRMOWJPX-UHFFFAOYSA-N,283183,"Rac-N-[1-{N&#8242;-cyano-N-[3-(difluoromethoxy)-5-fluorophenyl]carbamimidoyl}-3-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-4-yl]-N-ethyl-2-hydroxyacetamide::US10023539, Example 24",N-lysine methyltransferase SMYD2,, 63.1
318294,Cc1cnc(C)c2nc(CCc3nc(cn3C)-c3ccncc3)nn12,"InChI=1S/C18H19N7/c1-12-10-20-13(2)18-22-16(23-25(12)18)4-5-17-21-15(11-24(17)3)14-6-8-19-9-7-14/h6-11H,4-5H2,1-3H3",HQNLOVNPFMKKMR-UHFFFAOYSA-N,173194,"US9096589, 5,8-Dimethyl-2-[2-(1-methyl-4-pyridin-4-yl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyrazine","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A",Homo sapiens, 0.55
50378959,OC(C(=O)N1CCN(CC1)c1ccc2[nH]ncc2c1)c1ccc(Br)cc1,"InChI=1S/C19H19BrN4O2/c20-15-3-1-13(2-4-15)18(25)19(26)24-9-7-23(8-10-24)16-5-6-17-14(11-16)12-21-22-17/h1-6,11-12,18,25H,7-10H2,(H,21,22)",XWMMNGXDPDSMBN-UHFFFAOYSA-N,50208322,1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-(4-bromophenyl)-2-hydroxyethanone::CHEMBL239150::SR-899,Cytochrome P450 3A4,Homo sapiens, 4000
751831,CC#CCOc1cnc(cn1)C(=O)Nc1ccc2OCCC3(N=C(C)C(N)=N3)c2c1,"InChI=1S/C21H20N6O3/c1-3-4-8-30-18-12-23-16(11-24-18)20(28)25-14-5-6-17-15(10-14)21(7-9-29-17)26-13(2)19(22)27-21/h5-6,10-12H,7-9H2,1-2H3,(H2,22,27)(H,25,28)",LGQYIGQUEVQRCI-UHFFFAOYSA-N,136712,"US10231967, Example 13e::US8865911, 13e::US9918985, Example 13e",Beta-secretase 1 [1-460],, 22.0
355352,COc1n[nH]c2cc(NC(=O)N[C@H](COC(F)F)c3ccccc3)ncc12,,,199806,"US9226922, 442",Mitogen-activated protein kinase 1,Homo sapiens, 5.5
861391,COC(=O)Nc1cc(ccn1)-c1cnc(OC[C@](C)(N)CC(C)C)c(c1)C(F)F,"InChI=1S/C20H26F2N4O3/c1-12(2)9-20(3,23)11-29-18-15(17(21)22)7-14(10-25-18)13-5-6-24-16(8-13)26-19(27)28-4/h5-8,10,12,17H,9,11,23H2,1-4H3,(H,24,26,27)/t20-/m1/s1",LYPCNZGCERKJEG-HXUWFJFHSA-N,311388,"(R)-methyl (6-((2-amino-2,4-dimethylpentyl)oxy)-5-(difluoromethyl)-[3,4&#8242;-bipyridin]-2&#8242;-yl)carbamate::US10155760, Example 245::US10351563, Example 245::US10544120, Example 245::US10723734, Example 245::US10981910, Example 245::US9902722, Example 245",AP2-associated protein kinase 1,Homo sapiens, 11.0
611597,Fc1cccc(-c2ncccn2)c1C(=O)N1CC2CC(Nc3ccc(Br)cn3)C1C2,"InChI=1S/C22H19BrFN5O/c23-14-5-6-19(27-11-14)28-17-9-13-10-18(17)29(12-13)22(30)20-15(3-1-4-16(20)24)21-25-7-2-8-26-21/h1-8,11,13,17-18H,9-10,12H2,(H,27,28)",PGRFCBWNHDMEMV-UHFFFAOYSA-N,314987,"((1S,4S,6R)-6-((5-bromopyridin-2-yl)amino)-2-azabicyclo[2.2.1]heptan-2-yl)(2-fluoro-6-(pyrimidin-2-yl)phenyl)methanone::US10183953, Example 168::US9611277, Example 168",Orexin/Hypocretin receptor type 1,Rattus norvegicus,
351582,Cc1cc(N)ncc1-n1c(nc2c(Cl)ccc(Cl)c2c1=O)[C@@H](Nc1nc(N)nc(N)c1C#N)C1CC1,"InChI=1S/C23H20Cl2N10O/c1-9-6-15(27)30-8-14(9)35-21(32-18-13(25)5-4-12(24)16(18)22(35)36)17(10-2-3-10)31-20-11(7-26)19(28)33-23(29)34-20/h4-6,8,10,17H,2-3H2,1H3,(H2,27,30)(H5,28,29,31,33,34)/t17-/m0/s1",XPRIOGDYXUTIAO-KRWDZBQOSA-N,198102,"BDBM198103::US9221795, 98","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform",Homo sapiens, 640
50357011,CCO\N=C(/CCN1CCN(CC1)c1nccs1)c1ccccc1,"InChI=1S/C18H24N4OS/c1-2-23-20-17(16-6-4-3-5-7-16)8-10-21-11-13-22(14-12-21)18-19-9-15-24-18/h3-7,9,15H,2,8,10-14H2,1H3/b20-17+",JHVJCSPJYFYTJV-LVZFUZTISA-N,50193364,(E)-1-phenyl-3-(4-thiazol-2-ylpiperazin-1-yl)propanon-1-one O-ethyloxime::CHEMBL377388,D(4) dopamine receptor,Homo sapiens,
51052076,CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1,"InChI=1S/C17H18ClNO/c1-19-8-7-13-9-16(18)17(20)10-14(13)15(11-19)12-5-3-2-4-6-12/h2-6,9-10,15,20H,7-8,11H2,1H3/t15-/m1/s1",GOTMKOSCLKVOGG-OAHLLOKOSA-N,82247,"8-Chloro-3-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol(SCH 23390)::CAS_87134-87-0::CHEMBL2158641::CHEMBL62::SCH 23388::SCH 23390::SCH 23390 (R-enantiomer)::SCH 23390,R(+)",D(1A) dopamine receptor,,
50205117,Cn1c2nc[nH]c2c(=O)n(Cc2ccccc2)c1=O,"InChI=1S/C13H12N4O2/c1-16-11-10(14-8-15-11)12(18)17(13(16)19)7-9-5-3-2-4-6-9/h2-6,8H,7H2,1H3,(H,14,15)",YAYRUHPCXIPTID-UHFFFAOYSA-N,50113235,"1-Benzyl-3-methyl-3,7-dihydro-purine-2,6-dione::CHEMBL63944",Adenosine receptor A2a,Rattus norvegicus,
620430,Cc1nn(C)cc1Nc1ncnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c12,"InChI=1S/C24H18F3N7O3S/c1-12-17(10-34(2)32-12)31-24-19-13(9-28-23(19)29-11-30-24)22(35)20-15(26)7-8-16(21(20)27)33-38(36,37)18-6-4-3-5-14(18)25/h3-11,33H,1-2H3,(H2,28,29,30,31)",MZNUIROSGLQZKD-UHFFFAOYSA-N,317049,"N-{3-[4-(1,3-Dimethyl-1H- pyrazol-4-ylamino)-7H- pyrrolo[2,3-d]pyrimidine-5- carbonyl]-2,4-difluoro- phenyl}-2-fluoro- benzenesulfonamide::US9617267, Compound P-1154",Cytochrome P450 3A4,Homo sapiens,>10000
1139150,CNc1cc2n(nc(-c3cncc(c3)C(F)(F)F)c2cn1)C1CC[C@@H](CC1)Oc1ccc(=O)n(C)n1,"InChI=1S/C24H24F3N7O2/c1-28-20-10-19-18(13-30-20)23(14-9-15(12-29-11-14)24(25,26)27)32-34(19)16-3-5-17(6-4-16)36-21-7-8-22(35)33(2)31-21/h7-13,16-17H,3-6H2,1-2H3,(H,28,30)/t16?,17-",ATBDIPDCACEXQS-FITNRVMRSA-N,537227,"2-methyl-6-(((1s,4s)-4-(6- (methylamino)-3-(5- (trifluoromethyl)pyridin-3- yl)-1H-pyrazolo[4,3- c]pyridin-1- yl)cyclohexyl)oxy)pyridazin- 3(2H)-one::US11247990, Example 52",Tyrosine-protein kinase Mer,Homo sapiens, 350
50001102,OC(=O)C(=O)CC(=O)c1cccnc1,"InChI=1S/C9H7NO4/c11-7(4-8(12)9(13)14)6-2-1-3-10-5-6/h1-3,5H,4H2,(H,13,14)",PISWNSJFMUGNKU-UHFFFAOYSA-N,50137869,"2,4-Dioxo-4-pyridin-3-yl-butyric acid::CHEMBL177968::CHEMBL2040556",RNA-directed RNA polymerase,Hepatitis C virus,>50000
51365739,COc1cccc(c1)-c1cnc2OS(=O)(=O)C=Cc2c1,"InChI=1S/C14H11NO4S/c1-18-13-4-2-3-10(8-13)12-7-11-5-6-20(16,17)19-14(11)15-9-12/h2-9H,1H3",KXASSMVTZKGURM-UHFFFAOYSA-N,50552044,CHEMBL4798084,Carbonic anhydrase 12,Homo sapiens,
50162960,COc1ccc(cc1)N1CCN(CC1)c1ccc(cc1)S(=O)(=O)C1(CCOCC1)C(=O)NO,"InChI=1S/C23H29N3O6S/c1-31-20-6-2-18(3-7-20)25-12-14-26(15-13-25)19-4-8-21(9-5-19)33(29,30)23(22(27)24-28)10-16-32-17-11-23/h2-9,28H,10-17H2,1H3,(H,24,27)",QQPOIMHFFPBDQM-UHFFFAOYSA-N,50320410,CHEMBL1084208::N-hydroxy-4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenylsulfonyl)tetrahydro-2H-pyran-4-carboxamide,Matrix metalloproteinase-9,Homo sapiens, 722
1011768,Cc1cc(Nc2cc3ncccc3c(N[C@H]3C[C@@H]4CCC[C@H](C3)N4S(C)(=O)=O)n2)n[nH]1,,,277525,"US10072026, Example 4-16::US10947254, Example 4-16",Tyrosine-protein kinase JAK3,Homo sapiens,
